

10/644,807
10-17-5

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32675 A1

(51) International Patent Classification⁷: **C07H 21/04**,
21/02, C07K 5/00, 14/00, C12Q 1/68, C12N 1/21, 15/63,
15/85, 15/86

[US/US]; 122 Beckwith Street, Gaithersburg, MD 20878
(US).

(21) International Application Number: PCT/US00/29363

(74) Agents: **HOOVER, Kenley, K.** et al.; Human Genome
Sciences, Inc., 9410 Key West Avenue, Rockville, MD
20850 (US).

(22) International Filing Date: 25 October 2000 (25.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/162,239 29 October 1999 (29.10.1999) US
60/215,139 30 June 2000 (30.06.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): **HUMAN
GENOME SCIENCES, INC.** [US/US]; 9410 Key West
Avenue, Rockville, MD 20850 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RUBEN, Steven, M.**
[US/US]; 18528 Heritage Hills Drive, Olney, MD 20832
(US). **KOMATSOUKIS, George, A.** [US/US]; 9518 Gar-
wood Steet, Silver Spring, MD 20901 (US). **WEL, Ping**
[CN/US]; 19100 Baltimore Road, Brookeville, MD 20833
(US). **BAKER, Kevin, P.** [GB/US]; 14006 Indian Run
Drive, Darnestown, MD 20878 (US). **YOUNG, Paul, E.**

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: 32 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding re-
gions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing
human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating dis-
eases, disorders, and/or conditions related to these novel human secreted proteins.

WO 01/32675 A1

32 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides, polypeptides encoded by these polynucleotides, antibodies that bind these polypeptides, uses of
5 such polynucleotides, polypeptides, and antibodies, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins
30 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As

shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of
5 microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an
10 overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the
15 polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight
20 incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X
25 SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and
30 commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of

ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available

residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L, V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as

limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

Polynucleotides and Polypeptides of the Invention

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.
 10 gb|AAC39792.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "| (AF030435) glioma amplified on chromosome 1 protein [Homo sapiens]" A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >gb|AAC39792.1| (AF030435) glioma amplified on chromosome 1 protein [Homo
      sapiens] >sp|O75325|O75325 GLIOMA AMPLIFIED ON CHROMOSOME 1
      PROTEIN.
      Length = 713

20  Plus Strand HSPs:

      Score = 262 (92.2 bits), Expect = 3.5e-18, P = 3.5e-18
      Identities = 102/294 (34%), Positives = 140/294 (47%), Frame = +1

25  Q:   10 RRLPAPTM-PWPLLLLLAVSGAQTTRPCFPGCQCEVET-FGLFDSF-SLTRVDCSGLGPH 180
      R L A P + W      A V      P C P C C++ + S+ T VDC+ L
      S:   2 RLLVAPLLLLAWVAGATAAVPVVPHVPCPPQCACQIRPWYTPRSSYREATTVDCNDLFLT 61

30  Q:   181 IMPVPIPLDTAHLDLSSNRLEMVNESVLAGPGY-TTLAGLDLSHNLLTSISPTAFSRLRY 357
      +P +P T L L SN + V++S L GY L LDLS N + F L
      S:   62 AVPPALPAGTQTLLQNSIVRVDSQSEL---GYLANLTELDLSQNSFSDARDCDFHALPQ 118

35  Q:   358 LESLDLSHNGLTALPAESFTS-SPLSDVNLSHNQLREVSVSAFTTHSQGRALHVDLSHNL 534
      L SL L N LT L SF + L++ L+HNQL ++ AF+ S LH L+ NL
      S:   119 LLSLHLEENQLTRLEDHSFAGLASLQELYLNHNQLYRIAPRAPSGLSNLLRLH--LNSNL 176

40  Q:   535 IHRLVPHPTRAGLPAPTIQSLNLAWNRLHAV--PNLRDLP-LRYSLDGNPLAVIGPGAP 705
      + + +R P ++ L + N++ A+ N R L LR L L G L I A
      S:   177 LRAI---DSRFEMLPNLEILMIGGNKVDAILDMNFRPLANRLSLVLAGMNLREISDYAL 233

      Q:   706 AGLGGLTHLSLAS--LQRLPELAPSGFRELPGLQVLDLSGNPKLNWAGAEVFGSLSSLQE 879
      GL L LS L R+P A ++PGL+ LDL+ NP L G F+ + L+E
      S:   234 EGLQSLESLSFYDNQLARVPRRA---LEQVPGLKFLDLNKNP-LQRVGPGDFANMLHLKE 289
  
```

Q: 880 LDLS 891
L L+
S: 290 LGLN 293

5 The segment of gb|AAC39792.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: 209 Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been
10 described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 210 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as
15 described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding
20 these polypeptides are also encompassed by the invention.

Recently another group has published on this gene, naming it E2IG4 (See Genbank Accession AAF09483).

The gene encoding the disclosed cDNA is thought to reside on chromosome 11. Accordingly, polynucleotides related to this invention have uses, such as, for
25 example, as a marker in linkage analysis for chromosome 11.

This gene is expressed in normal breast tissue, as well as in ovarian, lung and liver tumor tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a
30 biological sample and for diagnosis of diseases and conditions which include but are not limited to: reproductive system diseases and/or disorders, as well as pulmonary and hepatic tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential

identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, pulmonary and hepatic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, pulmonary, hepatic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 This gene encodes a potential Leucine-rich receptor that shows homology to a protein that is glioma amplified on chromosome 1, leucine-rich alpha-2-glycoprotein and orphan G protein-coupled receptor HG38.

15 The tissue distribution suggests that this gene is widely expressed in various tissues with epithelial or endothelial origin. It has a very good signal peptide. No TM domain has been detected from the available sequence. Polynucleotides, translation products and antibodies corresponding to this gene could be used for the diagnosis and/or treatment of various cancers such as liver, breast, brain, breast, ovary or uterus cancers. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

25 Preferred polypeptides of the invention comprise, or alternatively consist of, a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 211. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Recently, another group has published on this gene, naming it activation-inducible lymphocyte immunomediatory molecule AILIM (See Genbank Accession BAA82129).

This gene is expressed primarily in the following tissues/cDNA libraries:

- 5 Activated T-cell(12h)/Thiouridine-re-excision; Soares_fetal_heart_NbHH19W and to a lesser extent in Activated T-Cells, 4 hrs, subtracted; Human T-Cell Lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune system diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 The tissue distribution in activated T-cells indicates that polynucleotides, translation products and antibodies corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis,

granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

The gene and its encoded polypeptide share homology with the polycystin-2 gene involved in polycystic kidney disease (See, e.g., Genbank Accession AF004873). The functional polycystin-2 is not fully understood but it is believed to play a role as an ion channel and may be important for calcium homeostasis, or is regulated by calcium (Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S "PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein." Science 1996 May 31;272(5266):1339-42).

This gene is expressed primarily in the following tissues/cDNA libraries:
Human Osteosarcoma; Human Endometrial Tumor.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: cancerous tissues. Similarly, polypeptides and antibodies directed to

these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of cancerous tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on tissue expression, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and treatment of neoplastic conditions, particularly endometrial tumors and osteosarcomas, either as a direct therapeutic or as a target for antibodies which reduce the biological activity of the polypeptides or mediate cytotoxic responses to cells expressing the polypeptide (immunotherapy). Furthermore, its homology to polycystin-2 suggests that this molecule may play a role in control as an ion channel and thereby maintain ionic homeostasis. The molecule may therefore be a target of small molecules and antibodies which disrupt this cellular function and thereby specifically target malignant cells. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 4

Translation products corresponding to this gene share sequence homology with Human rotavirus 4 outer capsid VP4 protein.

The gene encoding the disclosed cDNA is thought to reside on chromosome 12. Accordingly, polynucleotides related to this invention have uses, such as, for example, as a marker in linkage analysis for chromosome 12.

This gene is expressed in colon tissues, keratinocytes, and adult and infant brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: brain and heart diseases, as well as various cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution suggests that this gene is expressed mainly on fibroblast and/or epithelial cells. Polynucleotides and translation products corresponding to this gene may be involved in protein-protein interaction, receptor binding and signal transduction. Polynucleotides, translation products and antibodies corresponding to this gene potentially can be used for the diagnosis and/or treatment of brain and heart diseases, as well as various cancers.

The tissue distribution in keratinocytes suggests that polynucleotides, translation products and antibodies corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e.

cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athletes foot, and ringworm).

Alternatively, the tissue distribution in adult and infant brain tissues indicates that polynucleotides, translation products and antibodies corresponding to this clone
5 are useful for the detection and/or treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance,
10 and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the
15 above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

Translation products corresponding to this gene show sequence homology to a collagen protein (See Genbank Accession AAB66593).

20 This gene is expressed in prostate tissue and neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: immune disorders. Similarly, polypeptides and antibodies directed to
25 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,
30 urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Translation products corresponding to this gene share sequence homology to mouse alpha-1 type XII collagen and various other collagens from different species.

- 5 Expression in prostate tissue suggests polynucleotides, translation products and antibodies corresponding to this gene can be used as a marker for prostate tissue and for the diagnosis and/or treatment of prostate cancers. The expression in activated neutrophils suggests that polynucleotides, translation products and antibodies corresponding to this gene may be useful for immune system modulation and host
- 10 defense. Polynucleotides, translation products and antibodies corresponding to this gene may be used to treat cancer and other immune disorders.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

This gene is expressed in anergic T cells.

- 15 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to immunological disorders (for example, immunodeficiency and autoimmune disorders). Similarly, polypeptides and antibodies directed to these
- 20 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph,
- 25 serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- In specific embodiments, polypeptides of the invention comprise, or
- 30 alternatively consists of, an amino acid sequence selected from the group:
MTMITPSSNTTHYRESWYACRYRSGIPGSTH (SEQ ID NO: 212)
ASGLGDCPVLLVRLCCPALFICVIIFVNIVF (SEQ ID NO: 213),

SVVATSSPPASGSVCLPGLLAPHWAAPGSLP (SEQ ID NO: 214),
LIPGLAVRPSQQGPVTQQPAQSICFWGMGWG (SEQ ID NO: 215)
LLHRRFEPXTLGKGTLDHDTPLPSLHEAKGPV (SEQ ID NO: 216)
FPNVLP SFMCQMAPAHMPLPSXEWEPLLKCLNP (SEQ ID NO: 217).

5 Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind
10 polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The tissue distribution in T cells suggests that polynucleotides, translation products and antibodies corresponding to this gene are useful for the diagnosis and/or treatment of lung diseases, arthritis and other immune disorders. Polynucleotides and
15 translation products corresponding to this gene may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, polynucleotides, translation products and antibodies corresponding to this gene may show utility as a tumor marker and/or
20 immunotherapy targets for the above listed tissues. Therefore, polynucleotides, translation products and antibodies corresponding to this gene may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, polynucleotides, translation products and
25 antibodies corresponding to this gene may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy
30 targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

This gene is expressed in infant brain tissues, and to a lesser extent in primary dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Translation products corresponding to this gene encode a very hydrophobic protein demonstrating homology to G-protein coupled receptors and NTR. It potentially has 9 transmembrane domains. Based on its primary distribution in brain tissue and immune cells, it is likely a multi-TM receptor that can be useful for the diagnosis and/or treatment of neuronal disorders such as mental retardation, learning and memory disorder, brain cancer, Alzheimer's disease, Parkinson's disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Alternatively, the tissue distribution in primary dendritic cells indicates that polynucleotides, translation products and antibodies corresponding to this gene may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against

the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gb|AAD10950.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "WW domain binding protein-1 [Homo sapiens]" A partial alignment demonstrating the observed homology is shown immediately below.

20

```
>gb|AAD10950.1| WW domain binding protein-1 [Homo sapiens] >sp|O95637|O95637 WW
      DOMAIN BINDING PROTEIN-1.
      Length = 281
```

25

Plus Strand HSPs:

```
Score = 335 (153.5 bits), Expect = 2.6e-48, Sum P(3) = 2.6e-48
Identities = 52/79 (65%), Positives = 63/79 (79%), Frame = +3
```

30

```
Query: 171 QDKEACVGTNNQSYICDTGHCCGQSQCNNYYELWWFWLVWTIIILSCCCVCHHRAKH 350
      Q +E C G NNQ Y+C++GHCCG++ CC YYYELWWFWL+WT++I+ SCCC HRRAK
Sbjct: 35 QLRELCPGVNNQPYLCESGHCCGETGCCTYYYELWWFWLLWTVLILFSCCAFRHRAKL 94
```

35

```
Query: 351 RLQAQQRQHEINLIAYREA 407
      RLQ QQRQ EINL+AY A
Sbjct: 95 RLQQQQRQREINLLAYHGA 113
```


The segment of gb|AAD10950.1| that is shown as "S" above is set out in the sequence listing as Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in mesenchymal cells and fibroblasts, and to a lesser extent in a variety of hematopoietic cell types, including T cells, B cells, bone marrow, and tonsils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune and musculoskeletal systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and musculoskeletal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, musculoskeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the observed tissue distribution, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the diagnosis and/or treatment of a variety of disorders. Elevated expression of this gene product in mesenchymal cells, such as fibroblasts, may indicate possible involvement in such pathologies as fibrosis, scarring, arthritis, osteoarthritis, muscle wasting, osteoporosis, and inflammation. Similarly, elevated expression of this gene product in a variety of hematopoietic cells may indicate roles in the proliferation, survival, differentiation, and/or activation of a variety of blood cell lineages, and implicate this gene product in immune system dysfunction, autoimmunity, leukemias/lymphomas, susceptibility to infections, and circulatory disorders. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

This gene is expressed primarily in neoplastic and embryonic tissues as exemplified by the following tissues/cDNA libraries: Soares_NhHMPu_S1, NCI_CGAP_GCB1; Soares_parathyroid_tumor_NbHPA; Soares_total_fetus_Nb2HF8_9w; Soares_fetal_heart_NbHH19W; NCI_CGAP_Pan1; NCI_CGAP_Kid11; NCI_CGAP_Bm25; NCI_CGAP_Lu5; Osteoclastoma-normalized A; NCI_CGAP_GC2; IL-4 induced; NCI_CGAP_CLL1; Ovarian Tumor 10-3-95; Human T-Cell Lymphoma; NCI_CGAP_Co8; Human Fetal Lung III; NCI_CGAP_GC6; Soares_fetal_lung_NbHL19W; Colon Tumor II and T cell helper II, and to a lesser extent in normal tissues: Human Amygdala; Human Hippocampus; Human Epididymus; B-Cells; Human umbilical vein endothelial cells, Human Placenta; Stratagene colon (#937204); Soares_placenta_8to9weeks_2NbHP8to9W; Soares_senescent_fibroblasts_NbHSF; and Soares melanocyte 2NbHM.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include but are not limited to: embryonic and developmental diseases and/or disorders, as well as cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of embryonic tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., embryonic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the expression in many different tumor tissues, in addition to expression in embryonic/fetal tissues, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and treatment of neoplastic growths. Therapeutic use of translation products corresponding to this gene may be either used directly as a factor that inhibits growth of the neoplastic cells, or as a target for therapeutics which inhibit the action of the protein (e.g. antibodies). Expression within embryonic tissue and other cellular sources marked by proliferating cells suggests that translation products corresponding to this gene may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, polynucleotides, translation products and antibodies corresponding to this gene may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no.

gb|AAC96085.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "I (AF055062) envelope protein [Gibbon leukemia virus]" A partial alignment demonstrating the observed homology is shown immediately below.

```

>gb|AAC96085.1| (AF055062) envelope protein [Gibbon leukemia virus]
>sp|Q9YWM1|Q9YWM1 ENVELOPE PROTEIN.
Length = 681

Plus Strand HSPs:

Score = 527 (185.5 bits), Expect = 2.3e-62, Sum P(2) = 2.3e-62
Identities = 123/350 (35%), Positives = 175/350 (50%), Frame = +3

Q: 705 LMSILGGVHLLNLTQPKLAQDCWLCLKAKPPYY---VGLGVEATLKRGPLSCHTRPRA- 872
    L +++ G   LN T P   + CWLCL  PPYY   LG E       CH   +
S: 328 LFNLVQGAFLTLNATNPGATKSCWLCLAMGPPYYEIASLG-EVAYSTSQDRCHWGTQGK 386

Q: 873 LTIGDVSGNASCLISTGYNLSASPFQATCNQSLTTYISTSVSYQAPNN-TWLACTSGLTR 1049
    LT+ +VSG+ C+   +      Q CNQ+L  S   Y P+N +W AC++GLT
S: 387 LTLTEVSGHGLCIGKVFFT-----HQHLCNQTLINSSEGHQYLLPSNHSWWACSTGLTP 441

Q: 1050 CINGT--EPGPLLVLVHVLPPQVYVYSGPEGRQLIAPPELHPR-LHQXXXXXXXXXXXXX 1220
    C++ +      C+ V ++P++Y Y PE   L A   + HPR   +
S: 442 CLSTSVFNQSRDFCIQVQLIPRIYYY--PEEVLLQAYDDSHPRPKREAVSLTLAVLLGLG 499

Q: 1221 XXXXXXXXXXXXXVQG----ETGLISLSQQVDADFSNLQSAIDILHSQVESLAEVVLQNCR 1388
    ++G   + GL SL   +DAD  LQ ++  L   + SL+EVVLQN R
S: 500 ITAGIGTGSTALIKGPIDLQQGLTSLQIAIDADLRALQDSVSKLEDSLTLSEVVLQNR 559

Q: 1389 CLDLLFLSQGGLCAALGESCCFYANQSGVIKGTVKVRENLDHRHQQERENNIPWYQSMFN 1568
    LDLLFL +GGLCAAL E CCFY + SG ++ ++KK++E LD+ Q ER+ N WY+ FN
S: 560 GLDLLFLKEGGLCAALKECCFYIDHSGAVRDSMKKLKEKLDKRQLERQKNQWYEGWFN 619

Q: 1569 WNPWXXXXXXXXXXXXXXXXXXXXXXXXPCILNSFLNFIKRIASVKLTYLKTQYDTLVN 1742
    +PW                               PCI+N   + FI RI++VK+  L+ +Y  L N
S: 620 NSPWFTTLSTIAGPLLLLLLLLLLILGPCIINKLVQFINDRISAVKILVLRQKYQALDN 677

```

The segment of gb|AAC96085.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: 220 Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a

polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 221 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries: human endometrial tumors and breast cancer tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: cancerous tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of bodily tumors, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the expression in endothelial and breast tumors, and based on the homology to viral envelope protein, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and treatment of cancer, particularly those of the endometrium and breast, as well as other tumors which show dependence on female sex hormones (e.g., ovarian tumors). Polynucleotides, translation products and antibodies corresponding to this gene may also be useful in targeting for immunotherapy. Based on its homology to viral

envelope protein, polynucleotides, translation products and antibodies corresponding to this gene may be useful for treatment or diagnosis of viral infections, particularly as an antibody target.

5 FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with the human protein nephrin.

Based on this homology the gene product of this gene is expected to share
10 biological activity in common with nephrin and nephrin-like proteins.

```
>gb|AAC39687.1| (AF035835) nephrin [Homo sapiens] >sp|O60500|O60500 NEPHRIN.
      Length = 1241
```

Plus Strand HSPs:

15

```
Score = 105 (37.0 bits), Expect = 0.20, P = 0.18
Identities = 42/139 (30%), Positives = 64/139 (46%), Frame = +1
```

20

```
Query: 253 IDGQTWAERALRENERHAFTCRVAGGPGTTPRLAWYLDGQLQEAST----SRLLSVGGGEAF 420
      I+G ++ LR R C GG P L WY D + S SR + +G
Sbjct: 446 IEGPPEGQK-LRAGTRVRLVCLAIGGNPEPSLMWYKDSRTVTESRLPQESRRVHLGSVEK 504
```

25

```
Query: 421 SGGTSTFTVTAHRAQHELNCSLQDPRSGRSANASVILNVQFKPXIAQVGAKYQEAQGPGL 600
      SG T + + + N + ++G+ +AS L VQF P + A A PG
Sbjct: 505 SGSTFSRELVLVTGFSN-QAKFTCKAGQ-LSASTQLAVQFPPTNVITILAN-ASALRPGD 561
```

30

```
Query: 601 LVVLFAL-VRANPPANVTWIDQDG 669
      + L + V +NPP N++W D++G
Sbjct: 562 ALNLTCSVSSNPPVNLVSW-DKEG 584
```

The protein contains immunoglobulin-like domains and is thought to be involved in mediating cell-cell interaction and cell migration.

This gene is expressed primarily in the following tissues/cDNA libraries:

Soares infant brain 1NIB and to a lesser extent in Human Pituitary, subt IX; Human
35 Cerebellum; Soares_fetal_heart_NbHH19W; H. cerebellum, Enzyme subtracted;
Pancreas Islet Cell Tumor; NCI_CGAP_Kid11; Primary Dendritic cells, frac 2;
NCI_CGAP_Brn25; Soares_multiple_sclerosis_2NbHMSP; normalized infant brain
cDNA; Soares_fetal_lung_NbHL19W; H. hypothalamus, frac A, re-excision;
NCI_CGAP_Pr11; Breast, Cancer: (9806C012R); Human Colon; Human Pituitary,
40 subtracted; Human Thyroid; Mesangial cell, frac 2; Human retina cDNA randomly

primed sublibrary; Human Brain, Striatum; NCI_CGAP_Ut1; NCI_CGAP_Pr28; Human Hypothalamus, Schizophrenia; NCI_CGAP_Br2; Normal colon; NCI_CGAP_GC4 and NCI_CGAP_Bm23.

Therefore, polynucleotides and polypeptides of the invention are useful as
5 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: neural system and proliferative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For
10 a number of disorders of the above tissues or cells, particularly of the neural and proliferating systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, proliferating, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual
15 having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in human cerebellum indicates that polypeptides and polynucleotides of the invention are useful for the detection, treatment, and/or
20 prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,
25 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including
30 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse

formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation, migration, adhesion or survival. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility
5 in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Thus, aberrant expression of this gene product in tissues - particularly adult tissues - may correlate with patterns of abnormal cellular
10 proliferation, such as found in various cancers. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or
15 preventing said disorders and conditions, in addition to other types of degenerative conditions. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show
20 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

When tested against sensory neuronal cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene
25 activates neuronal cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed in ovarian and endometrial tumor tissues, and to a
30 lesser extent in pregnant uterus tissue and neural tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the reproductive system, such as tumors thereof, as well as diseases and/or disorders of the neural system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and neural systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

This gene encodes a multi-TM protein with tissue distribution enriched in various cancer tissues such as ovary tumor, endometrial tumor and brain tumors. Therefore, polynucleotides, translation products and antibodies corresponding to this gene can be used for the diagnosis and treatment of those tumors and for gene therapy. This gene likely encodes a receptor involved in signal transduction, and would therefore be useful as a target for small molecules that function as agonist or antagonist. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

This gene is expressed in senescent fibroblasts and infant brain tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural and integumentary systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the

neural and integumentary systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, integumentary, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution suggests that polynucleotides, translation products and antibodies corresponding to this gene can be used for the diagnosis and/or treatment of neural diseases and integumentary disorders. The tissue distribution in fibroblasts suggests that polynucleotides, translation products and antibodies corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm).

Alternatively, the tissue distribution in infant brain tissues indicates that polynucleotides, translation products and antibodies corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing

embryo, or sexually-linked disorders. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

This gene is expressed in human fetal heart, differential (fetal-specific).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: cardiovascular diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cardiovascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the specific expression in human fetal heart tissue, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and treatment of cardiovascular disorders including cardiac abnormalities, such as for example, heart disease, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

This gene is expressed primarily in human testes tumor tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include but are not limited to: testicular cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above
5 tissues or cells, particularly of the testes, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., testes, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,
10 the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the specific expression in testes tumor tissue, polynucleotides, translation products and antibodies corresponding to this gene may be used for the diagnosis and/or treatment of testicular cancer. Therapeutics may be either direct
15 therapeutics or indirect therapeutics where the protein is used to target a therapeutic towards the cancer cell (e.g., immunotherapy). More generally, the tissue distribution in testes tissue indicates that polynucleotides, translation products and antibodies corresponding to this gene are useful for the treatment and/or diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as
20 well as cancer. Therefore, polynucleotides, translation products and antibodies corresponding to this gene are useful in the treatment of male infertility and/or impotence. Polynucleotides, translation products and antibodies corresponding to this gene are also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, polynucleotides,
25 translation products and antibodies corresponding to this gene are useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, translation products corresponding to this gene may be expressed in other specific tissues or organs where it may play related functional roles
30 in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation

products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

5 This gene is expressed primarily in the following tissues/cDNA libraries:
Human Amygdala; the Hodkins Disease cell line, KMH2; Colon Tumor II; Soares
fetal liver spleen 1NFLS.

 Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
10 biological sample and for diagnosis of diseases and conditions which include but are
not limited to: diseases and/or disorders of the neural and gastrointestinal systems.
Similarly, polypeptides and antibodies directed to these polypeptides are useful in
providing immunological probes for differential identification of the tissue(s) or cell
type(s). For a number of disorders of the above tissues or cells, particularly of the
15 neural and gastrointestinal systems, expression of this gene at significantly higher or
lower levels may be routinely detected in certain tissues or cell types (e.g., neural,
gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from
an individual having such a disorder, relative to the standard gene expression level,
20 i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

 Based on the expression in Amygdala tissue, polynucleotides, translation
products and antibodies corresponding to this gene may be important for the treatment
and diagnostic evaluation of neuropathological conditions such as Alzheimer's disease,
25 Parkinson's Disease, dementia, depression, and other psychotic states. More
generally, the tissue distribution in amygdala tissue indicates that polynucleotides,
translation products and antibodies corresponding to this clone are useful for the
detection and/or treatment of neurodegenerative disease states and behavioural
disorders such as Huntington's Disease, Tourette Syndrome, schizophrenia, mania,
30 paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS,
psychoses, autism, and altered behaviors, including disorders in feeding, sleep
patterns, balance, and perception. In addition, the gene or gene product may also play

a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Alternately, the expression of this gene in KMH2 cells and colon tumor indicate that this gene and encoded polypeptides are important for the diagnosis and treatment of neoplastic growths such as Hodgkin's disease or bowel cancer. The gene and its encoded polypeptides may be used as targets for immunotherapy of neoplasms including the aforementioned pathological states. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

This gene is expressed in human umbilical vein endothelial cells and fetal heart tissues, and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: cardiovascular diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cardiovascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

This gene is primarily expressed in endothelial cells. Therefore, translation products corresponding to this gene can be used as a marker for this type of cells. Polynucleotides, translation products and antibodies corresponding to this gene may also have therapeutic potentials in angiogenesis or anti-angiogenesis. More generally, the tissue distribution in endothelial cells and fetal heart tissue indicates that polynucleotides, translation products and antibodies corresponding to this gene are

useful for the diagnosis and/or treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. dbj|BAA11507.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "ubiquitin-specific proteinase of *S.cerevisiae*. [*Homo sapiens*]" A partial alignment demonstrating the observed homology is shown immediately below.

```

>dbj|BAA11507.1|  ubiquitin-specific proteinase of S.cerevisiae.
                  [Homo sapiens] >sp|Q14694|UBPE_HUMAN UBIQUITIN CARBOXYL-TERMINAL
                  HYDROLASE 14 (EC 3.1.2.15) (UBIQUITIN THIOLESTERASE 14)
20                  (UBIQUITIN-SPECIFIC PROCESSING PROTEASE 13) (DEUBIQUITINATING
                  ENZYME 14) (KIAA0190). {SUB 16-813}
                  Length = 813

Plus Strand HSPs:

25 Score = 169 (59.5 bits), Expect = 8.3e-11, P = 8.3e-11
    Identities = 35/56 (62%), Positives = 37/56 (66%), Frame = +3

30 Q:   15 KNHSVNXXXXXXXXXXXXXXXXXVGPRNKTSVTRQADFXQTPITGIFGGHIRFVLF 182
      KNHSVN                               VGPRNKTSVTRQADF QTPITGIFGGHIR V++
      S:  575 KNHSVNEEQEEQEGSEDEWEQVGPRNKTSVTRQADFVQTPITGIFGGHIRSVVY SEQ ID NO:
224630

```

The segment of dbj|BAA11507.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: 224. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have

been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 225 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Based on the homology of this protein to ubiquitin specific protease this protein may have proteolytic activity. Dysregulation of this protease may occur in certain pathologies, especially degenerative pathologies involving tissue destruction and protein turnover. This protease may be a specific marker of disease states.

Alternately the protein may have a key role in pathogenic conditions. Inhibitors of the protease activity may prove advantageous in the treatment of such degenerative conditions in which this protease plays a role.

This gene is expressed primarily in the following tissues/cDNA libraries:
Human Cardiomyopathy, subtracted.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the cardiovascular system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cardiovascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a

disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the homology to ubiquitin specific protease, and the expression in cardiac myopathy samples, polynucleotides and translation products corresponding to this gene may be useful for the diagnosis and treatment of cardiac myopathies including cardiac hypertrophy. Polynucleotides, translation products and antibodies corresponding to this gene may also be useful for the diagnosis and treatment of myocardial infarction and other cardiac defects such as cardiac arrhythmia, septal defects and more generally for cardiovascular diseases such as hypertension or hypotension. More generally, the tissue distribution in cardiac tissue indicates that polynucleotides, translation products and antibodies corresponding to this gene are useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing.

Alternatively, based on the expression of this gene and its encoded polypeptides in the developing brain, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

This gene is highly expressed in activated monocytes, activated T cells, and macrophage, and to a lesser extent in other immune system cells and tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system,

expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to
5 the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this clone is compelling in that it is primarily expressed in hematopoietic cell lineage such as activated human T cells and monocytes. Polynucleotides, translation products and antibodies corresponding to this
10 gene can be useful for the diagnosis and/or treatment of various immune disorders such as leukemias and T-cell lymphoma, for example. More generally, the tissue distribution in immune system cells and tissues indicates that polynucleotides, translation products and antibodies corresponding to this gene may be involved in the regulation of cytokine production, antigen presentation, or other processes that may
15 also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune
20 deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as
25 antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

This gene is expressed in neutrophils and T cells, and to a lesser extent in
30 hypothalamus tissue isolated from a schizophrenia patient and in colon cancer tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the immune, neural and gastrointestinal systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, neural, and gastrointestinal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neural, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils, T cells, hypothalamus tissue, and colon cancer tissue suggests that polynucleotides, translation products and antibodies corresponding to this gene can be used for the diagnosis and/or treatment of immune, neural, and gastrointestinal diseases and/or disorders. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancers, such as colon cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, polynucleotides, translation products and antibodies corresponding to this gene may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore, polynucleotides, translation products and antibodies corresponding to this gene may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, polynucleotides, translation products and antibodies corresponding to this gene may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

This gene is expressed primarily in the following tissues/cDNA libraries:
Soares fetal liver spleen 1NFLS and to a lesser extent in Prostate BPH; Human 8
Week Whole Embryo, subtracted; Human Stomach, re-excision; Adipocytes; Human
5 Synovial Sarcoma; Human Bone Marrow, treated; Colon Normal III; Primary
Dendritic Cells, lib 1 and NCI_CGAP_GCB1.

Therefore, polynucleotides and polypeptides of the invention are useful as
reagents for differential identification of the tissue(s) or cell type(s) present in a
biological sample and for diagnosis of diseases and conditions which include but are
10 not limited to: diseases and/or disorders of the immune and hematopoietic systems,
and developmental diseases and/or disorders. Similarly, polypeptides and antibodies
directed to these polypeptides are useful in providing immunological probes for
differential identification of the tissue(s) or cell type(s). For a number of disorders of
the above tissues or cells, particularly of the immune, hematopoietic and developing
15 systems, expression of this gene at significantly higher or lower levels may be
routinely detected in certain tissues or cell types (e.g., immune, hematopoietic,
developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,
plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from
an individual having such a disorder, relative to the standard gene expression level,
20 i.e., the expression level in healthy tissue or bodily fluid from an individual not
having the disorder.

The tissue distribution suggests that polynucleotides, translation products and
antibodies corresponding to this gene can be used for the diagnosis and/or treatment
of immune, hematopoietic, and developmental diseases and/or disorders. Expression
25 of this gene product in immune system tissues suggests a role in the regulation of the
proliferation; survival; differentiation; and/or activation of potentially all
hematopoietic cell lineages, including blood stem cells. Polynucleotides and
translation products corresponding to this gene may be involved in the regulation of
cytokine production, antigen presentation, or other processes that may also suggest a
30 usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the
gene is expressed in cells of lymphoid origin, polynucleotides, translation products
and antibodies corresponding to this gene may show utility as a tumor marker and/or

immunotherapy targets for the above listed tissues. Therefore polynucleotides, translation products and antibodies corresponding to this gene may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, polynucleotides, translation products and antibodies corresponding to this gene may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The gene encoding the disclosed cDNA is thought to reside on chromosome 8. Accordingly, polynucleotides related to this invention have uses, such as, for example, as a marker in linkage analysis for chromosome 8.

This gene is expressed in placental and fetal tissues, and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: reproductive diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the placenta, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., placenta, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Since it is chiefly expressed in fetal tissues and placental tissue, in addition to some tumors, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and treatment of cancer, particularly those that are poorly differentiated and express fetal antigens. Polynucleotides, translation products and antibodies corresponding to this gene may also be useful as a target for immunotherapy. More generally, the tissue distribution in placental tissue suggests that polynucleotides and translation products corresponding to this gene may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also suggests that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, polynucleotides and translation products corresponding to this gene may play more generalized roles in vascular function, such as in angiogenesis. Polynucleotides and translation products corresponding to this gene may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. Polynucleotides and translation products corresponding to this gene may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

This gene is expressed primarily in 12 Week Old Early Stage Human.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: developmental diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of developing tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the specific expression pattern of 12 week human embryonic expression, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the prenatal diagnosis and treatment of developmental disorders associated with cell-type specific growth, differentiation, migration or cell-cell interactions (i.e., cell adhesion). In addition since many tumours express genes which are typically expressed only during embryogenesis, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and the treatment of poorly differentiated neoplastic growths either directly as a therapeutic or indirectly as a target for therapeutics (e.g., as a tumour antigen against which reagents such as antibodies are raised to kill tumour cells).

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

This gene is expressed in early stage human brain tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the neural system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the specific expression of this gene in early stage human brain, polynucleotides, translation products and antibodies corresponding to this gene may be important for the diagnosis and treatment of neurological conditions associated with the growth, differentiation and networking of the central nervous system. Polynucleotides, translation products and antibodies corresponding to this gene may be useful in the treatment of neurodegenerative disorders such as Alzheimer's, Parkinson's Disease or senile dementia. Polynucleotides, translation products and antibodies corresponding to this gene may also be useful for the treatment of cognitive impairment diseases and aid to improve learning and other cognitive functions as well as other neurological conditions such as depression and psychosis. Furthermore, polynucleotides, translation products and antibodies corresponding to this gene may also act as a bioactive peptides and functions to control metabolism, the immune system, mitogenic growth or other endocrine functions. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The polypeptide(s) may be used as direct therapeutics, or indirectly as targets of antibodies directed against the polypeptides (immunotherapy)

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. emb|CAB40387.1| (all information available through the recited accession number is incorporated herein by reference) which is described therein as "high affinity immunoglobulin E receptor alpha subunit [Equus caballus]" A partial alignment demonstrating the observed homology is shown immediately below.

```
>emb|CAB40387.1| high affinity immunoglobulin E receptor alpha subunit
[Equus
      caballus]
```


Length = 255

Plus Strand HSPs:

5 Score = 190 (66.9 bits), Expect = 3.1e-14, P = 3.1e-14
 Identities = 40/100 (40%), Positives = 55/100 (55%), Frame = +3

Q: 231 SEPFHLIVSYDWLILQGPAKPVFEGDLLVLRCAWQDWPLTQVTFYRDGSALGPPGPNRE 410
 SE HL V DWL+LQ A+ V EG LVLRC+ W+DW + +V +Y+DG L N+

10 S: 101 SEAVHLEVFSDWLLQASAEVIEGKALVLRRCRGWKDWDVFKVIYYKDGPLEYWYENKN 160

Q: 411 FSITVVQKADSGHYHCSGIFQSPGPGIPETASVVAITVQE 530
 SI +SG Y+C G F T+ + ITV++

15 S: 161 ISIESATTENSGTYCEGAFNFKRTSERYTSDYLNITVKK 200

The segment of emb|CAB40387.1| that is shown as "S" above is set out in the sequence listing as SEQ ID NO: 226 Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

20 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO: 227 which corresponds to the Q sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). Moreover,

25 fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides

30 of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in the following tissues/cDNA libraries: Soares melanocyte 2NbHM and to a lesser extent in NCI_CGAP_GCB1; NCI_CGAP_Lym12; B-cells (stimulated); Human Bone Marrow, treated; Raji Cells,

35 cyclohexamide treated; B-cells (unstimulated); B-Cells; Macrophage-oxLDL, re-excision; NCI_CGAP_GC6; Spleen, Chronic lymphocytic leukemia; Neutrophils IL-1 and LPS induced and Soares_NhHMPu_S1.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: disorders associated with melanocyte proliferation (e.g. malignant melanoma) and other disorders associated with pigmentation, e.g., vitiligo and melasma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the strong expression in melanocytes, and the homology to Ig receptors, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the treatment of disorders associated with melanocyte proliferation (e.g. malignant melanoma) and other disorders associated with pigmentation, e.g., vitiligo and melasma. Based on the weaker expression in B cells, and the homology to Ig receptors, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the treatment of allergic reactions regulated by immunoglobulin-like molecules particularly IgE. Polynucleotides, translation products and antibodies corresponding to this gene may also be useful for a target of immunotherapy for the selective killing of lymphomas particularly B-cell derived lymphomas or melanomas.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the amino acid set out in the sequence listing as SEQ ID NO: 228. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the

polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides) are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

- 5 This gene is expressed primarily in the following tissues/cDNA libraries:
 Stratagene fetal spleen (#937205); Human 8 Week Whole Embryo;
 Soares_NhHMPu_S1 and to a lesser extent in 12 Week Old Early Stage Human, II;
 NTERA2, control; Macrophage-oxLDL, re-excision; Human Adult Pulmonary, re-
 excision; Human Osteoclastoma; HUMAN B CELL LYMPHOMA; Osteoblasts;
 10 Soares_fetal_liver_spleen_1NFLS_S1; Soares fetal liver spleen 1NFLS; K562 +
 PMA (36 hrs), re-excision; HL-60, RA 4h, Subtracted; Breast, Cancer: (4005522 A2);
 Apoptotic T-cell, re-excision; Human retina cDNA randomly primed sublibrary; HEL
 cell line; Human Stomach, re-excision; B-cells (unstimulated); H. Meningioma, M1;
 Spinal Cord, re-excision; human ovarian cancer; NCI_CGAP_Pr28; Human
 15 Hippocampus; Human Thymus Stromal Cells; Human Ovary; Pancreas Tumor PCA4
 Tu; 12 Week Early Stage Human II, Reexcision; Human Fetal Heart;
 NCI_CGAP_GC6; NCI_CGAP_Brn23; Soares_placenta_8to9weeks_2NbHP8to9W;
 T Cell helper I; Human Endometrial Tumor; Hodgkin's Lymphoma II; T cell helper
 II; Soares_NFL_T_GBC_S1; Soares_testis_NHT; Primary Dendritic Cells, lib 1 and
 20 NCI_CGAP_GCB1.

- Therefore, polynucleotides and polypeptides of the invention are useful as
 reagents for differential identification of the tissue(s) or cell type(s) present in a
 biological sample and for diagnosis of diseases and conditions which include but are
 not limited to: hematopoietic diseases and/or disorders. Similarly, polypeptides and
 25 antibodies directed to these polypeptides are useful in providing immunological
 probes for differential identification of the tissue(s) or cell type(s). For a number of
 disorders of the above tissues or cells, particularly of the hematopoietic system,
 expression of this gene at significantly higher or lower levels may be routinely
 detected in certain tissues or cell types (e.g., hematopoietic, cancerous and wounded
 30 tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal
 fluid) or another tissue or sample taken from an individual having such a disorder,

relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal spleen indicates that polynucleotides, translation products and antibodies corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, polynucleotides, translation products and antibodies corresponding to this gene can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, polynucleotides, translation products and antibodies corresponding to this gene may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Polynucleotides, translation products and antibodies corresponding to this gene are useful in modulating signal transduction pathways and may play a vital role in development. Furthermore, polynucleotides, translation products and antibodies corresponding to this gene may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

Translation products corresponding to this gene share sequence homology with a putative ankyrin repeat-containing protein from *Mortierella alpina* (See Genbank Accession CAB56510).

This gene is expressed in colon, sinus piniformis and Hodgkin's lymphoma tumor tissues, and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders involving cellular proliferation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of proliferating cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., proliferating, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based on the homology to the ankyrin family of proteins, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and treatment of diseases associated with aberrant cell to cell signaling including cell proliferation, differentiation and migration. Proliferative disorders include diseases such as hyperplasia and neoplasia (cancer). Polynucleotides, translation products and antibodies corresponding to this gene may also be used as therapeutic target in order to kill cells that overexpress the gene products (i.e., immunotherapy).

25 FEATURES OF PROTEIN ENCODED BY GENE NO: 28

This gene is expressed primarily in fetal tissues and hepatocellular tumors, and to a lesser extent in activated endothelial cells and prostate tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: developmental diseases and/or disorders, and liver tumors. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of developing systems and liver tumors, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developing, hepatic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the observed tissue distribution, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the diagnosis and/or treatment of a variety of disorders. Elevated expression of this gene in fetal tissues and cancers may suggest a role in cell proliferation or differentiation. Such functions may indicate therapeutic or diagnostic applications to cancer, particularly prostate and liver cancer. Similarly, elevated expression in prostate may also indicate other roles in normal prostate function. Expression in the developing embryo or fetus may also implicate this gene product in diagnostic testing of embryonic or developmental defects. In addition since many tumours express genes which are typically expressed only during embryogenesis, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis and the treatment of poorly differentiated neoplastic growths either directly as a therapeutic or indirectly as a target for therapeutics (e.g., as a tumour antigen against which reagents such as antibodies are raised to kill tumour cells).

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

This gene is expressed primarily in osteoarthritic tissue, and to a lesser extent in cerebellum tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the musculoskeletal and neural systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in

providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal and neural systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g.,

5 musculoskeletal, neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Based upon the tissue distribution, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the diagnosis and/or treatment of osteoarthritis. Elevated expression of this gene product in connective tissue derived specifically from patients with osteoarthritis suggests a possible role in cartilage formation, cartilage degradation, inflammation, or normal joint function. Similarly,

15 elevated expression of this gene product in the cerebellum suggests a possible role in normal brain function, neuronal survival, or cognition, and indicates that polynucleotides, translation products and antibodies corresponding to this gene may be involved in neurodegenerative disorders, learning disabilities, loss of normal cognition, pain sensation, etc. Additionally, translation products corresponding to this

20 gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

When tested against U937 Myeloid cell lines, supernatants removed from cells

25 containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells.

30 Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. The gene encoding the disclosed cDNA is thought to reside on

chromosome 20. Accordingly, polynucleotides related to this invention have uses, such as, for example, as a marker in linkage analysis for chromosome 20.

This gene is expressed primarily in mesenchymal cells and fibroblasts, particularly in conditions of cardiomyopathy.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the cardiovascular system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing
10 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cardiovascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid
15 and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the observed tissue distribution, this gene product may be useful in the diagnosis and/or treatment of a variety of disorders of mesenchymal cells.
20 Elevated expression of this gene product in mesenchymally derived cells suggests a possible involvement in fibrosis, cardiomyopathy, cardiac failure, myocardial infarction, angina, scarring, scleroderma, pulmonary function, ARDS, arthritis, muscle wasting, and osteoarthritis. Alternatively, the observed biological activity indicates that polynucleotides, translation products and antibodies corresponding to
25 this gene may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the
30 above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and

psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

This gene is expressed primarily in the thymus and tonsils tissues, and to a lesser extent in fetal heart tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the cardiovascular and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cardiovascular, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the observed tissue distribution, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the diagnosis and/or treatment of cardiovascular disorders and hematopoietic/immune system dysfunction. Elevated expression of this gene product in thymus and tonsils suggests a possible role in hematopoiesis and the survival, proliferation, differentiation, and/or activation of blood cell lineages, particularly T cells, B cells, monocytes, macrophages, and neutrophils. Therefore, polynucleotides, translation products and antibodies corresponding to this gene may play a role in immune recognition,

inflammation, and immunity, and may be useful in a variety of pathologies, including immune system dysfunction, graft-v-host disease, tumor immunotherapy, and combating susceptibility to infections. Similarly, expression in fetal heart suggests a possible involvement in cardiac function and possibly cardiomyocyte proliferation, which may make polynucleotides, translation products and antibodies corresponding to this gene useful in the treatment of myocardial infarction, circulatory disorders, angina, arrhythmias, and regulation of normal blood pressure. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

The gene encoding the disclosed cDNA is thought to reside on chromosome 16. Accordingly, polynucleotides related to this invention have uses, such as, for example, as a marker in linkage analysis for chromosome 16.

This gene is expressed primarily in fetal liver and spleen tissues, and to a lesser extent in brain and testis tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include but are not limited to: diseases and/or disorders of the hematopoietic and neural systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic and neural systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Based upon the observed tissue distribution, polynucleotides, translation products and antibodies corresponding to this gene may be useful in the diagnosis and/or treatment of a variety of disorders. Elevated expression in fetal liver and spleen suggests a possible role in normal hematopoiesis and in the survival, proliferation, differentiation, and/or activation of blood cell lineages. Thus, polynucleotides, translation products and antibodies corresponding to this gene may be involved in immune system dysfunction, susceptibility to infection, autoimmunity, leukemia/lymphoma, inflammation, and immune modulation. Similarly, elevated expression of this gene product in brain suggests a possible involvement in neurodegenerative disorders, impaired cognition, learning disabilities, pain sensitivity, and balance. Elevated expression of this gene product in testis suggests a possible role in male fertility and a possible application of this gene product as a male contraceptive. Additionally, translation products corresponding to this gene, as well as antibodies directed against these translation products, may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HARMB79	PTA-841 10/13/99	pCMVSPORT 3.0	11	2601	1	2601	42	42	110	1	16	17	353
1	HARMB79	PTA-841 10/13/99	pCMVSPORT 3.0	43	2650	1	2567	31	31	142	1	16	17	353
2	HT2SG64	PTA-841 10/13/99	Uni-ZAP XR	12	2624	1	2624	36	36	111	1	19	20	199
2	HT2SG64	PTA-841 10/13/99	Uni-ZAP XR	44	2159	1	2159	150	150	143	1	19	20	199
2	HT2SG64	PTA-841 10/13/99	Uni-ZAP XR	45	553	1	553		293	144	1	1	2	74
3	HETDB76	PTA-841 10/13/99	Uni-ZAP XR	13	2199	1	2199	45	45	112	1	18	19	561
3	HETDB76	PTA-841 10/13/99	Uni-ZAP XR	46	364	1	364	40	40	145	1	18	19	85
3	HETDB76	PTA-841 10/13/99	Uni-ZAP XR	47	343	1	343		342	146	1	1	2	114
3	HETDB76	PTA-841 10/13/99	Uni-ZAP XR	48	576	1	469	326	326	147	1	1	2	59
4	HJBCY84	PTA-841 10/13/99	pBluescript SK-	14	2277	1	2277	51	51	113	1	21	22	363

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
4	HJBCY84	PTA-841 10/13/99	pBluescript SK-	49	974	1	974	39	39	148	1	21	22	285
4	HJBCY84	PTA-841 10/13/99	pBluescript SK-	50	2292	1	520		2023	149	1	1	2	417
5	HBZAI19	PTA-841 10/13/99	pSport1	15	2005	1	2005	38	38	114	1	19	20	103
5	HBZAI19	PTA-841 10/13/99	pSport1	51	364	1	364	45	45	150	1	19	20	70
5	HBZAI19	PTA-841 10/13/99	pSport1	52	754	1	754		701	151	1	1	2	194
6	HFITF82	PTA-841 10/13/99	pSport1	16	926	1	926		302	115	1	27	28	90
6	HFITF82	PTA-841 10/13/99	pSport1	53	546	1	546		67	152	1	19	20	101
6	HFITF82	PTA-841 10/13/99	pSport1	54	1210	1	504		1129	153	1	1	2	119
6	HFITF82	PTA-841 10/13/99	pSport1	55	309	1	309		256	154	1	1	2	58
7	HDPDI45	PTA-841 10/13/99	pCMVSPORT 3.0	17	1731	1	1731	79	79	116	1	25	26	445
7	HDPDI45	PTA-841 10/13/99	pCMVSPORT 3.0	56	1892	43	1892	136	136	155	1	25	26	477

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HUVDP63	PTA-841 10/13/99	Uni-ZAP XR	18	4150	1	4126	84	84	117	1	24	25	363
8	HUVDP63	PTA-841 10/13/99	Uni-ZAP XR	57	331	1	331	80	80	156	1	16	17	52
8	HUVDP63	PTA-841 10/13/99	Uni-ZAP XR	58	605	61	605		42	157	1	14	15	118
8	HUVDP63	PTA-841 10/13/99	Uni-ZAP XR	59	832	333	832		138	158	1	16	17	201
8	HUVDP63	PTA-841 10/13/99	Uni-ZAP XR	60	2376	1	617		1888	159	1	1	2	106
9	HHPDV90	PTA-841 10/13/99	Uni-ZAP XR	19	1690	1	1690	185	185	118	1	33	34	118
9	HHPDV90	PTA-841 10/13/99	Uni-ZAP XR	61	928	169	928	358	358	160	1	30	31	118
9	HHPDV90	PTA-841 10/13/99	Uni-ZAP XR	62	792	85	770		111	161	1	11	12	157
10	HETCP58	PTA-841 10/13/99	Uni-ZAP XR	20	2284	1	2284		305	119	1	16	17	438
10	HETCP58	PTA-841 10/13/99	Uni-ZAP XR	63	2086	122	2086		432	162	1	16	17	438
10	HETCP58	PTA-841 10/13/99	Uni-ZAP XR	64	647	1	647		189	163	1	1	2	63

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HCEVB32	PTA-841 10/13/99	Uni-ZAP XR	21	2287	1	2287	51	51	120	1	26	27	322
11	HCEVB32	PTA-841 10/13/99	Uni-ZAP XR	65	1159	1	1159	160	160	164	1	27	28	322
11	HCEVB32	PTA-841 10/13/99	Uni-ZAP XR	66	1327	1	1137		289	165	1	14	15	20
11	HCEVB32	PTA-841 10/13/99	Uni-ZAP XR	67	979	588	979		51	166	1	20	21	23
12	HETHW90	PTA-841 10/13/99	Uni-ZAP XR	22	1866	1	1866	157	157	121	1	28	29	264
12	HETHW90	PTA-841 10/13/99	Uni-ZAP XR	68	1361	1	1361	234	234	167	1	20	21	264
12	HETHW90	PTA-841 10/13/99	Uni-ZAP XR	69	783	1	783		574	168	1	1	2	115
13	HIBEB47	PTA-841 10/13/99	Other	23	2529	1	2529	148	148	122	1	17	18	155
13	HIBEB47	PTA-841 10/13/99	Other	70	820	1	820	160	160	169	1	41	42	57
13	HIBEB47	PTA-841 10/13/99	Other	71	357	1	357		158	170	1	1	2	52
13	HIBEB47	PTA-841 10/13/99	Other	72	794	291	794		570	171	1	1	2	49

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
14	HHFUC40	PTA-841 10/13/99	pBluescript	24	4784	1	4784	29	29	123	1			5
14	HHFUC40	PTA-841 10/13/99	pBluescript	73	1277	1	1277	17	17	172	1			5
15	HTTBS64	PTA-841 10/13/99	Uni-ZAP XR	25	2058	1	2058	95	95	124	1	17	18	42
15	HTTBS64	PTA-841 10/13/99	Uni-ZAP XR	74	819	1	819	100	100	173	1	17	18	42
15	HTTBS64	PTA-841 10/13/99	Uni-ZAP XR	75	501	1	501		327	174	1	1	2	76
16	HAGAN21	PTA-841 10/13/99	Uni-ZAP XR	26	843	1	843	34	34	125	1	17	18	91
16	HAGAN21	PTA-841 10/13/99	Uni-ZAP XR	76	610	294	610	335	335	175	1	17	18	91
16	HAGAN21	PTA-841 10/13/99	Uni-ZAP XR	77	659	1	659		452	176	1			4
16	HAGAN21	PTA-841 10/13/99	Uni-ZAP XR	78	189	1	189		146	177	1	13	14	14
16	HAGAN21	PTA-841 10/13/99	Uni-ZAP XR	79	637	1	637		321	178	1			6
17	HUSIE23	PTA-841 10/13/99	pSport1	27	702	1	702	250	250	126	1			13

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
17	HUSIE23	PTA-841 10/13/99	pSport1	80	878	136	878	386	386	179	1			13
18	HCMSC92	PTA-841 10/13/99	Uni-ZAP XR	28	752	1	752	216	216	127	1	44	45	71
18	HCMSC92	PTA-841 10/13/99	Uni-ZAP XR	81	472	1	472	221	221	180	1	44	45	79
19	HLHFR58	PTA-841 10/13/99	Uni-ZAP XR	29	1015	1	1015		206	128	1			21
19	HLHFR58	PTA-841 10/13/99	Uni-ZAP XR	82	733	1	733		205	181	1			21
19	HLHFR58	PTA-841 10/13/99	Uni-ZAP XR	83	741	1	741		454	182	1	1	2	67
19	HLHFR58	PTA-841 10/13/99	Uni-ZAP XR	84	951	277	940		698	183	1	1	2	91
20	HNGGK54	PTA-841 10/13/99	Uni-ZAP XR	30	1063	1	1058	154	154	129	1	25	26	35
20	HNGGK54	PTA-841 10/13/99	Uni-ZAP XR	85	535	1	535	195	195	184	1	34	35	44
20	HNGGK54	PTA-841 10/13/99	Uni-ZAP XR	86	801	1	801		773	185	1	1	2	150
20	HNGGK54	PTA-841 10/13/99	Uni-ZAP XR	87	470	2	470		202	186	1	1	2	67

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
21	HE8SE91	PTA-841 10/13/99	Uni-ZAP XR	31	2438	1	2438	174	174	130	1	33	34	58
21	HE8SE91	PTA-841 10/13/99	Uni-ZAP XR	88	2027	1	2027	206	206	187	1	33	34	56
21	HE8SE91	PTA-841 10/13/99	Uni-ZAP XR	89	687	1	585		491	188	1	1	2	88
22	HTTBM40	PTA-841 10/13/99	Uni-ZAP XR	32	2506	1	2506	264	264	131	1	40	41	62
22	HTTBM40	PTA-841 10/13/99	Uni-ZAP XR	90	3187	536	3187	792	792	189	1	40	41	62
23	HE2AX96	PTA-841 10/13/99	Uni-ZAP XR	33	1703	1	1703	205	205	132	1	27	28	31
23	HE2AX96	PTA-841 10/13/99	Uni-ZAP XR	91	775	1	775	217	217	190	1	27	28	31
23	HE2AX96	PTA-841 10/13/99	Uni-ZAP XR	92	1455	1	1455		39	191	1	25	26	26
24	HEBAH57	PTA-841 10/13/99	Uni-ZAP XR	34	3042	1	3042	46	46	133	1	20	21	56
24	HEBAH57	PTA-841 10/13/99	Uni-ZAP XR	93	2586	1	2586	49	49	192	1	20	21	56
24	HEBAH57	PTA-841 10/13/99	Uni-ZAP XR	94	1153	1	939		571	193	1	1	2	75

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
25	HRGBL78	PTA-841 10/13/99	Uni-ZAP XR	35	2108	1	2108	30	30	134	1	27	28	359
25	HRGBL78	PTA-841 10/13/99	Uni-ZAP XR	95	626	8	626	30	30	194	1	38	39	199
25	HRGBL78	PTA-841 10/13/99	Uni-ZAP XR	96	152	1	152		11	195	1			2
25	HRGBL78	PTA-841 10/13/99	Uni-ZAP XR	97	1760	127	1760		1048	196	1			32
26	HHPFU18	PTA-841 10/13/99	Uni-ZAP XR	36	1972	1	1972	89	89	135	1	16	17	25
26	HHPFU18	PTA-841 10/13/99	Uni-ZAP XR	98	2771	807	2771	888	888	197	1	16	17	25
27	HPRCA90	PTA-841 10/13/99	Uni-ZAP XR	37	1128	100	1128	189	189	136	1	18	19	143
27	HPRCA90	PTA-841 10/13/99	Uni-ZAP XR	99	543	1	543		317	198	1			18
27	HPRCA90	PTA-841 10/13/99	Uni-ZAP XR	100	1829	1	1829		311	199	1			18
27	HPRCA90	PTA-841 10/13/99	Uni-ZAP XR	101	1127	99	1127		933	200	1	22	23	26
28	HPRCE33	PTA-841 10/13/99	Uni-ZAP XR	38	1959	1	1959	125	125	137	1			35

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO:	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO:	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
28	HPRCE33	PTA-841 10/13/99	Uni-ZAP XR	102	538	1	538		129	201	1	35	36	101
29	HCEFI77	PTA-841 10/13/99	Uni-ZAP XR	39	2863	1	2863	79	79	138	1	20	21	21
29	HCEFI77	PTA-841 10/13/99	Uni-ZAP XR	103	1181	1	1181	73	73	202	1	20	21	21
29	HCEFI77	PTA-841 10/13/99	Uni-ZAP XR	104	1089	1	1089		1087	203	1	1	2	199
30	HHFDN48	PTA-841 10/13/99	Uni-ZAP XR	40	2143	1	2143	22	22	139	1	22	23	50
30	HHFDN48	PTA-841 10/13/99	Uni-ZAP XR	105	540	113	540	139	139	204	1	22	23	50
30	HHFDN48	PTA-841 10/13/99	Uni-ZAP XR	106	1326	594	1037		921	205	1	1	2	135
30	HHFDN48	PTA-841 10/13/99	Uni-ZAP XR	107	841	85	201		784	206	1	1	2	69
30	HHFDN48	PTA-841 10/13/99	Uni-ZAP XR	108	580	402	580		40	207	1			2
31	HHFFU55	PTA-841 10/13/99	Uni-ZAP XR	41	600	1	600	203	203	140	1			26
31	HHFFU55	PTA-841 10/13/99	Uni-ZAP XR	109	522	1	522		437	208	1	1	2	114

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
32	HHFDH56	PTA-841 10/13/99	Uni-ZAP XR	42	512	68	512	123	123	141	1	27	28	39

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently

accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also

5 hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

10 Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the

15 actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the

20 generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

25 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

30 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed

herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

Table 2 provides preferred epitopes contained in certain embodiments of the invention and polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column refers to each "Gene No." described above in Table 1. The second column provides the sequence identifier, "NT SEQ ID NO:X", for polynucleotide sequences disclosed in Table 1. The third column provides the sequence identifier, "AA SEQ ID NO:Y", for polypeptide sequences disclosed in Table 1. The fourth column provides a unique integer "ntA" where "ntA" is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer "ntB" where "ntB" is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both ntA and ntB correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where ntB is greater than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. Column 6 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf ((1988) CABIOS, 4; 181-186); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE

(Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 2 as "Preferred Epitopes".

- 5 Polypeptides of the invention may possess one, two, three, four, five or more antigenic epitopes comprising residues described in Table 2. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

- 10 Table 3 summarizes the expression profile of polynucleotides corresponding to the clones disclosed in Table 1. The first column provides a unique clone identifier, "Clone ID", for a cDNA clone related to each contig sequence disclosed in Table 1. Column 2, "Library Codes" shows the expression profile of tissue and/or cell line libraries which express the polynucleotides of the invention. Each Library Code
- 15 in column 2 represents a tissue/cell source identifier code corresponding to the Library Code and Library description provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. One of skill in the art could routinely use this information to identify tissues which show a predominant expression pattern of the corresponding polynucleotide of the invention
- 20 or to identify polynucleotides which show predominant and/or specific tissue expression.

- Table 4 provides a key to the Library Code disclosed in Table 3. Column 1 provides the Library Code disclosed in Table 3, column 2. Column 2 provides a description of the tissue or cell source from which the corresponding library was
- 25 derived. Library codes corresponding to diseased Tissues are indicated in column 3 with the word "disease".

Table 2

Gene #	NT SEQ ID NO: X	AA SEQ ID NO: Y	nt A	nt B	Preferred Epitopes
1	11	110	1 - 2587	15 - 2601	Ala-14 to Pro-19 Arg-321 to Ser-332.
1	43	142	1 - 2636	15 - 2650	Ala-14 to Pro-19.
2	12	111	1 - 2610	15 - 2624	Thr-66 to Gly-72 Asp-100 to Asn-105 Thr-165 to His-174 Thr-188 to Arg-193.
2	44	143	1 - 2145	15 - 2159	Thr-66 to Gly-72 Asp-100 to Asn-105 Thr-165 to His-174 Thr-188 to Arg-193.
2	45	144	1 - 539	15 - 553	Gly-21 to Pro-29 Ser-64 to Phe-74.
3	13	112	1 - 2185	15 - 2199	Arg-16 to Tyr-22 Glu-31 to Asn-38 Pro-134 to Thr-140 Trp-266 to Asn-271 Asn-300 to Leu-306 Asn-320 to Trp-325 Pro-406 to Asp-412 Pro-452 to Ser-460 Glu-484 to Glu-489 Lys-529 to Glu-541.
3	46	145	1 - 350	15 - 364	Arg-16 to Tyr-22 Glu-31 to Asn-38.
3	47	146	1 - 329	15 - 343	
3	48	147	1 - 562	15 - 576	Met-1 to Gly-9.
4	14	113	1 - 2263	15 - 2277	Ser-71 to Thr-76 Pro-103 to Cys-108 Ser-130 to Gly-137 Pro-178 to Trp-190.
4	49	148	1 - 960	15 - 974	Ser-71 to Thr-76 Pro-103 to Cys-108 Ser-130 to Gly-137 Pro-178 to Trp-190.
4	50	149	1 - 2278	15 - 2292	Pro-25 to Trp-37 Arg-351 to Phe-358 Pro-361 to Val-375 Pro-387 to Arg-395 Gln-404 to Arg-412.
5	15	114	1 - 1991	15 - 2005	Glu-58 to Tyr-71

					Pro-94 to Gly-101.
5	51	150	1 - 350	15 - 364	
5	52	151	1 - 740	15 - 754	
6	16	115	1 - 912	15 - 926	
6	53	152	1 - 532	15 - 546	Pro-55 to Ala-66 Arg-82 to Thr-87.
6	54	153	1 - 1196	15 - 1210	Glu-79 to Asn-92.
6	55	154	1 - 295	15 - 309	Pro-14 to Pro-23.
7	17	116	1 - 1717	15 - 1731	Ser-248 to Ser-255 Thr-261 to Lys-267 His-434 to Ser-445.
7	56	155	1 - 1878	15 - 1892	Ser-248 to Ser-255 Thr-261 to Lys-267 Tyr-335 to Cys-342 His-466 to Ser-477.
8	18	117	1 - 4136	15 - 4150	Ala-26 to Glu-33 Thr-38 to Tyr-43 Gly-48 to Glu-62 His-83 to His-89 Arg-135 to Tyr-143 Gln-149 to Leu-154 Asp-169 to Gln-178 Pro-181 to Ser-194 Lys-235 to Arg-240 Glu-242 to Gly-269 Asn-279 to Glu-289 Pro-312 to Leu-320 Pro-323 to Gly-332 Ile-348 to Ser-363.
8	57	156	1 - 317	15 - 331	Ala-17 to Glu-24 Thr-29 to Tyr-34 Gly-39 to Gln-46.
8	58	157	1 - 591	15 - 605	Ala-15 to Glu-22 Thr-27 to Tyr-32 Gly-37 to Glu-51 His-72 to His-78.
8	59	158	1 - 818	15 - 832	
8	60	159	1 - 2362	15 - 2376	Gly-1 to Arg-8.
9	19	118	1 - 1676	15 - 1690	Pro-47 to Gly-58 Leu-77 to Arg-90 Pro-100 to Ser-106.
9	61	160	1 - 914	15 - 928	Pro-47 to Gly-58 Leu-77 to Arg-90 Pro-100 to Ser-106.
9	62	161	1 - 778	15 - 792	Arg-28 to Arg-37 Ser-54 to Arg-61

					Ser-78 to Gln-91 Pro-106 to Gln-121 Pro-131 to His-136.
10	20	119	1 - 2270	15 - 2284	Ser-45 to Ile-50 Phe-61 to Val-68 Pro-81 to Leu-88 Thr-106 to Ala-111 Leu-134 to Leu-139 Ser-231 to Arg-236 Lys-354 to Asn-370.
10	63	162	1 - 2072	15 - 2086	
10	64	163	1 - 633	15 - 647	Pro-17 to Ser-27 Pro-55 to Glu-63.
11	21	120	1 - 2273	15 - 2287	Leu-28 to Asp-33 Leu-42 to Arg-47 Leu-109 to Ala-118 Lys-138 to Gln-143 Pro-224 to His-229 Ser-235 to Lys-241 Leu-263 to Ala-269 Gln-279 to Pro-291.
11	65	164	1 - 1145	15 - 1159	Leu-28 to Asp-33 Leu-42 to Arg-47 Leu-109 to Ala-118.
11	66	165	1 - 1313	15 - 1327	
11	67	166	1 - 965	15 - 979	Pro-11 to Gly-17.
12	22	121	1 - 1852	15 - 1866	Gly-26 to Gln-32 Pro-122 to Glu-127 Cys-214 to Gln-222 Leu-237 to Arg-242 Phe-251 to Ala-258.
12	68	167	1 - 1347	15 - 1361	Gly-26 to Gln-32 Pro-122 to Glu-127.
12	69	168	1 - 769	15 - 783	
13	23	122	1 - 2515	15 - 2529	Pro-40 to Ser-46 Asp-50 to Pro-60 Pro-76 to Cys-81 Pro-91 to Phe-96 Pro-149 to His-155.
13	70	169	1 - 806	15 - 820	
13	71	170	1 - 343	15 - 357	Lys-1 to Tyr-7 Ile-22 to His-27 Pro-43 to Lys-49.
13	72	171	1 - 780	15 - 794	Pro-3 to Cys-8.
14	24	123	1 - 4770	15 - 4784	
14	73	172	1 - 1263	15 - 1277	

15	25	124	1 - 2044	15 - 2058	Leu-37 to Asn-42.
15	74	173	1 - 805	15 - 819	Leu-37 to Asn-42.
15	75	174	1 - 487	15 - 501	Lys-41 to Arg-46.
16	26	125	1 - 829	15 - 843	Pro-56 to Leu-62 Pro-86 to Asp-91.
16	76	175	1 - 596	15 - 610	
16	77	176	1 - 645	15 - 659	
16	78	177	1 - 175	15 - 189	
16	79	178	1 - 623	15 - 637	
17	27	126	1 - 688	15 - 702	
17	80	179	1 - 864	15 - 878	
18	28	127	1 - 738	15 - 752	
18	81	180	1 - 458	15 - 472	
19	29	128	1 - 1001	15 - 1015	
19	82	181	1 - 719	15 - 733	
19	83	182	1 - 727	15 - 741	Pro-1 to Cys-8.
19	84	183	1 - 937	15 - 951	
20	30	129	1 - 1049	15 - 1063	
20	85	184	1 - 521	15 - 535	
20	86	185	1 - 787	15 - 801	Pro-2 to Gly-8.
20	87	186	1 - 456	15 - 470	Glu-60 to Arg-67.
21	31	130	1 - 2424	15 - 2438	
21	88	187	1 - 2013	15 - 2027	Trp-50 to Tyr-56.
21	89	188	1 - 673	15 - 687	
22	32	131	1 - 2492	15 - 2506	
22	90	189	1 - 3173	15 - 3187	
23	33	132	1 - 1689	15 - 1703	Pro-23 to Ser-31.
23	91	190	1 - 761	15 - 775	Pro-23 to Ser-31.
23	92	191	1 - 1441	15 - 1455	
24	34	133	1 - 3028	15 - 3042	Arg-50 to Ser-55.
24	93	192	1 - 2572	15 - 2586	Arg-50 to Ser-55.
24	94	193	1 - 1139	15 - 1153	Glu-1 to Lys-16 Ser-48 to Phe-55.
25	35	134	1 - 2094	15 - 2108	Thr-48 to Arg-56 Pro-122 to Glu-127 Lys-135 to Cys-143 Ala-180 to Gly-185 Ala-230 to Tyr-238 Thr-244 to Gln-255 Pro-274 to Ser-279 Thr-284 to Phe-306 Leu-345 to Thr-354.
25	95	194	1 - 612	15 - 626	Thr-48 to Arg-56 Pro-122 to Glu-127 Ala-136 to Tyr-141.
25	96	195	1 - 138	15 - 152	

25	97	196	1 - 1746	15 - 1760	Pro-24 to Arg-32.
26	36	135	1 - 1958	15 - 1972	Arg-13 to Cys-25.
26	98	197	1 - 2757	15 - 2771	Arg-13 to Cys-25.
27	37	136	1 - 1114	15 - 1128	Phe-22 to Leu-27 Leu-79 to Gln-88.
27	99	198	1 - 529	15 - 543	Thr-1 to Ser-14.
27	100	199	1 - 1815	15 - 1829	Thr-1 to Ser-14.
27	101	200	1 - 1113	15 - 1127	
28	38	137	1 - 1945	15 - 1959	
28	102	201	1 - 524	15 - 538	Glu-55 to Ala-61 Gln-82 to Glu-90.
29	39	138	1 - 2849	15 - 2863	
29	103	202	1 - 1167	15 - 1181	
29	104	203	1 - 1075	15 - 1089	
30	40	139	1 - 2129	15 - 2143	Asn-42 to Ser-50.
30	105	204	1 - 526	15 - 540	Asn-42 to Ser-50.
30	106	205	1 - 1312	15 - 1326	Ser-10 to Lys-21 Ala-27 to Gly-32.
30	107	206	1 - 827	15 - 841	
30	108	207	1 - 566	15 - 580	
31	41	140	1 - 586	15 - 600	
31	109	208	1 - 508	15 - 522	Gly-1 to Pro-17.
32	42	141	1 - 498	15 - 512	

Table 3

Clone ID	Library Codes
HARMB79	H0015 H0024 H0038 H0051 H0059 H0063 H0123 H0131 H0135 H0150 H0163 H0272 H0331 H0341 H0351 H0427 H0484 H0486 H0497 H0509 H0520 H0545 H0546 H0550 H0553 H0555 H0574 H0592 H0594 H0616 H0623 H0624 H0628 H0633 H0638 H0644 H0670 H0673 H0684 H0687 H0696 L1290 S0040 S0118 S0132 S0144 S0196 S0242 S0278 S0354 S0358 S0360 S0430 S0456 S0314 T0114
HT2SG64	H0090 H0220 H0556 L1290
HETDB76	H0046 H0252 L1290
HJBCY84	H0014 H0032 H0050 H0051 H0083 H0156 H0170 H0244 H0264 H0266 H0343 H0388 H0412 H0413 H0427 H0494 H0506 H0520 H0543 H0545 H0547 H0553 H0574 H0587 H0617 H0623 H0657 H0658 H0662 H0670 H0674 H0687 H0690 L1290 S0026 S0031 S0045 S0046 S0112 S0116 S0126 S0132 S0242 S0330 S0344 S0358 S0360 S0366 S0380 S0384 S0446 S0312 S6024
HBZAI19	S0053 S0188
HFITF82	L1290 S0114 S0196
HDPDI45	H0009 H0083 H0158 H0341 H0370 H0427 H0484 H0494 H0506 H0521 H0523 H0539 H0544 H0545 H0549 H0556 H0580 H0581 H0616 H0618 H0622 H0634 H0646 H0662 H0663 H0684 H0689 L1290 S0036 S0142 S0150 S0212 S0344 S0374 S0376 S0420 S0446
HUVPD63	H0011 H0012 H0024 H0040 H0052 H0056 H0081 H0135 H0144 H0156 H0181 H0264 H0265 H0309 H0318 H0329 H0393 H0402 H0413 H0423 H0427 H0486 H0494 H0539 H0545 H0547 H0556 H0581 H0587 H0593 H0622 H0637 H0641 H0652 H0658 H0662 H0663 H0668 L1290 S0116 S0150 S0152 S0192 S0276 S0354 S0358 S0360 S0374 S0418 S0426 S0468 S6022 S6024 S6028 T0041
HHPDV90	H0051 H0212 H0423 H0543 H0547 L1290
HETCP58	H0046 H0370 H0664 H0673 H0674 L1290
HCEVB32	H0052 H0085 H0213 H0261 H0424 H0522 H0539 H0664 L1290 S0049 S0051 S0210 S0220 S0374 T0067
HETHW90	H0014 H0038 H0046 H0052 H0081 H0135 H0170 H0171 H0179 H0265 H0266 H0352 H0422 H0431 H0522 H0556 H0616 H0627 H0660 H0663 L1290 S0036 S0038 S0116 S0126 S0132 S0134 S0142 S0356 S0358 S0360 S0428 T0041
HIBEB47	H0149 S0356 T0010
HHFUC40	H0242 H0538 L1290
HTTBS64	H0040
HAGAN21	H0445 H0560 L1290 S0010 S0360
HUSIE23	H0412 H0413 H0623 L1290 S0045 S0242 S0358 S0360 S0374 S0460
HCMSC92	H0052 H0156 H0196 H0352 H0413 H0428 H0494 H0563 H0618 L1290 S0007 S0027 S0280 S6024 T0002
HLHFR58	H0008 H0014 H0024 H0032 H0056 H0060 H0061 H0069 H0075 H0076 H0090 H0109 H0116 H0123 H0134 H0139 H0140 H0141 H0158 H0159 H0179 H0190 H0192 H0220 H0222 H0223 H0224 H0225 H0242 H0247 H0250 H0254 H0265 H0271 H0369 H0416 H0422 H0423 H0518 H0521 H0539 H0555 H0556 H0575 H0581 H0585 H0591 H0598 H0634 H0635 H0638 H0657 H0701 H0707 L1290 N0009 S0002 S0052 S0053 S0114 S0144 S0216 S0280 S0360 S0428 S6022 T0023
HNGGK54	H0263 H0538 H0543 L1290 S0051 S0052
HE8SE91	H0244 H0486 H0521 H0581 H0644 L1290 S0040
HTTBM40	H0013 H0038 H0040 H0050 H0051 H0156 H0328 H0412 H0428 H0494

	H0539 H0553 H0581 H0615 H0624 H0644 H0651 H0660 H0662 L1290 T0023
HE2AX96	H0170
HEBAH57	S0007
HRGBL78	H0046 H0134 H0306 H0318 H0402 H0429 H0445 H0560 H0581 H0650 H0656 H0657 H0689 L1290 S0038 S0344
HHPFU18	H0013 H0046 H0050 H0051 H0171 H0318 H0328 H0392 H0428 H0429 H0478 H0486 H0492 H0497 H0519 H0542 H0543 H0551 H0575 H0598 H0624 H0625 H0656 H0663 H0686 L1290 S0003 S0126 S0218 S0260 S0330 S0344 S0380
HPRCA90	H0032 H0038 H0046 H0318 H0423 H0445 H0478 H0486 H0497 H0521 H0543 H0579 H0586 H0615 H0673 H0696 L1290 S0026 S0036 S0051 S0132 S0192 S0328 S0358 S0360 S0390 S0422 S0432
HPRCE33	H0009 H0012 H0013 H0032 H0050 H0059 H0251 H0543 H0580 H0612 H0628 H0632 H0646 H0667 H0696 L1290 S0002 S0010 S0046 T0082
HCEFI77	H0052
HHFDN48	H0009 H0014 H0038 H0046 H0050 H0052 H0069 H0078 H0090 H0102 H0109 H0124 H0125 H0130 H0134 H0144 H0156 H0171 H0181 H0192 H0194 H0196 H0222 H0266 H0267 H0294 H0318 H0331 H0333 H0412 H0421 H0423 H0431 H0435 H0438 H0445 H0494 H0529 H0543 H0544 H0545 H0547 H0550 H0551 H0555 H0556 H0574 H0575 H0586 H0587 H0591 H0594 H0595 H0615 H0617 H0619 H0620 H0624 H0628 H0634 H0635 H0638 H0644 H0652 H0657 H0658 H0660 H0668 H0670 H0672 H0682 H0684 H0686 L1290 S0003 S0007 S0010 S0013 S0026 S0040 S0045 S0046 S0126 S0134 S0150 S0192 S0194 S0222 S0278 S0308 S0328 S0358 S0388 S0422 S0424 T0010 T0039 T0042 T0049
HHFFU55	H0050 H0264 H0392 H0393 H0433 H0486 H0519 H0543 H0550 H0587 H0593 H0594 H0599 L1290 S0053 S0192 S0222 S0356 S0358 T0041
HHFDH56	H0050 H0625 L1290 S0222

Table 4

Library Code	Library Description	Disease
H0008	Whole 6 Week Old Embryo	
H0009	Human Fetal Brain	
H0011	Human Fetal Kidney	
H0012	Human Fetal Kidney	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0015	Human Gall Bladder, fraction II	
H0024	Human Fetal Lung III	
H0032	Human Prostate	
H0038	Human Testes	
H0040	Human Testes Tumor	disease
H0046	Human Endometrial Tumor	disease
H0050	Human Fetal Heart	
H0051	Human Hippocampus	
H0052	Human Cerebellum	
H0056	Human Umbilical Vein, Endo. remake	
H0059	Human Uterine Cancer	disease
H0060	Human Macrophage	
H0061	Human Macrophage	
H0063	Human Thymus	
H0069	Human Activated T-Cells	
H0075	Human Activated T-Cells (II)	
H0076	Human Membrane Bound Polysomes	
H0078	Human Lung Cancer	disease
H0081	Human Fetal Epithelium (Skin)	
H0083	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	
H0085	Human Colon	
H0090	Human T-Cell Lymphoma	disease
H0102	Human Whole 6 Week Old Embryo (II), subt	
H0109	Human Macrophage, subtracted	
H0116	Human Thymus Tumor, subtracted	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0125	Cem cells cyclohexamide treated	
H0130	LNCAP untreated	
H0131	LNCAP + 0.3nM R1881	
H0134	Raji Cells, cyclohexamide treated	
H0135	Human Synovial Sarcoma	
H0139	Activated T-Cells, 4 hrs.	
H0140	Activated T-Cells, 8 hrs.	
H0141	Activated T-Cells, 12 hrs.	
H0144	Nine Week Old Early Stage Human	
H0149	7 Week Old Early Stage Human, subtracted	
H0150	Human Epididymus	
H0156	Human Adrenal Gland Tumor	disease
H0158	Activated T-Cells, 4 hrs., ligation 2	
H0159	Activated T-Cells, 8 hrs., ligation 2	
H0163	Human Synovium	
H0170	12 Week Old Early Stage Human	
H0171	12 Week Old Early Stage Human, II	

H0179	Human Neutrophil	
H0181	Human Primary Breast Cancer	disease
H0190	Human Activated Macrophage (LPS)	
H0192	Cem Cells, cyclohexamide treated, subtra	
H0194	Human Cerebellum, subtracted	
H0196	Human Cardiomyopathy, subtracted	
H0212	Human Prostate, subtracted	
H0213	Human Pituitary, subtracted	
H0220	Activated T-Cells, 4 hrs, subtracted	
H0222	Activated T-Cells, 8 hrs, subtracted	
H0223	Activated T-Cells, 8 hrs, differentially expressed	
H0224	Activated T-Cells, 12 hrs, subtracted	
H0225	Activated T-Cells, 12hrs, differentially expressed	
H0242	Human Fetal Heart, Differential (Fetal-Specific)	
H0244	Human 8 Week Whole Embryo, subtracted	
H0247	Human Membrane Bound Polysomes- Enzyme Subtraction	
H0250	Human Activated Monocytes	
H0251	Human Chondrosarcoma	disease
H0252	Human Osteosarcoma	disease
H0254	Breast Lymph node cDNA library	
H0261	H. cerebellum, Enzyme subtracted	
H0263	human colon cancer	disease
H0264	human tonsils	
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0267	Human Microvascular Endothelial Cells, fract. B	
H0271	Human Neutrophil, Activated	
H0272	HUMAN TONSILS, FRACTION 2	
H0294	Amniotic Cells - TNF induced	
H0306	CD34 depleted Buffy Coat (Cord Blood)	
H0309	Human Chronic Synovitis	disease
H0318	HUMAN B CELL LYMPHOMA	disease
H0328	human ovarian cancer	disease
H0329	Dermatofibrosarcoma Protuberance	disease
H0331	Hepatocellular Tumor	disease
H0333	Hemangiopericytoma	disease
H0341	Bone Marrow Cell Line (RS4,11)	
H0343	stomach cancer (human)	disease
H0351	Glioblastoma	disease
H0352	wilm's tumor	disease
H0369	H. Atrophic Endometrium	
H0370	H. Lymph node breast Cancer	disease
H0388	Human Rejected Kidney, 704 re-excision	disease
H0392	H. Meningima, M1	
H0393	Fetal Liver, subtraction II	
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision	
H0412	Human umbilical vein endothelial cells, IL-4 induced	
H0413	Human Umbilical Vein Endothelial Cells, uninduced	
H0416	Human Neutrophils, Activated, re-excision	
H0421	Human Bone Marrow, re-excision	
H0422	T-Cell PHA 16 hrs	
H0423	T-Cell PHA 24 hrs	
H0424	Human Pituitary, subt IX	

H0427	Human Adipose	
H0428	Human Ovary	
H0429	K562 + PMA (36 hrs),re-excision	
H0431	H. Kidney Medulla, re-excision	
H0433	Human Umbilical Vein Endothelial cells, frac B, re-excision	
H0435	Ovarian Tumor 10-3-95	
H0438	H. Whole Brain #2, re-excision	
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0478	Salivary Gland, Lib 2	
H0484	Breast Cancer Cell line, angiogenic	
H0486	Hodgkin's Lymphoma II	disease
H0492	HL-60, RA 4h, Subtracted	
H0494	Keratinocyte	
H0497	HEL cell line	
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0518	pBMC stimulated w/ poly I/C	
H0519	NTERA2, control	
H0520	NTERA2 + retinoic acid, 14 days	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells,frac 2	
H0523	Primary Dendritic cells,CapFinder2, frac 1	
H0529	Myeloid Progenitor Cell Line	
H0538	Merkel Cells	
H0539	Pancreas Islet Cell Tumor	disease
H0542	T Cell helper I	
H0543	T cell helper II	
H0544	Human endometrial stromal cells	
H0545	Human endometrial stromal cells-treated with progesterone	
H0546	Human endometrial stromal cells-treated with estradiol	
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)	
H0549	H. Epididymus, caput & corpus	
H0550	H. Epididymus, cauda	
H0551	Human Thymus Stromal Cells	
H0553	Human Placenta	
H0555	Rejected Kidney, lib 4	disease
H0556	Activated T-cell(12h)/Thiouridine-re-excision	
H0560	KMH2	
H0563	Human Fetal Brain, normalized 50021F	
H0574	Hepatocellular Tumor, re-excision	disease
H0575	Human Adult Pulmonary,re-excision	
H0579	Pericardium	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	
H0585	Activated T-Cells,12 hrs,re-excision	
H0586	Healing groin wound, 6.5 hours post incision	disease
H0587	Healing groin wound, 7.5 hours post incision	disease
H0591	Human T-cell lymphoma,re-excision	disease
H0592	Healing groin wound - zero hr post-incision (control)	disease
H0593	Olfactory epithelium,nasalcavity	
H0594	Human Lung Cancer,re-excision	disease
H0595	Stomach cancer (human),re-excision	disease
H0598	Human Stomach,re-excision	

H0599	Human Adult Heart, re-excision	
H0612	H. Leukocytes, normalized cot 50 B	
H0615	Human Ovarian Cancer Reexcision	disease
H0616	Human Testes, Reexcision	
H0617	Human Primary Breast Cancer Reexcision	disease
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart	
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0623	Human Umbilical Vein, Reexcision	
H0624	12 Week Early Stage Human IL, Reexcision	
H0625	Ku 812F Basophils Line	
H0627	Sa0s2 Cells, Vitamin D3 Treated	
H0628	Human Pre-Differentiated Adipocytes	
H0632	Hepatocellular Tumor, re-excision	
H0633	Lung Carcinoma A549 TNFalpha activated	disease
H0634	Human Testes Tumor, re-excision	disease
H0635	Human Activated T-Cells, re-excision	
H0637	Dendritic Cells From CD34 Cells	
H0638	CD40 activated monocyte dendritic cells	
H0641	LPS activated derived dendritic cells	
H0644	Human Placenta (re-excision)	
H0646	Lung, Cancer (4005313 A3): Invasive Poorly Differentiated Lung Adenocarcinoma,	
H0650	B-Cells	
H0651	Ovary, Normal: (9805C040R)	
H0652	Lung, Normal: (4005313 B1)	
H0656	B-cells (unstimulated)	
H0657	B-cells (stimulated)	
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0662	Breast, Normal: (4005522B2)	
H0663	Breast, Cancer: (4005522 A2)	disease
H0664	Breast, Cancer: (9806C012R)	disease
H0667	Stromal cells(HBM3.18)	
H0668	stromal cell clone 2.5	
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	
H0672	Ovary, Cancer: (4004576 A8)	
H0673	Human Prostate Cancer, Stage B2, re-excision	
H0674	Human Prostate Cancer, Stage C, re-excision	
H0682	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0684	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0686	Adenocarcinoma of Ovary, Human Cell Line	
H0687	Human normal ovary(#9610G215)	
H0689	Ovarian Cancer	
H0690	Ovarian Cancer, # 9702G001	
H0696	Prostate Adenocarcinoma	
H0701	NK yao15(control)	
H0707	Stomach Cancer(S007635)	
L1290	Soares fetal liver spleen 1NFLS S1	
N0009	Human Hippocampus, prescreened	
S0002	Monocyte activated	
S0003	Human Osteoclastoma	disease

S0007	Early Stage Human Brain	
S0010	Human Amygdala	
S0013	Prostate	
S0026	Stromal cell TF274	
S0027	Smooth muscle, serum treated	
S0031	Spinal cord	
S0036	Human Substantia Nigra	
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0040	Adipocytes	
S0045	Endothelial cells-control	
S0046	Endothelial-induced	
S0049	Human Brain, Striatum	
S0051	Human Hypothalamus,Schizophrenia	disease
S0052	neutrophils control	
S0053	Neutrophils IL-1 and LPS induced	
S0112	Hypothalamus	
S0114	Anergic T-cell	
S0116	Bone marrow	
S0118	Smooth muscle control 2	
S0126	Osteoblasts	
S0132	Epithelial-TNF α and INF induced	
S0134	Apoptotic T-cell	
S0142	Macrophage-oxLDL	
S0144	Macrophage (GM-CSF treated)	
S0150	LNCAP prostate cell line	
S0152	PC3 Prostate cell line	
S0188	Prostate,BPH, Lib 2	disease
S0192	Synovial Fibroblasts (control)	
S0194	Synovial hypoxia	
S0196	Synovial IL-1/TNF stimulated	
S0210	Mesangial cell, frac 2	
S0212	Bone Marrow Stromal Cell, untreated	
S0216	Neutrophils IL-1 and LPS induced	
S0218	Apoptotic T-cell, re-excision	
S0220	H. hypothalamus, frac A, re-excision	
S0222	H. Frontal cortex, epileptic, re-excision	disease
S0242	Synovial Fibroblasts (II1/TNF), subt	
S0260	Spinal Cord, re-excision	
S0276	Synovial hypoxia-RSF subtracted	
S0278	H Macrophage (GM-CSF treated), re-excision	
S0280	Human Adipose Tissue, re-excision	
S0308	Spleen/normal	
S0328	Palate carcinoma	disease
S0330	Palate normal	
S0344	Macrophage-oxLDL, re-excision	
S0354	Colon Normal II	
S0356	Colon Carcinoma	disease
S0358	Colon Normal III	
S0360	Colon Tumor II	disease
S0366	Human Soleus	
S0374	Normal colon	
S0376	Colon Tumor	disease
S0380	Pancreas Tumor PCA4 Tu	disease

S0384	Tongue carcinoma	disease
S0388	Human Hypothalamus, schizophrenia, re-excision	disease
S0390	Smooth muscle, control, re-excision	
S0418	CHME Cell Line, treated 5 hrs	
S0420	CHME Cell Line, untreated	
S0422	Mo7e Cell Line GM-CSF treated (1ng/ml)	
S0424	TF-1 Cell Line GM-CSF Treated	
S0426	Monocyte activated, re-excision	
S0428	Neutrophils control, re-excision	
S0430	Aryepiglottis Normal	
S0432	Sinus piriformis Tumour	
S0446	Tongue Tumour	
S0456	Tongue Normal	
S0460	Thyroid Tumour	
S0468	Ea.hy.926 cell line	
S3012	Smooth Muscle Serum Treated, Norm	
S3014	Smooth muscle, serum induced, re-exc	
S6022	H. Adipose Tissue	
S6024	Alzheimers, spongy change	disease
S6028	Human Manic Depression Tissue	disease
T0002	Activated T-cells	
T0010	Human Infant Brain	
T0023	Human Pancreatic Carcinoma	disease
T0039	HSA 172 Cells	
T0041	Jurkat T-cell G1 phase	
T0042	Jurkat T-Cell, S phase	
T0049	Aorta endothelial cells + TNF-a	
T0067	Human Thyroid	
T0082	Human Adult Retina	
T0114	Human (Caco-2) cell line, adenocarcinoma, colon, remake	

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the

polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough
5 endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of
10 the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal
15 charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of
20 these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et
25 al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

30 As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence

shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the
5 polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal
10 sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited
15 clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

The present invention is directed to variants of the polynucleotide sequence
20 disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the
25 polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%,
30 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the

complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

- 5 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 10 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% 15 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% 20 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified 25 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best 30 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp.

App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, 5 Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' 10 deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 15 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected 20 score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query 25 sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score 30 calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the

deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.

These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window

Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not

matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing
5 alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced
10 for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an
15 organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA
20 technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after
25 deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological
30 activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem.* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over

3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, 5 Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological 10 functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic 15 activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the 20 art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural 25 selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid 30 substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic
15 residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the
20 genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino
25 acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification or (v) fusion of the polypeptide with another compound, such as albumin (including, but not limited to, recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by
30 reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,

and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40,

41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or
5 smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the
10 carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are
15 preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-
20 forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides
25 encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased
30 undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5 In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope
10 of the invention.

Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide
30 encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies

described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to

an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very
5 least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., *supra*; Wilson et al., *supra*, and Bittle et al., *J. Gen. Virol.*, 66:2347-
10 2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS),
15 while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an
20 immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the
25 peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides
30 of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof), or albumin (including but not limited to recombinant

albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown

5 for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an

10 FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*,

15 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991,

20 *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni²⁺

25 nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to

30 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721;

5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin

molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be

excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, or 10^{-15} M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the

epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes
5 antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand
10 binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described
15 supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent
20 ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but
25 do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists
30 for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No.

5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entirety).

- 10 Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g.,
- 15 Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

- As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus
- 20 or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438;
- 25 WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

- The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include
- 30 antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of

numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

5 The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of- interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal
10 antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and
15 potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be
20 produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not
25 limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma
30 technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an

immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are
5 selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating
10 monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody
15 able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments).
20 F(ab')₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which
25 carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid
30 surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage

gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods* 182:41-50 (1995); Ames et al., *J. Immunol. Methods* 184:177-186 (1995); Kettleborough et al., *Eur. J. Immunol.* 24:952-958 (1994); Persic et al., *Gene* 187 9-18 (1997); Burton et al., *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol.*

Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entirety.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into

mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using

techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library

generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., *J. Mol. Biol.* 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino

acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other
5 alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes
10 from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized
15 antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain
20 antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

25 *Methods of Producing Antibodies*

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment,
30 derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a

polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as

bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems
5 infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO,
10 BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole
15 recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2
20 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which
25 direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic
30 Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such

fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.

Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp^rt- or ap^rt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt,

which confers resistance to mycophenolic acid (Mulligan & Berg, *Proc. Natl. Acad. Sci. USA* 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 *Clinical Pharmacy* 12:488-505; Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215; and hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegl, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci. USA* 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for
5 the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

10 The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through
15 linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention
20 to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS
25 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may
30 be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any

combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341 (1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred
5 embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags
10 useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used
15 diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent
20 materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No.
25 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone,
30 fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin,

and aequorin; and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ¹¹¹In or ⁹⁹Tc.

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ²¹³Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports
5 include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results,
15 And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

20 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can
25 be used as a therapeutic.

Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present
30 invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific

epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with
5 antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to
10 prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

Assays For Antibody Binding

15 The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions,
20 gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by
25 reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1%
30 Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A

and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ³²P or ¹²⁵I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes

the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

10 The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of increasing amounts of an unlabeled second antibody.

Therapeutic Uses

25 The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any

one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or
5 conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the
10 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

15 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

20 The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment,
25 human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and
30 therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention,

including fragments thereof. Preferred binding affinities include those with a dissociation constant or K_d less than 5×10^{-2} M, 10^{-2} M, 5×10^{-3} M, 10^{-3} M, 5×10^{-4} M, 10^{-4} M, 5×10^{-5} M, 10^{-5} M, 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other

desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific
5 embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or
10 indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be
15 accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun;
20 Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target
25 cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT
30 Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination

(Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra et al., *Nature* 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in
5 tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

10 In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene
15 transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary
20 developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various
25 methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy
30 encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages,

neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

5 In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or
10 progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

15 In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

20 *Demonstration of Therapeutic or Prophylactic Activity*

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition
25 include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a
30 specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment;

this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when
5 administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)
10

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J.Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose
20 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)).
25

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote
30 expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by

use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,
5 Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a
10 pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic
15 is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid
20 carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering
25 agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as
30 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of

the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with
5 routine procedures as a pharmaceutical composition adapted for intravenous
administration to human beings. Typically, compositions for intravenous
administration are solutions in sterile isotonic aqueous buffer. Where necessary, the
composition may also include a solubilizing agent and a local anesthetic such as
lignocaine to ease pain at the site of the injection. Generally, the ingredients are
10 supplied either separately or mixed together in unit dosage form, for example, as a dry
lyophilized powder or water free concentrate in a hermetically sealed container such
as an ampoule or sachette indicating the quantity of active agent. Where the
composition is to be administered by infusion, it can be dispensed with an infusion
bottle containing sterile pharmaceutical grade water or saline. Where the composition
15 is administered by injection, an ampoule of sterile water for injection or saline can be
provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.
Pharmaceutically acceptable salts include those formed with anions such as those
derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those
20 formed with cations such as those derived from sodium, potassium, ammonium,
calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol,
histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the
treatment, inhibition and prevention of a disease or disorder associated with aberrant
25 expression and/or activity of a polypeptide of the invention can be determined by
standard clinical techniques. In addition, in vitro assays may optionally be employed
to help identify optimal dosage ranges. The precise dose to be employed in the
formulation will also depend on the route of administration, and the seriousness of
the disease or disorder, and should be decided according to the judgment of the
30 practitioner and each patient's circumstances. Effective doses may be extrapolated
from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human
5 antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the
10 antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture,
15 use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically
20 bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body
25 fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder,
30 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level,

whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium (^{99}Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods

including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce
5 diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of
10 Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the
15 labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by
20 repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label
25 used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

30 In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with

a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may

also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound

recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

Fusion Proteins

5 Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target
10 cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur
15 through linker sequences.

 Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell
20 or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

 Moreover, polypeptides of the present invention, including fragments, and
25 specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins
30 consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).) Polynucleotides comprising or alternatively consisting of
5 nucleic acids which encode these fusion proteins are also encompassed by the invention.

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a
10 fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for
15 example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker
20 sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for
25 instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides
30 or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,

pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-

mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some
5 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A
10 main step in the methanol metabolism pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main
15 carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., et al., *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., et al., *Yeast* 5:167-77 (1989); Tschopp, J.F., et al., *Nucl. Acids Res.* 15:3859-76 (1987).
20 Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding
25 a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal
30 peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately
5 located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an
10 expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have
15 been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control
20 regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650,
25 published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and
30 Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a

polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the
5 common amino acids, 2,4-diaminobutyric acid, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-
10 amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation,
15 amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; metabolic
20 synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and
25 addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the
30 polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for

derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may

be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ($\text{ClSO}_2\text{CH}_2\text{CF}_3$). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,

15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are
5 discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their
10 preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers.
15 As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid
20 sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having
25 identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or
30 more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional

embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627

(hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves
5 use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different
10 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide
15 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are
20 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

25 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-
30 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers

of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into

liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Uses of the Polynucleotides

5 Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

 The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers,
10 since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

 Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be
15 selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

20 Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled
25 flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety)..

 Precise chromosomal location of the polynucleotides can also be achieved
30 using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see

Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g., Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31'mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or

estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,

thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ($T_{sub.m}$) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in *Neoplastic Diseases of the Blood*, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal

cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456

(1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while
5 antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One
10 goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

15 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for
20 identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative
25 to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an
30 individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression

in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (^{125}I , ^{121}I), carbon (^{14}C), sulfur (^{35}S), tritium (^3H), indium (^{112}In), and technetium ($^{99\text{m}}\text{Tc}$), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

10 In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ^{131}I , ^{112}In , $^{99\text{m}}\text{Tc}$), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of $^{99\text{m}}\text{Tc}$. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also

be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

5

Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Beldegrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver,

and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences
5 that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such
10 methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors
15 include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving
20 the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter;
25 the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing
30 naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA

sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the nakednucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

10 In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,
15 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20 Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially
25 available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of
30 DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.

Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference.

Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily
5 available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these
10 materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be
15 prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at
20 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar
25 vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., Methods of Immunology, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass
30 tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a

suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca^{2+} -EDTA chelation (Papahadjopoulos et al., Biochim. Biophys. Acta, 394:483 (1975); Wilson et al., Cell, 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA, 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis

virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy, 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);

Rosenfeld et al., Cell , 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature , 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

10 Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

 In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

 For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including

lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention.

- 5 These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the
10 polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method
15 involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently
20 complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

25 The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the
30 amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can
5 be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such
10 that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth
15 factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention
20 contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be
25 homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct
30 needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid

(tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

Biological Activities

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

Immune Activity

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of

the present invention can be used as a marker or detector of a particular immune system disease or disorder.

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells.

Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g., agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing autoimmune disorders. Many autoimmune disorders result from inappropriate

recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Autoimmune diseases or disorders that may be treated, prevented, and/or diagnosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following:

10 autoimmune hemolytic anemia, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, autoimmunocytopenia, hemolytic anemia, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, glomerulonephritis (e.g, IgA nephropathy), Multiple Sclerosis, Neuritis, Uveitis Ophthalmia,

15 Polyendocrinopathies, Purpura (e.g., Henloch-Schoenlein purpura), Reiter's Disease, Stiff-Man Syndrome, Autoimmune Pulmonary Inflammation, Autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye, autoimmune thyroiditis, hypothyroidism (i.e., Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Pemphigus, Receptor autoimmunities such as, for example, (a) Graves' Disease, (b) Myasthenia Gravis, and (c) insulin

20 resistance, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, rheumatoid arthritis, scleroderma with anti-collagen antibodies, mixed connective tissue disease, polymyositis/dermatomyositis, pernicious anemia, idiopathic Addison's disease, infertility, glomerulonephritis such as primary glomerulonephritis and IgA

25 nephropathy, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis), chronic active hepatitis, primary biliary cirrhosis, other endocrine gland failure, vitiligo, vasculitis, post-MI, cardiomyopathy syndrome, urticaria, atopic dermatitis, asthma, inflammatory myopathies, and other inflammatory, granulomatous,

30 degenerative, and atrophic disorders.

Additional autoimmune disorders (that are probable) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are

not limited to, rheumatoid arthritis (often characterized, e.g., by immune complexes in joints), scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA),
5 pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by
10 glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic
15 drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional autoimmune disorders (that are possible) that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle
20 antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondrial antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial
25 antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

30 In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated,

prevented, and/or diagnosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention.

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost
5 immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

B cell immunodeficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID)-X linked, SCID-autosomal, adenosine deaminase deficiency (ADA deficiency), X-
10 linked agammaglobulinemia (XLA), Bruton's disease, congenital agammaglobulinemia, X-linked infantile agammaglobulinemia, acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, transient hypogammaglobulinemia of infancy, unspecified hypogammaglobulinemia,
15 agammaglobulinemia, common variable immunodeficiency (CVI) (acquired), Wiskott-Aldrich Syndrome (WAS), X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, selective IgA deficiency, IgG subclass deficiency (with or without IgA deficiency), antibody deficiency with normal or elevated Igs, immunodeficiency with thymoma, Ig heavy chain deletions, kappa
20 chain deficiency, B cell lymphoproliferative disorder (BLPD), selective IgM immunodeficiency, recessive agammaglobulinemia (Swiss type), reticular dysgenesis, neonatal neutropenia, severe congenital leukopenia, thymic aplasia, aplasia or dysplasia with immunodeficiency, ataxia-telangiectasia, short limbed dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof
25 syndrome-combined immunodeficiency with Igs, purine nucleoside phosphorylase deficiency (PNP), MHC Class II deficiency (Bare Lymphocyte Syndrome) and severe combined immunodeficiency.

T cell deficiencies that may be ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof include, but
30 are not limited to, for example, DiGeorge anomaly, thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia,

immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity. In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are ameliorated or treated by, for example, administering the polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

Other immunodeficiencies that may be ameliorated or treated by administering polypeptides or polynucleotides of the invention, and/or agonists thereof, include, but are not limited to, severe combined immunodeficiency (SCID; e.g., X-linked SCID, autosomal SCID, and adenosine deaminase deficiency), ataxia-telangiectasia, Wiskott-Aldrich syndrome, short-limber dwarfism, X-linked lymphoproliferative syndrome (XLP), Nezelof syndrome (e.g., purine nucleoside phosphorylase deficiency), MHC Class II deficiency. In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are ameliorated or treated by administering the polypeptides or polynucleotides of the invention, and/or agonists thereof.

In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, and/or diagnosed using antibodies against the protein of the invention.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed using polypeptides, antibodies, or polynucleotides of the invention, and/or

agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Moreover, inflammatory conditions may also be treated, diagnosed, and/or prevented with polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. Such inflammatory conditions include, but are not limited to, for example, respiratory disorders (such as, e.g., asthma and allergy); gastrointestinal disorders (such as, e.g., inflammatory bowel disease); cancers (such as, e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (such as, e.g., multiple sclerosis, blood-brain barrier permeability, ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (such as, e.g., Parkinson's disease and Alzheimer's disease), AIDS-related dementia, and prion disease); cardiovascular disorders (such as, e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (such as, e.g., chronic hepatitis (B and C), rheumatoid arthritis, gout, trauma, septic shock, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus (i.e., type 1 diabetes), and allogeneic transplant rejection).

In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to treat, diagnose, and/or prevent transplantation rejections, graft-versus-host disease, autoimmune and inflammatory diseases (e.g., immune complex-induced vasculitis, glomerulonephritis, hemolytic anemia, myasthenia gravis, type II collagen-induced arthritis, experimental allergic and hyperacute xenograft rejection, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also be used to modulate and/or diagnose inflammation. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to treat, diagnose, or prognose, inflammatory conditions, both chronic and acute conditions, including, but not limited to, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, and resulting from over production of cytokines (e.g., TNF or IL-1.).

Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

Additional preferred embodiments of the invention include, but are not limited to, the use of polypeptides, antibodies, polynucleotides and/or agonists or antagonists in the following applications:

Administration to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

Administration to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741.

A vaccine adjuvant that enhances immune responsiveness to specific antigen.

An adjuvant to enhance tumor-specific immune responses.

10 An adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, 15 or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, 20 Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever.

An adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meisseria meningitidis*, 30

Streptococcus pneumoniae, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, *Borrelia burgdorferi*, and Plasmodium (malaria).

An adjuvant to enhance anti-parasitic immune responses. Anti-parasitic
5 immune responses that may be enhanced using the compositions of the invention as
an adjuvant, include parasite and parasite associated diseases or symptoms described
herein or otherwise known in the art. In specific embodiments, the compositions of
the invention are used as an adjuvant to enhance an immune response to a parasite. In
another specific embodiment, the compositions of the invention are used as an
10 adjuvant to enhance an immune response to Plasmodium (malaria).

As a stimulator of B cell responsiveness to pathogens.

As an activator of T cells.

As an agent that elevates the immune status of an individual prior to their
receipt of immunosuppressive therapies.

15 As an agent to induce higher affinity antibodies.

As an agent to increase serum immunoglobulin concentrations.

As an agent to accelerate recovery of immunocompromised individuals.

As an agent to boost immunoresponsiveness among aged populations.

As an immune system enhancer prior to, during, or after bone marrow
20 transplant and/or other transplants (e.g., allogeneic or xenogeneic organ
transplantation). With respect to transplantation, compositions of the invention may
be administered prior to, concomitant with, and/or after transplantation. In a specific
embodiment, compositions of the invention are administered after transplantation,
prior to the beginning of recovery of T-cell populations. In another specific
25 embodiment, compositions of the invention are first administered after transplantation
after the beginning of recovery of T cell populations, but prior to full recovery of B
cell populations.

As an agent to boost immunoresponsiveness among individuals having an
acquired loss of B cell function. Conditions resulting in an acquired loss of B cell
30 function that may be ameliorated or treated by administering the polypeptides,
antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are

not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

As an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, recovery from surgery.

As a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonization of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

As an agent to direct an individuals immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

As a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

As a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

As a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect.

As a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence such as observed among SCID patients.

As an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

As a means of activating T cells.

As a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leshmania.

As pretreatment of bone marrow samples prior to transplant. Such treatment would increase B cell representation and thus accelerate recover.

5 As a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

Additionally, polypeptides or polynucleotides of the invention, and/or agonists thereof, may be used to treat or prevent IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema.

10 All of the above described applications as they may apply to veterinary medicine.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, or ribozymes. These would be expected to reverse many of the activities of the ligand described above as well as find clinical or
15 practical application as:

A means of blocking various aspects of immune responses to foreign agents or self. Examples include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and pathogens.

20 A therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythramatosus and MS.

An inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in
25 disrupting immune responses, and blocking sepsis.

An inhibitor of graft versus host disease or transplant rejection.

A therapy for B cell and/or T cell malignancies such as ALL, Hodgkins disease, non-Hodgkins lymphoma, Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, and EBV-transformed diseases.

30 A therapy for chronic hypergammaglobulinemeia evident in such diseases as monoclonalgammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonalgammopathies, and plasmacytomas.

A therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

A means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

An immunosuppressive agent(s).

5 Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

In another embodiment, administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention, may be used to treat or prevent IgE-mediated allergic reactions including, but not limited to, asthma,
10 rhinitis, and eczema.

The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

The agonists or antagonists may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of
15 neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain auto-immune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes. The antagonists or agonists may also be employed to treat infectious diseases including
20 silicosis, sarcoidosis, idiopathic pulmonary fibrosis by, for example, preventing the recruitment and activation of mononuclear phagocytes. They may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration. The antagonists or agonists or may also be employed for treating atherosclerosis, for example, by preventing monocyte
25 infiltration in the artery wall.

Antibodies against polypeptides of the invention may be employed to treat ARDS.

Agonists and/or antagonists of the invention also have uses in stimulating wound and tissue repair, stimulating angiogenesis, stimulating the repair of vascular
30 or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to treat or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii.

In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to treat, diagnose, and/or prevent (1) cancers or neoplasms and (2) autoimmune cell or tissue-related cancers or neoplasms. In a preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent acute myelogenous leukemia. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat, diagnose, and/or prevent, chronic myelogenous leukemia, multiple myeloma, non-Hodgkins lymphoma, and/or Hodgkins disease.

In another specific embodiment, polynucleotides or polypeptides, and/or agonists or antagonists of the invention may be used to treat, diagnose, prognose, and/or prevent selective IgA deficiency, myeloperoxidase deficiency, C2 deficiency, ataxia-telangiectasia, DiGeorge anomaly, common variable immunodeficiency (CVI),

X-linked agammaglobulinemia, severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome.

Examples of autoimmune disorders that can be treated or detected are described above and also include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prognosed, prevented, and/or diagnosed using antibodies against the polypeptide of the invention.

As an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

Additionally, polynucleotides, polypeptides, and/or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related

glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and

brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be detected and/or treated by polynucleotides, polypeptides, and/or antagonists of the invention, include, but are not limited to neoplasms located in the: liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides, polypeptides, and/or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Hyperproliferative Disorders

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may
5 be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can
10 be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral),
15 lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:
20 hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to
25 inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said
30 polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals

comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature

320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference.

5 In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes
10 needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use
15 of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts,
20 which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the
25 polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in
30 tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for
5 producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may
10 be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of
15 the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as
20 described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or
25 activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or
30 polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those

with a dissociation constant or K_d less than $5 \times 10^{-6}M$, $10^{-6}M$, $5 \times 10^{-7}M$, $10^{-7}M$, $5 \times 10^{-8}M$, $10^{-8}M$, $5 \times 10^{-9}M$, $10^{-9}M$, $5 \times 10^{-10}M$, $10^{-10}M$, $5 \times 10^{-11}M$, $10^{-11}M$, $5 \times 10^{-12}M$, $10^{-12}M$, $5 \times 10^{-13}M$, $10^{-13}M$, $5 \times 10^{-14}M$, $10^{-14}M$, $5 \times 10^{-15}M$, and $10^{-15}M$.

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as
5 activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering
10 compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides,
15 heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present
20 invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Cardiovascular Disorders

25 Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral
30 arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus

arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural

hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol
5 embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment
10 syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

15 Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous
20 injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*,
25 described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

Anti-Angiogenesis Activity

The naturally occurring balance between endogenous stimulators and
30 inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound

healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes

5 pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995);

10 Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have

15 accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or

20 antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the

25 present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety

30 of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors,

including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non- small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising

the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of

diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause),
5 toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-
15 angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent
20 complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing
25 front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbal corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbal cornea interspersed
30 between the corneal lesion and its undesired potential limbal blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-

3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to
5 a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other
10 embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided
15 for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide,
20 polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist
25 and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or
30 agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,

pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uviitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized

to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat
5 tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized
10 during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide,
15 agonist and/or antagonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the
20 anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides,
25 agonists and/or antagonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

30 The polynucleotides, polypeptides, agonists and/or antagonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive

Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

5 Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

10 Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

15 Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl
20 complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example,
25 molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

 A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4;
30 protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence

of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; 5 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradeecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; 10 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolimidazole; and metalloproteinase inhibitors such as BB94.

15

Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as 20 follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast 25 cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and 30 adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or

agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis,

Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g.,
5 hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

10 In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.
15 Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat
20 exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal
25 loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists
30 of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,

epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omental graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and,

thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

5 In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or
10 prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

15 Neurological Diseases

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which
20 result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1)
25 ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of
30 the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is

destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists

or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motor-sensory Neuropathy (Charcot-Marie-Tooth Disease).

Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to

stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or
5 detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency,
10 pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as
15 ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral
20 arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency,
25 vascular dementia such as multi-infarct dementia, periventricular leukomalacia,
30 vascular headache such as cluster headache and migraine.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as
5 Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome,
10 Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic
15 epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure
20 hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural
25 empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention
30 include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as

Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes
5 bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention
10 include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral
15 sclerolus which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue
20 Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's
25 Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett
30 Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity,

encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention

5 include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia,

10 apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia,

15 broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia,

20 myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic

25 Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism,

30 spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron

disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Infectious Disease

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or

diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*, *Nocardia*), *Cryptococcus neoformans*, *Aspergillus*, *Bacillaceae* (e.g., *Anthrax*, *Clostridium*), *Bacteroidaceae*, *Blastomycosis*, *Bordetella*, *Borrelia* (e.g., *Borrelia burgdorferi*), *Brucellosis*, *Candidiasis*, *Campylobacter*, *Coccidioidomycosis*, *Cryptococcosis*, *Dermatocycoses*, *E. coli* (e.g., *Enterotoxigenic E. coli* and *Enterohemorrhagic E. coli*), *Enterobacteriaceae* (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), *Erysipelothrix*, *Helicobacter*, *Legionellosis*, *Leptospirosis*, *Listeria*, *Mycoplasmatales*, *Mycobacterium leprae*, *Vibrio cholerae*, *Neisseriaceae* (e.g., *Acinetobacter*, *Gonorrhea*, *Menigococcal*), *Meisseria meningitidis*, *Pasteurellacea Infections* (e.g., *Actinobacillus*, *Heamophilus* (e.g., *Heamophilus influenza type B*), *Pasteurella*), *Pseudomonas*, *Rickettsiaceae*, *Chlamydiaceae*, *Syphilis*, *Shigella spp.*, *Staphylococcal*, *Meningiococcal*, *Pneumococcal* and *Streptococcal* (e.g., *Streptococcus pneumoniae* and *Group B Streptococcus*). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,

meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.

- 5 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

- 10 Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis,
- 15 Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS
- 20 related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

- 25 Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the
- 30 polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues
5 could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs
10 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the
15 present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel
20 syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a
polynucleotide or polypeptide and/or agonist or antagonist of the present invention to
25 proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral
30 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-

Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

Chemotaxis

5 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then
10 fight off and/or heal the particular trauma or abnormality.

 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system
15 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

20 It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

25

Binding Activity

 A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit
30 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural
5 receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell
10 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

15 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,
20 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

25 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be
30 identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein

polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opin. Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide

sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and ^3H thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of ^3H thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of

3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of,

any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional
5 embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

Targeted Delivery

10 In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or
15 prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic
20 protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific
25 destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of
30 toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes

known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the

present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Polypeptides of the Invention Binding Peptides and Other Molecules

The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the polypeptide of the invention binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

This method comprises the steps of:

- a. contacting a polypeptide of the invention with a plurality of molecules; and
- b. identifying a molecule that binds the polypeptide of the invention.

The step of contacting the polypeptide of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the polypeptide of the invention on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptide of the invention. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptide of the invention. The molecules having a selective affinity for the polypeptide of the invention can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptide of the invention to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be "probed" by the polypeptide of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptide of the invention and the individual clone. Prior to contacting the polypeptide of the invention with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for a polypeptide of the invention. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptide of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be

determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

5 In certain situations, it may be desirable to wash away any unbound polypeptide of the invention, or alternatively, unbound polypeptides, from a mixture of the polypeptide of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptide of the invention
10 or the plurality of polypeptides is bound to a solid support.

 The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind to a polypeptide of the invention. Many libraries are known in the art that can be used, e.g., chemically
15 synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature* 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer
20 et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

25 Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R. B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157; Kay et al., 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

30 In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9022-9026.

By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide
5 functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list
10 benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

Non-peptide libraries can be classified broadly into two types: decorated
15 monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are
20 assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer
25 libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of
30 peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al.,

1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a molecule that binds a polypeptide of the invention can be carried out by contacting the library members with a polypeptide of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptide of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a polypeptide of the invention.

Where the polypeptide of the invention binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

As mentioned above, in the case of a polypeptide of the invention binding

molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a polypeptide of the invention binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

The selected polypeptide of the invention binding polypeptide can be obtained by chemical synthesis or recombinant expression.

Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is

heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10MM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,

forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non-translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication

NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., *BioTechniques*, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end,
5 the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,
10 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,
15 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,
25 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl
30 phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded

hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).

The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same
5 manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since
10 ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or
15 prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the
20 present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or
25 diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense
30 molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

Other Activities

5 The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed
10 above.

 The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

15 The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may
20 be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

 The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

 The polypeptide of the invention may also be employed for preventing hair
25 loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

 The polypeptide of the invention may also be employed to maintain organs
30 before transplantation or for supporting cell culture of primary tissues.

 The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5 The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to
10 modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

 Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases,
15 disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

 Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or
20 decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

 Other preferred embodiments of the claimed invention include an isolated
25 nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

 Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of
30 positions beginning with the nucleotide at about the position of the 5' Nucleotide of

the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of
5 positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the
10 range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

20 A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X
25 in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under
30 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization

conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1,
5 which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous
10 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the
15 complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule
20 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete
25 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X
30 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table

1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

5 Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence
10 determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic
15 acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained
20 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least
25 one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a
30 biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a

nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

5 The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

10 Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID
15 NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

20 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

 Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of
25 positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the
30 amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid
5 sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human
10 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in
15 Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA
20 clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human
25 cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1
30 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence

selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 5, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 5 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 5. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 5. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 5

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HARMB79	11	1017148	AI702079, AI744097, AI342358, AA009451, AI860314, AI738613, AI884558, AI269100, AA088181, AA305745, AI130828, AW014412, AA489798, AI140834, AA009735, AA558470, H25381, AI631362, AA489929, AA552059, AA045801, AI039657, R42077, H30105, AI074139, AA974256, AI559202, AI457945,

				AI245758, H14907, R18704, R48910, AI147891, AI074399, R18703, H25380, AA437138, AI613032, T79590, AI817313, AI041484, AA088651, H14614, R42078, R48801, T64172, Z45402, AW197727, T64360, AA336102, AI598048, AA972077, AI758636, H27507, AA045868, AA299901, T70902, T70952, T40081, AI867492, H44671, T40105, AA335281, AA345072, Z41115, AA506906, M85390, T72431, T41013, C03221, AI695691, AA772775, AA335297, H27581, AI758844, T95706, R13844, AI826822, AW183447, R36989, R71936, T79670, W21234, AA335299, T40996, T61886, AI814352, AA651701, N93464, T60387, AW190667, T68359, AL110276, and AF191019.
1	HARMB79	43	905152	AI702079, AI744097, AI342358, AA009451, AI860314, AI738613, AI884558, AA088181, AI269100, AA305745, AI130828, AA489798, AW014412, AI140834, AA009735, AA558470, H25381, AI631362, AA552059, AA489929, AA045801, AI039657, R42077, H30105, AI074139, AA974256, AI559202, R18704, AI457945, AI245758, H14907, AI147891, R48910, AA437138, T79590, H25380, AI613032, AI074399, AI817313, R18703, AI041484, AA088651, H14614, R42078, R48801, T64172, Z45402, AW197727, T64360, AI598048, AA336102, AA972077, AI758636, AA045868, H27507, T70952, AA299901, T70902, T40081, T40105, AI867492, H44671, AA335281, AA345072, Z41115, AA506906, M85390, T72431, T41013, AA772775, AI695691, C03221, AA335297, AI758844, H27581, T95706, AI826822, R13844, AW183447, R36989, R71936, T79670, W21234, AA335299, T40996, T61886, AI814352, N93464, AA651701, T60387, AW190667, T68359, AL042533, AL042655, AL135012, AL045327, AL134524, AL042508, AL042420, AL042519, AL045494, AL042523, AL042488, AL046356, AL043089, AL043321, AL042832, AL045328, AL043295, AL042741, AL045891, AL042898, AL047163, U46344, AL110276, AF191019, AL133053, AL133049, AL133074, AL122101, AL133082, and A85203.
2	HT2SG64	12	963215	AW451448, W57945, W58028, AW188759, A97630, and AB023135.
2	HT2SG64	44	904620	W57945, T03269, D80195, D80193, D59927, D51423, D59619, D80210, D51799, D80391, D80240, D80253, D80227, D80188, D81030, D58283, D80196, D80219, D80043, D80038, D80366, D80212, D80022, D59889, D80134, D51250, D59275, D80378, D80045, C75259, C14014, F13647, D50995, D80166, D59859, D81026, D80269, C14429, D59502, AA285331, D80949, D80168, D80024, D50979, C14227, D80268, AI910186, D57483, D59610, D80241, D58253, AW178893, D59787, D80164, D81111,

				AW177440, T11051, C14389, C14331, C15076, D59467, D51060, AW179328, AW178775, AA305409, AW378532, AI905856, AW352158, D51097, AW369651, AW177501, AW177511, AW178762, T11417, AW352117, D51022, AW360834, AW360811, AA305578, D80522, AW176467, AW375405, D80251, AW377671, AW378540, D80014, AW366296, AW360844, AW360817, AW375406, AW378534, D80248, AW179332, AW377672, AW179023, AW178905, AA514188, AW352171, AW377676, AW352170, AW177731, AW178907, AW179019, AW179024, AA514186, D80133, AW177505, AW178906, AW360841, AW179020, AW178909, AW177456, AW179329, AW178980, AW177733, AW378528, AW178908, AW178754, AW179018, D80064, C05695, AW179004, AW178914, AW378525, AW352174, AW177728, AI557751, D80302, AW178774, AW178911, AW378543, D80132, AW352163, AW367967, D80439, AW352120, D80247, AW178983, T48593, AW178781, D51103, AW177723, D80258, D80157, AW367950, D51759, AW178986, AA033512, C06015, T03116, D58246, AW378533, AW177734, D45260, AI557774, D59503, D58101, C03092, H67854, AW378542, H67866, AW378539, AA809122, AI525923, AW360855, AI525917, D59317, D80314, AA514184, AI525920, D59551, AI535686, AI535959, AI525227, AI525913, AI525925, A97630, AB023135, A67220, A25909, A62300, X67155, A62298, D34614, D26022, AR025207, A78862, Y17188, D89785, A84916, AJ132110, X68127, D88547, A85396, AB012117, AR066482, A85477, A86792, U87250, I19525, X93549, X82626, AR018138, AF135125, Y12724, A44171, AF058696, AR008278, AB028859, AR064240, A45456, A94995, AR008443, I50126, I50132, I50128, I50133, AR066488, A82595, AR016514, Y17187, AR060138, Y09669, A26615, AR052274, S69292, AR060385, A30438, AB002449, AR066487, A43192, A43190, AR038669, I18371, X89963, A43601, D88507, D50010, AR066490, S78798, AR016691, AR016690, U46128, I18367, A70867, A63261, AB033111, Z32749, AR008408, AR062872, D13509, AR060133, I15997, A64136, A68321, A80951, X92518, I14842, AR054175, U87247, AR050680, AF123263, U79457, AR032065, X93535, and AR008382.
2	HT2SG64	45	462279	AW451448, W58028, AW188759, AB023135, and A97630.
3	HETDB76	13	1002108	AI860869, AW117463, AW451689, AI016507, and AI149631.
3	HETDB76	48	560632	AI860869, and AI149631.
4	HJBCY84	14	1037540	AA746226, AA573750, AA236296, AW161827, AA100812, AI809272, AI814417, AA600756, AI435028, AI952058, AI827881, AI669150,

				W94256, AA812943, AI808020, AA306000, AI300864, AW026387, AA931878, AI694590, AI459100, AW072665, AW007290, AI346638, AA664274, AW157692, AI376246, AI499354, AA126954, W94441, AI984523, AI243221, AW243843, AW157153, AI686902, AA903712, AI301646, AA877280, AI377065, AI680057, AA721330, R53227, AA194102, T82203, AW084970, AI022296, AA693624, R52411, AI538995, AA722895, AI803272, AI769338, AA219348, AI244836, T57283, AI445306, AA447739, AI079234, AI240429, AI270490, AA683509, R34900, R85862, AA172009, AW192397, AI758507, AW135133, AL047822, AW340772, R53228, AA236230, T90533, AI282353, AI364022, AA504085, T83068, AW339342, AA370946, AI903187, R87773, AW163123, AI627596, T56598, AI632989, R84465, T82202, AW135701, AW207618, R49289, AA328743, Z42488, AW376775, N23184, AI873742, F02007, AW376774, Z38683, AA127163, F05758, U25896, AW161261, AA081761, AW161371, AI611929, AA081750, AA453671, AL133355, AL049712, AC010072, and AC007450.
4	HJBCY84	49	897474	R53227, AA306000, R52411, R34900, AL047822, T83068, AW163123, Z42488, F05758, and AI611929.
4	HJBCY84	50	897568	AA746226, AA573750, AA236296, AW161827, AA100812, AI809272, AI814417, AA600756, AI435028, AI952058, AI827881, AI669150, W94256, AA812943, AI808020, AI300864, AW026387, AA931878, AI694590, AI459100, AW072665, AI376246, AW007290, AI346638, AA664274, AW157692, AI499354, AA126954, W94441, AI984523, AI243221, AW243843, AA127163, AW157153, AI686902, AA903712, AI301646, AA877280, AI377065, AI680057, AA721330, AA194102, T82203, AW084970, AI022296, AA693624, AI538995, AA722895, AI769338, AI803272, AA219348, AI244836, T57283, AI445306, AA455731, R84465, AA447739, AI079234, AI240429, AI270490, AA683509, R85862, AW135701, AW192397, R53227, AA172009, R52411, AI758507, AW135133, AW340772, R53228, AA236230, T90533, AW163123, AI282353, AI364022, AA504085, AW339342, AA370946, AA306000, R34900, AI903187, R87773, AI627596, T56598, AI632989, T82202, AW207618, R49289, AA328743, AA453671, AW376775, T83068, N23184, AI873742, F02007, AW376774, Z38683, AL047822, Z42488, U25896, AW161261, AA081761, AW161371, AA081750, F05758, AL133355, AL049712, AC010072, and AC007450.
5	HBZAI19	51	892848	AP001053.

5	HBZAI19	52	896938	AL134524, AL038878, AL045327, AL134110, AL045328, U46344, AL047163, AL135012, AI318479, AL037295, AL038838, AL037343, AL042898, AI547295, AL038983, AI142134, D29033, AL037436, AL037335, AL048657, AL037323, AL048677, AL038651, AL045494, AL042523, AL037727, AL037443, AL038532, AL038822, AL038761, AL038040, AL042420, AL038024, AL037435, AL042468, AW363350, AL038041, AL041955, AL045817, AL040472, AL043941, AL039432, AL038745, AL045753, AL045891, AL042135, AL042741, AL042655, AL040576, AL039360, AL037341, AL039643, AI547258, AL049018, AP001053, AR066494, A93923, D17247, A93931, A93916, A85203, AL133053, AL122101, AR023813, and AL133074.
6	HFITF82	16	992842	AI926463, AL038837, AL039074, AL039564, AL039108, AL039156, AL039659, AL038531, AL037051, AL036725, AL039625, AL039648, AL039629, AL039678, AL039109, AL039150, AL039128, AL037726, AL039085, AL040992, AL045337, AL042909, AL039423, AL039410, AL045353, AL036973, AL044407, AL039538, AL039386, AL039924, AL038821, AL044530, AL037526, AL036418, AL037639, AL039566, AL039509, AL036196, AL043441, AL043445, AL038025, AL037615, AL038851, AL037082, AL045341, AL036924, Z99396, AL043422, T24119, T24112, AL036767, AL043423, H00069, AL036190, AL036117, AL036238, AL045794, AL036679, AI535783, AW013814, AL036733, AW452756, T23947, AW451070, AL037601, AL037027, AL037178, R47228, AL037054, AL036998, AL036191, AI535983, AL036158, D51250, AL036765, AL036964, AL037177, AL036858, T23659, T02921, AL037021, AL037077, D80253, AL036174, AL037643, D59787, D80043, D59275, AL037600, D80219, AL036167, AL036268, Z25782, AL038447, T48598, AA514190, AL036900, D80227, D80240, AL036953, AL036808, AA631969, D80134, T11051, AL037085, AL036719, D51423, AL036999, Z25783, D80210, D59619, AW450376, AL037002, H00072, AL036227, AL037047, AL037016, AL036207, C14227, AL037094, D80193, AL037569, D80196, AW135155, D80168, D59927, AL039440, D80366, AL037679, AL038509, C75259, AW392670, AW372827, AL119324, AW384394, AL038520, AL119497, AW363220, U46350, AL119335, AL119319, AL119443, AL119399, AL119341, AL134524, AL119457, AL119363, U46341, AL119496, AL119484, AL119391, AL119483, C14389, AL119355, AL119522, AL042614, AL119418, U46349, AL119396, U46351, AI557751, AL134528, AL048425, U46346, AL119444,

				AL036836, U46347, AL042544, U46345, AL119439, D59889, AL042433, AL037205, AL134518, AL042965, AL042975, AL134531, AL134533, AL042984, AL042970, AL042551, AL134538, AL119488, AL042450, AL043019, AL043029, AL134542, AL134529, AL042542, AL119464, AL043003, X67056, X82571, A97211, Z96142, AR062871, E16590, X68127, AR036905, A95051, A15078, I18371, AJ244003, AJ244004, AJ244005, I03665, A85477, AR025207, A85396, AR031374, A49700, AR031375, I03664, X73004, A67220, AR017907, A38214, A58521, A44171, I56772, I95540, AR018924, A63067, A51047, A63064, AR018923, A48774, A63072, AR020969, A48775, AR068507, AR068506, AR015960, AR000007, AR015961, A98767, A02712, A25909, I19516, A93963, A93964, I63120, A92133, A95052, AR043602, AR043603, AR043601, A95117, A18053, I06859, A18050, A84772, A23334, A75888, I70384, A60111, A23633, AR007512, D88984, A23998, I60241, I60242, A84776, A84773, A84775, AR062872, E00523, A84774, AR062873, A64081, AR067731, AR037157, AR067732, I66495, I00074, I66494, A86792, A58522, A91750, I66498, I66497, I66496, I66486, I66487, AR054109, A20702, A43189, A43188, A20700, E13740, V00745, AF156296, A58524, A58523, I92483, AR038286, A81878, I03343, AR036903, A24783, A24782, D28584, A07700, AR022240, A11245, A02710, E12615, AR035193, E14304, A13392, A13393, I19517, A27396, Y11923, A76773, A22413, A82653, AR027100, I28266, I21869, I13349, A35536, A35537, A93016, AF156294, A49045, E16678, A02135, A02136, A04663, A04664, E16636, I01992, A70040, I25027, AJ230933, I26929, I44515, I26928, I26930, I26927, A58525, I08051, I25041, AR038762, AF118808, AR000006, U87250, Y11926, A51384, AR008430, D34614, I49890, I44516, I00077, A92636, D14548, E03165, E02221, E01614, E13364, A58526, A91753, I00079, AF019720, S70644, AF096810, AB012117, A91754, AR064706, U52688, X58217, I68636, AR035975, AR035974, AR035977, AR035976, AR035978, A60957, I84554, I84553, A18722, A10361, Y11449, A60968, AR066482, A60985, A60990, A60987, A97221, AF096793, AF156304, X15418, D44443, AB007195, AF156302, Y17188, AF156303, AF156299, M32676, S65373, A10363, X73003, E04616, I08250, AF130655, I07429, S83538, X13220, Y11447, A91965, AR063812, I07888, I69350, Y11920, I03663, AR027069, A20701, A02711, AR051692, A04447, A04448, A52326, A04710, A04441, A04442, S78798, I12420, AR060234, I19525, A80951, E03018, AR066494, AF156300, Y11458, AF096796, I02343, and AR023813.
--	--	--	--	---

6	HFITF82	54	896291	AA961192, AA909747, AC005914, Z95114, AB023048, AP000510, AC006515, AC006163, and AF011889.
6	HFITF82	55	896133	AI926463, X67056, and X82571.
7	HDPDI45	17	979731	AW083127, AW327290, AW410645, AI798681, AI797284, AW183981, AI096678, AI092936, AI144400, AA236980, AI685511, AI074319, AI860643, AI885247, W46771, AI521427, AW295119, AW327628, AW273299, AI801043, AW300673, AA745647, AI095832, AI457885, AI399827, AW137947, AA813851, AI924126, AW295118, AI381953, AW029034, AI393856, R43938, AI811198, AW151914, AI458562, AA235918, AI823612, R16113, AA651935, T62960, AW198081, T99938, T16212, AA430674, Z39341, F09974, AA884361, AW197763, AA427483, T63211, AI493592, AA338639, T73975, R40698, AA360550, AI926977, F12356, AI420802, AW073824, AA380903, AA861954, R18827, F02261, H00554, Z43270, AA664368, F06017, T32088, AL045886, AA853151, F08301, AI473459, R13263, AW263814, C01020, AA159389, AA404569, T96081, AI583558, AI590043, AI624293, AI621341, AW029566, AI699823, AI474646, AI249389, AI698391, AL046466, AW051088, AI401697, AL036638, AL045349, AI687168, AL045774, AW162194, AL121365, AW192300, AI923989, AI927233, AI610446, AI433611, AI866127, AI814594, AI540674, AI632850, AI445620, AW192687, AW050850, AI669864, AI273189, AW087445, AI581033, AI589134, AI434731, AI289791, AI251221, AL118781, AI355779, AW268964, AI421091, AI433157, AI702073, AI589428, AI559752, AI582932, AI537677, AI270183, AI633125, AI538564, AI915291, AI500714, AW152182, AW022584, AI866090, AW167083, AI889189, AW075382, AI590020, AI422688, AI538885, AI473536, R36271, AI866469, AI536685, AI884318, AI446046, AI587121, AI638644, AI570056, AI866820, AW084056, AW170725, AI309306, W74529, AW079432, AL042944, AI741158, AW148423, AI445992, AI955899, AL110306, AI471429, AI799674, AI929108, AW080746, AL037454, AI475371, AI612913, AI445069, AI918449, AL046618, AW410259, AW059828, AI580214, AI802695, AL036901, F34800, AI281757, AI610399, AI348914, AI797538, AI866770, AW021717, AI610402, AI306610, AL039011, AL036673, AI612750, AI500514, AW161098, AI561356, AI539690, AI554343, AW102794, AI285439, AI623941, AI628325, AL045500, AL120254, AI797908, N57346, AL036631, AW020397, AI679266, AI267185, AI539260, AL046595, AI553645, AI250627, AI860897, AI859991, AI091468, AI560545, AW081255, AI635492,

				AI917963, AI288285, AI538764, AI270429, AI445611, AI499890, AI620302, AL079963, AI446373, AI440238, AL037030, AL038778, AI961589, AA572758, AW151283, AI432570, AA503384, AL037649, AA806719, AI435253, AW163834, AL047344, AI340519, N33175, AI636619, AI340603, AI345415, AI318280, AI274768, AI494201, AW129659, AI345613, R32821, AF028823, E01614, E13364, X66871, AF111849, I89947, I48978, AL117457, I33392, A91160, AR034821, A91162, AF177401, S68736, U87620, AF026124, AL122100, AL137533, AL137480, AL133560, AL117416, AL133619, A08910, AR038854, A08909, AL133081, AL050277, A65341, A77033, A77035, I32738, AL137292, AL137479, X72889, A08916, A08913, AL137574, X76228, AJ003118, A08912, X63574, AF026816, AF079763, X84990, AL133031, S76508, I48979, AF031147, AF044323, AL080124, AF113019, AL049347, AF067728, AL133072, AJ005690, Z97214, X80340, A08908, A45787, AL133606, S61953, AL110218, S36676, X79812, AF087943, Z13966, AF090886, AF061795, AF090903, AF151685, I09499, AF117657, AF199027, AF185576, AF106657, AL080148, AF079765, D83032, AC004883, AL023657, AL133637, I26207, AF180525, AL080126, AF200464, Y10080, A08907, I89931, Z82022, AL133016, I49625, AF097996, A65340, AL122050, E06743, S69510, AL117440, AF146568, AL117435, AL133112, A58524, A58523, A18777, Y16645, AL137530, I46765, AL110225, L04504, I89934, AR020905, AF100781, AL049283, A76335, AL096720, AL117394, AL050138, AB008792, U35846, AL122121, AF008439, AF182215, AB008791, I00734, AF017437, U67958, AJ000937, AL137258, AL050155, E00617, E00717, E00778, Y07905, AL050393, AF113691, A21103, AF091084, Y10823, AL133080, S82852, AL122123, U86379, AL137550, AF139986, AL096751, M92439, A15345, AL110159, X81464, S83456, X56039, A07588, AF118070, AL080159, AF151109, AF069506, AF115392, AL110296, AF017790, AF047716, AL137529, Y09972, S77771, AF061981, AL110222, AF032666, U49908, AR011880, AL122110, A57389, AL049300, AL137478, U58996, AL050149, D16301, U80742, AJ012755, X98834, I29004, AL137271, AL049464, M19658, AL133640, E02349, AR068753, AF141289, X52128, AF017152, AL137711, AL050108, AL133665, A12297, AL137665, A08911, AL137537, E12747, I79595, AF002985, AR029490, AL117583, AL137459, AF183393, AL110158, AL050116, AL137558, U77594, AL050092, AL137547, I89944, AL137463, AF067790, Y10655, AF113694,
--	--	--	--	---

				X82434, X70685, AF118090, E01963, AF111851, AF153205, AL110221, M27260, E08631, AL096744, AF158248, AF039138, AF039137, AL137488, AF057300, AF057299, X83508, AF205861, AF114170, AL049339, AL117587, Y10936, AL049430, AL080154, AL049466, AF210052, AF192557, AL049452, A93350, E01314, AL080162, E07108, Y14314, S83440, U78525, AF162270, U88966, and U75932.
7	HDPDI45	56	905871	AW083127, AW327290, AW410645, AI798681, AI797284, AW183981, AI096678, AI092936, AI144400, AA236980, AI685511, AI074319, AI860643, AI885247, W46771, AI521427, AW295119, AW327628, AW273299, AI801043, AW300673, AI095832, AA745647, AI457885, AI399827, AW137947, AA813851, AI924126, AW295118, AI381953, AW029034, AI393856, R43938, AI811198, AW151914, AI458562, AA235918, AI823612, R16113, AA651935, T62960, AW198081, F12356, AA360550, T16212, T99938, AA430674, Z39341, F09974, AA884361, AW197763, AA427483, AI493592, T63211, Z43270, AA338639, AL045886, T73975, R40698, AI926977, AI420802, AW073824, AA380903, AA861954, R18827, F02261, H00554, AA664368, F06017, T32088, AA853151, F08301, AI473459, R13263, AW263814, C01020, AA159389, AA404569, AI927233, T96081, AI289791, AI583558, AI866503, AI590043, AI624293, AW084056, AI621341, AI860003, AI567953, AW029566, AI699823, AI474646, AI432644, AL042595, AI433157, AI648567, AI690946, AI554821, AI249389, AW151136, AI698391, AI539771, AI436429, AI537677, AI494201, AI500659, AI866465, AI815232, AI801325, AI500523, AL046466, AI538850, AW162194, AI887775, AI582932, AI923989, AI284517, AI872423, AI500706, AI445237, AI491776, AW151138, AI889189, AI521560, AW051088, AI500662, AI539800, AW172723, AI284509, AI582912, AI538885, AI440263, AI889168, AI866573, AI633493, AI401697, AI434256, AI866469, AI805769, AI434242, AI888661, AI500714, AI284513, AI888118, AI702065, AI285439, AI859991, AI355779, AI623736, AI889147, AI581033, AI371228, AI491710, AI440252, AI431307, AL047422, AI866786, AI610557, AI242736, AI828574, AI866461, AI887499, AI446495, AW151979, AI539781, AI539707, AL036638, AI885949, AL045349, AI559957, AW089557, AI285419, AI521571, AI469775, AI687168, AI866581, AI815150, AL045774, AL121365, AW192300, AI371243, AI610446, AL042865, AL118781, AI433611, AI866127, AI814594, AI540674, AI632850, AL045500, AI866820, AI445620, AI561170, AW192687, AW050850, AI890907, AI669864,

				AI273189, AW087445, AI610426, AI589134, AI273179, AI371251, AI866510, AI476086, AI434731, AI923046, AI251221, AL079960, AL039390, AW268964, AI620284, AI421091, AI431316, AI702073, AL048403, AI589428, AI559752, AA878808, AI270183, AL045626, AI274759, AI633125, AI538564, AI499508, AI867068, AI915291, AW152182, AW022584, AI866090, AW167083, AI434255, AW075382, AI590020, AI422688, AI473536, R36271, AI371265, AI433976, AI536685, AI587121, AI884318, AI446046, AI638644, AI570056, AI366900, AL047187, AW170725, AI309306, AF028823, A91160, E01614, E13364, X66871, AF111849, I89947, I48978, AL117457, I33392, AR034821, A91162, AF177401, S68736, U87620, AL133081, AF026124, AL122100, AL137533, AL137480, AL133560, AL117416, AL133619, A08910, AR038854, A08909, AL050277, A65341, A77033, A77035, I32738, AL137292, AL137479, A08916, A08913, AL137574, X72889, X76228, AJ003118, A08912, X63574, AF026816, I46765, AF079763, X84990, AL133031, S76508, I48979, AF031147, AF044323, AL080124, AF113019, AL049347, AF067728, AL133072, AJ005690, Z97214, A08908, X80340, A45787, AF002985, AL133606, AC004883, S61953, S36676, X79812, AF087943, Z13966, AF090886, AF061795, AF090903, AF151685, I09499, AF117657, AF199027, AF185576, AF106657, AL080148, AL110218, AF079765, D83032, AL023657, AL133637, AF180525, AL080126, I26207, Y10080, A08907, I89931, AF200464, Z82022, AL133016, I49625, AF097996, A65340, AL122050, E06743, S69510, AL117440, AF146568, AL117435, AL133112, A58524, A58523, A18777, AL122049, Y16645, AL117587, AL137530, AL110225, L04504, I89934, AR020905, AF100781, AL049283, A76335, AL096720, AL117394, AL050138, AB008792, U35846, AL133049, AL122121, AF008439, AF182215, AB008791, I00734, AL122123, AF017437, U67958, AJ000937, AL137258, S77771, E00617, E00717, E00778, Y07905, AL050393, AF113691, AL050155, A21103, AF091084, Y10823, AL133080, S82852, U86379, AL137550, AF139986, AL096751, M92439, A15345, AL110159, AL035458, X81464, S83456, AL049300, X56039, A07588, AF118070, AL080159, AF151109, AF069506, AF115392, AL110296, AF017790, AF047716, AL137529, Y09972, AF061981, AL110222, AF032666, I29004, U49908, AR011880, AL122110, A57389, AL137478, U58996, AF081195, AL050149, D16301, U80742, AJ012755, X98834, AL049464, M19658, AL137271, AL133640, E02349, AR068753, AF141289, X52128, AF017152,
--	--	--	--	---

				AL137711, AL050108, AL133665, A12297, AL137665, A08911, AL137537, E12747, I79595, AL137547, AR029490, AL117583, AL137459, AF183393, AL110158, AL050116, AL137558, AL133077, U77594, AL050092, E07361, I89944, AL137463, AF067790, Y10655, AF113694, X82434, X70685, AF118090, E01963, AF111851, AF153205, AL110221, M27260, E08631, AL096744, AF158248, AF039138, AF039137, AL137488, AF057300, AF057299, X83508, AF114170, AL137526, AL049339, Y10936, AL049430, AL080154, AL049466, AF210052, AF192557, AF205861, X55446, AL049452, A93350, and E01314.
8	HUVP63	18	1037883	AL041330, AL039218, AI983091, AI026948, AW007308, AA187443, AI313476, AW150958, AI184989, AW081153, AW051414, AW103092, AI400495, AA555192, T31299, AI393501, AI984107, AA187617, AI278262, AA687653, AI933328, AW264063, AI554618, AI936114, AA825438, AI263371, AI369298, AI872012, AA573410, T58131, AW392614, AI827952, AA780995, AW403022, AW264562, AA430020, AA310172, AA445968, AI459545, W42765, AI582810, T08226, AW117700, AI907736, AA866012, AA125861, T08674, AW117718, AA573401, AA983333, AA775349, AA125860, T96126, AI159920, AA234055, AI419782, AA309637, AA565298, AW304779, AA723908, AI355922, AI200433, AI802359, AI075125, AA758121, AI807096, AA953036, AI381630, AW006719, F24405, AI978991, W57719, AA954841, F31087, W40553, T96208, AW375057, T90761, H10599, AA777249, W57718, H04978, AI215566, H10390, AI220877, R89064, R39116, T83210, T34123, AA398261, AI638808, H04979, AW277147, R89161, AA757325, H25348, AW295563, R37587, AI126638, AI091370, T63068, AW419058, R13993, Z44248, AA340597, R49772, AA907581, R02011, AW149920, R02010, AA878773, AL041331, AI638643, W19394, N90908, Z40207, T80172, AA514684, AI470293, AA504514, AI500504, AW087901, AA937558, AI269580, AI251830, AI889818, AA631120, AI932949, AI419440, AI872914, AW188573, AI669639, AI654750, AI540179, AW005614, AI440511, AI802477, AI364135, AW129230, AW189268, AW168031, AW082532, AI952302, AI679631, AI824648, AI909661, AI888501, AW190042, AI583065, AW024374, AA814782, AI921371, AI273003, AI640873, AA916033, AI801536, AI863466, AI758812, AI624604, AI537643, AF070644, AF009664, AC004908, AC004842, U43563, AL031259, AE000665, AC002430, AC007384, U95739, AL117629, AF113690, AE000664, AC005209, AC006112, AF179633, AL033521, AP000697, AI8777,

				AC005156, AC002060, Y12860, AF146568, I30339, I30334, AC000053, AC004797, AL110252, AC018767, AC006203, AC004989, AP000247, AB028451, Y16258, Y16257, E02756, Y16256, AP000130, AP000208, I89944, AC006479, I09360, AL122050, AP000344, AC002540, M92439, X56039, AF104032, AL049460, AL080060, AF044221, Z37987, AL080127, AC005815, AC007172, AC005876, AC006299, AL137300, AL133559, AC005488, AF030635, X83544, AL133081, M86826, U58653, AC002287, Y16645, AL137429, AF207750, AL035587, AL117626, AR038969, I48978, AC007392, AF031903, AC004383, AF065135, E12579, S77771, AC002464, and AL034417.
8	HUVPD63	57	865263	AC004842, AC004908, and U43563.
8	HUVPD63	58	865264	U43563, AC004842, and AC004908.
8	HUVPD63	59	865262	AI459545, AW375057, and AA398261.
8	HUVPD63	60	829527	AL039218, AL041330, AI983091, AI026948, AW007308, AA187443, AI313476, AW150958, AI184989, AW051414, AW103092, AI400495, T31299, AA555192, AI393501, AI984107, AW081153, AA187617, AA687653, AI933328, AI554618, AA825438, AI936114, AI075125, AI278262, T58131, AW264063, AA573410, AI369298, AI872012, AI827952, AW392614, AI263371, AW403022, AW264562, AA430020, W42765, AA445968, T08226, W57718, AI582810, AW117700, AA125861, AA866012, T08674, AW117718, AA573401, AA775349, AA125860, AA983333, T96126, W40553, AA780995, AA309637, AI159920, AA234055, AA723908, AI419782, AA565298, AW304779, AI355922, AI200433, AI802359, AI807096, AA953036, AA758121, AI381630, AW006719, F24405, AI978991, W57719, AA954841, F31087, T90761, T96208, H10599, AA777249, AI215566, AI220877, H04978, R89064, H10390, R39116, AA310172, T83210, T34123, H04979, AI638808, R89161, AW277147, AA757325, H25348, R37587, AI126638, AW419058, R13993, T63068, Z44248, R49772, AA907581, AA340597, AW295563, R02011, AW149920, AI091370, R02010, AA878773, AI638643, W19394, AL041331, N90908, Z40207, T80172, F24012, AF070644, AC004908, and AL031259.
9	HHPDV90	19	963213	AI653359, AI811005, AI743036, AI568555, AA625521, AI824027, N40011, AA193304, AI130747, AI936637, AI379074, AI126543, AI275538, AI368011, AA404268, AI080358, AI624113, AW236922, AI276027, AA564363, AI275570, AA962422, AI191276, AI368003, AI480304, W45197, AI492368, AI635306, W38715, AA731161, AI333916, AA443016, AA488874, AI291511, AI934349, AA488954, AI582669, AI274931, AI581645, N92570, W38762, AI696471, AI383502, AA071470,

				AA625343, AI480410, AA824555, AI693424, AA613349, AI096708, N27277, AA861317, AI796055, AA401229, AA463456, AI041748, AA335410, AI523346, AI933211, AI224569, AA194258, AI868719, AA451885, AA135295, AA360398, C16240, AA257150, AW250238, AA135165, AI868703, N34385, N42846, AA419446, AA736543, AA584194, AI085242, AA745092, AC002364, AC006241, AL049776, AC002126, AC009247, AC005231, AF196779, AC006160, Z85986, AC020663, U89337, U80017, AC004991, U62293, U91323, AC005488, AC004999, AC005288, AC004106, AL035086, AC006101, AL080243, AC005377, AL023807, AL049872, AC004491, Z95115, AP000008, and AC004983.
9	HHPDV90	61	880018	AA401229, AA488954, AI041748, AI811005, and AC002364.
9	HHPDV90	62	889155	AI653359, AI743036, AI568555, AI824027, AA625521, AI130747, AI936637, AI368011, AI080358, AA404268, AW236922, W38715, AI275538, AA564363, AI276027, AI624113, AI126543, W45197, AI379074, AI191276, AI635306, AI275570, AI368003, AI333916, AA962422, AI480304, AI492368, AA193304, N40011, N92570, AI934349, AI291511, AA731161, AI274931, AA488874, AI582669, W38762, AI581645, AA071470, AI696471, AI383502, AI480410, AA824555, AA613349, N27277, AA443016, AI693424, AI096708, AA861317, AI796055, AA463456, AA335410, AI523346, AA625343, AI933211, AI811005, AA194258, AI868719, AA451885, C16240, AW250238, AA135165, AA135295, AI868703, AI224569, AA257150, N34385, AA360398, AA419446, AC002364, and AA825569.
10	HETCP58	20	973133	AI075041, AA548124, AW015293, AA876653, AA876910, AW104181, AI682229, AI215001, AA813699, AW161086, N42363, AA548279, AW161341, H00093, AI681265, AI702810, H00079, H00070, H00054, H00096, H00049, N42593, AB019440, AC007275, AC007276, AC004924, AL031846, AC007274, AC006991, AL009179, AC007690, AF057177, AF159056, AC006033, AC005996, AC007283, AL024498, AC006458, AB020859, and AC006509.
10	HETCP58	63	872971	AW104181, AI682229, AI215001, AA876653, N42593, AI075041, AW161086, N42363, AA548124, AW161341, H00093, H00079, H00070, H00054, H00096, H00049, AB019440, AC007275, AC007276, AC004924, AC007690, AF057177, AF159056, AC006033, AC005996, AB020859, AL024498, AC006458, AC007283, and AC006509.
10	HETCP58	64	750968	AI075041, AA548124, AW015293, AA876653, AA876910, AA813699, AA548279, AI681265, AI702810, AL031846, AC007274, AC006991,

				AB019440, and AL009179.
11	HCEVB32	21	908120	AI657153, AI870598, W92765, AI084891, N71092, AI569855, W73738, AA570031, AI199112, AI655677, AI954725, AI979295, D59505, W26939, N92655, AI335935, N99601, W05461, AI423310, AI631667, AI636229, AA533729, AA326569, F09930, W73414, W93164, T66308, T66362, R24945, R45208, F12303, AI189391, AA932677, AI279064, AI784363, AW131005, AI909372, AA385468, AI553660, and H19535.
11	HCEVB32	65	904995	AA326569, AI189391, AI279064, AI784363, D58283, D80195, D80253, D80227, D81030, D80038, D51799, D51423, D59619, D80210, D80391, D80240, D80193, D80196, D80188, D80219, D59927, D80043, D59275, D80366, D80212, D80022, D59889, D80378, D80045, F13647, T03269, C75259, D59859, D50995, D80166, D80269, AI655677, AI979295, C14014, C15076, D80164, D59502, D81026, D80134, D80024, C14429, AI954725, D50979, D80268, D59467, D59787, D80949, D80168, D57483, C14227, D58253, D81111, D59610, D80241, D51060, C14389, D59695, C14331, AA285331, AW178893, AA305409, D80522, H19535, D51079, T11051, AW177440, D51022, AA305578, AW179328, AW178775, AW378532, AI905856, D51097, AW352158, D80251, AW377671, AA514188, D52291, D80248, AW178762, AW177501, AW177511, AA514186, D80133, AW360811, AW352117, AW176467, AW375405, AW366296, AW360844, AW360817, AW375406, AW378534, AW179332, AW377672, AW179023, AW178905, D80302, D80132, AW179018, AW179024, AW352171, AW377676, D51103, D80439, AW178906, AW352170, AW177731, AW178907, AW179019, D80247, AW177505, AW179020, AW178909, AW177456, AW179329, AW178980, AW177733, AW378528, AW178908, AW178754, AW179004, AW178914, AW178774, T48593, AA033512, C14975, AW367967, AW352174, AI335935, AW179220, A62298, A62300, X67155, A84916, A67220, A25909, AJ132110, D26022, D34614, AR025207, A78862, D89785, Y17188, AR018138, D88547, X68127, A85396, AR066482, AB012117, A85477, A86792, X93549, I19525, X82626, AF058696, AF135125, AR008278, AB028859, A44171, U87250, Y12724, AR064240, A82595, AB002449, AR060385, A94995, AR008443, I50126, I50132, I50128, I50133, S69292, AR066488, AR016514, AR060138, A45456, A26615, AR052274, D88507, Y09669, I18371, A43192, X89963, A43190, AR038669, A43601, AR066487, AB033111, A30438, Z32749, I18367, S78798, D50010, AR008408, AR066490, AR062871, AR062872, D13509, U87247, I15997, AR037157, A80951,

				X92518, AB023656, A91750, X55486, X60736, U79457, A20702, AR017907, A43189, AR062873, A43188, A20700, AR000511, M60510, A84772, AR023705, AR067731, AR067732, A58522, A84776, A84773, A84775, X93535, and A84774.
11	HCEVB32	66	904994	AI657153, AI870598, W92765, AI084891, N71092, W73738, AI569855, AA570031, AI199112, D59505, W26939, N92655, W05461, N99601, AI631667, AI423310, AI636229, AA533729, AI335935, AI655677, F09930, AI954725, W73414, AI979295, W93164, T66362, T66308, R24945, F12303, R45208, AA932677, AW131005, AI909372, AA385468, and AI553660.
11	HCEVB32	67	853535	AW392670, AL119319, AL119457, U46350, U46347, U46351, AL119324, AL119522, AL119439, AL119484, AL119391, AL134536, AL119443, AL134920, AW372827, AW363220, AW384394, U46349, U46341, AL119497, AL119483, AL119401, Z99396, AL134531, AL119363, AL119444, AI142131, AL119355, AL134527, AL037205, U46346, AL119418, AL119335, AL134538, AL119399, AL134533, AL042614, AL042544, AL042975, AL039912, AL042542, AL043019, U46345, AL042965, AL043029, AL042450, AL042984, AL043003, AL042551, AL119464, U83115, AB026436, AR066494, AR054110, AR060234, and A81671.
12	HETHW90	22	947656	AA747448, AW139953, AA884238, W24225, AA290680, AA287219, AA284533, AA429355, AI360321, AI633676, N95536, AA455138, AA400112, AI906283, AA430003, AI554641, AA464322, AI690929, W40459, AW081221, AI249479, AI937162, AA804908, AW237463, AA056408, AI811265, AA156431, AI916817, AI808357, AI205335, AA827123, AA908237, AA401384, AA147559, AI962527, AA056656, W92590, R18687, AA209520, AW083915, AI872884, N93957, W94536, AA836309, AA330781, AA071079, F11246, F08909, AA339983, AA337901, T12293, AA214166, AI686359, AW079602, AA748362, AA804883, AA071163, AA214325, AI468075, AA747518, and AA291085.
12	HETHW90	68	895189	AI205335, R18687, AA209520, AW083915, AI906283, AA330781, F11246, AA056656, AA337901, AA214166, D80227, D80269, D51799, D80166, D59467, D59502, D80195, C14389, D80164, D59275, D51022, D80378, D81026, D58283, D59859, D50979, D80022, D51423, D59619, D80210, D80391, D80240, D80253, D80043, D59787, C14331, D80038, D59610, C15076, D50995, D81030, D80212, D80268, D80366, D80193, D59927, D80196, D80188, D80248, D80045, D80219, AA514188, D80522, AA305409, D80302, AA305578, D80247, D80251, D57483, C14014, D59889, D80133, D80024, D80439, D80241, AW360811, AW177440,

				D51103, D80157, AA514186, T03269, AW178893, D51759, C06015, AW377671, AW375405, AW178906, AW177731, AW178908, AW366296, AW360817, AW179328, AW179020, AW375406, AW378534, AW179332, AW377672, AW179023, AW178905, AW178907, AW378532, D58101, AW178986, T03116, T48593, H67854, AW378528, AW178762, AW352171, AW377676, AW179019, AW352170, C03092, H67866, AW179024, AA809122, AI525920, D51250, D45260, D80132, AW360834, T11417, AW177456, D80134, AW178980, AW178911, AW177733, D59503, AW367950, AW179018, F13647, D80258, AI525923, C14344, AW378533, D59317, AW178914, D58246, D81111, AW178774, AA514184, AI535686, D80014, C14227, D80064, AI525917, AW378525, AW352163, C14973, AI525235, D59695, D52291, D51221, AI525227, D59474, D59551, AW378543, AW378540, T02868, AW177728, C14407, AI525242, AI557774, C14046, D45273, AW178781, AI525925, AI525928, AI525237, AW378542, AI525912, AA285331, AI525215, AI557751, D59627, Z33452, C16955, C05763, T02974, D80168, Z21582, AW360855, AI525222, C14298, T03048, C13958, D51213, H67858, D31458, AW369651, Z30160, AI535665, A82595, AF058696, A84916, AB028859, AJ132110, A62300, A62298, AR018138, AR008278, AR060385, AB002449, I50126, I50132, I50128, I50133, A94995, X67155, Y12724, AR066488, D89785, Y17188, D34614, D26022, A25909, A26615, AR052274, AR016514, A67220, A78862, AR060138, A45456, I14842, Y09669, AR066487, AR008443, A43192, A43190, AR038669, AR054175, A30438, D88547, Y17187, AR008408, A63261, AR008277, AR008281, X82626, A70867, D50010, AR016808, AR025207, AR062872, I79511, A64136, A68321, AR016691, AR016690, U46128, D13509, X68127, I18367, I82448, AR060133, and AF123263.
12	HETHW90	69	896653	AA747448, AW139953, AA290680, AA884238, AA287219, AA284533, AI633676, W24225, AA429355, AI360321, AA400112, AA430003, N95536, W40459, AI554641, AI690929, AA455138, AI249479, AA804908, AI937162, AA156431, AA056408, AA464322, AW081221, AI808357, AW237463, AA827123, AI811265, AA401384, AI916817, AA908237, AI962527, AA147559, W92590, AA836309, N93957, W94536, AI872884, AA071079, AA339983, F08909, T12293, AI686359, AI906283, AW079602, AA748362, AA214325, AA804883, AA071163, AI468075, AA747518, T18597, AI535660, D50992, AI541205, AI525500, AI525556, AI557533, Z32887, AI557262, Z33559, D59751, AI525302, AI535639, AI540903, C14228,

				AI536138, AI541075, AI557864, AI557731, AI526078, AI557082, AI525316, AI541034, AI557084, AI525852, AI541365, AI541356, AI541321, H65400, AI557809, AI557312, AI557602, R29657, AI557317, AI557474, AI525856, AA058620, AI535813, AI541353, AI525757, C14322, AI535994, AI557234, Z33585, D51002, AI540974, AI541154, AI557238, AI536070, AI541450, AI557155, AI546829, AI557258, AI536150, AI535828, D30843, AW022815, AI541346, AJ239433, AI557543, AI557041, N71206, AI525666, AI525661, AI541027, AI525656, AI541362, AI557810, AI541048, AI557241, AI557279, AI557697, AI541336, AI557408, AI557039, T70101, AI547177, A62298, AR050070, A82595, A82593, Z30183, U94592, A62300, AF006072, U45328, and AR025466.
13	HIBEB47	70	892619	AA351042.
13	HIBEB47	71	902488	AA351041, R46381, W44601, AA311079, AI219575, AA601495, AA457599, AW391396, AA749350, N70891, AA346163, AI026925, AA493718, AA088281, AW270695, H96481, AA446541, AI457847, AA099766, AI263739, AA595695, M85754, AA321733, AI198511, AA004797, AW080711, AA446359, AA420526, AA420593, AA435704, AA147639, W44620, N29555, AI688042, N59837, AW104748, AL079697, AI860789, N41014, AW206065, T53696, T06803, AA348763, AC008282, AC005204, Z96074, AP000346, AC007751, AC008174, AL009028, AB019440, AL009029, AC003973, Z98753, AC000055, AC007970, U82696, AL109662, AE000661, AB020871, AC006556, AL078615, AL022728, AL009176, AC002085, Z99569, AC004047, AP001137, AL049696, AC004474, AC006366, AC003082, AC002301, AC000037, AC000032, AF191071, AC004389, AC006984, AP000542, AL133249, AC004054, AC009514, AJ006996, AC010436, AL049176, Z95126, Y15155, AC005066, AC005225, Z95114, AL031780, AC009241, Z84470, AC004385, Z81009, AC006370, AL022577, AJ239318, AC003081, AL022144, AL022154, AL031074, AC006978, Z80774, AL023802, AL049844, AC003666, AL096867, Z81007, AC005177, AC002454, AC006395, AC005922, U50871, AL121592, AC000125, AP000034, AL035443, AC003085, AP000036, AL079305, AC006288, AL109981, AL008722, AC002523, AL022576, AL121823, AL133246, AP000262, AP000264, AC005201, AF188025, AP000101, AP000099, AL035695, AL033521, AL024507, AL137191, AC005900, AL132985, AC007319, AL133244, AC006985, AC005549, AC007253, AL049634, AF051687, AL132820, Z84816, AL109656, Z70227, AC002122,

				AC002078, AC004842, AC004806, Z95118, Z84487, AC004478, AC007157, AC009411, AC006946, AC006548, AL035698, AF129077, AC003016, AL031782, and AC006227.
13	HIBEB47	72	897748	W44620, W44601, AA205647, R46381, AA351041, AA205870, AI656469, AI970353, AI141706, AI688042, AA311167, AI651237, AI383946, AA968756, AI989717, AI675276, AA975275, AW204874, H19652, AA004536, AI652826, R77550, H19584, AI023113, AI949006, AI471734, AA934519, H20333, N74439, H66274, AI189579, N53213, AA988199, AA878222, N59837, AA311079, AA074101, N70891, AA088281, H96481, AI457847, AA457599, AA099766, AI219575, AI263739, AA595695, AI198511, AA004797, AW080711, AW391396, AA601495, AA420526, AA321733, AA420593, M85754, AA346163, AA749350, AA147639, AA493718, N29555, AA435704, AI026925, N53191, AA446359, AA446541, AL079697, AW270695, AI860789, AW104748, N41014, AC005204, AP000346, AC005337, AC006254, AL034348, AL078615, AL049832, Z82200, AC000080, AC000090, AC008282, AC007680, AC006556, AC007406, AP000337, U82671, AB020864, AP000215, AP001137, AC002301, AL109662, Y15155, AC002085, AC003973, AL009176, U95626, Z96074, AJ006996, AL049562, Z99569, AC003082, AC007275, AL080272, AL049176, AC007751, AP000345, AL049696, AC010200, AC000032, AL122020, AC000037, AC004047, AF191071, AB020871, AL022728, AC005993, AL009028, AC008174, AL031078, AC005378, AL009029, AC004054, Z95126, AC007566, AL050308, AC005281, AC006984, AL022574, AC005225, Z95114, AL022171, AL133249, AC008115, AC006960, AC006395, AL079342, AC009533, AC004156, AC003081, AC002065, AC004389, Z23022, AC007878, AC000055, AB019440, Z72522, AC003031, AC004662, AC005040, Z98753, AE000661, AJ239318, AC007970, AC005066, AC009514, AC006366, AC004474, AC004825, AC007253, U82696, AL035688, Z93931, AC009241, AC018633, AP000542, AC010436, AC004551, AC006370, Z81009, Z84470, AC004385, AL132994, AL096867, AL022577, and AL022144.
15	HTTBS64	25	1008159	AI866975, R45283, AI097558, AI214225, AW007566, AA147509, AL045179, W56131, AI439494, AI500233, H99972, N26740, AA077991, R70752, AW058517, AA078630, AW131608, AA730643, AA078488, AA077989, AC006356, AL034428, AL049873, Z83819, AL035552, AC005406, AC009069, AL050401, AC004988, AL133247, AF003528, AL021877, AL031391, AC002076, AL121577, AL022718,

				AF003529, Z98753, AC005799, AC004216, AC007543, AL033522, Z99571, AC006979, AC002302, AC005873, AC007214, AC004160, U82828, AL034369, AC006351, AC002065, AC005284, AC005249, AC006007, AC006459, AL109941, AL137100, AC007065, Z93403, AC005386, Z97055, AC002072, AC007919, AC007092, AC006374, AC000112, AC007911, Z95325, AC002519, AF002994, Z98303, Z82205, AC001642, AL034407, AC007277, AC006479, AC006195, AP000567, AL049834, AC004949, U82672, AC007368, AC005019, AC000109, AC007655, AL050308, AP001067, AP000473, AC004911, AC006957, AF029308, AC008498, AC002412, AL022171, AC007126, AP000346, AF126403, AC002523, AC007380, AC008109, AL135960, AJ131016, AC004388, Z84720, Z82900, AC006482, Z83821, AL020991, AC006362, AC004103, AJ229043, AL032822, AC008173, AL132800, AC006288, AJ239329, AC004470, AL022151, AL008713, AL021307, AE000661, AF064865, AC007023, AL022721, AC004381, AC007785, AP000968, AC002383, AC006249, AL117340, AC004081, AL096801, AL121840, AC010385, AC007392, L11910, AP001069, AC003084, and AL096867.
15	HTTBS64	75	754125	AI866975, AI097558, AI214225, R45283, AW007566, AA147509, AL045179, W56131, AI439494, AW058517, AI500233, H99972, N26740, AW014758, AI659923, H90366, AA077991, R70752, AA078630, AW131608, AA730643, AA078488, AA077989, W67645, AI831590, AI572089, AA077958, AA689483, AI990093, AI798295, AA078242, AI587585, AA021479, AA928045, H27065, AA078073, AI032142, AA078271, R76636, AL039748, N72437, AI796126, AA078270, AA078152, AA075792, N24046, AA078573, AI902812, AA078359, N54855, N80352, N62578, AI890136, AA827722, H13732, AA078254, AI889782, H84628, AW297499, AA515135, AA496937, AA507857, H25470, AW160391, U46225, AA652558, AA297575, AI057291, AW439455, AW022205, AI918839, AA584142, AA078230, AA078067, T95863, W52493, AW162664, AI033109, AA078172, AA412444, AW243749, AI376371, H85417, N73251, R68563, N72631, AW250302, H70683, AW069159, AW026692, AW249541, AA078071, AA078288, AL041247, R91003, AI367586, AI985740, AA384699, R69671, AI431322, AA400012, AA405769, AA401570, AI459814, AA078672, AI758738, AI091414, N52345, AI902813, H01805, AA504796, AA078379, N90370, AA078224, AA516129, AA077784, AA975993, H93010, AA077755, AA078390, N66537, AW377693, AA776949, AA632711, AI510841, AA078583,

				AC007425, AC010205, AC005879, AC002324, AL109758, AC007021, AC002541, AF121351, AL021877, AC007869, AL109982, Z22773, AP000518, AL022238, AC005259, AC006012, AP000365, AC003042, AL022722, AC005358, AL122056, AL080243, AL031230, Z70758, AF073797, AC007792, AC005992, AC006256, AF229844, AC007049, Z99127, AL022337, AF002654, AC004617, AC004216, AL022326, D86993, AC004685, X79482, Z84469, AC005409, AC007625, AF084363, AC002544, AC007245, AL033522, AC005019, X77078, AC008008, AC000115, AC006584, AC004405, U06762, AC004908, AC006305, AC002302, AC004673, AC003061, AF177767, AL031293, Z98950, M14088, AC005962, U62019, AC000398, AF116519, AC004961, AF002994, AC004407, M22670, AC006035, AC006062, M33196, Z69721, Z68756, Z97181, AC006991, AC004650, Z82901, AC007680, AC003019, AL117694, AE000664, Z95116, X66854, AJ131017, AC004522, AC006965, AC006961, AF130642, M97232, M64685, AL035552, AC005820, AL022327, AL035494, Z80998, AC004203, AC004869, AC005960, AB030238, AC000112, AC000385, AF139987, AL031771, AP000167, AP000052, AP000120, X56936, M60766, AP000113, AP000045, AF100956, AC009113, AC004804, AL034409, AC004812, AC005697, U01226, L10619, AC002487, AP000031, AL133246, Z47052, U54614, AC019014, X66494, AP000255, AC004968, AF071080, AC008044, AJ007715, AC004470, AC005912, U20365, AC004931, AF207955, AC006959, AL121840, AC007151, AC006478, AC005158, AC007277, AL021069, AL034375, AC005881, AB023054, AC007182, U82742, AC002536, AC007564, AF111103, U58105, AC009363, AJ230874, X55225, L22403, M80521, Z97632, A51135, AC004125, AC011013, AL035415, AC007461, AP000213, AP000561, AC005971, L12553, Z99128, AL121595, AC007540, Z99570, Z11815, AC004921, AL121578, AP000135, AC006480, AC010722, AC007380, U70436, X16818, AL034412, L38954, X06862, Z93931, AC005516, AL035702, AC005353, AC006355, AC005352, AL137100, AF016856, AC006600, AL021937, AB020867, AC002076, AC005921, Z98052, AC005351, AC002109, AC003037, AC004491, AC007056, AL139228, AL035469, AC009227, AC006374, X12925, AC006956, AF133093, AC005280, AL050325, AL031677, X99946, AC007877, AC004103, AC007632, U77989, AF141325, AF050157, and AC004983.
16	HAGAN21	26	1026956	Z69655 and AC004841.
16	HAGAN21	76	864914	Z69655.
16	HAGAN21	77	902027	N33610 and U88048.

16	HAGAN21	78	902026	Z98046.
16	HAGAN21	79	902025	N33610, U88048, and AL050114.
17	HUSIE23	27	910142	AA583044, C75049, AA902384, AI707471, AI783835, AA630607, AI468047, T63012, F13604, R46513, AA011062, AA011061, H27961, T63157, AA010702, AA489383, AL035668, AF040249, AF041421, and L25602.
17	HUSIE23	80	886653	AA583044, C75049, AA902384, AI707471, AI783835, AA630607, AI468047, T63012, F13604, R46513, AA011062, AA011061, AA010702, H27961, T63157, AA489383, AA853353, AI569017, AL045494, AL042523, AL135012, AL045327, AL134110, AL134524, AL042420, AL042468, AL042519, AL045328, AL047163, AL042741, AL042655, AL045891, U46344, AL042898, AL043089, AL043321, AL046356, AL042488, AI547258, AL035668, AF040249, AF041421, L25602, I08620, AJ001817, AR066494, A85203, AL133053, AL122101, AL133074, and AL133049.
18	HCMSC92	28	1007977	AW023111, AI923052, AI254779, T74524, AA410788, N57681, AA720774, AA644090, AW410354, AA613624, H07953, AA449997, AL037910, AA833896, AA904211, AI056177, AW021399, AA455483, AI061313, AA833875, AI962030, AW020094, AI206841, AL047349, AA714011, AA574442, AI247101, AA715814, AI250552, AI284543, T09219, AI675615, AI282479, AA228778, R70986, AA613627, AI066646, AI267818, AW302017, AI251284, AI251203, AI251034, AW188427, AI278972, AI189682, AI186438, AW340905, AI267269, AI587583, AI587565, AW303098, AW341978, AA206707, AW274078, AW238253, AI254770, AA558404, F29968, AI446623, AW338021, AW157731, AA629540, AI473995, Z84488, AC002477, AC002425, AC006953, AL096701, AC005837, AC005500, AP000557, AC003098, AL021878, U78027, AC004033, Z98044, AC010205, AC005409, AC004865, AL121658, AC006120, AC007785, AC004686, AL132641, AL078638, AC005736, AP000556, AC004224, Z98744, AC006316, AC007192, AC007227, AC006277, AC005696, AL031710, AC007686, AL022476, AC004778, AC008056, AP000355, AL096791, AP000359, AC005844, AC005189, AC007182, AL021917, AL023283, AC005598, AC010170, AC002543, AC009516, AC005049, AC005225, Z95331, AL022238, AC002418, AL133500, AC006251, AC009247, AC000159, AC004694, AC004386, AC005781, U91321, AC007655, AC007842, AC004771, AC004858, AC005261, AC007688, AC005632, AF217403, AD000833, AC005519, AF196779, AL022315, AL109963, AF109907, AP001053, AC005057, AD000092, U91323, AC006077, AL023803, AC007226, L78833, AC007546, AC004815,

				AC007774, AP000152, AP000704, AC005620, AC003101, AL031666, AL031186, AP000032, AF053356, AC009946, AL117694, AL020993, AC004887, AL050338, AC007999, AL022320, AP000045, AC004097, AL049709, AC002504, AC002544, AC005215, AC004000, U96629, AP000251, AL135960, AJ131016, AC005206, AC004822, AC002369, AC002551, AC005081, AP000008, AL008719, AC005667, AC008115, AP000030, AL033524, AL031282, AL022313, AC004383, AC005702, AC005520, AP000358, AL023807, Z95114, AL031300, AC007406, AL033392, AC002558, AC005619, AC004659, AL035681, AP000311, U91327, AL121652, AP000212, AP000134, AL031672, Z97196, AP000688, AC008041, AC005722, AL031255, AL096712, AC004913, AC005913, AF196969, AP000113, AC004819, AP000555, AC005378, AC005775, AL022302, AC005940, AL023284, AL022323, AL035458, AC006536, AL031283, AL096774, AC004542, AC005841, AC006312, AP000213, AL021394, Z97056, AB023058, AL049569, AC005015, AC005071, AP000135, AC007216, AC006254, AC002375, AC005209, Z85986, AL035405, AC002126, Z83826, AB001523, AC002045, AP000117, AF207550, AP000553, AC008064, AC004259, AC006061, U91326, AP000270, U82828, AL049540, AC004611, AP000299, AP000031, AL109865, AC004605, AL022312, Z82203, AC004600, AC004671, Z85987, AC004973, AL049766, AL008718, AP000502, AC005800, AC003690, AC004790, AC005369, AC016026, AC002378, Z98036, AP000521, AC006449, AC006271, U85195, AL031311, Z86090, AC005529, AC006597, AC004491, AC005755, AL031680, Z97054, L44140, AC002550, AC000085, AC004226, AF001549, AC005387, AC002115, AC000134, AL096703, AL031005, AF165926, AE000658, AF196971, AL031659, AC005933, AL050347, AC005088, AC006130, R16694, R23244, R78526, H24067, R87506, R98946, H80426, N50148, N62476, N80670, W73606, AA137081, AA226922, AA468656, AA766390, AA768482, AA811085, AA847774, AA862807, AA975165, AA995577, AA453634, AA609502, AA628355, AA644232, AA719540, AA813039, AA884482, AI001882, AI004405, AI015767, AI034164, T16377, R10879, AI245639, AI245727, AI278658, AI283903, AI493468, AI570705, AI125001, AI338369, AI763081, AI862627, AW080224, AW083608, AW089049, AW089305, AW090711, AW198229, and AW078905.
18	HCMSC92	81	867608	AW369274, W28613, AW369304, W26402, AA465611, R12305, T75147, D80012, A83860, and AP000533.
19	HLHFR58	29	919888	R09539.

19	HLHFR58	83	897241	R09539.
19	HLHFR58	84	894001	AI302152, AI950224, AW006861, AI523695, AI031546, AI765207, AA777287, AI347734, AI338904, AA887236, AI343539, AI341064, AI669076, AI862912, AA173871, AI224473, AI688619, AA362106, AW242796, AW293656, AI436708, AI928485, AA362105, AW361107, AI301910, AI688323, AI261560, AA701133, AW134978, N29753, AI632318, AI765277, AA767773, AA987449, AA639801, AW088643, AA361933, D20771, AI478303, AA361932, H62985, AI765472, AW059845, AA361935, AI224410, AI823993, AI359523, H62864, AA362272, AA362360, AA361984, AW059871, AA361934, AA362120, AA380871, AA362351, AA380898, AA362119, AA362359, AA358458, T29074, AW269035, AA362271, AA362193, AA381340, AA343963, AA380889, AA779311, AA366670, AA362121, AA381417, T96001, AI952167, AA371401, N57175, AA362201, AA362183, T35987, AA382176, AA362287, AA362169, AA172380, AA381916, AA362350, AA362243, AW450104, T95900, AA515104, AC003976, X53682, J04130, X16166, M25316, M23502, M57503, X53683, M69201, S56704, M69203, A17134, A17136, and M69202.
20	HNGGK54	85	895182	D80043, D51022, D58283, D80253, D80366, D59467, C14389, D80522, D80248, D80022, C14331, D80391, D59787, D57483, D80247, D51423, D59859, D80196, D59275, D80166, D80195, D59889, D59619, D80210, D51799, D80164, D80240, D80227, D59502, AA305409, D81030, D81026, D80269, D80212, D80188, D80251, D50979, D80219, D50995, D51060, D59927, C15076, D80038, D80024, AA305578, D59610, C14014, D80439, D80268, D80193, D80133, D80045, AA514186, AA514188, AW360811, D80378, C14429, AW177440, D80302, D80241, AW177505, AW178893, D80132, AW377671, AW375405, AW179328, C75259, T03269, D51103, D58253, AW178906, AW366296, D80157, AW360844, AW360817, AW375406, AW378534, AW179024, AW179332, AW377672, AW179023, AW178905, D51759, AW378532, AW352170, AW177501, AW177511, AW378528, AW178762, T11417, C05695, D59373, AW352171, AW377676, AW178774, AW176467, AW177731, AW178907, AW179019, D80168, D80134, T48593, AW178980, D51250, AW178983, AW352120, AW360841, AW367967, AW369651, AW179020, AW178775, C06015, AW178909, AW177456, AW179018, AW179329, AW178914, AW177733, AW178908, AW178754, AW352158, D59653, AW352117, D51079, AW378543, AW177728, AW360834, D45260, AW179004, AW179012, AW378525, AW352163, C03092, H67866, C14227, AW178781,

				AW367950, D59627, AW378540, D80258, AW352174, H67854, D80014, AA809122, AW179009, AW178911, D59503, AW177722, AI910186, C14407, D80064, D60010, C14298, AI905856, AI525923, F13647, C14077, AW178986, AW177508, D58101, C14344, T03116, AI525917, D58246, C14973, D81111, D45273, D51213, D59317, AW177497, AW378533, AI535850, D51221, D59474, AI525227, AW177723, AI525920, AA514184, AI535686, C14046, C14957, AW177734, AI557774, D59551, D60214, Z33452, AI525235, T02974, AI557751, C16955, AI525242, T03048, AI525222, AI525912, AA285331, AW378542, AI525925, AW378539, AI525215, D51097, C05763, Z21582, H67858, D51053, AW360855, AI525237, C04682, D51231, T02868, AI525228, AI525928, D50981, Z30160, C13958, D80314, AA305720, AR018138, A62300, AF058696, A62298, A84916, AB028859, AJ132110, AR008278, A82595, AR060385, AB002449, X67155, Y17188, A94995, D26022, Y12724, A25909, A67220, D89785, A78862, D34614, AR008443, I50126, I50132, I50128, I50133, AR066488, AR016514, D88547, AR060138, A45456, A26615, AR052274, AR054175, Y09669, A43192, A43190, AR038669, X82626, AR066487, I82448, A30438, AR008277, AR008281, I14842, D50010, AR025207, Y17187, AR066490, A63261, I18367, X64588, AR008408, AR062872, A70867, AR016691, AR016690, U46128, D13509, A64136, A68321, AR060133, I79511, AB012117, X68127, U79457, AF123263, AR032065, and AR008382.
20	HNGGK54	87	893214	AA527573, AW014742, C15076, D59787, C14389, D81026, D59467, D80366, D51423, D50995, D80196, D80014, D59619, D80253, D80219, D80268, C14227, D59889, D80164, D59275, D59927, D80045, D51213, D80043, D50979, C75259, D81111, D80022, F13647, D80193, D80210, D80391, D80227, D80168, T02974, D80134, D80522, D80949, D80240, C14014, D80038, C14331, D80188, D81030, D80195, C06015, D80378, D59502, C14077, C14429, D80133, AA285331, D58283, D59627, D80269, D51799, T03269, D57483, D80024, AI557774, D51250, D80212, AW378532, C14407, D80248, D59859, D80166, AW377671, D51079, D80258, AW360834, D59610, D51022, D80251, D51060, D80241, D59373, AI557751, AA305409, AW178893, AA305578, D80247, AA514188, AW177440, D80064, Z21582, AW378539, AI535686, AW360811, D80439, AW352158, AA514186, D51103, C14344, AW369651, D80132, D80302, D80157, AW375405, AW179328, D51759, AW177731, AA809122, AW367967, AW177505, AW366296, AW360844, D58101, AW360817, AW179020, C05695, AW375406,

				<p>AW178906, AW378534, AW179332, AW377672, AW179023, AW178905, AW352170, AW178908, AW178762, T48593, AW178775, C14298, D59653, AW178980, AW378540, D52291, AW352171, AW377676, AW179004, AW179009, AW179012, D59695, AW176467, AW178907, AW378528, AW179019, AW179024, AW352163, H67866, H67854, AW360841, T11417, AW178909, AW177456, AI535959, AW178774, AW179329, AW178914, AW178911, AW177733, AW178754, AW179018, AW378525, AW177722, AI910186, D58246, AW178986, D59503, D45260, C03092, AW367950, C14957, AI525923, AW352120, AW177728, C14973, D80228, D51221, AA514184, D59317, D59474, AW378543, AI525237, D60010, D59551, AW179011, C14046, D60214, AI525912, Z33452, AI535961, AW178781, AI525920, N66429, T03116, AI525235, AI525917, D45273, AI525242, C16955, AW378533, C05763, AI525215, AI525227, AW177734, H67858, T03048, D51053, AW177508, AW177497, C04682, T02868, A25909, D34614, A67220, D26022, A62300, A84916, A62298, AR018138, X68127, AR025207, Y17188, A82595, AF058696, AJ132110, AR008278, AB002449, AB028859, X82626, X67155, D89785, A78862, AR060385, Y17187, Y12724, D88547, A94995, AR008443, I50126, I50132, I50128, I50133, AR016514, AR066488, A26615, AR052274, AR054175, AR060138, A30438, A45456, AR008277, AR008281, A43192, A43190, I82448, AR038669, Y09669, I14842, AR066487, D50010, AR016691, AR016690, U46128, AR008408, A63261, I79511, I18367, AR062872, A70867, D13509, A64136, A68321, AR060133, and AR032065.</p>
21	HE8SE91	31	996287	<p>AW372208, AA746363, AA809342, AI016451, AA211519, AI168226, AA889536, AI089046, AA634138, H91421, AA378036, AA749224, AI873337, T67642, AW051323, AA748201, H91318, AI821864, AA572714, AA484366, AI821120, H69411, AA055800, AI521417, AA338986, AA635295, AA658935, T91114, N57939, AA829242, AI885995, F33212, AI033445, AW084883, AI242866, AI580252, AA705418, AI248117, N34987, AI652371, AA700548, AI651533, AA015593, AI086222, H30037, AL110255, AC005803, AC004858, AC005015, AC005823, AC005702, AL049795, Z95125, AF109907, AP000344, AF085956, AL109627, AC005619, AC003662, Z82203, U91323, AC004890, AF111168, AC004079, AC006013, AF053356, AP000952, AC002400, AC007314, AC020663, AL133304, AC004638, AC005224, AC005081, Z83844, AL035653, AC007263, AC008044, AC008009, AF196779, AL022399, AC004087, AC009044, AC005484,</p>

				AC004770, AL008724, AC005156, AC005086, AC004877, AC009509, and AC005011.
21	HE8SE91	88	874035	AA746363, AW372208, H91421, AA378036, AI821120, AI821864, H69411, AA055800, AI521417, AA338986, AA635295, AA484366, AA658935, T91114, N57939, AI885995, F33212, AI033445, AW084883, AI242866, C14014, AI580252, AA705418, AI248117, N34987, AI652371, AA572714, AA700548, AI651533, AA015593, AI086222, H30037, AA255722, N63093, H67854, AL110255, D88547, AC005803, Z95125, AC004877, AC003662, AC005823, AC009509, AF085956, AF109907, AL109627, AC004858, AC005619, AC005702, AC004079, Z82203, AP000343, AL133304, AC003665, AC004671, AP000952, AC005049, AC002400, AC004953, M63315, U91323, AC004087, AL049795, U88965, AP000344, M88642, AF053356, AC006953, AL022399, AC004770, AC004762, AL079342, AC004228, AP000496, AC006537, AF111168, AC004923, AC005015, AC002375, and AC008044.
21	HE8SE91	89	527222	AA809342, AI016451, AI168226, AA889536, AI089046, T67642, AA211519, AA634138, AA749224, AI873337, AW051323, AA748201, H91318, and AL110255.
22	HTTBM40	32	1034648	AI632224, C06145, AI610818, AA988123, N42193, AI332448, AI077315, AW078877, AI129637, AI628659, AI149002, AI076708, AI971253, AA701521, AI159820, N70666, H79461, AI973232, AI148741, AI659197, W05175, T86378, H12147, H63214, H58420, N99811, R66766, AA132069, W90649, Z43054, T86279, AA928618, AI092378, N75943, Z45653, AI867953, R14931, AA041554, N57671, AA234990, H90829, R81100, AI648611, AI680625, AA366166, H79346, F06260, R32400, T23440, AI669762, R81099, N77529, H11634, AA236185, AW274458, Z41324, F02533, AA041555, R41245, H63127, and AA132130.
22	HTTBM40	90	906532	AI632224, C06145, AI610818, AA988123, N42193, AI332448, AI077315, AW078877, AI129637, N57671, AI149002, AA132130, AI076708, AA701521, AI628659, AI971253, AI159820, N70666, AA234990, H79461, AI973232, AI148741, AI659197, W05175, T86378, H12147, H63214, H58420, N99811, R66766, AA132069, W90649, Z43054, T23440, T86279, H11634, AA928618, AI092378, N75943, AA041554, Z45653, AI867953, R14931, R41245, AW274458, H90829, Z41324, F02533, AI648611, R81100, H63127, AA366166, AI680625, H79346, F06260, AA902144, R32400, AI669762, R81099, N77529, AA236185, and AA041555.
23	HE2AX96	33	961220	AL138265, AL046409, AI281881, AI284640, AI431303, AI963720, AW193265, AI064864, AW419262, AW303196, AA720702, AA581903,

				<p> AW274349, AW301350, AI334443, AA101689, AI270117, AW407578, AI076616, AI613280, AW265385, AI708009, AL041690, AW072923, AW023672, AI345654, AL044940, AW270270, AA490183, AL138455, AW410400, AL119691, AA610491, AW021583, AI538852, AI312309, AI754658, AW238278, AA469451, AI537506, AW088846, AI633025, AW327868, AL042420, F36273, AI457397, AW072587, AW276827, AW021207, AL042853, AI350211, AW238583, AI133164, AI956131, AA491814, AI754955, AI370094, AI799642, AA455483, AL048626, AW265393, AI370074, AI718446, AL120687, AW020340, AI355206, AW276435, AA402129, AA610688, AA488746, AI345681, AI345675, AA503475, AW270382, AW088202, AA908687, AA483223, AA468131, AA649642, AI561060, AI888518, AL119984, AA682912, AA846876, AI267818, AW004911, AW029038, AA623002, AI053672, AL119295, AA177061, AW103758, AW304584, AI619997, AW302659, AW302705, AI434695, AI471481, AI341548, AL046457, AI289067, AI341664, AI287485, AW193432, AL048925, AI962050, AI679782, AA719292, AW438643, AL121235, AA679514, AI375710, AI085719, AI635274, AL038474, AI814735, AW269488, AI623898, W79504, AI624142, AI821494, AA657918, AI679132, AI801482, AI537955, AI610159, H71429, AA526787, AL040130, AA846935, AI688846, AA601253, AA177063, AA503473, AA665021, AA491284, AI148277, AW265170, AI446601, AW083402, AW338086, AA579179, AL120343, AI305766, AW167372, AI568678, AA127353, AI828208, AA584581, AI282832, AW162049, AI929531, AI521679, AI732186, AW070892, AI246119, AW162489, AL038785, AI446464, AI061334, AA178953, AA192740, AI821271, AI340453, AI539563, AI792518, AA501809, AI151261, AI053790, AL042213, AI133102, AI904894, AW166815, AW261871, AI334435, AA521323, AA613345, AI471543, AI623720, AW373587, AI859438, AI371070, AI610376, AW406447, AW169151, AI017415, AA598586, AA577906, AA515829, AA523843, AI240168, AI287651, AI685198, AW169537, AI828463, AI499938, AF002223, AC007541, AF015151, AL133289, X54178, D83989, I51997, X54181, X53550, AC004485, X54175, U57009, U18394, AC005913, X54176, U18392, AC020663, U18391, X55925, AF015149, X55924, AF015156, AC004782, AC005385, X55926, X54180, AL135747, U57005, X75335, AF109907, AC000052, X55931, U57006, U18395, AC004019, AC007240, AF015148, U18398, AF015157, AF015147, U18393, U57008, U18396, AC005180, U18387, U57007, X54179, AL031734, AF077058, AC005324, AC004895, </p>
--	--	--	--	--

				U67801, U18390, AP000513, U57004, U18399, AC005722, AC008038, AP000171, AL121578, AC004673, AC006947, AF126403, AC008044, AP000330, AP000567, AC015853, AC006138, AC006501, AC007387, AL117340, AC005666, AL035091, X55923, X55927, M37551, AL049591, Z83838, AL109623, AL133244, AL035457, AC007688, AL049766, AC012384, AC005940, AC007308, X55922, AP000501, Z22650, AC006466, AL031680, AL031319, U02531, AC002457, AL031432, AF111169, AC010849, Z54246, AL031257, U67221, AF111168, AF015153, AC004884, AC004690, AC004805, U18400, AC006251, AP000255, X54177, AC007349, U12581, Z82975, AL022302, AC005911, AC006270, AC006965, AF015154, AC002350, AC005755, U02532, AC005083, AC007055, L47228, AC003035, AC012599, X74558, AC006071, AC002364, AC007671, AC006367, AC006146, AP000339, AP000135, AL031230, AC005237, AP000217, AP000557, AC005632, X55932, M13254, AL022316, AL080313, AL133238, AL117258, L48473, AC006530, AP000031, AF015155, AF195658, AB003151, AC004525, AC002549, AL049709, AC007066, AL078603, AC005229, AC002070, AC003003, AL049839, AL009177, U67831, AC003029, AC009411, U67211, AL009179, AC004593, U67231, AC004087, AJ011930, AL031283, AL031228, AC005565, AL049780, AL031722, AF015167, AL034351, U67832, AC004605, AC009516, AC008268, AC007537, A39972, AL008721, AC006480, AC004622, AL024497, AL023694, AP000696, AC006079, AC005534, AC004615, AC005082, AC004583, U12580, AE000660, AC009223, AL035411, U91326, AC004833, AL050308, Z94721, AF053356, AL109758, AL035045, X55930, AL031178, AL031659, AC004643, AL035410, AL109984, AC005529, AL109755, AL109941, U67826, AC007172, AC007065, AB000882, Z98200, AC005859, AL031447, AC006241, Z49816, AC002543, AF196972, AL121603, U01311, AL034384, AC004924, AC003991, AC005072, AC005899, AL031133, U67222, Z83822, AC002300, AC004634, AC005274, AC007051, AF068862, AF121781, AC005046, AC005412, AC004167, AC002352, AC007845, AF200465, AC005332, AC004528, and AP000099.
23	HE2AX96	92	897806	AL046409, AI281881, AI284640, AI431303, AW419262, AI963720, AW303196, AW193265, AL138265, AA720702, AI064864, AW301350, AI334443, AW274349, AI076616, AA581903, AA101689, AW407578, AI270117, AI613280, AW265385, AW276827, AW270270, AA610491, AL041690, AI708009, AI538852, AW072923, AW238278, AI345654, AL119691, AA490183,

				AL138455, AW410400, AL042420, AW021583, AI312309, AI754658, AL042853, AW238583, AI537506, AA469451, AI633025, AW088846, AW327868, AW265393, AL120687, F36273, AI457397, AW021207, AA491814, AA610688, AW072587, AI133164, AI350211, AW270382, AI754955, AI370094, AA468131, AI799642, AI956131, AA483223, AA455483, AL048626, AI370074, AI536138, AW020340, AI718446, AI525316, AA402129, AI355206, AW276435, AI345681, AA488746, AL134524, AL119984, AI345675, AA503475, AW088202, AA908687, AW302705, AA649642, AL044940, AA682912, AW304584, AA846876, AI888518, AW023672, AI821494, AI561060, AI267818, AW029038, AA630362, AL119295, AW004911, AW265170, AI053672, AA846935, AL046457, AA177061, AW103758, AA623002, AA579179, AA501784, AW302659, AI619997, AI434695, AI471481, AI341548, AL121235, AI679782, AI289067, AI341664, AI962050, AA719292, AI287485, AA493708, AL038474, AW193432, AL048925, AA679514, AW438643, AI375710, AI085719, AA525824, AI635274, AI679132, AA601253, AW269488, AI623898, AI814735, W79504, AA501809, AI624142, AI801482, H71429, AW062724, AI305766, AW373587, AI537955, AI610159, AA526787, AA177063, AI688846, AA503473, AA507547, AL040130, AA491284, AW083402, AI148277, AA665021, AL120343, AI446601, AW338086, AW167372, AA127353, AA584581, AI334435, AI568678, AI828208, AW162049, AA515829, AW406447, AI929531, AI282832, AI564185, AL038785, AI792518, AI732186, AA578997, AI246119, AW162489, AI521679, AW070892, AI446464, AA178953, AA192740, AL042213, AA828042, AI061334, AA551503, AI821271, AI340453, AA747105, AI539563, AI151261, AI281903, AI053790, AI904894, AI133102, AW166815, AW261871, AI471543, AI623720, AA521323, AA613345, AI859438, AI371070, AI610376, AR038762, AC005913, AF015151, D83989, X54178, AF077058, X54181, I51997, X53550, U18394, X54175, U57009, X55925, X55924, X54176, U18392, U18391, AF015157, AF015149, AF015156, U57005, X55926, X54180, U57006, X75335, X55931, U18395, AC007240, U18398, U57008, AC005180, X54179, AF015148, AF015147, U18396, U18393, U18387, U67801, U57007, U57004, U18390, U18399, X55927, X55932, X55923, AL049766, M37551, Z22650, AC005940, AL109827, AC003029, X55922, U67221, AC004531, AF111169, U02531, AC004884, AC005083, AF111168, AL031257, AF015153, X74558, Z54246, U18400, U12581, AC005755, X54177, AL121603, AL022302,
--	--	--	--	---

				AC005071, AF015154, U02532, AC006965, AC006071, L47228, AC006367, AC020663, AP000339, AL049709, U67831, AP000217, AC006538, L48473, AC005534, AJ011930, AC006530, AL031228, AC002549, AL034351, AL022316, AL023586, AC005046, AF015155, AL049780, AP000555, U67211, AL031722, U67231, AC005324, AF196972, AC005565, U12580, AF015167, AC008268, U67832, AE000660, A39972, AC009516, AC007065, AC004622, AC006539, AL023694, Z86090, AL031602, Z94721, U67826, AC005043, AL031447, Z99716, AL050308, AL031659, AC005072, AC007681, AB000882, AL031178, X55930, AC002300, AC007845, AC002073, AC005004, Z98200, AC008079, Z49816, AC007842, AP000506, AL021808, AC006146, AC006241, Z83822, AC004263, AC003658, U67222, AC002470, AC007051, AC007537, AC004634, Z85986, AC002465, AF068862, AL031681, AL034420, AF165138, AL023882, AL035423, AC006130, AC005274, AC007787, AF121781, AC006111, AC005183, AC004755, AF158642, U67226, AP000248, AC005722, AL035659, AF015158, X76629, AC005212, AC004383, AL035681, Z98884, AC002067, AB011147, Z84485, AL049713, S43650, Z98304, AB000878, AC009330, AC007308, AP000211, AP000133, AC007073, S75201, AC016026, AF015150, AC007016, AC006116, AC016025, AP000556, Z93241, AC009044, AL049610, S83526, AL031255, AC004782, AF200465, AF064861, AL121655, AC002564, AC004913, AL135744, AL133396, AL031846, U12584, AL109764, AP000552, AC005772, AL050312, AF001549, AP000131, AP000209, AC002368, AL049776, AC005281, AC006285, AL022147, AC006365, AC004894, AC004259, AC004149, AC004033, AL031432, AP000553, AC006597, AL096862, U63313, AC006958, AP000512, AL031009, AP000557, X88791, AC006022, AC002132, AC004600, AC006312, U67233, AC007666, U12582, AC004984, AC002431, AP000692, AL024498, AC005993, AL049697, AC004041, and AC004854.
25	HRGBL78	35	910133	AW205367, AW402801, AW402242, AW402928, AW403946, N24246, AI654541, N28316, N29315, N38941, AW383418, AA458944, AI276242, AA215300, N33010, AW383426, AW383396, N20230, AI439520, N29316, AA459158, N25452, W03476, AW383428, AW402824, N30453, N28949, N21241, AI760983, N20533, N73074, AI434284, N72999, N20563, AW403434, N67502, AI470743, AA837208, AW407871, H84381, AW404443, N26470, W02963, AI864746, N46511, W02298, H98912, H84382, N35519, H99497, AA761778, N71796, AI222330, and AA814390.

25	HRGBL78	95	904040	AW402928, N29315, AW402824, N28949, AW403434, AW403946, AW402242, N29316, W02298, N46511, and W02963.
25	HRGBL78	96	904621	D80188, D81030, C75259, D80253, D58283, D51423, F13647, D59619, D80210, D51799, D80240, D80227, D80366, D80195, D80193, D80219, D80391, D80043, D59889, D80196, D80134, D80212, D59927, C15076, D80038, D59502, D59275, D80022, T03269, D80268, D81026, D80164, D80378, D58253, D59859, D80045, D80949, D80166, D59467, D50995, D59787, C14014, D80168, D80269, C14227, D50979, D59695, D57483, C14429, D51250, D81111, D80024, D80522, C14298, AA285331, D51079, D59610, D80241, AI910186, C14389, C14331, D80014, AW178893, D51060, T11051, AA305409, T11417, AW377671, D51097, Z21582, AW177440, AW179328, AW178775, D59627, AW378532, D80064, D51022, T02974, D80251, AW352158, AA305578, D51213, AI905856, C14407, AW178762, D80248, AW177501, AW177511, AW179220, D80132, D58101, AA514188, AW360834, AW378539, AI557751, AW360811, AA514186, D80133, AW352117, AW176467, AW375405, AW378540, C05695, AW352174, T03116, AW366296, AW360844, AW360817, AW375406, AW378534, AW179332, AW377672, AW179023, AW178905, AW367967, AW177505, D59373, D80258, AW352171, D80247, AW352170, AW377676, AW178906, AW177731, AW178907, AW179019, AW179024, D80439, D80302, D59503, AW360841, AW179020, AW179018, AW178909, AW177456, AW179329, AW178980, AW177733, AW378528, AW178908, AW178754, D51103, AW179004, AW179012, AW178914, AW378525, AW177722, D45260, D80157, D51759, AW177728, AW378533, AW177508, AW179009, AW178774, AW178911, AW378543, AW352163, C06015, AW177497, AW352120, AI557774, AW178781, T48593, AW177723, D80228, D50981, D59653, H67854, AW367950, AA033512, C03092, AA809122, AW178986, H67866, AI525917, D58246, AW177734, AI535961, AI525923, D51221, D59474, C14957, D59317, C14973, AI525920, AA514184, C14344, AI525235, AI525912, D60010, AI535686, D60214, AW378542, D59551, AI525227, C14046, AI525222, AI525215, C16955, AI525242, AI525925, AW360855, AI525237, A62298, A62300, X67155, A67220, A25909, D26022, A84916, D34614, Y17188, AJ132110, AR025207, A78862, D89785, X68127, AR018138, D88547, U87250, A85396, AR066482, AB012117, A85477, A86792, I82448, X93549, X82626, AR008278, I19525, AF058696, A44171, AF135125, AB028859, Y12724, AB002449, AR064240,

				A94995, A82595, AR008443, AR060385, S69292, AR066490, I18367, I50126, I50132, I50128, I50133, AR066488, AR016514, AR060138, A45456, A26615, AR052274, Y09669, A43192, A43190, AR038669, AR054175, AR066487, X64588, A30438, AR062871, D88507, Y17187, I14842, AR008277, AR008281, D50010, I18371, X89963, A43601, AB033111, AR008408, A63261, S78798, Z32749, AR062872, A70867, A64136, A68321, AR016691, AR016690, U46128, D13509, AR060133, I79511, I15997, AR037157, A80951, U87247, X92518, X55486, AB023656, X60736, AF123263, A20702, AR017907, A43189, AR062873, A43188, A20700, AR032065, AR000511, M60510, AR023705, A84772, A84776, A84773, A84775, A84774, AR067731, AR067732, A58522, A91750, X93535, and A47134.
25	HRGBL78	97	863802	AW205367, AW402801, N28316, AW402242, N24246, N38941, AW383418, AA215300, N33010, N20230, AI654541, AW383426, AI276242, W03476, AW383396, N25452, AA459158, N21241, AI439520, AA458944, N30453, AW383428, N20533, N72999, N73074, N20563, AI760983, N67502, H84381, AI434284, AW404443, AI470743, AA837208, AW407871, N29316, N26470, W02963, W02298, AI864746, AW403946, H84382, H98912, N35519, H99497, N29315, N46511, AA761778, N71796, AW403434, AI222330, AW402928, and AW402824.
26	HHPFU18	36	975486	AW068647, AI798600, AA830785, W86447, W86543, AI907502, AI418197, AI188655, AA833695, AW237705, AI948876, AI651151, AA424655, AA424558, H55854, T51291, AA909409, H55762, AA256218, AI860538, AI432619, AI868909, AA256160, AW068648, AF080435, AL117602, L15355, L15354, AF031463, and AF083325.
26	HHPFU18	98	906527	AI188655, AW068647, AI798600, AW247715, AA830785, AA833695, W86447, AW068648, W86543, AI907502, AI418197, AW237705, W27578, AA424655, AI948876, AI651151, AA329968, AA424558, H55854, T51291, AA909409, AI149393, H55762, AA256218, T51417, AI860538, AI432619, AI868909, AA329803, T51416, AA256160, AL117602, AF031463, L15354, L15355, AF080435, AF083325, U38236, AF083324, and AF080434.
27	HPRCA90	37	945018	AA811609, AI392846, AI754385, AI565035, AW007245, AW268863, AA906509, AI092244, AI698734, AA861761, AW438768, AA459681, AW118314, AA782718, AI537049, AA928445, AA130593, AW050550, D63077, AW273355, N51495, AA742361, AW151132, AI608882, AI244249, AW029199, AI245008, AI798456, AI473536, AI491842, AI814063, AI613038, AI935799, AI568061, AI147292, AI478902, AI525653, AW084873, AI148113, AI445829,

				AI522256, AL137550, AF126372, S36676, AF090900, AF167995, AF006516, AF030513, AF139986, A44314, AL133429, AL136884, AF081825, X15132, X59812, AF043345, AR066485, S73498, AF118094, S56212, AF124728, S71381, and I77092.
27	HPRCA90	100	904819	AA811609, AI392846, AI754385, AI565035, AW007245, AW268863, AA906509, AI092244, AI698734, AA861761, AW438768, AA459681, AW118314, AA782718, AI537049, AA928445, AA130593, AW050550, D63077, AW273355, N51495, AA742361, Z57391, and Z57390.
27	HPRCA90	101	902154	AA811609, AI392846, AI754385, AI565035, AW007245, AW268863, AA906509, AI092244, AI698734, AA861761, AW438768, AA459681, AW118314, AA782718, AI537049, AA928445, AA130593, AW050550, D63077, AW273355, N51495, AA742361, AW151132, AI608882, AI244249, AW029199, AI245008, AI798456, AI473536, AI491842, AI814063, AI613038, AI935799, AI568061, AI147292, AI478902, AI525653, AW084873, AI148113, AI445829, AI522256, AL137550, AF126372, S36676, AF090900, AF167995, AF006516, AF030513, AF139986, A44314, AL133429, AL136884, AF081825, X15132, X59812, AF043345, AR066485, S73498, AF118094, S56212, AF124728, S71381, and I77092.
28	HPRCE33	102	873251	AA347391, AA430006, AA424075, AA424383, AW179234, N84944, W85949, W68823, H92438, AC005332, AC005562, and AL137380.
29	HCEFI77	39	1022457	C17879, AA515723, AI479148, AI753113, AI635819, AI491765, AI251576, AI583466, AI306232, AW274191, AC004780, AC005005, AC002543, Z95115, AL121658, AC004098, AL049843, AP000210, U91327, AC002302, AC004854, AC007731, AC005500, AC005006, AC006960, AC002365, Z84466, Z97054, AC004796, AL022323, AL023807, AC006430, AC009509, AC006211, AL049872, AL031311, AC005832, AC003071, AL109628, AP000194, AF045555, AC007057, AC005846, AC007021, AC016026, AL117337, AL080317, AC004814, AC005747, AL139054, AC005365, AC007790, AC004638, AF205588, AC004765, AL117352, AF165926, AL009173, AC004104, AC005015, AL133246, Z84487, AC004762, Z97989, AC006353, AL022332, AL035413, AL022721, AC005081, AC004834, AC006312, AF111168, AL049778, AC006947, AL050318, AL080243, AC003692, AL049570, U95739, U89335, AC004491, AL009182, AL049569, and AL035455.
29	HCEFI77	103	843235	AC004780.
29	HCEFI77	104	730521	C17879, AI306232, AI583466, AW274191, AI753113, AI479148, AI635819, AA515723, AI491765, AI251576, AC004780, AC004491,

				AC005015, AF053356, AL080243, AL049778, AL022318, AC005081, AC004520, AL121658, AF030876, AF196970, AF031078, AC003071, AC005332, Z84466, AL023807, Z98743, AC007707, AC009509, AJ246003, AC004966, AL049843, AC005280, AF108083, Z85986, AL050341, AL009181, AL031311, AC009510, AC004098, Z83822, AC005486, AC005529, AL050338, AC004217, AC004983, AC004216, AC006948, Z93241, AL049869, AC005005, AF001549, AP000210, AL031681, AC005231, AC004757, AC006211, U62293, AC005484, AC004638, AC006241, AP000314, U91323, Z93023, AC005632, AC005057, AL022323, AC005899, AL033381, AC005823, AC006360, AC002432, AL031733, U95740, AP000194, AC004707, AC004812, AC004542, AC006312, AC006101, AF129756, AC004876, AC004687, Z95115, AC000029, AC007685, AL034548, AC004801, AC002369, and AC002543.
30	HHFDN48	40	1033580	AI190033, AL048978, AI146833, AI269761, AI870846, N71918, N22682, AA806555, AA868546, AI264224, AA706140, AI885696, AI470203, AI186694, AI217129, AI074984, AI288618, AI348242, AL048977, AI380377, AI376798, AI074867, AI923821, AI470162, AA099829, AI141890, AI335851, AI904605, AI240855, AI088758, AA594481, AA805592, AI879885, AW104954, AA236495, AA586933, AI571818, AI871853, AA232719, T15547, AA281815, W22838, AI198280, N67676, T33894, R89577, AI749579, AA336666, AA306846, H91374, AW379763, AA464623, AA351876, AA293216, H91076, R37393, AA484984, AI370018, T77419, H22596, R88895, AA531340, Z45937, T30978, AA658387, R59644, T84756, R59586, AA430715, AI042279, AA280306, T51683, T52709, AI868379, H97511, AA291993, AI290854, AI422917, AI184434, AA375084, AA962486, Z41554, R17327, AA972461, AA427524, R42673, R44651, AI264500, AA099827, R38362, AW176267, AA326864, AI970778, AW176266, F07514, R23519, N31161, AI497877, AW194662, AI084702, AI240997, AL022330, AC004032, AC006121, AC012380, AC000078, and AL031118.
30	HHFDN48	105	429711	AA099827.
30	HHFDN48	106	879110	AI190033, AL048978, AI146833, AI269761, AI870846, N71918, N22682, AA806555, AA868546, AI264224, AA706140, AI217129, AI885696, AI470203, AI186694, AI074984, AI348242, AI288618, AL048977, AI380377, AI376798, AI074867, AI923821, AA099829, AI470162, AI141890, AI335851, AI904605, AI240855, AI088758, AA594481, AA805592, AI879885, AA586933, AW104954, AA236495, AI571818, AI871853, AA232719, T15547,

				AA281815, AI198280, W22838, N67676, R89577, AA336666, AI749579, H91374, AA306846, AW379763, AA293216, AA464623, AA351876, H91076, T77419, AA484984, H22596, AI370018, R88895, AA531340, T33894, R37393, Z45937, AA430715, AA658387, T30978, T84756, R59586, T51683, AI042279, T52709, AA280306, AI868379, H97511, AA291993, AI290854, AI422917, AI184434, R59644, AA375084, R17327, AA962486, AA427524, AA972461, R42673, Z41554, R44651, AI264500, R38362, AW176267, AA326864, AI970778, F07514, R23519, AW176266, N31161, AI497877, AW194662, AI084702, AI240997, AA346900, and R13485.
30	HHFDN48	107	766137	AW152643, AI744294, AI092711, AI803450, AI140525, AI564343, AA127883, AW152156, AI554689, AI620740, AA127853, AI161209, AI339745, AI290242, AI374611, AI347388, AI858296, AI140529, AI366124, N24639, AW022264, AI144126, AA406235, AA493912, AI097277, AA493889, AI057160, AI080051, N53469, AA983529, N70752, AA843767, N70628, AA424577, AA860507, AW392056, AA983537, N22266, N81163, AI191012, R32511, AI057152, AA028001, AA626688, AA811773, AI095356, AA235977, AW194479, AA458646, AI375272, AA150439, AA527598, AI359198, AI522171, AA993793, D81608, AI034344, R22731, T59504, AW051665, AI370715, AI474968, AA908704, AI265939, AW015165, AI819644, AI079750, AI144233, AW004605, AI378641, AI373113, AI434979, AA634575, AI144390, AA505492, N80723, AA868318, AW166642, R26294, AA778417, AI089515, R65721, AI140223, AA382785, AA916240, AI419106, AA152273, T59549, AA307208, AA548596, H58537, D19621, AA488115, W05510, AA447892, AI191008, W07504, AW449675, AA316220, AA424683, N72473, AA730753, AA406507, AA442109, W01788, N35844, AI079590, R32624, T24669, AA592977, H58536, R22730, AF017732, and Z47727.
30	HHFDN48	108	705954	AA152273, W05510, AA488115, AI819644, AI378641, AA778417, AI089515, AW004605, AI144233, AI434979, W07504, AI079750, AI373113, AA916240, AA505492, AA634575, AI144390, AI265939, AA447892, AA730753, AW392056, AA406507, AA424683, AA316220, AA868318, AW015165, AI140223, N72473, N80723, AA442109, W31234, N35844, W01788, H58536, AI744294, C15459, AA747605, AA235894, D19621, AW166642, R65720, R22730, R32624, N41438, AA382786, AA592977, AI079590, R22731, AI906935, AI906934, AA527598, AA127853, R32511, N75649, R25469, AA091230, AA873039, N85572, AA455545, AI089516, AI093724, AW152643, N54870,

				AA424577, N75678, AI803450, AI564343, AI140525, AI366124, AA493889, AA493912, AI290242, AW152156, AA235977, AI620740, AI092711, AA127883, AA724691, AI557443, AI161209, AI339745, AI858296, AI347388, AI374611, AI140529, AI554689, Z47727, and S63758.
31	HHFFU55	41	871904	L44397 and AC004611.
31	HHFFU55	109	772590	AA778110, AA310449, AI865364, AI284640, AA768905, AW023672, AA767376, AI334443, AW303196, AI355238, AW301350, AA521323, AA493708, AA521399, AA629992, AW086257, AA610491, AA483731, AW274349, AA468022, AA111909, AL138265, AA630925, AA678436, AA679009, R97634, AA469021, AA491284, AA665330, AL046457, AI200051, AA610493, AI334435, AI474085, AW020992, AL042856, AI267823, AI110770, AA649705, AW088846, AA493170, AA558060, AA135119, AL138455, AW419262, AA657918, AA973803, AA610783, AA679514, AA235466, AA446657, AA156538, AL039958, T91024, AA564859, AA601253, AI630203, AL119691, AA708352, AA810370, AA521355, AA574110, AI133164, AA533725, R84238, AW249224, AI349748, AA720702, AA434388, AI016000, AL079645, AI354397, AW074398, AA306534, AI246796, AA492166, AW327868, AA492140, AI358343, AI064864, AA587256, AA857486, AA191198, AA252534, AA847128, T91187, AW265197, AA149614, AI473943, M77899, H86860, AL120187, F35113, AA610611, AA338486, AA533092, AI271217, F36273, F09736, U67274, X58156, AP000114, AP000046, AP000302, AC004534, AL139054, AC002431, AL031427, AL132712, AB014085, AL021918, U11309, AF193806, AC006277, AL009174, AC004187, AF031076, AC004966, AP000515, AC002558, AC004079, AL021707, AC007664, AC007277, AF031078, AC005550, AL035420, AF030876, AC001164, A26236, L04965, AP000072, AC005781, AL121655, AF042090, AC009248, Z97183, AF060568, Z98946, AB023051, AL031656, AB002059, AP000566, U40369, AC005529, AC005773, AL008583, AC012599, AC004452, Z84474, AC006204, AC006016, AP000475, AC004828, AC004949, U07561, AC002472, AC004253, AP000512, AL021940, AL031295, AC005678, AF001549, AC003041, AL035458, AC004382, AL031983, Z83847, AL022098, AC000007, AL096816, AL078463, AL021939, AC002368, X62695, AC005527, AC004707, Z98745, Z84483, AF045555, AL022318, Z83313, AJ238481, AC016027, AL080239, AC006115, AC007038, AC005032, Z82188, AL020993, Z95328, AC007066, AC005924, Z46936, S83362, AL023494, AC007270, AC005048, AC007536,

				AL035587, AL021977, AL034554, AL133038, AC005245, AL031224, AC002492, Z92844, AC008045, AC007043, AC006480, X96421, X75335, Z95114, AC005081, AC004890, AL022323, AC005778, L43392, AC005666, AC006380, AP000884, AF038458, AL035400, AL133245, AC005360, AL121603, AC006064, AC002545, AC005060, AC004913, AC016830, AL022237, AC006525, AL034420, X60152, AC005553, AC005562, U14694, AF064866, AC004915, AL031320, AC005341, AL022397, AL133371, AC005091, AC010202, AC002075, AP000130, AP000208, AC003954, AF165142, AL049539, AC005566, AF055066, AC006312, AC002525, AC007652, AL023575, AP000116, AC006285, Z81370, AC007298, AC004087, AC007707, AC004194, AL050320, AC004047, AL121852, AL021878, AL021392, L44140, Z94721, AL137345, AF027390, AC005610, AC006236, AC005827, AL049776, AL096768, AL122126, AL031732, AP000431, AL031985, AC005018, AL031662, AP000010, AF196779, AC006040, AC004485, AL031432, AL049869, AC006479, AC004861, AC004384, AC007406, AL034349, AC003678, AC005829, AL049636, AB009667, and AC007193.
32	HHFDH56	42	858052	AI631585, AA633356, AA713980, AI079564, AW236477, H47619, AA758094, H80100, N52461, N77424, AI668991, and AI202215.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.
 10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being
 15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR [®] 2.1	pCR [®] 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap
 XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos.
 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res.
 30 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res.
 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are
 commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey

Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl ori origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

- 10 Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR[®]2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

- 25 The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.
- 30

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

- 5 Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).)
- 10 The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate.
- 15 These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

- Alternatively, two primers of 17-20 nucleotides derived from both ends of the
- 20 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 μg of the above cDNA template. A convenient reaction mixture is
- 25 1.5-5 mM MgCl_2 , 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and
- 30 the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with

high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then
5 washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-
10 NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50
15 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC
20 Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The
25 promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR
30 primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

5 The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous
10 centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

15 The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

20 The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

 Following high speed centrifugation (30,000 xg) to remove insoluble particles,
25 the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

 To clarify the refolded polypeptide solution, a previously prepared tangential
30 filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive

Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

5 Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40
10 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

15 The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL
20 assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus

Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a
25 polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the
30 plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral

sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug
5 of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded
10 in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed,
15 as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page
20 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are
25 harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the
30 medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of ³⁵S-methionine and 5 uCi ³⁵S-cysteine (available from Amersham) are added.

The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of
5 purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which
10 mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long
15 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV I, HIV I and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),
20 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

25 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the
30 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of

interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279
5 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

10 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,
15 with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate
20 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.
25 Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%
30 agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector

are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for
5 transfection. Five μ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5
ug of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-
neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an
enzyme that confers resistance to a group of antibiotics including G418. The cells are
seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the
10 cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in
alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1
mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in
6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50
nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest
15 concentrations of methotrexate are then transferred to new 6-well plates containing
even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM).
The same procedure is repeated until clones are obtained which grow at a
concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed,
for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

20

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other
proteins. These fusion proteins can be used for a variety of applications. For
example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG
25 domains, and maltose binding protein facilitates purification. (See Example 5; see
also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to
IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization
signals fused to the polypeptides of the present invention can target the protein to a
specific subcellular localization, while covalent heterodimer or homodimers can
30 increase or decrease the activity of a fusion protein. Fusion proteins can also create
chimeric molecules having more than one function. Finally, fusion proteins can
increase solubility and/or stability of the fused protein compared to the non-fused

protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGC
CCAGCACCTGAATTTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTACCGTCCTGCACCAGGACT
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
CCCGTGCTGGACTCCGACGGCTCCTTCTCCTCTACAGCAAGCTCACCGTG
```


GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

5 **Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred
10 method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal
15 antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more
20 preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

25 The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as
30 described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with
5 this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-
10 specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')₂ and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using
15 enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use
20 "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et
25 al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening

30 Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

- 5
- 10 Plate 293T cells (do not carry cells past P+20) at 2×10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

- 15 The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.
- 20

- 25 Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.
- 30

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl₂ (anhyd); 0.00130

mg/L $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$; 0.050 mg/L of $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$; 0.417 mg/L of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$; 311.80 mg/L of KCl; 28.64 mg/L of MgCl_2 ; 48.84 mg/L of MgSO_4 ; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO_3 ; 62.50 mg/L of $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$; 71.02 mg/L of Na_2HPO_4 ; .4320 mg/L of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine- H_2O ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- H_2O ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- H_2O ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na- $2\text{H}_2\text{O}$; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person

B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
20	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
35	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)
40							

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., *Immunity* 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCATCCCGCCCTAACTCCGCCAGTTCCGCCATTCTCCGCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1×10^7 cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄·7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37 degrees C for 45 min.

- 5 Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

- 10 These cells are tested by harvesting 1×10^8 cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10^5 cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10^5 cells/well).

- Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

20 **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

- 5 5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)
 5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the
10 EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and
15 allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split
20 done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine
25 growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640
30 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count

the cell number and add more low serum medium to reach final cell density as 5×10^5 cells/ml.

- 5 Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10^5 cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

10 **Example 16: High-Throughput Screening Assay for T-cell Activity**

- NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB
15 regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

- In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded,
20 causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants
25 produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

- To construct a vector containing the NF-KB promoter element, a PCR based
30 strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTCCCC) (SEQ ID NO:8), 18 bp of sequence

complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

5 The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is
10 digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC
15 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC
ATCCCGCCCCTAACTCCGCCCAGTCCGCCCATTCTCCGCCCCATGGCTGA
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA
GCTT:3' (SEQ ID NO:10)

20

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

25 In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

30 Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described

in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

5 As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

15 Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

20 Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for

20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2.5×10^6 cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is

unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in

Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na₃VO₄, 2 mM Na₄P₂O₇ and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is
5 shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after
10 detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

15 Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for
20 a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg₂⁺ (5mM ATP/50mM MgCl₂), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl₂, 5 mM MnCl₂,
25 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

30 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20

min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and

cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

- 5 After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard
10 procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

15 **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

- RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA
20 is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

- PCR products are then sequenced using primers labeled at their 5' end with T4
25 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

- 30 PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United

States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in

Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulation

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials

(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,
5 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped
10 Therapeutics of the invention (see generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang
15 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the
20 optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (see Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

25 Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically
30 acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.

5 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

10 The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten
15 residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar
20 alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or
25 stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a
30 stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized

formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

5 The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use
10 or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

 The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus
15 deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,
20 Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,
25 whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic
30 mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate

administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not
5 limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are
10 administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

15 In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta),
20 OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF),
25 and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International
30 Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In

another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment,

5 Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat

10 or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with

15 ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment,

20 Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered

25 with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin,

30 beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,

erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-

acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

5 In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-
10 FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl
15 estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and
20 etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with
25 Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered
30 with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered

with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PlGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but

are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example,
5 radiation therapy.

Example 24: Method of Treating Decreased Levels of the Polypeptide

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising
10 administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the
15 secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily
20 dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

25 The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

30 In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of

decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy-Ex Vivo

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is

maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

5 The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the
10 packaging cells are now referred to as producer cells).

 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is
15 removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been
20 efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

25 **Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

 Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent
30 NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935

(1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining
5 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains
10 approximately 3×10^6 cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with
15 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the
20 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap
25 (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but
30 the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following
5 day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a
10 patient as described above.

Example 28: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the
15 introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in
20 the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

25 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

30 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or

precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg

body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 μ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper

dosages and other treatment parameters in humans and other animals using naked DNA.

Example 29: Transgenic Animals.

5 The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are
10 used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear
15 microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic
20 stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-
25 mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into
30 enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or
5 head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When
10 it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the
15 nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent
20 to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA
25 expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies
30 specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding

strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of
5 heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of
10 interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in
15 ameliorating such diseases, disorders, and/or conditions.

Example 30: Knock-Out Animals.

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*,
20 see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding
25 regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination,
30 results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &

Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

5 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not
10 limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention,
15 e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve
20 expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

 Alternatively, the cells can be incorporated into a matrix and implanted in the
25 body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

30 When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For

example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

10 **Example 31: Production of an Antibody**

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line

(SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which
5 secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In
10 accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention.
15 Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells
20 producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO
25 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed

polypeptide(s) of the invention From A Library Of scFvs

30 Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the

invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10⁹ E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10⁸ TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10¹³ transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10¹³ TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to

stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 µg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can,

in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10^5 B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10^{-5} M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and 10^{-5} dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3 H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice

receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

Example 33: T Cell Proliferation Assay

Proliferation assay for Resting PBLs.

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 °C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls.

After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0.5 microcuries of ³H-thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and

5 incorporation of ³H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

Alternatively, a proliferation assay on resting PBL (peripheral blood

10 lymphocytes) is measured by the up-take of ³H-thymidine. The assay is performed as follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the

15 plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2 x 10⁴ cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T

20 supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2 (*), IFN γ , TNF α , IL-10 and TR2. In addition to the control supernatants, recombinant human IL-2 (R & D Systems, Minneapolis, MN)

25 at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of ³H-thymidine (NEN, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ³H-thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

30 (*) The amount of the control cytokines IL-2, IFN γ , TNF α and IL-10 produced in each transfection varies between 300pg to 5ng/ml.

Costimulation assay.

A costimulation assay on resting PBL (peripheral blood lymphocytes) is performed in the presence of immobilized antibodies to CD3 and CD28. The use of antibodies specific for the invariant regions of CD3 mimic the induction of T cell activation that would occur through stimulation of the T cell receptor by an antigen. Cross-linking of the TCR (first signal) in the absence of a costimulatory signal (second signal) causes very low induction of proliferation and will eventually result in a state of "anergy", which is characterized by the absence of growth and inability to produce cytokines. The addition of a costimulatory signal such as an antibody to CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on activated APCs, results in enhancement of T cell responses including cell survival and production of IL-2. Therefore this type of assay allows to detect both positive and negative effects caused by addition of supernatants expressing the proteins of interest on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with 100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using 2×10^4 cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFN γ , TNF α , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is

pulsed with 1uCi of ^3H -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of ^3H -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

5 Costimulation assay: IFN γ and IL-2 ELISA

The assay is performed as follows. Twenty-four well plates are coated with either 300ng/ml or 600ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 500ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the costimulation assay. The assay is performed in the pre-coated twenty-four well plate using 1×10^5 cells/well in a final volume of 900ul. The supernatants (293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 300ul are added to 600ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only(negative control), IL-2, IFN γ , IL-12 and IL-18. In addition to the control supernatants recombinant human IL-2 (all cytokines were purchased from R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml, IL-12 at a final concentration of 1ng/ml and IL-18 at a final concentration of 50ng/ml are also used. Controls and unknown samples are tested in duplicate. Supernatant samples (250ul) are collected 2 days and 5 days after the beginning of the assay. ELISAs to test for IFN γ and IL-2 secretion are performed using kits purchased from R & D Systems, (Minneapolis, MN). Results are expressed as an average of duplicate samples plus or minus standard error.

30

Proliferation assay for preactivated-resting T cells.

A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then
5 cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would have an effect on a naïve T cell. Therefore the use of this type of cells might enable
10 to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve) T cells.

The assay is performed as follows. PBMC are isolated by F/H gradient centrifugation from human peripheral blood, and are cultured in 10% FCS (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the
15 presence of 2 µg/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5 ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are washed and rested in starvation medium (1% FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to
20 determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate using 2×10^4 cells/well in a final volume of 200 µl. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60 µl are added to 140 µl of in 10% FCS/RPMI containing the cells. Control
25 supernatants are used at the same final dilution and express the following proteins: vector (negative control), IL-2, IFN γ , TNF α , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 at a final concentration of 10 ng/ml is also used. After 24 hours of culture, each well is pulsed with 1 µCi of ^3H -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing
30 and incorporation of ^3H -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

The studies described in this example test activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

10 Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- α , causes a rapid
15 change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC γ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3
20 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

25

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to
30 measure the IL-12 release as follows. Dendritic cells (10^6 /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell

cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

5 Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the
10 antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

 FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or
15 LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

20 Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be
25 screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

30

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results

from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10^6 /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACSscan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10^5 cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at 2×10^5 cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20 µl 1N NaOH per well. The absorbance is read at 610

nm. To calculate the amount of H₂O₂ produced by the macrophages, a standard curve of a H₂O₂ solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 35: Biological Effects of Polypeptides of the Invention

Astrocyte and Neuronal Assays

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 α for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP⁺) and released.

Subsequently, MPP^+ is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP^+ is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin-coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at $2-5 \times 10^4$ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF₁₆₅ or a

polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida *et al.*, *J. Biol. Chem.* 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 39: Stimulation of Endothelial Migration

5 This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 μ m (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours
10 at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 μ l of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter
15 between lower and upper chamber, 2.5×10^5 cells suspended in 50 μ l M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO₂ to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a
20 Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
25 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.


Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells

30 Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be

assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of KNO_2 (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and H_2SO_4 . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per 1×10^6 endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. β -estradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse

In vivo angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the

Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug
5 are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 44: Rescue of Ischemia in Rabbit Lower Limb Model

15 To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb
20 is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid
25 containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1
30 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow

during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

Example 45: Effect of Polypeptides of the Invention on Vasodilation

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean \pm SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as $p < 0.05$ vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 46: Rat Ischemic Skin Flap Model

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- 5 a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- 10 d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
15 invention.

Example 47: Peripheral Arterial Disease Model

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic
20 strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is
25 delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the
30 contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 48: Ischemic Myocardial Disease Model

5

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

10 a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

15 c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
20 invention.

Example 49: Rat Corneal Wound Healing Model

This animal model shows the effect of a polypeptide of the invention on
25 neovascularization. The experimental protocol includes:

a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.

b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.

30 c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).

d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing

Models

10

A. Diabetic db+/db+ Mouse Model.

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These

homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/-m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

- 5 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post
10 treatment (day 8). The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

- 15 Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by
20 treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

- 25 Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

- 30 Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary

antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is
5 considered significant.

B. Steroid Impaired Rat Model

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-
10 Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *Am. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*,
15 *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth*
20 *Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing
25 process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and
30 are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*

libitum. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

5 The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue
10 punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

 Wounds are visually examined and photographed at a fixed distance at the day of
15 wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

 The polypeptide of the invention is administered using at a range different doses,
20 from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

 Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue
25 cassettes between biopsy sponges for further processing.

 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

 Wound closure is analyzed by measuring the area in the vertical and horizontal
30 axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8).

The wound area on day 1 is 64mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

5

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

15 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20 **Example 51: Lymphadema Animal Model**

or The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

30 Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing.

Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of
5 dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main
10 lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose
15 tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying
20 muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated
25 places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb
30 movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then
5 dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca²⁺ comparison.

10 Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee
15 (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to
20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention

25 The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and
30 endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and

extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

5 Tumor necrosis factor alpha (TNF- α), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- α induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- α treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO₂.

15 HUVECs are seeded in 96-well plates at concentrations of 1×10^4 cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 μ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are incubated at 37 degree C for

25 either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca⁺⁺ and Mg⁺⁺) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 μ l of

30 diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution

of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with
5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 (10^0) > $10^{-0.5}$ > 10^{-1} > $10^{-1.5}$. 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is
10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [
15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
20 invention.

Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation

This assay is based on the ability of human CD34+ to proliferate in the
25 presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range
30 of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone

has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5×10^5 cells/ml. During this time, 100 μ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10 μ l of prepared cytokines, 50 μ l SID (supernatants at 1:2 dilution = 50 μ l) and 20 μ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100 μ l. The plates are then placed in a 37°C/5% CO₂ incubator for five days.

Eighteen hours before the assay is harvested, 0.5 μ Ci/well of [3H] Thymidine is added in a 10 μ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μ l Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined

via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the $\alpha_5\beta_1$ and $\alpha_4\beta_1$ integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating

stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with
fn fragment at a coating concentration of $0.2 \mu\text{g}/\text{cm}^2$. Mouse bone marrow cells are
5 plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the
presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control,
conditions under which little self-renewal but pronounced differentiation of the stem
cells is to be expected. Gene products are tested with appropriate negative controls in
the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent
10 10% of the total assay volume. The plated cells are then allowed to grow by
incubating in a low oxygen environment (5% CO_2 , 7% O_2 , and 88% N_2) tissue
culture incubator for 7 days. The number of proliferating cells within the wells is
then quantitated by measuring thymidine incorporation into cellular DNA.
Verification of the positive hits in the assay will require phenotypic characterization
15 of the cells, which can be accomplished by scaling up of the culture system and using
appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the
activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or
antagonists and fragments and variants thereof.

20 If a particular gene product is found to be a stimulator of hematopoietic
progenitors, polynucleotides and polypeptides corresponding to the gene may be
useful for the diagnosis and treatment of disorders affecting the immune system and
hematopoiesis. Representative uses are described in the "Immune Activity" and
"Infectious Disease" sections above, and elsewhere herein. The gene product may
25 also be useful in the expansion of stem cells and committed progenitors of various
blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest
and/or agonists and/or antagonists thereof, may also be employed to inhibit the
proliferation and differentiation of hematopoietic cells and therefore may be
30 employed to protect bone marrow stem cells from chemotherapeutic agents during
chemotherapy. This antiproliferative effect may allow administration of higher doses

of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF α stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 μ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 μ g/ml hEGF, 5mg/ml insulin, 1 μ g/ml hFGF, 50mg/ml gentamycin, 50 μ g/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for

AoSMC contains SM basal media, 50mg/ml gentamycin, 50µg/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls.

- 5 For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO₂ until day 5.

- 10 Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

- 15 On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

- On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of
20 Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

- 25 Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 µl/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

- Add 100 µl/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each
30 assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or

smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vasculogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial**Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 μ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μ l of 0.1% paraformaldehyde-PBS(with Ca⁺⁺ and Mg⁺⁺) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10 μ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 μ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 μ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of

the ExtrAvidin-Alkaline Phosphatase in glycine buffer: $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$. 5 μ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μ l of pNPN reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 μ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

Example 57: Alamar Blue Endothelial Cells Proliferation Assay

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The

plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction

This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM[®], density 1.0770 g/ml,

Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to 2×10^6 cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2×10^5 cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 μ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 μ g/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 μ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO₂, and 1 μ C of [³H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, the contents of U.S. Provisional Applications Serial Nos. 60/162,239 and 60/215,139 are all hereby incorporated by reference in their entirety.


400

Applicant's or agent's file reference number	PS701PCT	International application No.	UNASSIGNED
---	----------	-------------------------------	------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13 bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>55</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 13 October 1999	Accession Number PTA-841
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer  S. R. Hosoya	Authorized officer

ATCC Deposit No. PTA-841**Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

ATCC Deposit No.: PTA-841**Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit
- 10 No:Z, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
- 20 having biological activity;
- (f) a polynucleotide which is a variant of SEQ ID NO:X;
- (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
- 5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 20 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 25 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
- 30 9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15 (g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

30 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of
10 claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to
15 a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the
30 method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 32 Human Secreted Proteins

<130> PS701PCT

<140> Unassigned

<141> 2000-10-25

<150> 60/162,239

<151> 1999-10-29

<150> 60/215,139

<151> 2000-06-30

<160> 228

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gccc aaatct	tctgacaaaa	ctcacacatg	cccaccggtg	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tcccccaaaa	acccaaggac	accctcatga	120
tctcccgga	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcagg	tctccaacaa	agcctccca	accccatcg	360
agaaaacat	ctccaaagcc	aaagggcagc	cccagagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctgggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccgggagaac	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccggtg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaagtgtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp	Ser	Xaa	Trp	Ser
1				5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag	atttccccga	aatctagatt	tccccgaaat	gatttccccg	aaatgatttc	60
cccgaatat	ctgccatctc	aattag				86

<210> 4
 <211> 27
 <212> DNA
 <213> Homo sapiens

<400> 4
 gcggcaagct ttttgcaaag cctaggc 27

<210> 5
 <211> 271
 <212> DNA
 <213> Homo sapiens

<400> 5
 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
 aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120
 gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180
 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
 ttttgaggc ctaggctttt gcaaaaagct t 271

<210> 6
 <211> 32
 <212> DNA
 <213> Homo sapiens

<400> 6
 gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7
 <211> 31
 <212> DNA
 <213> Homo sapiens

<400> 7
 gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8
 <211> 12
 <212> DNA
 <213> Homo sapiens

<400> 8
 ggggactttc cc 12

<210> 9
 <211> 73
 <212> DNA
 <213> Homo sapiens

<400> 9
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60
 ccatctcaat tag 73

<210> 10
 <211> 256
 <212> DNA
 <213> Homo sapiens

<400> 10
 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60

caattagtca	gcaaccatag	tcccgccct	aactccgccc	atcccccccc	taactccgcc	120
cagttccgcc	catttctccg	cccattggctg	actaattttt	tttatttatg	cagaggccga	180
ggccgcctcg	gcctctgagc	tattccagaa	gtagtgagga	ggcttttttg	gaggcctagg	240
cttttgcaaa	aagctt					256

<210> 11
 <211> 2601
 <212> DNA
 <213> Homo sapiens

<400> 11						
ccacgcgtcc	gcggtctgtg	cgaggcttc	cagcccccac	catgccgtgg	cccctgctgc	60
tgctgctggc	cgtgagtggg	gcccagacaa	cccggccatg	cttccccggg	tgccaatgcg	120
aggtggagac	cttcggcctt	ttcgacagct	tcagcctgac	tcgggtggat	tgtagcggcc	180
tgggccccca	catcatgccg	gtgcccattc	ctctggacac	agcccacttg	gacctgtcct	240
ccaaccggct	ggagatgggt	aatgagtcgg	tggtggcggg	gccgggctac	acgacgttgg	300
ctggcctgga	tctcagccac	aacctgctca	ccagcatctc	acccactgcc	ttctcccgcc	360
ttcgctacct	ggagtgcgtt	gacctcagcc	acaatggcct	gacagccctg	ccagccgaga	420
gcttcaccag	ctcacccttg	agcgacgtga	accttagcca	caaccagctc	cgggaggtct	480
cagtgtctgc	cttcacgacg	cacagtcagg	gccgggcaat	acacgtggac	ctctcccaca	540
acctcattca	ccgcctcgtg	ccccacccca	cgaggggcgg	cctgcctgcg	cccaccattc	600
agagcctgaa	cctggcctgg	aaccggctcc	atgccgtgcc	caacctccga	gacttgcccc	660
tgcgctacct	gagcctggat	gggaaccctc	tagctgtcat	tggtccgggt	gccttcgcgg	720
ggctgggagg	ccttacacac	ctgtctctgg	ccagcctgca	gaggctccct	gagctggcgc	780
ccagtggcct	ccgtgagcta	ccgggcctgc	aggtcctgga	cctgtcgggc	aaccccaagc	840
ttaactgggc	aggagctgag	gtgttttcag	gcctgagctc	cctgcaggag	ctggaccttt	900
cgggcaccaa	cctggtgccc	ctgcctgagg	cgctgtcctc	ccacctcccc	gcactgcaga	960
gcgtcagcgt	gggcccaggat	gtgcgggtgc	gggcgcctgt	gccgggaggc	acctaccccc	1020
ggaggccctg	ctccagcccc	aaggtggccc	tgcaactgct	agacaccogg	gaatctgctg	1080
ccagggggccc	caccatcttg	tgacaaatgg	tgtggcccag	ggccacataa	cagactgctg	1140
tcctgggctg	cctcaggtcc	cgagtaactt	atgttcaatg	tgccaacacc	agtggggagc	1200
ccgcaggcct	atgtggcagc	gtcaccacag	gagttgtggg	cctaggagag	gctttggacc	1260
tgggagccac	acctaggagc	aaagtctcac	ccctttgtct	acgttgcttc	cccaaaccat	1320
gagcagaggg	acttcgatgc	caaaccagac	tcgggtcccc	tcctgcttcc	cttccccact	1380
tatcccccaa	gtgccttccc	tcattgctgg	gccggcctga	cccgcgaatg	gcagagggtg	1440
ggtgggaccc	cctgctgcag	ggcagagtcc	aggtccactg	ggctgagtgt	cccttggggc	1500
ccatggccca	gtcactcagg	ggcgagtctc	ttttctaata	tagccctttc	tttgccatga	1560
ggccatgagg	cccgcttcat	ccttttctat	ttccctagaa	ccttaatggt	agaagggaatt	1620
gcaaagaatc	aagtccaccc	ttctcatgtg	acagatgggg	aaactgaggc	cttgagaagg	1680
aaaaaggcta	atctaagttc	ctgcgggcag	tggtcatgact	ggagcacagc	ctcctgcctc	1740
ccagcccgga	cccaatgcac	tttcttgtct	cctctaataa	gccccaccct	ccccgcctgg	1800
gtcccccttg	ctgcccctgc	ctgttcccca	ttagcacagg	agtagcacga	gcaggacagg	1860
caagagcctc	acaagtggga	ctctgggcct	ctgaccagct	gtgcggcatg	ggctaagtca	1920
ctctgccctt	cggagcctct	ggaagcttag	ggcacattgg	ttccagccta	gccagtttct	1980
caccctgggt	tggggctccc	cagcatccag	actggaaacc	taccattttt	cccctgagca	2040
tcctctagat	gctgccccaa	ggagtgtctg	cagttctgga	gcctcatctg	gctgggatct	2100
ccaagggggc	tcctggattc	agtccccact	ggccctgagc	acgacagccc	ttcttaccct	2160
cccaggaatg	ccgtgaaaag	agacaaggtc	tgcccagccc	atgtctatgc	tctacccccca	2220
gggtagcatc	tcagcttccg	aacctggggc	tgtttcctta	gtcttcattt	tataaaaagtt	2280
gttgcccttt	taacggagtg	tcactttcaa	ccggcctccc	ctacccctgc	tggccggggga	2340
tggagacatg	tcattttgta	aagcagaaaa	aggttgcaat	tgttcaattt	tgtaaatattg	2400
tcctgggcct	gtgttggggg	gttgggggaa	gctgggcatc	agtggccaca	tgggcatcag	2460
gggctggccc	cacagagacc	ccacagggca	gtgagctctg	tcctccccca	cctgcctagc	2520
ccatcatcta	tctaaccggg	ccttgattta	ataaacacta	taaaaagtaa	aaaaaaaaaa	2580
aaaaaaaaaa	aaaaaaaaag	g				2601

<210> 12
 <211> 2624
 <212> DNA
 <213> Homo sapiens

<400> 12						
ccccggggcga	ggactgttaa	ctgtttcttg	caaacatgaa	gtcaggcctc	tggtattttct	60
ttctcttctg	cttgccgcat	aaagttttta	caggagaaat	caatgggtct	gccaattatg	120

agatgtttat	atttcacaac	ggaggtgtac	aaattttatg	caaatatcct	gacattgtcc	180
agcaatttta	aatgcagttg	ctgaaagggg	ggcaaatact	ctgcgatctc	actaagacaa	240
aaggaagtgg	aaacacagtg	tccattaaga	gtctgaaatt	ctgccattct	cagttatcca	300
acaacagtg	ctcttttttt	ctatacaact	tggaaccatt	tcattgccaac	tattacttct	360
gcaacctatc	aatttttgat	cctctcctt	ttaaagtaac	tcttacagga	ggatatttgc	420
atatttatga	atcacaaact	tgttgccagc	tgaagttctg	gttaccata	ggatgtgcag	480
cctttgttgt	agtctgcatt	ttgggatgca	tacttatatt	ttgggttaca	aaaaagaagt	540
attcatccag	tgtgcacgac	cctaacgggt	aatacatggt	catgagagca	gtgaacacag	600
ccaaaaaatc	tagactcaca	gatgtgacct	tataatatgg	aactctggca	cccaggcatg	660
aagcacgttg	gccagttttc	ctcaacttga	agtgcagat	tctcttattt	ccgggaccac	720
ggagagtctg	acttaactac	atacatcttc	tgtctggtgt	ttgttcaatc	tggaagaatg	780
actgtatcag	tcaatgggga	ttttaacaga	ctgccttggt	actgccgagt	cctctcaaaa	840
caaacaccct	cttgcaacca	gctttggaga	aagcccagct	cctgtgtgct	cactgggagt	900
ggaatccctg	tctccacatc	tgctcctagc	agtgcacag	ccagtaaaac	aaacacattt	960
acaagaaaaa	tgtttttaag	atgccagggg	tactgaatct	gcaaagcaaa	tgagcagcca	1020
aggaccagca	tctgtccgca	tttcaactat	atacactctc	ttctttctgt	agggatgaga	1080
attctctctt	taatacagtc	agggagatgc	ttcaaagctg	gagctatttt	atttctgaga	1140
tgttgatgtg	aactgtacat	tagtacatac	tcagtactct	ccttcaattg	ctgaacccca	1200
gttgaccatt	ttaccaagac	tttagatgct	ttcttctgct	ctcaattttc	tttttaaaaa	1260
tacttctaca	tgactgcttg	acagcccaac	agccactctc	aataagagagc	tatgtcttac	1320
attctttctc	ctgctgctca	atagttttat	atatctatgc	atacatatat	acacacatat	1380
gtatataaaa	ttcataatga	atatatttgc	ctatattctc	cctacaagaa	tatttttgct	1440
ccagaaagac	atgttctttt	ctcaaattca	gttaaaatgg	tttactttgt	tcaagttagt	1500
ggtaggaaac	attgcccggg	attgaaagca	aatttatttt	attatectat	tttctaccat	1560
tatctatgtt	ttcatgggtg	tattaattac	aagtttagtt	ctttttgtag	atcatattaa	1620
aattgcaaac	aaaatcatct	ttaatgggct	agcattctca	tggggtagag	cagaatattc	1680
athtagcctg	aaagctgcag	ttactatagg	ttgctgtcag	actataccca	tggtgcctct	1740
gggcttgaca	ggtcaaaatg	gtccccatca	gcctggagca	gccctccaga	cctgggtgga	1800
attccagggt	tgagagactc	ccctgagcca	gaggccacta	ggtattcttg	ctcccagagg	1860
ctgaagtcac	cctgggaatc	acagtggtct	acctgcattc	ataattccag	gatctgtgaa	1920
gagcacatat	gtgtcagggc	acaattccct	ctcataaaaa	ccacacagcc	tggaatttgg	1980
ccttgccctt	tcaagatagc	cttctttaga	atatgatttg	gctagaaaga	ttcttaaaata	2040
tgtggaatat	gattattctt	agctggaata	ttttctctac	ttcctgtctg	catgcccaag	2100
gcttctgaag	cagccaatgt	cgatgcaaca	acatttgtaa	ctttaggtaa	actgggatta	2160
tgttgtagtt	taacattttg	taactgtgtg	cttatagttt	acaagtgaga	ccgatatgtg	2220
cattatgcat	acttatatta	tcttaagcat	gtgtaatgct	ggatgtgtac	agtacagtac	2280
tgaacttgta	atttgaatct	agtatgggtg	ttctgttttc	agctgacttg	gacaacctga	2340
ctggctttgc	acaggtgttc	cctgagttgt	ttgcaggttt	ctgtgtgtgg	ggtgggggat	2400
ggggaggaga	accttcatgg	tggcccacct	ggcctgggtg	tccaagctgt	gcctcgacac	2460
atcctcatcc	ccagcatggg	acacctcaag	atgaataata	attcacaaaa	tttctgtgaa	2520
atcaaatcca	gttttaagag	gagccactta	tcaaagagat	tttaacagta	gtaagaaggc	2580
aaagaataaa	catttgatat	tcagcaactg	aaaaaaaaaa	aaaa		2624

<210> 13
 <211> 2199
 <212> DNA
 <213> Homo sapiens

<400> 13						
ggcacgagga	gagtgcgaca	cgggctgccc	tgagagacat	ttccatggac	atcctcatgc	60
tgcttctgct	tttgtgtgta	atatatggga	gattttccca	agatgaatac	tccttcaatc	120
aagctatccg	gaaagaattt	acaagaaatg	ccagaaactg	cttgggtggc	ctgagaaaca	180
tcgctgactg	gtgggactgg	agtctgacca	cacttctgga	tggcctgtac	ccgggaggca	240
ccccgtcagc	ccgtgtgccg	ggggctcagc	ctggagctct	tgaggagaaa	tgctacctaa	300
taggcagttc	cgtaattagg	cagctaaaag	tttttctctag	gcattttatg	aagcctccca	360
ggccattttc	agcactcatc	gaagactcta	ttcctacatg	tagtcccga	gttgagggcc	420
ctgagaaacc	ctacctgata	gacccagaga	accaaaacgt	gacctgaat	ggtcctgggg	480
gctgtgggac	aagggaggac	tgtgtgctca	gcctgggcag	aacaaggact	gaagcccaca	540
cagccctgtc	ccgactcagg	gccagcatgt	ggattgaccg	cagcaccagg	gctgtgtctg	600
tgcaacttcc	tctctataac	cctccaaccc	aactcttcac	cagcgtgtcc	ctgagagtgg	660
agatctctcc	tacggggagt	ctcgctccct	cactcctggg	ggagtcatte	agcatcttcc	720
gcagcgactc	agccctgcag	taccacctca	tgttctccca	gctggtcttc	ctggcactca	780
gctgatccca	cctctgtgtt	caactctacc	gtatgatgga	caagggcgctc	ctcagctact	840
ggcgaaagcc	aaggaactgg	ctggagctct	ccgtggttgg	agtgagcctc	acctactatg	900
cagtttccgg	ccacctgtgt	actcttgctg	gagatgtcac	taaccagtgt	cacagaggac	960

tttgccgagc	atttatggac	ctcaccctta	tggcatcatg	gaatcagagg	gctcgatggc	1020
tccgggggaat	cctcttattc	ctcttcacat	taaaatgcgt	ctatcttcct	ggcattcaaa	1080
acacaatggc	atcctgctcc	tccatgatgc	gccactcact	ccccagcatc	tttgtagcag	1140
ggctggtggg	ggcactgatg	ctggccgccc	tctcccacct	gcaccgattt	ctgctctcta	1200
tgtgggttct	accacctggc	accttcacag	acgccttccc	cgggctgctg	tttcattttc	1260
ccagaagaag	ccaaaaagac	tgcctccttg	gcctttccaa	gtctgaccag	cggggccatgg	1320
cctgttactt	tgggacccct	ttaatagtct	ctgccacact	gtgttttgga	atgctgagag	1380
gttttctcat	gactttaccc	caaaaaagaa	aatcttttca	aagtaaactc	tttgtgagac	1440
ttaaagatgt	cactgcttat	atgtgggaaa	aggctctcac	ctttctgaga	ctggaaacac	1500
caaagtggga	agaggctgag	atggttgaga	atcacaaat	ctacttggat	gaatttgcaa	1560
atctgttaga	cgaacttctg	atgaagatta	atggtttgtc	cgcacgccta	caactcccc	1620
ttctggaaaa	aacatccaac	aacacagggg	aggcaaggac	agaagagagt	cccttagtgg	1680
acatttctag	ttaccaagct	gctgagccag	cagacatcaa	ggacttctga	ggagcctggt	1740
accttgcata	ggcactatgg	accctgtttt	gcttaaccca	cccaacagcc	aatttttagca	1800
gacatcctag	ttttgcaggt	gagaagagct	gaggtacgaa	gaagttttgt	taatttttcc	1860
agttcacgta	acaagtaaat	gggaaaccag	gatgaaaatc	aaggtttatc	tgctcatcaga	1920
ctgttactca	taatcaccat	tcggagagtt	cagatgtggg	acaagattct	aactccagcc	1980
ttctcccaaa	tggtaatttt	gccagttgcc	ctagagttac	atattgtctt	atttgtttgt	2040
tttactgaat	ctgtctgagt	attaaaagcc	ttgtatcttg	tgaattttct	ttcaggtctc	2100
ataaaagcga	tgaagagac	caggataaca	ttctaataat	taaataagat	ttttgaagta	2160
aatccttat	tttgtaaat	taaaaaaaa	aaaaaaaaa			2199

<210> 14
 <211> 2277
 <212> DNA
 <213> Homo sapiens

<400> 14						
aattcggcac	gagccagccc	tggcgtgggc	ccagcccggc	ccaggcagca	atgggggttcc	60
tgcaagtgtc	ggctgtagcg	gtgctggcat	ccgaacaccg	ggtggctggg	gcagccgagg	120
tcttcgggaa	ttccagcgag	ggtcttattg	aattttctgt	ggggaaattt	agatacttcg	180
agctcaatag	gccctttcca	gaggaagcta	ttttgcatga	tatttcaagc	aatgtgactt	240
ttcttatttt	ccaaatacac	tcacagtatc	agaataacaac	tgtttctctt	tctccgactc	300
tcctttccaa	ttctcgggaa	acaggcactg	ccagtggact	ggttttcatc	cttagaccag	360
agcagagtac	atgcacttgg	tacttgggga	cttcaggcat	acagcctgtc	cagaatatgg	420
ctatcctact	ctcctactca	gaaagagatc	ctgtccctgg	aggctgtaat	ttggagttcg	480
atttagatat	tgatecccaac	atttacttgg	agtataattt	ctttgaaacg	actatcaagt	540
ttgccccagc	aaacctaggc	tatgcgagag	gcgtagatcc	cccaccatgt	gacgctggga	600
cagaccagga	ctccagggtg	agggtgcagt	atgatgtcta	tcagtatttt	ctgcctgaga	660
atgacctcac	tgaggagatg	ttgctgaagc	atctgcagag	gatgggtcagt	gtgccccagg	720
tgaaggccag	tgctctcaag	gtggttaccc	taacagctaa	tgataagaca	agtgtttcct	780
tctcctccct	cccgggacaa	ggtgtcatat	acaatgtcat	tgtttgggac	ctgttttctaa	840
atacatctgc	tgcctacatt	cctgctcaca	catacgcttg	cagctttgag	gcaggagagg	900
gtagttgtgc	ttccctagga	agagtgtctt	ccaaagtgtt	cttcactctt	tttgccctgc	960
ttggtttctt	catttgtttc	tttggacaga	gattctggaa	aacagaatta	ttcttcatag	1020
gctttatcat	catgggattc	ttcttttata	tactgattac	aagactgaca	cctatcaagt	1080
atgatgctga	acatactgac	ttgtggagtc	attggctcct	attcgggtgg	tttagccatt	1140
gacagt tact	ggtccacaag	cctttctctac	atcactttga	acgtactcaa	gagagcgctc	1200
aacaaggatt	ttccacagagc	tttcacaaat	gtgccttttc	aaactaatga	cttcattatc	1260
ctggcagtat	ggggcatgct	ggctgtaagt	ggaattacgt	tacagattcg	aagagagaga	1320
ggacgaccgt	tcttccctcc	cccccatac	aagtatatga	agcaagagag	agagcgccga	1380
gtgacaaaca	ttctggaccc	tagctaccac	attcctccat	tgagagagag	gctctatggc	1440
cgattaaacc	agattaaagg	gctcttccag	aaggagcagc	cagctggaga	gagaacgcct	1500
ttgcttctgt	agatgccccg	gggcttggtc	agtgtgcctc	agctttggag	ttcatgctctg	1560
gagtgggttca	acagtctctg	gtgcaagtct	aataagagat	caggcatata	tatctgttct	1620
ttgcataata	ttatggtgcc	cttattgata	tatggtaagg	gtgtactagg	ggattaggat	1680
gattgtaaga	gaatgagaaa	gatgaccaa	aggttgggtg	tagggaggct	ttttcttatt	1740
tccaaatact	tgagaaatta	ccttttgggt	tacaaatcta	tgatcaactt	attccattaa	1800
atagatacat	taaaaaaatt	aaaaactgat	tcttctgcag	agcactgggt	tttcttttta	1860
taaccccttg	aaacaagtct	ctcacctgag	cctgtctaaa	ctttcggagg	gagtttatta	1920
ttgagtcttt	atctgtgaca	gtatttggag	atttagggat	ttgatactta	ggcctttgaa	1980
ttttagaata	caaaaagaga	agcaagccag	acatgggtggc	tcacacctgt	aatcccaata	2040
ctgggaagcc	aaggtggggag	tatcgcttga	gcccaggagt	ttgagaccga	catgggcaac	2100
atgacaagac	cccattctcta	caaaaaaatt	aaaaaattag	ccaggcatgg	tggcacatgc	2160
ctactccag	ctcccaagga	gactgagatg	ggaggatccc	tggagccctg	aagcttgagg	2220

ctacagttag ccttgattgt gtcactgcac tccagcttgg gtgacagaga ccctgtc 2277

<210> 15
<211> 2005
<212> DNA
<213> Homo sapiens

<400> 15
ccacgcgtcc gcctctacct gtgtaccacg gcctgggatg gacctgcag ctgtggccct 60
cctggcacta tccctaccct gtgccctggt ggggtgtgcag tgggaacagg caccctgggg 120
tccttgaggg ctcagcctcc tcagccctca ccccgagag cccatcgtgg cgctgtgtc 180
cactcagggg ttatcccaag cctggccaga ggctcgggagg ggacagaggg agccacatag 240
gagcctctac cagccccctt cttaccacag ggtgggggag cttccctccc acaggggtctc 300
aggcttgttg gctcccccca gctgcacagg ccccgagagg cacttctgac ccttctcttt 360
ggggctctgcc ctgggggggct ccaggccact tgctccacc catccctctt ctggagcctc 420
ccagcacctc agttccgact gtggggaaaa cagaacccta ggaagcaacc tcacggctgt 480
gggcagggga gggcgcccg gagccccagc tggccacag ggacattgag tgaaggcaga 540
gcctgggagg gaagtccagat ccgtgcatgg gtcccttccct gttggtgttg gcgtccctga 600
gtgagcagcc atccgccgccc cctggaaaag agacctggag aagcagcttc aagctttgga 660
gcccagccca gctgctagca gcccctgggt cacagtgcga agggggaagg caggggcttg 720
aggaagaaaag tgagaggatt gtgcctgggg gccctggag ggccagtctg gaggcgcgtt 780
gggggtgagg ggtgctggct gtgcccgtct gagatgggca gaggaaggc gccagggct 840
gagcccgagg tccccaggcc agtccctcac tgctctggg ttcagtttcc tcacctgcac 900
aaaggcgagg tcccgctgctc tccggaggcc acacggggtc tccctgaggc actgagtctg 960
gcttgtttct ggaactgag gcacaggagg acgttgataa ccggccttcc tctgttctct 1020
ttcccagggg tgcagctcgt ccgtcccatg gtttcagatt tgcccgggtg gttgcaacca 1080
ccacctggca ctcagcttgc ccggtgccgc ctggccccc agcctttccc aggccttgca 1140
agggtggcac agatgggaa actccatctg caggggcgtc acccccagg gatgtgtcct 1200
ccacactccc ttgatggta cgtgggtccc gggaggggcg gtgtgactct tcccaggatt 1260
gcagcgttgg ggcgttgtgc cagcctggcc ccgtgggtgc ggagtgccgt ggaccctcg 1320
gccctcccga ccttgtttcc cttgatgta gaagtctgca tggcatgaat tccagtga 1380
atgggcccgg ccaggctccc tgtcccctg gtactgctgc ccaggggccg tctctgcagt 1440
caccctcctt ccttccctgt ggctccctcc tccctccttt gttcttcttt tctgcctaa 1500
atgtttatcg agtccctcct gcattaagta ccgctgctgt gcaacaaatt acctgaa 1560
tggtgacttc accaccactg catgtcagcg cccagccgta gacgagggtt tgggaggcat 1620
ggctgggcct gccaggggct ccctggctga agtgggtgct gaagctgcca ggcactggag 1680
gctgggcctc tcgcacactc cctggctgtt gggagggtgc attcttcttt cttccttgtc 1740
ttctagagga tgcactcttg gctgtaggcc tcccgtttct ctcacgggct attcctgggg 1800
ttccctcaga tctggagggt gccacagcc ccttccccg aggtctcccc cccacacac 1860
tctgcgtccg cagagggttg tgagggtcca tgaaatactt gagttaccag gatgttcatt 1920
ttgcaacatt ttcaacattt gtaatccagt gaaatatcaa taaaaacccc acagggttct 1980
ggtaatagga aaaaaaaaaa aaaaaa 2005

<210> 16
<211> 926
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (17)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (28)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (72)
<223> n equals a,t,g, or c

<220>

<221> SITE
 <222> (102)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (900)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (917)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (920)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (923)
 <223> n equals a,t,g, or c

<400> 16						
gcagtggcga	ttcattnagc	agctggcncg	acagggtttcc	gactggaaag	cgggcagtgga	60
gcgcagcgca	antaatgtga	gttagctcac	tcattaggca	cnccaggctt	tacactttat	120
gcttccggct	cgtatgttgt	gtggaattgt	gagcggataa	caatttcaca	caggaaacag	180
ctatgaccat	gattacgcca	agctctaata	cgactcacta	tagggaaagc	tggtagcctt	240
gcaggtagcg	gtccggaatt	cccggttcga	cccacgcgtc	cgggctgggg	gaytgcccag	300
ttgtacttgt	cagrcgtgtg	tgcccagccc	tgtttatctg	tgtaattatt	tttgtaaaca	360
ttgtattctc	tgtggtcgcc	acctcctcgc	ccccagcctc	gggttcagtc	tgtcttccag	420
gcctgcttgc	acctcactgg	gctgctccgg	ggtctctgcc	cctcattcca	ggcctggctg	480
tcaggcccgag	ccagcagggg	cccgtagacc	agcagcctgc	ccaaagcatt	tgtttctggg	540
ggatgggggt	ggggctgtgc	cacaggaggt	ttgagcccar	caccctgggg	aaggggaccc	600
tgacagacac	cccttgcgcc	tccctccatg	aggctaaagg	cccagtcctc	ccaaatgtgc	660
tgccctcggt	catgtgccaa	atggccccag	cccacatgcc	cctcccytct	stggartggg	720
agcccccttct	gaagtgtctg	aatccctgaa	gtgttcattt	gtccgtcctc	tgtgcagtgga	780
cagccccgggc	caagccacct	ctaatectct	gtagcaataa	cggtgcgccg	cccatccctg	840
ccatttgtgc	accactagga	ttttaagtc	catagatttt	aatgaaattt	ctattcctgn	900
caaaaaaaaa	aaaaaanggn	cgncccc				926

<210> 17
 <211> 1731
 <212> DNA
 <213> Homo sapiens

<400> 17						
gagcgtgtct	ggccctaggt	gggaaaagaa	ctggctgtga	cctttgccct	gacctggaag	60
ggcccagcct	tgggctgaat	ggcagcacc	acgcccgccc	gtccggtgct	gaccacactg	120
ctgggtggctc	tcttcggcat	gggctcctgg	gctgcggtca	atgggatctg	ggtggagcta	180
cctgtggtgg	tcaaagagct	tccagagggt	tggagcctcc	cctcttacgt	ctctgtgctt	240
gtggctcttg	ggaacctggg	tctgctgggt	gtgacctctt	ggaggaggct	ggccccagga	300
aaggacgagc	aggcccccat	ccgggtgggtg	cagggtgctg	gcatggtggg	cacagccctg	360
ctggcctctc	tgtggcacca	tgtggcccca	gtggcaggac	agttgcattc	tgtggccttc	420
ttagcactgg	ccttttgtgt	ggcactggca	tgctgtgccc	cgaatgtcac	tttctgccc	480
ttcttgagcc	acctgccacc	tcgcttctta	cggctattct	tcctgggtca	aggcctgagt	540
ggcctgtgct	cctgctgtgt	ggccctagtg	cagggtgtgg	gccgcctcga	gtgcccgcga	600
gcccccatca	acggcaccac	tggcccccg	ctcgacttcc	ttgagcggtt	tcccgcagc	660
accttcttct	gggactgac	tgcccttctg	gtcgcttcag	ctgtgcctt	ccagggtctt	720
ctgctgctgt	tgcgcgccac	accatctgta	cccacagggg	agttaggatc	aggcctccag	780
gtgggagccc	caggagcaga	ggaagagggt	gaagagtcct	caccactgca	agagccacca	840
agccaggcag	caggcaccac	ccctgggtcca	gaccctaagg	cctatcagct	tctatcagcc	900
cgcagtgcct	gcctgctggg	cctgttgccc	gccaccaacg	cgctgaccaa	tggcgtgctg	960
cctgccgtgc	agagcttttc	ctgcttacc	tacgggcgtc	tggcctacca	cctggctgtg	1020

gtgctgggca	gtgctgcaa	tcccctggcc	tgettctctgg	ccatgggtgt	gctgtgcagg	1080
tccttggcag	ggctgggcgg	cctctctctg	ctgggcgtgt	tctgtggggg	ctacctgatg	1140
gcgctggcag	tcctgagccc	ctgcccggcc	ctgggtgggca	cctcggcggg	ggtggctcctc	1200
gtggtgctgt	cgtgggtgct	gtgtcttggc	gtgttctcct	acgtgaaggt	ggcagccagc	1260
tccttctctg	atggcgggg	ccggccggca	ttgctggcag	ccggcgtggc	catccagggtg	1320
ggctctctgc	tcggcgctgt	tgctatgttc	ccccgacca	gcctctatca	cgtgttccac	1380
agcagaaaagg	actgtgcaga	cccctgtgac	tcctgagcct	gggcagggtg	ggaccccgct	1440
ccccaacacc	tgtctttccc	tcaatgctgc	caccatgcct	gagtgcctgc	agcccaggag	1500
gcccgcacac	cgtacactc	gtggacacct	acacactcca	taggagatcc	tggctttcca	1560
gggtgggcaa	gggcaaggag	caggcttggg	gccagggacc	agtgggggct	gtagggttaag	1620
cccctgagcc	tgggacctac	atgtggtttg	cgtaataaaa	catttgtatt	taaaaaaaaaa	1680
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	a	1731

<210> 18
 <211> 4150
 <212> DNA
 <213> Homo sapiens

<400> 18						
ggcacgagag	agggttagagg	aggagaggga	ggaggaggag	ggaggtggcg	gcgcgctggc	60
ggaggagcag	gagcaggagg	gggatggaga	ggagaaggct	cctgggtggc	atggcgctcc	120
tgctcctcca	ggcgctgccc	agcccttgt	cagccagggc	tgaacccccg	caggataagg	180
aagcctgtgt	gggtaccaac	aatcagagct	acatctgtga	cacaggacac	tgctgtggac	240
agtctcagt	ctgcaactac	tactatgaac	tctggtggtt	ctggctggtg	tggaccatca	300
tcatcatcct	gagctgctgc	tgtgtttgcc	accaccggcg	agccaagcac	cgccttcagg	360
cccagcagcg	gcaacatgaa	atcaacctga	tcgcttaccg	agaagcccac	aattactcag	420
cgctgccatt	ttatttcagg	tttttgcaa	actatttact	acctccttat	gaggaagtgg	480
tgaaccgacc	tccaaactcct	ccccaccat	acagtgcctt	ccagctacag	cagcagcagc	540
tgctgcctcc	acagtgtggc	cctgcagggtg	gcagtcccc	gggcatcgat	cccaccaggg	600
gatcccaggg	ggcacagagc	agccccctgt	ctgagcccag	cagaagcagc	acaagacccc	660
caagcatcgc	tgacctgat	ccctctgacc	taccagtga	ccgagcagcc	accaaagccc	720
cagggatgga	gcccagtggc	tctgtggctg	gcctggggga	gctggacccg	ggggccttcc	780
tggacaaaaga	tgcagaatgt	agggaggagc	tgctgaaaga	tgacagctct	gaacacggcg	840
caccgcagac	caaagaaag	acgcctggga	gacatcgccg	cttcacaggt	gactcgggca	900
ttgaagtgtg	ttgtgtgcaac	cggggccacc	atgacgatga	cctcaaagag	gtcaacacac	960
tcatcgacga	tgctctggat	gggcccctgg	acttctgcca	cagctgccat	gtgcggcccc	1020
ctgggtgatga	ggaggaaggc	ctctgtcagc	cctctgagga	gcaggctcga	gagcctgggc	1080
accgcacact	gccacggccg	cccgcatgcc	tgctgctgaa	caccatcaac	gagcaggact	1140
ctcccaactc	ccagagcaac	agctccccc	gctagagcag	gtcctgccag	caccagcaa	1200
cttggcacaag	caaccagggt	aggggagaac	cacgagagaa	gcattaagtg	actttcaaag	1260
actttcagag	tacagccact	tggttccttt	ttgtttgttt	tccttctcct	ctcctgcatt	1320
ttcctccatc	tcaggtaca	gttcggggtg	tggatgcctc	ttcctccaca	agggcacagt	1380
gttgtggagg	gctaagtgtg	ttctgtgact	cattcctcat	accctaactc	catctccttt	1440
ctttaaagtc	aaatctcacc	tacctgtttg	ggtcagagag	atgtgtttta	aaagccccc	1500
aggaaggagg	ctgggactgt	gccctgacat	gattcctggg	gatggaatag	gtttgtgctc	1560
tgattctagt	ttaagagaac	gttgctgtat	ctcagtcacg	gagaggcagc	ccatcttggc	1620
cctggatgaa	gaaggaaacc	cacagaggcc	caggccttgt	cattgggctg	ccagtgtctg	1680
ccaagccagc	attgagctaa	tcctgtggga	ggatgagagc	tactgggccc	ttgtatgata	1740
ggttggtacg	gggcttgttg	atctgtcaaa	ttccagggtga	caagatctat	gcaccccatg	1800
cgctccttag	gggcctcttc	cccgcaggct	ctggctggcc	gcaggctggg	tctgggtgtga	1860
aaggttatac	tgcccttttct	ttgtttgttt	gtttttttct	ctaaaaacaa	acagcaaaaag	1920
acagctgaaa	acaagaactt	cactggtggg	caggcaagaa	ttctcttctg	gaaaatgacg	1980
tttgtggctc	tttcccaagt	tggccttcaa	agagcctgcc	tgccgttgag	ccagaagatg	2040
tctcgtgtga	aggctggggt	ggcggtgtgc	ttggaaacctc	tgtgagcagg	aggccctaag	2100
ccgcagcagt	ggatagaggt	gcagctctct	gcctctctgc	cctttgggtct	atgttcacag	2160
gtgacccgtg	tcagcctgca	tcgcaagcac	acacccctgcg	ggccttcaag	tctcactgtt	2220
ccgtagtagg	aaacagacag	cggactgagg	aagcgtatggc	cccagagaaa	gggcccctgt	2280
agcctggctc	tcacacagta	ttttatcttt	gattctgaat	aaatatTTTT	tgtgggggttt	2340
tttttttttt	tttgggtggca	gttgtttgtt	ttaaactgac	catttggaag	aaacaccttg	2400
gttatctgtg	gttttcttgc	cttgtccctg	cctctacccc	cacccctttt	gagtcgggtg	2460
actatttttt	ctgtgtagag	actcgtggc	ccagcgagga	ggtgaaagcg	gccatccgga	2520
agggcctggg	gacccttgtg	cctgttgctc	gccttcagggt	caccagctga	gctgcgatag	2580
gaaaatctga	atggaggcag	caaacagcca	aaacaaacat	tccccacccg	gccctgtgca	2640
tatgaagtct	ttcttcccc	aactcttgaa	cgatgatgat	attcagacga	agcattgatg	2700
ttatggaaga	aagaaagaaa	caagcaaaaa	atatatatat	atgtccaaaa	acagacaaat	2760

ccaaggggtgt	gaggtaaacy	agtgtctgca	tttagattcc	acaaaaccaa	aatccatgtt	2820
gaacaaagtt	aagtccgtac	acagtgaactt	ttttgggtgag	ccgtgtgtgt	ctgtctgttg	2880
tgtgtgtgcc	tcaagccctg	ttttcctgtg	aagatacttt	gagtggcagc	cattctctcc	2940
acgtgaacca	cacgtctgga	gcacagacag	gcctctcaag	gtcattgatc	ttacgcattt	3000
actgtttacc	gaacaaatgt	ctgactgtgt	actcgggtgt	actccgcagc	attgtcgact	3060
gcagtccctt	gtgtttgcca	gagatactgt	gctcgaagta	gaggttttac	tctactcatc	3120
actgcgatgt	gcacattgct	ccgtggacac	tcggaggcct	gcgttctgtt	ccctataaat	3180
ggaagcgtgc	tctgagcctg	tctgcctccc	tcggctgctg	ctggctcctca	gtaccagcgc	3240
ccgggggtgt	ccacaaccac	ttggggacaga	agaaggtgga	atttcagaca	gaagcttgac	3300
tgggtcttca	atgacaggct	tggactagct	gtggcccaga	catcgccctt	gcccagaatt	3360
gccaggagga	ggctttgcag	gctctagagg	agccgcaggg	cctgcctgcc	tctggtgagt	3420
ccaacaggca	caagcaagct	ggcgtgtggc	cagaggtagc	cggagtgtgt	cacagccctt	3480
cagatgcctt	tctctccacc	tttttttatt	tttttaagaa	tcccaaataa	ctcactgaag	3540
tgtctcaaag	gcgaacaagt	tttaccaaaa	tgaatccttt	ttcagttaac	agatcaaatg	3600
gatgagttct	gagcctctca	agttcctttc	cccagttaga	gtggggaaact	gggcaagtgt	3660
taactgtggg	actcactgca	gcgtcctatc	ctaaaggcac	gagaagacgg	aaatgcaacc	3720
tgcggagctg	ggcttgggtc	ccaggtcaca	gtttggcccc	cgctacagga	tgtgcccctg	3780
ctcagagaga	gatttaatat	ggagctgaag	gaatcggttag	ggggccaggg	agatgtgact	3840
gaggctggct	ttccacgtga	atgagacggg	gtcgggtggag	ggtttggtgc	tacagccagt	3900
cagaagattt	gcaaatgcga	acacattcct	gtgtgaggca	tgttaccctt	tgtcagttat	3960
tgtgaatatg	tgtattttta	gcaataagat	tcagctggct	agacttttct	gggcagtctc	4020
agtgcagcat	ttcctgtgct	gtgattgttc	tgaagacaga	gtggctctaa	ccactgtgag	4080
aagcccaaat	aaaaattgat	ccccaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	4140
aaaaaaaaaa						4150

<210> 19
 <211> 1690
 <212> DNA
 <213> Homo sapiens

<400> 19						
ggcacgagca	gaactcttcc	tcttggacct	ttcttccctt	cccttggagg	tatccctttg	60
aatcaggcct	ctctcttctc	atcagtctgt	agcttccccc	cttgtataac	ctgctttcct	120
ttttacattt	attaaaagtg	gattttgtta	aagcatttca	ttgacacgcy	acctatcaca	180
gacaatggaa	ttcgtcagtg	gtggtaagac	tgaatcctg	atgcttttca	cacttcttgt	240
ctcttgcctat	gtatttctgc	ctctagcctt	gccatgtttt	gccttttttt	tttctttttg	300
gccaatctct	tttttatatg	gcccacaaca	gaggtgggga	gacacggagc	accctgggtc	360
cttcccagcg	ctgctgggca	ggccccgtct	ccaggcccca	gctgttgaaa	ctttgaaggg	420
caacaaacaa	ccatccacac	tgcgggaccc	taggctgttc	agggaggcag	ctcatttcca	480
ccccggcccc	aggacaccca	gcctgtgccc	cacaaggatc	tctctaaatg	ggagggattg	540
aggctacttt	tctgccaagc	cctattaagt	agtaatgtgg	ggaaaccac	tgtgtcagtg	600
caggaagccc	tagacaaatg	ttttcaaata	aatttctactg	cccagcctgc	acagatttcc	660
atltgaagta	cttcccatcc	accctgacac	ccaaaggggt	ttttttgttt	tgttttgttt	720
ttgagacagc	gtcttgcctt	gttgcccagg	ctggagtgc	gtgacgtggt	catagctcac	780
tgcagcctca	acctcctggg	ctcaagtgc	cctcctgcct	cagcctccca	aagttctgag	840
atgataggca	tgagccattg	tgcctagcct	atlttgattt	ttttcttaga	gtcaaggctc	900
tgtctgtttg	cccaggctga	tcttggactt	gcgagccacc	atgcctggct	gggtttttta	960
aaaatagaat	ctcactgata	gcctgcaaga	aacagatgca	gtgcctgctt	ccgtatcagt	1020
ccaaggagcc	ctcgtgtttg	ccacctttac	ctttgaacct	ccccctgcct	ccctgcctgt	1080
gtccgctttt	gcagctcaat	gcagccatga	caaggaaaaga	aaagacaaa	gaaggccaga	1140
gagccgcgca	gttctctgca	ggtgcagatg	caggcagtg	aggtggcctg	agcaggcaga	1200
aggacaccaa	gcgcccctatg	ttgcttgc	ttcatgacgt	ggctctggag	cttctgacta	1260
gttcagactg	ccagcccaac	cccagaaaat	acccacatg	ccagaaaagt	gaagtcctag	1320
gtgtttccat	ctatgtttca	atctgtccat	ctaccaggcc	tcgcgataaa	aacaaaaaaa	1380
aaaaacgctg	ccagggtttta	gaagcagttc	tggtctcaaa	accatcagga	tcctgccacc	1440
agggttcttt	tgaatatagta	ccacatgtaa	aagggaattt	ggctttcact	tcacttaata	1500
actgaattgt	caggctttga	ttgataattg	tagaaataag	tagccttctg	ttgtgggaat	1560
aagttataat	cagtattcat	ctctttgttt	tttgtcactc	ttttctctct	aatttgtgtca	1620
tttgtactgt	ttgaaaaata	tttcttctat	aaaattaaac	taacctgcct	taaaaaaaaa	1680
aaaaaaaaaa						1690

<210> 20
 <211> 2284
 <212> DNA

<213> Homo sapiens

<400> 20

ggcacgagat	ttgccgggtca	taggagcagg	aagtgtcgac	cttgacgagc	gatttggaca	60
ctctggggagc	caaactggat	gtggaagctc	caaaggtgca	gaaaaagggc	tccaaaatgt	120
tgactttttac	ctctgtcctg	gaaatcaccc	tgacgctagc	tgtagagata	cttaccagtt	180
tttctgcccc	gattggacat	gtgtaacttt	agccacctac	tctgggggat	caactagatc	240
ttcaactctt	tccataagtt	gtgctctcac	tcctaaatta	tgtactagaa	aaaattgtaa	300
tcctcttact	ataactgtcc	atgaccctaa	tgcagctcaa	tggtattatg	gcatgtcatg	360
gggattaaga	ctttatatcc	caggatttga	tggtgggact	atgttcacca	tccaaaagaa	420
aatcttgggtc	tcatggagcc	cccccaagcc	aatcaggcct	ttaactgac	taggtgaccc	480
tatatctccag	aaacaccctg	acaaagttag	tttaactgtt	cctcagccat	tcttagttcc	540
tagacccccag	ctacaacaac	aacatcttca	acccagccta	atgtctatac	taggtggagt	600
acaccatctc	cttaacctca	cccagcctaa	actagcccaa	gattgttggc	tatgtttaaa	660
agcaaaaccc	ccttattatg	taggattagg	agtagaagcc	acacttaaac	gtggccctct	720
atcttgtcat	acacgacccc	gtgctctcac	aatagagatg	gtgtctggaa	atgcttctcg	780
tctgattagt	accgggtata	acttatctgc	ttctcctttt	caggctactt	gtaatcagtc	840
cctgcttact	tacataagca	cctcagctctc	ttaccaagca	cctaacaata	cctggttggc	900
ctgcacctca	ggtctcactc	gctgcattaa	tggaactgaa	ccaggacctc	tcctgtgcgt	960
gttagttcat	gtacttcccc	aggatatgt	gtacagtggg	ccagaaggac	gacaactcat	1020
cgctccccct	gagttacatc	ccagggttga	ccaagctgtc	ccacttctgg	ttccccctatt	1080
ggctgggtctt	agcatagctg	gatcagcagc	catttggtacg	gctgccctgg	ttcaaggaga	1140
aactgggata	atatccctgt	ctcaacaggt	ggatgtgat	tttagtaacc	tccagtctgc	1200
catagatata	ctacattccc	aggtagagtc	tctggctgaa	gtagttcttc	aaaactgccg	1260
atgcttagat	ctgctattcc	tctctcaagg	aggtttatgt	gcagctctag	gagaaagttg	1320
ttgcttctat	gccaatcaat	ctggagtcac	aaaagggtaca	gtaaaaaaag	ttcgagaaaa	1380
ctagataggg	caccaacaag	aacgagaaaa	taacatcccc	tggtatcaaa	gcatgtttaa	1440
tgggaaccca	tggctaaacta	ctttaatcac	tggttagct	ggacctctcc	tcctctact	1500
attaagtttta	atttttgggc	cttgatatatt	aaattcgttt	cttaatttta	taaaacaacg	1560
catagcttct	gtcaaaactta	cgtatcttaa	gactcaatat	gacaccttg	ttaataactg	1620
aggaatcaac	aatttgattc	cccgaataca	tgggtggtga	atgtaatgcc	caacattggt	1680
tttactaacc	ctgttttttag	actctccctt	ttgctctctt	aatcacctag	cctgttttcc	1740
acatgactaa	aactctcgct	tagctgagaa	agccggacaa	actccatctg	gcccccttga	1800
tttgtaagac	attaaggact	ccttaccac	ccccttcttc	aaggagttaa	cttgtgtaaa	1860
cagattctca	acatatcaaa	agagtccaat	taactgataa	ggtactgaaa	caaacaatgt	1920
acgaagttcc	caggattttg	ctcaaaagat	aacaccacaa	agcattgagt	ctgtgtccgg	1980
catagcacc	atatctaaca	tcttatgaag	gatttagagc	ccccgcacct	gctaccgttg	2040
cttttctgta	aacatttgtc	ttttaaatgt	tctgtttctc	tgtaatcatt	tgtcctttta	2100
atttttgcac	attttttactt	ctgtagaatt	gttgctgttg	agctcccttc	cccttcttaa	2160
accaaagtat	aaaagaaaat	caagccccct	cctcatggcc	gagagaattt	tgagcgtag	2220
cggctctctt	ggccaccggc	taaataaagg	actcttaatt	catcccaaaa	aaaaaaaaaa	2280
aaaa						2284

<210> 21

<211> 2287

<212> DNA

<213> Homo sapiens

<400> 21

ggcacgagcg	gggaggggagc	cagcagccta	gggcctaggg	ccggggccacc	atggcgctgc	60
ctccaggccc	agccgccctc	cggcacacac	tgtgtcctct	gccagccctt	ctgagctcag	120
gttgggggga	gttgagagcca	caaatagatg	gtcagacctg	ggctgagcgg	gcacttcggg	180
agaattgaacg	ccacgccttc	acctgccggg	tgccaggggg	gcctggcacc	cccagattgg	240
cctggtatct	ggatggacag	ctgcaggagg	ccagcacctc	aagactgctg	agcgtgggag	300
gggaggcctt	ctctggaggc	accagcacct	tcactgtcac	tgcccatcgg	gccagcatg	360
agctcaactg	ctctctgcag	gacccagaa	gtggccgatc	agccaacgcc	tctgtcatcc	420
ttaatgtgca	attctaagca	gagattgccc	aagtcggcgc	caagtaccag	gaagctcagg	480
gcccaggcct	cctggttgtc	ctgtttgccc	tggtgctgtc	caacccgcgc	gccaatgtca	540
cctggatcga	ccaggatggg	ccagtgaact	tcaaaccttc	tgacttctct	gtgctggatg	600
cgcagaacta	ccccctggct	accaaccaca	cgggtgcagc	gcagctccgc	agcctggcac	660
acaacctctc	ggtgggtggc	accaatgacg	tggtgtgcac	cagtgcgtcg	cttccagccc	720
caggccccctc	ccggcaccca	tctctgatat	caagtgaact	caacaacctc	aaactcaaca	780
acgtgcgcct	gccacgggag	aacatgtccc	tcccacccaa	ccttcagctc	aatgacctca	840
ctccagatct	cagagcagtg	aaaccagcag	accggcagat	ggctcagaac	aacagccggc	900
cagagcttct	ggaccgggag	ccggcgggc	tcctcaccag	ccaaggttcc	atccgcctcc	960

cagtgtctggg	ctatatctat	cgagtgtcca	gcgtgagcag	tgatgagatc	tggctctgag	1020
ccgagggcga	gacaggagta	ttctcttggc	ctctggacac	cctcccatc	ctccaaggca	1080
tctctacct	agctaggta	ccaacgtgaa	gaagtattgc	cactgccact	tttgcttgcc	1140
ctcctggctg	gggtgccctc	catgtcatgc	acgtgatgca	tttactggg	ctgtaaccgc	1200
caggggcaca	ggtatctttg	gcaaggctac	cagttggacg	taagccctc	atgctgactc	1260
agggtgggccc	ctgcatgtga	tgactgggccc	cttccagagg	gagctctttg	gccaggggtg	1320
ttcagatgtc	atccagcatc	caagtgtggc	atggcctgct	gtatacccca	ccccagtact	1380
ccacagcacc	ttgtacagta	ggcatggggg	cgtgcctgtg	tgggggacag	ggagggccct	1440
gcatggattt	tcctccttcc	tatgctatgt	agccttgttc	cctcaggtaa	aatttaggac	1500
cctgctagct	gtgcagaacc	caattgccct	ttgcacagaa	accaaccct	gaccagcg	1560
taccggccaa	gcacaaacgt	cctttttgct	gcacacgtct	ctgcccttca	cttcttctc	1620
tctgtcccca	cctcctcttg	ggaattctag	gttacacgtt	ggaccttctc	tactacttca	1680
ctggggcacta	gacttttcta	ttggcctgtg	ccactgcgca	gtattagcac	aagttaggga	1740
ggaagaggca	ggcgtatgag	ctagtagcac	ccaggacggc	ttgtagctat	gcatcatttt	1800
cctacggcgt	tagcacttta	agcacatccc	ctaggggagg	gggtgagtga	ggggcccaga	1860
gccctctttg	tggcttcccc	acgtttggcc	ttctgggatt	cactgtgagt	gtcctgagct	1920
ctcgggggtg	atgggttttc	tctcagcatg	tctctggcac	cacgggaccc	cagccctgac	1980
caacccatgg	ttgcctcatc	agcaggaagg	tgccttccct	ggaggatggt	cgccacaggc	2040
acataattca	acagtgtgga	agctttaggg	gaacatggag	aaagaaggag	accacatacc	2100
ccaaagtgc	ctaagaacac	tttaaaaagc	aacatgtaaa	tgattggaaa	ttaatatagt	2160
acagaatata	tttttccctt	gttgagatct	tcttttgtaa	tgtttttcat	gttactgcct	2220
agggcggtgc	tgagcacaca	gcaagtttaa	taaacttgac	tgaattcaaa	aaaaaaaaaa	2280
aaaaaaa						2287

<210> 22
 <211> 1866
 <212> DNA
 <213> Homo sapiens

<400> 22						
agccccgcc	gctgcctggc	gctgctgcat	ctcctgcagc	tgggttacct	gtacaggtgc	60
gtgcaggagc	tgcggcaggg	gctgctgggt	tggcagcagg	aggagccctc	tgagtttgac	120
ttggcctacg	ccgacttctc	cgccctggac	atcagcatgc	tgcggctctt	cgagaccttc	180
ttggagacgg	caccacagct	cacgctgggt	ctggccatca	tgctgcagag	tggccgggct	240
gagtactacc	agtgggttgg	catctgcaca	tccttctctg	gcatctctgt	ggcactgctc	300
gactaccacc	gggccttgcg	cacctgcctc	ccctccaaag	cgctcctggg	cctgggctcc	360
tccgtgatct	acttctctgt	gaacctgctg	ctgctgtggc	cccgagtcct	ggctgtggcc	420
ctgttctcag	ccctcttccc	cagctatgtg	gccctgcact	tcctgggctc	gtggctggta	480
ctgctgctct	gggtctggct	tcagggcaca	gacttcatgc	cggacccag	ctccgagtgg	540
ctgtaccggg	tgacgggtgg	caccatcctc	tatttctcct	ggttcaacgt	ggctgagggc	600
cgcacccgag	gcccggccat	catccacttc	gccttctctc	tgagtgcag	catttctctg	660
gtggccacct	gggtgactca	tagctcctgg	ctgcccagcg	ggattccact	gcagctgtgg	720
ctgcctgtgg	gatgcggctg	cttctttctg	ggcctggctc	tgcggcttgt	gtactaccac	780
tggtgtgacc	ctagctgctg	ctggaagccc	gacctgacc	aggtagacgg	ggcccggagt	840
ctgctttctc	cagaggggta	tcagctgcct	cagaacaggc	gcatgaccga	tttagcacag	900
aagtttttcc	ccaaggctaa	ggatgaggct	gcttcgccag	tgaagggata	gggtgaacggc	960
gtcctttgaa	gcaggatcag	accagccag	cagagatgga	gagtgactct	gttggcagaa	1020
ggcaggcgag	gataagctaa	cgatgctgct	gtggcctcta	tgcactcagc	aagagcggga	1080
cgctgtgct	gggcccggca	ccagggatgg	tgctgagtcg	ggcagaggcc	tcctttcaag	1140
gagttcacag	tgaacaagat	gagaagggct	gggccctgga	gggtcaagag	ccccaattat	1200
gtacaagaca	ctttgggagg	aaagaagact	accttttccc	cctgccattg	gtatagctgg	1260
tgccccaaaa	cttccacctc	cctccctggc	cacctctaaa	atgactggta	taggtgctgc	1320
ccccccctt	agctccccta	tcctgggcta	ggaggccaca	gggctgtcc	tctagaattc	1380
ttccttccct	ccccacacc	attcattcaa	ttcatgaaac	aaatctttgc	caagagcagt	1440
ttatgtgcc	ggaacatcat	tctgtccttg	caacctggaa	caagaccagc	taccagccta	1500
gcttcatccg	ctacttgac	caaccagtcc	cgggttagat	cccaaagtct	agaagccagg	1560
gatgcccaac	tctgggtggc	cccagtcaga	acctctggga	tctcagtga	gctggcctgg	1620
cctctgctcc	tgtctcaag	gggctgcttt	tcaaccaaga	gccttgtgag	cctggtctga	1680
gccttgacaca	gccactgagt	attttttttg	ccttagccag	tgtacctcct	acctcagctc	1740
atgtgagagg	aagagaatgt	gtgtgcctgt	gggtctctac	aagtgcacaga	tgtgtgtgtt	1800
tcaacagtat	tattaggtta	tgaataaagc	ctcatgaaat	cctcaaaaaa	aaaaaaaaaa	1860
aaaaaa						1866

<210> 23

<211> 2529
 <212> DNA
 <213> Homo sapiens

<400> 23
 tggcaccgagg tggcaccgagg tagattctca atcaagtcct ttagccttat tgattaaaaat 60
 agagacatttt actatcacaa aatgatgcc ccaaacagcc tcaaacctga cacattagtt 120
 tcccttttctt gctcttgccc aaaatgaatg tttttcttct tcttcccttg ggttcttctc 180
 tccctccccct cctcttcccc cctctctctc ctctcttatt cttccctctc cctctctatt 240
 tgctcttctc tgctccaagt cctgccacaa ccccaggatt catcagctc cctggacaca 300
 tccccatccag ctcttgaccg ctcacctcct tcaactctca tcttcagggc cctttctctc 360
 atctgctcca gcccatgcc gggccatgc tgtgcacctg gagggggccac ccacctgcca 420
 ggaaacagca cattcagcca tgcacctgac tgcagcctcc actctagcag attagctcag 480
 tcacctgtga cacactgttc ctctggctct ttgggacttt cagcccatgg acacctccat 540
 gcccatccct caatctctgt ttctccacat ctctcccttt ccatctcaaa tccatgctcc 600
 agcaccaaac actaaactct tccattctaa actccctctc cccattgttc ttcccttaca 660
 ggcacctggc aaaactccag tctcaacaa atgcagccaa tggcgtttgc taatgccagc 720
 aggcctggcc ctgtccaact gtggtctcct cctcagctg ggcctgcagc agcatccggc 780
 aacctgtctg ctctagtct agctcttgct cccatcctcc tcaaagacca cactccacat 840
 cctcagactc tgacaagcag gccaaaccag tgggtgtgct gcagatgctt aacaacaggc 900
 tctagaggag gtggggaaag ccctgatttg tagtgtttgc ccattcttgt ggtataagta 960
 ttctcacaaag aatctgaata tgaggccaga ctcatgtggt cacacctgta gtcccagcac 1020
 tttggggaggc cgggggtgggt ggatcacttg aggcaggag ttcaagatta tcttgaccaa 1080
 catggtaaaa ctctgtctct actaaaaata caaaaattag ctgggtgtgg tggcacatgc 1140
 ctgtggtccc ggctactcgg gaggtgaga tgggaggatc actggaactg ggaggtggag 1200
 gtttcagtg gctgagactg tgccactata cccgagactg ggcaacagag tgagacccta 1260
 tctttaaaaa aaaaaagtaa ttaatagcct atcaaccaa aaaaagcccag gaccagacga 1320
 ttcacagcca aattctacca gaggtacaaa aaggaaactgg taccattcct tctgtgttgc 1380
 aggaattcag ggaccccgaa tggagggact ggctggagcc ttggcagagg acataaattg 1440
 tgaagatttc atggacattt atcagtttcc aaataatact ttcataattt ctactcctg 1500
 tctttatttt aatctcttaa tctgttatc ttcgttaaatt gaggatgtac gtcacctcag 1560
 gatcactgtg atgattgtgt ttactgtaca aattgattgt aaaacatgtg tgtttgaaca 1620
 atatgaaatc agtgcacctt gaaaaagaac agaataacag tgattttagg gaacaaggga 1680
 agacaacccat ggggtctgac tgctgtagg gtcaggcaaa aggagccata tttttcttct 1740
 tgcagagagc ctataaatgg gtgtgcaagt aggagagata tcgctaaatt cttttcctag 1800
 caagaaatat taatatattg accttaggaa aataattgca tcccttgggg gaggtctata 1860
 aatggccact ctgggagtgt ctgtcttaag tgggtgagat aaagcctgaa ataaggctct 1920
 gggagtgtct gtcttaagtg gttgagataa ggccctggtc tctgcagta ccatcaggct 1980
 tactaggatt gggaaacccc aacctggta aatttgagtt cagactgggt ctctgctctt 2040
 gaacctgtt ttctgttaag atgtttatca agactatatg tgcactgtg aacgtagacc 2100
 cttatcggga gttctgattt tgctcttctg gtgttctctc agaagcatgt gatctttgct 2160
 ctgcttttta ccccttaaag catgtgacct actccctgtt tgtacacccc ctcccccttt 2220
 gaaatccctg ataaaaactt gctggttttg cagctcaggt tggcatcacg gtccctaccg 2280
 tatgtgatgt cacccccagc agcccagctg tagaattcct ctctttgtac tctttatttc 2340
 tcagaccagc caacacttg ggaaaaataga aggagcctac gttgaaatat tggggggcgg 2400
 tcccccaat acttctgaaa ctattccaaa caattgaaaa ggagggacac ctcctaact 2460
 cattttatga ggccagcatc atcctgatac taaaacctgg cagagacaca gcaaaaaaaa 2520
 aaaaaaaaaa 2529

<210> 24
 <211> 4784
 <212> DNA
 <213> Homo sapiens

<400> 24
 aattcggcac gaggggaatgt cactgcaaat gtctcgactg ctgtgaggtg tggggccctg 60
 cgggtgggcca ggccttttga atctgctctg ggctgcttct tgggaattgt cctgtggctcc 120
 ccagctctct tctccacatg caggcggcag gagggctgac agaacggctt tgtctcacat 180
 ctcgaggttc ttgggtgtgt agtggatgt gagtgcacaa ggaataagag gggagtatca 240
 gacagagaca agaggccttg gggctccctg cagctttgat ttgggggcat tgatgacact 300
 tttgttgct cccatccatg ttctgtgccc tgggtctagg attttactca tttttttttt 360
 cttttctctg caataagtca tgaggcaatg tggctgttat tatccccatt ttatagatga 420
 ggaaactgtc ttgggaagggt aacgaatttg cccaaggcca cacagctagc aaatgcacaa 480
 gctgtgctta taccagctc tgctcctat gcctgggcca acctgcccac gctgcccac 540
 cactgagcat ggcctgaccc cacagaacgg gcgccagtgt cagggtgac tttcacaggg 600

tggagcgtgg	aaatacaggt	atcttggggc	taactggctg	agagggcttt	ccccctgcac	660
ggagccgagg	aagctgtatt	tccagacgtc	tttcttagat	ggtttaattg	atctgccaac	720
aagtatttat	tggctcaatg	gctgagcaga	ggaggctggc	agctagccaa	ggcttctggt	780
attgatgaag	gccagagaga	gtttgctctc	acgatgacta	caaggacact	gtctccttgc	840
cagagctgca	ctcaagacct	tctcgctaga	cccccgtaga	tctccccggg	tagtgaggtc	900
ctcccagcct	ccaggacatc	tggacttggc	ccctctgggc	ctggctgccc	ctttgcccc	960
atcccttate	aatctgtcct	gaccccgact	cacctccagg	cctcagccga	ggactctggc	1020
tctgcatggg	gagtttagca	ctgagttctt	ctgcatctgc	agggttcact	catttttcca	1080
cccataggcc	ttctttcccc	aagtggttat	gaagttcctc	agggcaggga	tggaaacca	1140
ggaggtatgc	atggtgaact	gggaagatta	gggacatcat	atgtgcctat	ttacttgata	1200
tcgcttggat	atttgtttcc	tccaaatctc	gtgttgaaat	gagatcccc	aagttggagg	1260
tgggggttgg	tgggaggtga	ttgggcccgt	gcagatacat	catgaatggc	ttggtgccct	1320
cctcggtgga	atgagtgagt	tctcactatt	agttcatgtg	ggagctgggt	gtttaaaaga	1380
gcctggcatc	tctcttactg	gctctcttac	catgtgacac	acctactttc	cctttgcctt	1440
tcgtcatgag	taaaagcttc	ctgaggccct	cagcagaagc	cgtgccatgt	ttgtacagcc	1500
tgagagagcc	tgagccaaat	aaaccttgtt	tctttataaa	ttaccagcc	tcagatat	1560
ctttatagcg	acacaaaaca	gactaaaaca	ttactcttga	aaggaaagct	gtgcatgtgg	1620
caacagattt	aaatactacc	aaagggcgta	tggtgaaata	acctctctcg	agtatctcgg	1680
ccccccatcc	gctcctgctg	gcagccacta	ttagcagttt	cttgtctttc	cagagacatt	1740
tgtgacagat	aattttttaga	tcatactgaa	aacattcccc	tgtatcttgt	tttctccctt	1800
caatggacct	tggcagttat	ctactatcag	ttaatgtaga	gctgcttcat	tctttcttag	1860
cagtgcgatg	ggtccatgat	atggttgtgt	tataatctaa	ttacttagat	ccccatattt	1920
ggacattttg	cgagtttcca	atcttttgagc	atacattttg	atcccaattg	aaatttcctt	1980
tctgccccct	ctagctaaat	aacatcccca	agcctcagtt	ttccccatcg	tgcaagtggga	2040
ataattatat	gtacctttca	gagttgctgt	gagtattaga	agtgatgcag	aatgaagca	2100
ctgcccagca	tgagggtcac	agtaggttaa	tattgatatg	cgttccctga	atttctgatt	2160
cggtgtctga	gctcatcttg	cgcacctgat	gaaggctcgt	gaatgacttt	gtttccagtt	2220
taaaatacac	tagaatcacg	ttaatttttt	ctctttttaa	aatattataa	tttgatatta	2280
aggaggcttc	agacacattg	ttggattaat	attatttgag	gtgtctaatt	cagccagttc	2340
ttacatagtg	tgtagtcaac	ataagacacc	tagcccttta	cttcacagaa	taagcccata	2400
atgtgtgtgt	tgtgtctttc	tgttattgct	gctgctgcta	atggtgaaag	tggtggctct	2460
ttgtgtggc	aactgcatct	tggccttttc	aaccacccta	tagcagccct	tgcaacagag	2520
tacatagtcg	gtgctcagta	aatgcatatt	aatgtcctgg	cctcccacca	actgaataag	2580
cttttctttc	ctctgccaca	gggggacttg	agtcacagtt	ggctggagca	gaggggctgg	2640
ctatgagctg	cccttgagtg	accctttttc	catctctcat	tgtgtcctgt	gtacagcaca	2700
tctgtccctg	cacacaggcc	aagcagaggg	tgttgatagg	gtcaggcatg	tcaatgcagg	2760
atcctgacat	tcagaaactg	ccccctaccc	tttgtttgaa	aggaacagtc	tctcagttga	2820
gaaaaggcct	cgatcagatg	ctgtggccct	tctttgaagg	aggttttcat	attaacatag	2880
tcataattcg	gttcattggaa	gtttggcttg	cagaaagggtg	gctttgaaat	gcaggtgaca	2940
gcatttgaaa	tcaggcttaa	tcaggacaag	catcacctgt	ggccacagca	tggtcttggt	3000
ggaagagcag	gggttcagggg	tcttccagca	ctggcttggc	ttcagtcctg	acttggtttc	3060
taattagctg	tgaccttgaa	caagtcattt	catgcccagg	ccttcatttt	ctccatctga	3120
aaaacaaact	tactttgcta	cgaggtgtca	ggatcatgga	ttaatatata	gaaagtgact	3180
gatctagtgc	ctagaacgta	gctactgaaa	aagcggtagg	tttaaaaaatg	gctaattatg	3240
actattactg	ctctcataaa	ttggtaaaat	tacagttatt	aaatatagaa	ataattatgg	3300
ttattaaatt	ttgtgtccaca	ctgtgaaact	gaagagatttc	acacgaggga	atctgtgggt	3360
gtttggatgg	tcttggactc	gtttctctct	aaagatacatg	atggaaatgc	cacctgaggt	3420
tcacaggcca	ttgtgagttt	gttgcaaatg	agctgggagt	gttttagcct	ccctgtgagc	3480
ggtttccggc	tgcattgtctt	attcaagtgt	ttctctaaaa	ggccgcagct	ccccgtgggt	3540
acttgccctg	tggacatgca	ttcacaagga	tacccaaatg	agcagcacct	tcaccagctg	3600
tgtgcaggca	gacattcagc	agggatgagc	tgccgaggtg	gcgccctga	gggcccggct	3660
ccacctctgc	gaaaatagtg	acttggctta	gttgtgggct	ggccattatt	ggacctttgg	3720
gaaaagggga	aggggaagag	gtaaaagggtc	tcaccttttc	agggcctggc	agaagggtga	3780
aggcaaaagg	cccagacaca	gggatagaag	agatggtatc	tggcagccaa	tgcaagacct	3840
acctttttaca	gatgggagct	gactggacca	gagagctggg	aggctttgcc	caaggttacc	3900
tgccaggtag	tggcagaacc	tgaactaaaa	cccaggcctc	caatccccct	tgaaaatggt	3960
ccccctcaga	aacaagggag	tgagaattca	atgcagtttc	tgagtcctga	ttgaaaaaca	4020
cagctgtggg	aggatgtagg	agcttaggag	gagagtgatt	agggccaggg	gtgatgctga	4080
tgggttggag	ggactttctg	aggggaggcc	ttggagcttg	ggcagagttt	agaccagtgt	4140
ctccccacaa	cacacacaga	tgaagaccct	ccatggcttc	tcagtgcctc	ctgcatgtca	4200
gagaccctgt	cctggccggc	gctcagacca	tacacccagg	gggttagcac	agtcacagat	4260
accaggttaa	gaactgtctt	tctgttttag	tacctgcgtg	acctgggcat	aagtttcccta	4320
actttgtagt	tcctcggtat	cctcacctgt	aaagtgggca	tagtgatggc	acttaccocg	4380
tagagttgtc	agcaaacatt	ctcaaaccct	agtggtgatt	caagccacct	ggtgaccttc	4440
ttaaaatgct	gattctgact	tagtaggact	gggtcgggcc	caagattctg	catttctaac	4500
aagctcctgg	atgatgtcta	tgaagatgta	acagagatca	agggccccc	atcacagctt	4560

atccccacgc	cccaccatcc	acccatctac	ccgccatgct	gaatgatccc	gcagccaagc	4620
taaaatgcat	attccagccg	ggctttgtgg	ctcacgcttg	taatcccagc	actttgggag	4680
gccgaggcag	gcggatcact	tgagggtcagg	agttcgcagac	caccctgtcc	aacacgcagc	4740
aaccctgtct	ctactaaaaa	tacaaaaaaa	aaaaaaaaaa	aaaa		4784

<210> 25
 <211> 2058
 <212> DNA
 <213> Homo sapiens

<400> 25

ggcagcagct	caaagagtaa	gaatccaagt	gtgtgacatt	acatagcttt	gcattctatgg	60
aaacctaaat	cataattggt	tccactgccc	aattatgttc	cttttcataa	catttactat	120
tctggctata	tttatcatag	aacctaggaa	ccttagagtt	gacctgaatc	taattaaatt	180
tcagacctcc	tggccaaaga	ccctagtggg	agagcaaac	taaatcaaca	tattaccaat	240
ctcaagtatt	tctctgagga	cccagaccac	tgactttttg	ttgtcatttt	caggttgatc	300
ctataactgt	atgttctaca	atatctgtgc	tccaccagct	cagtgaggaa	tcaacggaat	360
atcaaaagta	aattattggtc	accatatacc	ttttggtact	agtctacgaa	ataattggct	420
gaggaactgt	ttcatattaa	agaaaagcta	aaagcaatgt	gtgatccttag	attagacct	480
tgattggaat	gtatgtatat	tttatataca	aaatattgag	gaaattgaca	aaatttaaat	540
acagaatatg	gattagataa	taggaatgta	tcaagggtcaa	tatttaaaaa	gataatttca	600
acttttattt	tattcagtgg	gtacatgtgc	agactttgtt	ttacatagta	cccaacagtt	660
tttcaacgct	tatccccac	cctctagtaa	tctgcaggtg	ctattattgt	catcttcgtg	720
gctattgtac	atgggattcc	atacttgatt	ttgctctcaa	catgaacatt	attgggtgtag	780
agaaatgcc	ctaagttttg	tacgttgctt	ttgtatcctg	aaactttgct	aaagttattt	840
atcattttcca	ggagcctttc	gttggagtct	ttagggtttt	ctagtttagag	agtcacagtt	900
gaagagagat	aatttgactt	cttcttttcc	tttttgggtg	ccttttactt	ctttctcttc	960
cctgattgct	ctggctaggg	tttctaaccat	caaatttttt	gatgttgatc	attatactgt	1020
agttatgcag	gggaatgtct	ttgttctttc	taaagaacat	tcaatgttaa	acattgaaat	1080
gtttaacaat	gaaagatcat	tatatgtaat	ttactctcaa	atggtcaagg	gagaggagag	1140
agaaagagac	agagagaaag	aataagaaaa	gagagttagt	aaatggggca	aaatgcaaac	1200
aatttgtcaa	tctatgtaaa	atgtttacaa	gagttctgtg	ttacattttt	gcaactcttc	1260
tgatgtttta	aaataatggt	aaaataacaa	ttttcccaaa	tgtcaaatgt	tgccacatac	1320
aagcattttat	gagcatggaa	aatgtggctt	ctgaatgata	ggatacaaaa	tctgggtgatg	1380
agcgaatata	ctgaatatat	caagattgag	ttgccatctt	agaaggagaa	tattagctat	1440
aaatcacatg	atgaatacat	caatatataa	tagactagaa	aaccaataat	tataaggtca	1500
caagagtgc	ataaacatga	attatctcca	ttgcattgat	tttcatctct	acttgccagt	1560
tttatgagat	tcagtcacca	atatattttc	aattaattca	acatagaaga	ttcacttcta	1620
gtatgttttc	aaattgtttc	aaaccctgac	catctttttg	attgctctac	cttccaaaag	1680
aaaagaaggg	aacactaatt	ttcttttcctg	atttacttca	ttgtttttct	ctgttagatt	1740
aaactttacct	ataaaagatt	gtctcttgac	tttatatata	tatatatgtg	tgtgtgtgtg	1800
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tatttgaaaga	ggacatgtgc	ctccataaaa	1860
ggaaataaaa	tgagagaata	cattattgat	tttgtgaaat	caaaatat	gaattatggt	1920
ttctcaatat	tcaaaaactc	ttgcagtttc	tgtacttatt	tcttctgatg	catagagttt	1980
cggggactac	atatgtttca	caaccaaga	tatccacttg	aaataaaaac	attataaagt	2040
taaaaaaaaa	aaaaaaaa					2058

<210> 26
 <211> 843
 <212> DNA
 <213> Homo sapiens

<400> 26

acgagcccac	ccgtttctgc	agatgcccgc	atcatggctc	tgaggggatg	ggggctggcc	60
tgagcctttt	cccccggtgt	gtgtggctat	agcggggaga	tgaagggggt	gtgttgggga	120
cgtagtgaac	actcccttct	accgtcagag	atcctgtctc	cccccgcccc	ctgccccctc	180
tcggctgtcc	ttcataaccc	cccacccact	ccccacctgc	catctcctgt	gcttgtgcgg	240
atccaggaag	cacctacctg	ggcacagaga	tcattcgctg	gtgcctcgcc	cctacacaag	300
ggcgattaac	ttctctgtta	tgaactccta	cttagtaatt	ctgacatgaa	actcccacta	360
ggataaaaact	tggcgagaa	cagcaattac	tgaaaacaca	tttttaaaaa	ggttgatgtt	420
ttgtaagagt	tcattcctct	ccactcctca	gcctcctcaa	ggagacacat	atttagatct	480
tctctgtgtg	agtcctaact	ggagactgtg	agttgcagtt	taaaaggggc	tctggggcca	540
ggtgcggtgg	cacacacttg	tggctctcagc	tactgaagag	gctgagatgt	gaggaacgct	600
tgagcccagg	agttcaagac	cagcctgagc	aacatgggta	gatgggatct	acccaaaaa	660

15

tttaacaata	aggctggcat	ggtggcatat	gcctgtggtc	ccagctactt	ggaggctgag	720
gcaggagaat	catttaagcc	tgggagatcg	aggctgcagt	gagggtatggt	ttcaactgct	780
gtgctccagc	ctggggagaca	gggcaatact	gtgtctctaa	aaaataaaaa	aaaaaaaaaa	840
aaa						843

<210> 27
 <211> 702
 <212> DNA
 <213> Homo sapiens

<400> 27						
cccacgcgtc	cgatttttaat	cagagaatta	ttcctttaaag	attttaaagt	tatttagttg	60
tacattttat	atgggttcaa	ccccagcaca	tgaagtataa	tggtcagatt	tattttgtat	120
ttattttact	ttataaccac	tttttaggaa	aaaaatagct	aatttgtatt	tatatgtaat	180
caaaagaagt	atcgggtttg	tacataattt	tccaaaaaatt	gtagttgttt	tcagttgtgt	240
gtattttaaga	tgaaaagtct	acatggaagg	ttactctggc	aaagtgtcta	gcacgtttgc	300
ttttttgcag	tgctactggt	gagttcacaa	gttcaagtcc	agaaaaaaaa	agtggataat	360
ccactctgct	gactttcaag	attattatat	tattcaattc	tcaggaatgt	tgcagagtgg	420
ttgtccaatc	catgagaatt	tacatcctta	ttagggtgaa	tatttgata	agaaccagac	480
attgctgatac	tattatagaa	actctcctcc	tgccccctaa	tttacagaaa	gaataaagca	540
ggatccatag	aaataattag	gaaaacgatg	aacctgcagg	aaagtgaatg	atggtttgtt	600
gttcttcttt	cctaaattag	tgatcccttc	aaaggggctg	atctggccaa	agtattcaat	660
aaaacgtaag	atttcttcat	tattaaaaaa	aaaaaaaaaa	aa		702

<210> 28
 <211> 752
 <212> DNA
 <213> Homo sapiens

<400> 28						
ggcacgagca	aaaaccactc	ggtcaatgaa	gaagagcagg	agaacaagg	tgaaggaagc	60
gaggatgaat	gggaacaagt	gggcccccg	aacaagactt	ccgtcaccgc	ccaggcggat	120
ttgtttcaga	ctccaatcac	cggcattttt	ggtggacaca	tcaggtttgt	gcttttctgg	180
aataaacttaa	tatttgcctt	ttctagggtt	ttgccatgtt	ggtgaagggg	gaagggtgta	240
ggcttgtttt	gagacttctt	ggacgtaatg	gtttgcatct	tgtccctctg	cctgctcttc	300
tcttgcaact	cctgatgtct	cccttgtcag	ccccctgggc	ttattctctc	cctgctggcg	360
catgtcttga	ggggacaggg	agctcctccc	ttctactctg	tcaagttcag	ctgctcactg	420
ctaggggagta	agagaaaagc	cagctaattg	gccatacgcg	gtggttcatg	cctgtaatcc	480
caggactttg	ggaggccaag	gcgggtggat	cacctgaggt	tagaagtctg	agatcaacct	540
gatcaacatg	tgaaaacccc	gtctctacta	aaaatacaaa	aatcaaccag	gtgtggtgac	600
aggcacctgt	aatcccagct	attagggagg	ctgaggcagg	agaatcgctt	gaaccaggga	660
ggcagagggt	gcagtggccc	agatagcgcc	attgcactcc	agcatgggtg	acagagtggg	720
actctgtctc	aagaaaaaaa	aaaaaaaaaa	aa			752

<210> 29
 <211> 1015
 <212> DNA
 <213> Homo sapiens

<400> 29						
ggcacgagca	aaaggggctt	ctattgtatt	ggtcatattt	tattttgggt	taaaaaattt	60
tagagtaaat	gtggcaaaat	gttaatgctt	gttaaatctg	agtggagagt	acattgggtg	120
taagtgtgct	gctatgcagg	gtgagtgaat	tactcaataa	ctaaataatt	gtgacataat	180
atattttatt	atgcttccct	gttatgatct	acacataaaa	ttactggagc	attattgctt	240
aacttcttgt	aaaaaagttc	tgcaattgta	gtgttattta	gaaagtaata	ttgatttgta	300
tagtgacaga	ggattttttc	agtgtcactt	tgccagcaga	gatcttcatg	gtgggcattg	360
cccctgcccc	tgtctcactt	ggccctgggc	ttgccccact	aggtaccctg	cccacctggc	420
caggcaggct	gtgcttggct	tgagctctgg	cccagatcct	gcacttgctc	tgcggctgag	480
ccaggcatgc	catgacctac	ttccaccttg	ggagccggcg	tctggatgag	gggaatgctg	540
tgacacttga	acagaggtgg	gcatgtgacc	ccaaagcccc	aaaggggggtg	ttacagcatg	600
ctaacagttc	tttcagttct	acatccacag	cccaacaaat	ggaggtgtgt	ggtgcccaga	660
ggtcccttct	cccattgttt	ggcaagcagg	aggggtgtgc	tacagggtta	cagctttgtt	720
tgcacttgcc	gtttgggtgg	tcttgagttc	ttttcccatg	tccaagaata	aggttggtgt	780

gacagctagc	ggttgagtga	ggcaaagagt	tttactcagt	aacaaaacag	ctctcagcag	840
agaaggaagc	ctgagttgga	cagcaccctt	acctgaagtt	gggtagtcct	cccaccacct	900
aaaagtgggt	agcccaaagt	gtggctgagc	ctggggcctt	tatatgctca	gaatgggagt	960
gtatgtgcta	attggtttgt	gagtatgcaa	aaaaagctaa	aaaaaaaaaa	aaaaa	1015

<210> 30
 <211> 1063
 <212> DNA
 <213> Homo sapiens

<400> 30						
ggcacgagag	aagatttttc	aggcaaaacc	cagatctgct	ttagtgactt	cagaagaaaa	60
agatctgagg	gaggatgaga	agccgatagc	caatgggatg	tgtgtgaaaa	cacgtggcag	120
acacacatgc	tctccagcat	tctatctcag	ctgatgggtca	gcaagccttg	gggcgtcttc	180
atctccttct	ccttcacatc	actgtctttc	taccatgcca	tctctatcag	ttcagttccc	240
agtgaagac	aggtggttta	gccaaagaaa	atctaataag	gggtctatct	atctgtggtc	300
agggtttggg	atgcccattg	gcagtagtga	tgccccaggg	atgagcaaga	gtgggaagct	360
ctggccacct	tgagacctca	gggccaaacag	aagggaactat	gcttctggag	ccctggggag	420
cgaggagcttg	gaagagggca	agaggggtca	cctcagaagc	tatagtcaca	gggagatgca	480
accactgccc	agactgtggc	aaggcatggc	gggagcaggg	ggaatcaaca	cccagcacct	540
gtccctttga	ccctttgact	tgctgggtggc	ttgcattggc	taaaccagaa	actggaggggc	600
aagagccctt	cagtgtagca	gcctatgggg	gccaaccttc	tgaggtcaaa	gcaggacaga	660
agggtggagaa	gggacttggg	gggacacatg	gagaacaatc	aacaaagtct	accccttttg	720
tcacttggca	ctggaataac	tgagaagcac	cagatgttgt	gagttaccta	agaggggttt	780
gttgcttcaa	tgtctttcca	atttggggga	tttttgaaag	aagtgtttat	gagcagggga	840
gcttgccctt	ttacctagtc	ttccaagaat	aaaagacaag	gcctcagttt	ttagtcagtt	900
gtaaacactt	atattcttta	tttttaggtt	atgaggatga	gggtcgctat	ccaaaggatt	960
gagagagtag	gcttttgac	tatgtagcca	tggtattcaa	tcccagcatt	accattgatt	1020
agcttggggc	ttttataaag	ttagttacct	ctcttagtct	cga		1063

<210> 31
 <211> 2438
 <212> DNA
 <213> Homo sapiens

<400> 31						
ccccgggct	gcaggaattc	ggcacgagaa	acccctgtga	tgtgaacctt	agattgtgaag	60
gcaagccagt	gcaactgtga	atatgcaaag	ggagtgtgtc	aaaagagaag	gcacccgtcc	120
cagctctcca	tgcccttttc	ctggcaggcg	ctgactgaga	tggtgctgag	tgaatgtgga	180
agggtgtaag	accagtcctc	ttcactgcag	ggctgtttac	agccagtctt	ttttactctg	240
accttaaggt	ttccactgag	ctcatgaaac	ttcaacatat	gggtgtttaa	agtttccac	300
tcaaatgcac	acttgaaaat	tggtgccctc	agcctcaatt	actgaactaa	ataagtgaag	360
aagttgtatc	tttggggtaa	aaactttccag	ggccacttaa	ttttttaacc	agttaagtac	420
gcatcttccct	gggtgttcag	actttttaag	tcagtgtctaa	agctgaaaag	cgccttctaa	480
atatgactgt	gagtttagtt	tgtatcttac	athtagtaac	tggtctgttg	ggccaggact	540
atgactttaa	ttactatgta	cttattcatc	ccacactctg	cactaaatac	accatagcta	600
ctatagcatt	gtggcaggca	ctcatttttg	tggaactcatt	ccatacttct	gctggcatat	660
ttcggtttaa	atctagctaa	agattttcat	agtactgtgt	taactagcca	gggctgaaaa	720
gtgtgacagg	atatcaaatt	gactttcctt	ggggaaaatg	ttgctttggc	aatagtgaag	780
tccaactcct	tcattttacag	aattagtgtat	tactcatcaa	tttttgaaag	ttgtagatta	840
agtagtttta	tttactaaat	tcttaaccac	tttgaagatt	taagccagtt	gaaatgaaac	900
attggctgga	tgcagttggc	tagcacctgt	aatcccaaca	ccttggggagg	ccaagggtggg	960
aggattgctt	gaggccagga	gctcaagacc	agcctgggaa	acatagattt	gaaatctttt	1020
caaaaatgta	taaaaattta	ataaataaat	aatgaatcc	ttactcaacc	ataattatgg	1080
ctttaaaacc	caaccaacag	taaacactta	cttgaagcca	aaacagtaaa	ttttgaatga	1140
aatttgaatt	aatgttttgg	aagctgccat	gtcttaattc	ttgctggatt	ttgattttca	1200
attttgggaag	tttttatcaa	aactgtccag	tcatgatata	tcaggtagca	gcctttaagg	1260
atctaagttt	cattcctata	aagaacagga	gggtgctgta	tttcttgtct	tagcaagtga	1320
tctgatgcag	gtctaaatgg	gggttagcat	ctataactatg	gcttaaaagt	ttcctccttg	1380
gtcaccattt	gggaggtgat	ggcttcaaaag	cttaactttg	ctctcatgtg	acccttcttt	1440
atcttaatac	ccaataagat	ataaacctct	cagagtcaac	ccagtgtaga	ctcaaagggt	1500
cttagcttca	tctatcagat	aagatctatc	tgattttatc	aaagaatggg	gctgttttta	1560
tatacatact	aaaaaaatct	aattctcaaa	caattttctt	aatatttatg	ccagcaaggt	1620
caggaaagac	tattttgtcc	tgtttaactt	tagtagtgaa	caaactgcta	gagacatctg	1680

tcatccttaa	caggccactg	tggtccttat	atactgaccc	tcctttccaa	ttaacgtcct	1740
ttaatcccat	actagttcca	taagagactt	ggcacataaa	agcagtattt	tttttaatgc	1800
ctagtaaaact	ggccagaaaa	aaatattgcc	atgggtggacc	tgtttctatc	cacctctttc	1860
tatggctata	taagtctata	catgccagtt	ccgtacatac	tccatttcca	aagagccccc	1920
aaacctgga	cagtagcact	accatgaatt	ttagggtcac	aaaacatttc	cttctgaagg	1980
aagcagctgc	ctcagcagtg	tcactttagt	gaccactgcc	caggcttact	tcactttgcc	2040
tccccctaca	catcactgcc	ctctttctgc	caccaaacct	cactattcca	gcaatgatgc	2100
ctccctgggtg	tctggaaaaac	ccatctgggtg	cactaaaatg	ctatgcaaca	ccaaatggct	2160
tcttccccta	atattgtcca	acaatgtaaa	ttcttcaaga	ataaacttca	tgctatgta	2220
acatcaatgt	atgggttacag	cttccttttt	tttttttttc	ccttttaaaa	tgaagcaaac	2280
cacctccatt	aaaatccatg	ttttggggct	tgtttttgtc	tctcaagtgt	gaaatataaa	2340
tcatgttttt	atgatttttg	taaatctttt	tacacctgtg	ttttgtaagc	aaaagtttct	2400
tattaaaaga	ataaaatgac	aaaaaaaaaa	aaaaaaaaaa			2438

<210> 32

<211> 2506

<212> DNA

<213> Homo sapiens

<400> 32

ggcacgagcc	cggaggaggc	ggagtgaggg	gggctgcgtg	gcaagtgtgc	cccgacatgg	60
tggcctttta	tgagtatacc	atgtagtgtg	tgagtccttt	ccgcgttaga	aagaatagag	120
agtctacttt	ttgcctatat	ttgataattg	gacctctgtt	tctttattta	atgaactctc	180
acacacactg	tgactccttg	gtgaacacgt	gcagggattg	tacatttgat	tgcccttattg	240
cagaaatatt	cacctatcag	tccatgtttt	gcagaaactg	gagatgtgaa	tttatgatgc	300
tctcccataa	tacagcagta	atgatttgca	gtttctcaca	aaatgatttt	catgctgctc	360
tgtgtgtgag	ttctgtttca	gaacttccgt	acctttttct	tgtagtagc	acgtataaat	420
gcagctgtca	tgcagttcct	ttcttttgct	agaaaattag	tcaggaggta	agatgaatct	480
tccaaagtta	tgttaaattt	tgtttaactt	gacaaattaa	actttgttct	tattaaacaa	540
atcgtataac	aaatactgga	aaagcaaaag	ttatatattg	gagtaaaatg	tatcttaaaa	600
tgcattgtca	tcttttgctg	agggagggaat	agcttcttgt	atgtccactg	gatagtaaca	660
gtgggttcttt	tttggaattt	tatttttacc	tcttttgaac	ttctaaatcg	gtccctttat	720
tttcttaaaa	catttgctct	cttttttggt	tacagattaa	agaagtatgg	atcaatttta	780
gtcagttgat	aattttcatt	aggaacacatt	gtcttgctca	ttatagagag	ttaagactgt	840
gcataaaata	ctgaagtgcc	tcttttttat	taggctcata	tgtttgctct	tgcaaaagcga	900
gatgcctatt	gtgattgggtg	ttagatctgt	aagaagctgt	gttttttcca	caagaataat	960
cgacgaccag	tttgagagca	tctctcgcgt	tctttttctg	tctgcttact	gtccttgaca	1020
atgtgatcct	gcacagtatc	aggtgccagt	tatgcgtccc	tggaagggtg	gctcttatca	1080
gcaagtctctg	cagatatctc	ttagataaaa	gtggtttgaa	agaaaaggta	tatttttctt	1140
ttttgttttaa	aagtaaaaata	aaacctccag	ttacactgtg	cattccccctc	acgtaaaaaac	1200
aagacaaaaa	cccttttctg	agttgctcgg	catgcactcc	tgtgctgttt	catgcatgtg	1260
gatgttcctt	ccgtttgttc	ctgtggaaata	actgagtgtg	cctgatggca	gaacacactg	1320
cagtgttatc	agtgtctgca	tgttttttta	tagaacaggt	ttacttgatc	tgcatctctg	1380
tatggaaaaa	acagcaatta	cttttgcatc	catctagcta	aatctataat	ctgtgtcaat	1440
cactttatac	tatcaatcat	ccgtatctat	tcacctgtcc	tctatgtctg	tcttctctca	1500
gtctacatcc	atctagcctt	ctgtcaatca	tctacttttt	tttttaatag	aacaagaagt	1560
ttacttatca	agtcttgaaa	gggggacatg	tttcaattgg	tgttcaaaaca	aaaattccag	1620
cttgtattag	aaccttgaaa	tggtgaagtt	gtggagggtt	tctttgttcc	ataatacaga	1680
gacaagttca	taatttttag	tataacagct	aagttgacaa	attctaagtt	tcctcaggta	1740
aatagtcgta	actgtccctt	tccttagaga	agtgcctgct	gggatagtaa	aaacatacac	1800
cattttcatga	cttctgcaaa	tactttccag	cggaagtcag	tgtaggtttg	tttttggtca	1860
acatgggtcct	gctgcgcagg	aatgtaaaaca	ctgtgtttga	aactctggaa	atcacgtgtg	1920
tggggagatg	gggacgcttc	ccatgttggtg	gggagctctg	tggctgtgat	ggctgcagtt	1980
gccgtgcctc	tgttggaacg	ccaagtgcct	gcaactcacg	tcaatcatag	aattgtgacg	2040
cacagttggc	aaaatagttc	tttatgctat	ttctcaaaat	ttgaggacaa	acccagattg	2100
ggattggaat	atgcactgta	aatcaaat	ttcttatcta	caaagactaa	tgtaaaaatg	2160
attttttctt	ctgtgcctga	ttaaattaac	tgtggttttt	aatataaata	tttattgggtg	2220
tgctttggga	gaaaaattat	cttttcttga	agaagttat	caaagcaaat	ttattatctt	2280
cacaagttaa	tgggagaatg	tggttttgat	tctgggtgtt	tgaattgtgt	aaacacacag	2340
cttccctgtg	tgaagagagt	tgctctgtgc	tccttctact	gtactttttt	tatttttttaa	2400
taggaaaagt	atgtgcttca	gagaagggtt	cctccttaat	gttgagggtt	tttaaaaaata	2460
aaaatactgt	tttttaagct	ctttccttaa	aaaaaaaaaa	aaaaaa		2506

<210> 33

<211> 1703
 <212> DNA
 <213> Homo sapiens

<400> 33
 gaactagtca gtcctatgct tgaaacgaga tgccccttca atttttgaga cttactatcc 60
 aagttatggt ttcagatcta acacttcttg taatcagtg gcaataaatg atgaaatgac 120
 attcctggaa atcactaagc gatttactta ctctttttct agctcaggct cagcagactt 180
 tttctgtaaa gggccaggta gtaaatgttt gaggttttat gggccacaga ctatctctgt 240
 tgctctctct tatttgtgtc tttttttcga ccacttcaaa aatgtaaaaa tcattcttag 300
 ctcaacaagc ataaaaaaca gactacaggc cagatttggc ccatggggcca tagtttgcca 360
 acccggtttta aacactgagg ttcgagtcct ccattaatgg tggcattctc tgggataacg 420
 cctaaaacat tggagtttta attaatgtgt attaatgcac cattatcgaa aagatgtatt 480
 agaaattatg acccgtagag actgggttaa aatgtggctt gtgtgtcttc tgcagcttgc 540
 acctgcctgc ccgcccagggt gattttgcag gcacaatctg aggtgctaga acctggggct 600
 ttctctgcct ctgtctagtc ctgctggatt gtaagctcca tgagggcagg agcttgcttg 660
 ttgtttgcta ctatgttccc agcacacaga acactgctgg gaaatatgtt cggggcttgg 720
 tctcatttct cttagatagca tccagatttt tccaagtagt tggctttccg tatgtccatt 780
 ttactctctg tccatatata tacacaacat tacatagtag tcatgcacca gttaccattc 840
 ccagggatta tgaattcct cagtacagcc ctgtgtggtc ttgtgtctcc atcttacaga 900
 tgagaggcca tgatcaggca gctagtgtgt agaaagctgc cagggtttgc acccagccat 960
 tatggctaca ctgctgggac tcttagcacc cctaaaggga agcacttgag tggctcgttg 1020
 ttatgtcacc atcaggcttc catctcccag cagatgtcag aggatctctg gttttcactt 1080
 ctgtaacttt tcaaaagctct atcaccttt ggagaatata agaaccattct gagacagaca 1140
 tacagatttg tcaaaactgc cgagtgtgtc caaactcact gaactgtacc cttaaaatgg 1200
 gtgtgttcta ttatatataa gttgtatctc agtaaaagtgt atttttaaaa ttgttctcat 1260
 cacaaagtca aatggatttg gaaagcttta attagagaag aaaaaaagaa acctttttta 1320
 atcagaagag tccagctct tccaacaaaa gttgtaatgt cttgttttcc caagctagct 1380
 atttaaaaat caggagtctt ggccaggcat ggtggctcac gcctgtaatc ccagcacttt 1440
 gggaggcccc aggcaggcag atcacgaggt caggagattg agaccatcct ggctaacacg 1500
 acgaagcccc gtctctacta aaaaatacaa aaaattagct gggcatggtg gcgggcgcct 1560
 gtagtccag ctactcagga ggctgaggca ggagaatggt gtgaaccggg gagggcgagc 1620
 ttgcagttag ccaagatctc gccactgcac tccagcctgg gtgacagagc aagactccat 1680
 ctcaaaaaaa aaaaaaaaaa aaa 1703

<210> 34
 <211> 3042
 <212> DNA
 <213> Homo sapiens

<400> 34
 ggcacgaggc atgcctaaga ttttcaggac agaagtcaag tgtaaatgat gatatatattt 60
 gctcttctat tagcatccct ttttttctg cttaaagtta aaagtcactt tggatgtaaa 120
 aatgtaacta ccacatcagc caggattttt ttaaagccat tgtgtactcc aaagtctatt 180
 ttccctctga gtagatatgg aagaatgagc tctaagaga ctagcctaatt caaatttaaa 240
 agcaaatgta aattttaaact aaccatgcag ccctgctgtg tggcaattaa catttcaagg 300
 taaaatgaaa tgtgatgata gtaaatacca gttctacgca gaatcggaat cattctgttc 360
 catggtatat ttgggcagag aatggaaaagt tgaaaggaaa accattatta acacaccaac 420
 tttgacattt caagatatata ttcaaacttg attagaactt ccactaaaaa taaagtcttc 480
 tattaaaaaa atcacagttt cccccacctc ataggctaca tcacagcctc tcaaccttgg 540
 cactctggac attttggact atctaattct taggggcttt cttgtgcatt gtgggacgtt 600
 taactgcac cctggcccta catactagat gccagtagta actcaccttc ttccatcatt 660
 gacagctatg aaaatcaaaa atgtctccat ataactactga ttgaagaatt tagggaaactg 720
 ggttactact cactaggctt accagtcctt aactgtgtgt tttgtttgtt tgtttgtttt 780
 gggttttttg tggtttctta ttctctccgt atcatatttc aacttaataa tatgaggatt 840
 tatagttagt ttattaagct ctaaaatgat ctggttgaat ctctctatta cttttttaa 900
 gggaaaaaac actattttag agacagaagc tctctgagg aggtctttt ggggataagc 960
 agaaggaagt atgatatgaa aaaagggttt aaaattgttt gcagcaaaaag caaaactacc 1020
 agagccatgc atatttttta taagtgtcat ccaagagtcg gaatttttac agttgttgtt 1080
 ggttaccatg gatattagtt tgaaggactt ggaaaagtgg aagaggaggg ttgtgggtag 1140
 tgggatgatg gccataatac atttcttagg agtgttcaag aagtaaaatt tacgttctat 1200
 gtaatttgta taatttttct gaaaagaaaa acttttcagg taaaacaggt attattattt 1260
 ataccttact gatcaggagc tgtatagttc tgagttaagt gactcaccta aaattatgat 1320
 ctagcaatta cgttggctca agcttcttta ctctactta gaaagtggag gaaagcattt 1380
 gccttctgaa ggcggaaggc catttgctaa ttttactgtt tcacaaaatc tgctgctgtg 1440

gtatttctcg	ggcttctgac	aaggacagga	agccacacat	tggtgaagca	tccatgcatt	1500
ggcagcacta	ttgctggata	atggagattc	taattttaatc	agcctgagtt	agggaaagca	1560
caatacaaat	gaacactttg	taaagatgct	tgatttgc	tgatcagaac	agaatatcca	1620
ggtagacctg	gtgcttcttc	ctttattgtg	tttgttcac	ctggctcttt	tctaagacat	1680
cagttgctca	ttgccccctt	ccccagatca	tctgatgtga	ttgtgacatg	tacacttggt	1740
gtgattgtga	ttaacaatag	ctggccagtg	ggcactgctg	ctgggtgcgg	caaactcatc	1800
ctttcttctc	gatgagaaat	cactttttat	ggacgttatc	cttaatcacc	agtcaaata	1860
gcctctcttg	aaatctggct	tctctgtaac	ctgctgttac	cacatttact	ctattggcat	1920
caaacagggt	cgtatatcaa	tgcaagttaa	tttcttgaaa	tctgttaaag	aggatgatct	1980
tttgctctgt	agcatgcaga	ttatgttggt	aaacttagta	atacatagta	atacattgga	2040
gttagcacag	gaatagggca	attctgttct	ttttcttggt	gcaaagctag	gggacaggta	2100
atttattata	cacgtattca	ccctgaatag	gtcagaacca	tgaaatttaa	gaatccttca	2160
ttggaggcta	tcaagtcatt	ggggagatta	aatctacatt	gtactttaat	ctgccggatg	2220
gccattgcc	tcagtaaaat	gtcggatctg	tcggcattgt	taatgtaagg	ggcaccgtct	2280
gggtaatcat	caactgaatg	cagtgcacag	taattttat	gaagtaccaa	gtaagaactt	2340
aacctctctg	atttttttcc	cttgaacca	ttttcttact	tttgatggaa	tgaggacatt	2400
tttagaaaa	acagtgaatt	ctatgtcagt	tttaaacaaa	atgtttctca	cccttacacc	2460
taaatttagt	tcatctgaga	ggatatgcc	agaagaaaag	aagaattaac	agattaccaa	2520
aaaaaaaaag	taattttaca	aaatttaaag	cactctcttt	ttctatcttt	gataagtcac	2580
tatttttata	gtaatccttt	ggagtattta	cattttgctt	ctgaacagag	agacaaattc	2640
ttctccacc	acgtatgtac	tgagtcgta	ttaatccttg	atattgctgg	aactaacttt	2700
tcataataga	atatgttctc	tttccctttt	agactgagaa	tttagtaggt	aaaaagaaga	2760
atacagatta	aactttgagc	ttcttaaata	attcaagatg	ataggatttt	acaaaagctt	2820
agaagtcaga	tattaaaaat	ggaatctgta	ttctgcagtt	gttgataacc	agtataagct	2880
tgatcacaaa	tttttctgtt	tataaaatat	aaaatcacaa	tttgatacat	acgtgtatag	2940
gcactctatt	catgcttagg	aaaatataac	tgtgaagtga	attgtaagta	attttctaag	3000
tacttactat	actgatatca	gaaaaaaaa	aaaaaaaaaa	aa		3042

<210> 35
 <211> 2108
 <212> DNA
 <213> Homo sapiens

<400> 35						
ggcagcaggg	agacctaaac	acagtcacca	tgaagctggg	ctgtgtcttc	atggcctggg	60
ccctctacct	ttcccttggt	gtgctctggg	tgcccagat	gctactggct	gccagttttg	120
agacgctgca	gtgtgaggga	cctgtctgca	ctgaggagag	cagctgccac	acggaggatg	180
acttgactga	tgcaaggga	gctggcttcc	aggtcaaggc	ctacactttc	agtgaacctt	240
tccacctgat	tgtttctctat	gactggctga	tcttccaagg	tccagccaag	ccagtttttg	300
aaggggacct	gctggttctg	cgctgccagg	cctggcaaga	ctggccactg	actcagggtga	360
ccttctaccg	agatggctca	gctctgggtc	ccccggggcc	taacaggga	ttctccatca	420
ccgtgtgaca	aaaggcagac	agcgggcact	accactgcag	tggtcatctc	cagagccctg	480
gtcctgggat	cccagaaaca	gcattctgtg	tggtatcac	agtccaagaa	ctgtttccag	540
cgccaattct	cagagctgta	ccctcagctg	aacccaagc	aggaggcccc	atgaccctga	600
gttgtcagac	aaagttgccc	ctgcagaggt	cagctgcccc	cctcctcttc	tccttctaca	660
aggatggaag	gatagtgc	agcagggggc	tctcctcaga	attccagatc	cccacagctt	720
cagaagatca	ctccgggtca	tactgggtgtg	aggcagccac	tgaggacaac	caagtttgga	780
aacagagccc	ccagctagag	atcagagtgc	aggggtgctc	cagctctgct	gcacctccca	840
cattgaatcc	agctcctcag	aaatcagctg	ctccaggaac	tgctcctgag	gaggccccctg	900
ggcctctgcc	tcgccacca	accccatctt	ctgaggatcc	aggcttttct	tctcctctgg	960
ggatgccaga	tctcatctg	tatcaccaga	tgggccttct	tctcaaacac	atgcaggatg	1020
tgagagtcct	cctcggtcac	ctgctcatgg	agttgaggga	attatctggc	caccggaagc	1080
ctggggaccac	aaaggctact	gctgaataga	agtaaacagt	tcattccatga	tctcacttaa	1140
ccaccacca	aaatctgatt	ctttattttc	tcttctgtc	ctgcacatat	gcataagtac	1200
ttttacaagt	tgctccagtg	ttttgttaga	ataatgtagt	taggtgagtg	taataaaatt	1260
tatataaagt	gagaattaga	gttttagctat	aattgtgtat	tctctcttaa	cacaacagaa	1320
ttctgtctgc	tagatcagga	atttctatct	gttatatcga	ccagaatggt	gtgattttaa	1380
gagaactaat	ggaagtggat	tgaatacagc	agttctcaact	gggggcaatt	ttgcccccca	1440
gaggacattg	ggcaatgttt	ggagacattt	tggtcattat	acttgggggg	ttgggggatg	1500
tggggatgtg	tgtgtactag	gcattccagta	aatagaagcc	aggggtgccc	ctaaacatcc	1560
tataatgcac	agggcagtag	cccacaacga	aaaataatct	ggcccaaaat	gtcagttgta	1620
ctgagtttga	gaaacccag	cctaataaaa	ccctaggtgt	tggtgctctg	aatgggactt	1680
tgctcccttct	aattattatc	tctttccagc	ctcattcagc	tattcttact	gacataccag	1740
tctttagctg	gtgctatggg	ctgttcttta	gttctagttt	gtatccccctc	aaaagccatt	1800
atgttgaaat	cctaataccc	aaggtgatgg	cattaagaag	tggtgctttg	ggaagtgtat	1860

agatcaggag	tgcagagccc	tcattgattag	gatttagtgcc	cttattttaaa	aaggccccag	1920
agagctaact	cacccttcca	ccatatgagg	acgtggcaag	aagatgacat	gtatgagaac	1980
caaaaaacag	ctgtcgccaa	acaccgactc	tgctggtggc	ttgatcttga	acttccagcc	2040
tccagaacta	tgagaaataa	aattctgttg	tttghtaagct	aaaaaaaaaa	aaaaaaaaaa	2100
aaaaaaaa						2108

<210> 36
 <211> 1972
 <212> DNA
 <213> Homo sapiens

<400> 36						
ggcagcaggga	atgcccttcc	tgccctgctg	atctataagg	ggggtgaatt	gatcggcaat	60
tttgttcctg	ttactgacca	gctgggggat	gatttctttg	ctgtggacct	tgaagctttt	120
ctccaggaat	ttggattact	cccagaaaag	gaagtcttgg	tgctgacatc	tgctcgtaac	180
tctgccacgt	gtcacagtga	ggatagcgac	ctggaaatag	attgaactga	tagtctagtt	240
gcatagatatt	ctcattgttt	gggttggaat	acacgtcatt	gtttattttt	gttcctttgt	300
cttctggcct	ttcagctggt	ctttgtagtc	ccttttatta	tgcatataat	aaagaaattc	360
ttagattaaa	tcagaatgct	gaataacctt	gtagctagca	ataagggtgac	ttacagttgt	420
ataaacaggga	agccaggcct	ttgaactggt	tacttaagat	tctgtggtgt	gacatctctg	480
ttattgtttc	cagtcaatat	ttacaaagca	tcctaaagac	agggtccttg	aaattgtctt	540
cagatgatct	tagaggctct	tgccaagtct	gagagtataa	ttctgtaggt	attgtgttat	600
ttgcaacgta	aatagtgcat	ttctttaatc	aaatgattgt	aaattatatt	tacttgtaat	660
cagttccata	gcttttagacg	gtggttagat	tttttttttc	cccaccaggg	tcttgtttaa	720
aggggtgagc	caccgcaccc	agtcctgagg	gggtggcctc	gctgctggat	ttcatgtctt	780
cctccagcat	gactaagtct	ggaacagcag	gaagggttga	tgcttactga	cctgggtgatg	840
ttagaagaca	agtagtttat	ggattttaa	attagagctg	gagtggggct	ggaaatcttt	900
gtaaagggaag	ttcttttcagt	aagatgcccc	tgcttgcctt	tgctctcttt	ttgtttaaca	960
aggtaacttt	ttgttttaaca	aggtaacttt	ttgtttaacc	tagatttttt	ttaaaaacttt	1020
tttttttttt	catattggaa	aagtaattca	tattcagtag	aggaaaactg	accaaaacag	1080
aagcaaaaaat	aagaaaaatta	aaataatctc	taatcctact	acctagaata	aaacactatt	1140
aatatttttg	tctgttttct	gccaaagggt	tttctgtgta	tacatggata	ttttgtttgt	1200
ttttaaacaa	aacgatggga	tcattctgaa	catactgttc	tatagtatgg	tcagctaata	1260
atataatcaga	cctttttttta	tattattaaa	tattctacaa	cttttttaaaa	atgtctatta	1320
atattccatc	gtatagatgt	gatataattt	gcttgatggt	tgctctctta	aaagaaagat	1380
agcaaaatact	tttttttaaat	tacaaaagtg	atagatgttc	attgtagaaa	atgtaataaa	1440
cactgttaag	acttaaaagc	catataattc	caccaaccaa	aattaatccc	ttttgtcata	1500
tttctagtca	tttttatagc	ctttttttct	atgtatttat	aataattatc	atttgcgttt	1560
ttttcctttt	tttaacttta	aaaatgtata	ttctagggtc	aggggaaatg	taatctggaa	1620
ttaaatatta	gccttaaaat	tcacaatttt	gattttcctg	gcttttcagg	aattgactaa	1680
ctgtaaaaga	gtcttgaaag	tatttagtca	acaaacagag	tgcatatttt	ttttttttga	1740
ctaagaaaagc	tcgttgtagt	agaaagggtg	gaatgtattg	aaaattatta	gaagcaggga	1800
agtattgtta	gtctagctta	tttcctttca	gtcttttttc	aatattttta	taa'acattga	1860
gtacttactg	aatttagttc	tgtgctcttc	cttatttagt	gttgtatcat	aaatactttg	1920
atgtttcaaa	cattctaaat	aaataatttt	cagtggcttc	aaaaaaaaaa	aa	1972

<210> 37
 <211> 1128
 <212> DNA
 <213> Homo sapiens

<400> 37						
gagaaaactgg	ctctctggac	ttcagaacat	tttgtacatc	atgtctttata	aggaagccat	60
taaggctcact	ccactgccat	gtatgcaact	gctgtgtggc	tcgatatgat	caacactgcc	120
tgtggactgg	acgggtgcata	ggttttggca	accatcacta	ttacatatcc	ttcttgtttt	180
ttctttccat	ggtagtggc	tggattatat	atggatcttt	catctatttg	tccagtcatt	240
gtgccacaac	attcaaagaa	gatggattat	ggacttacct	caatcagatt	gtggcctggt	300
cccttgggt	tttatatatc	ttgatgctag	caactttcca	tttctcatgg	tcaacatttt	360
tattattaaa	tcaactcttt	cagattgcct	ttctgggctc	gacctcccat	gagagaatca	420
gctgcagaa	gcagagcaag	catatgaac	agacgttgct	cctcaggaag	acaccataca	480
atcttggatt	catgcagaac	ctggcagatt	tctttcagtg	tggtctgctt	ggcttgggtga	540
agccctgtgt	ggtagattgg	acatcacagt	acaccatggg	ctttcaccca	gccaggggaga	600
aggttcttcg	ctcagtatga	agaaaagcaa	cccaaaactc	tcaatctgat	ttgtttttgt	660
ttatgtcgat	gcctgtagat	ttgaaagtga	agtaaaagatt	tagaattcac	ctaagtccaa	720

agggaaacac	gtgggttttta	aagccattag	gtaaaaaaag	ttctcaataa	aggcattaca	780
atTTTTtagg	tttagaaaaga	tggacttttc	tgataaatct	tggcagacat	ctaaaaaaa	840
aaccatattt	ttcacaagaa	aatgcaagtt	actttttttg	gaaataatac	tcactgatta	900
tggataaaat	ggaatatttt	cagatactat	attggctgtt	tcaaaatagt	actattcttt	960
aaacttgtaa	tttttgctaa	gttatttgtc	tttgtgtgat	ctataaatat	gtaaaaata	1020
tttaaataga	tgtacctgtt	ttgctttcac	acttaataaa	aaatTTTTTT	ttgtagttga	1080
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaactcga		1128

<210> 38
 <211> 1959
 <212> DNA
 <213> Homo sapiens

<400> 38						
ggcagcaggt	ttcactctct	aaatgaacaa	agtgggagat	cactgtcatg	gccaaagtta	60
catggccaag	acaaactatg	gcctgggagt	cccaggttct	cctgtgtggg	cactttcctg	120
gcatatgcta	aatgatggga	aagtctgggt	ctcatgtttc	tgtgtgggtc	tcacctcact	180
cgactttctg	tctttctgtt	cactctgggc	ttctgtgctt	tcattaatat	agttcttagt	240
tttccactgg	tctgtatccc	attctgcctt	ggacgccttt	acttctgtct	gctcactgag	300
aagcctcatc	aggaggcctg	tcctggagat	gagcttgcca	caggtcactt	gcacataggt	360
ctcggagcag	tccgtcttca	aggccagat	aacatgagaa	atgaagcttc	tcacatcggt	420
gttgggggatg	acggactgta	gttgatgggt	tagcggaatt	tcaaactgat	cacctgggga	480
tgagagcaat	gggtaactga	agcttttggg	ctcgggggac	aggtcagtcg	ccacgttggt	540
gtattcccat	tttgtctcag	tttgtttaac	agttggctct	aagttgaatg	cagtcctagt	600
gggaatctgc	ctcaggaaga	tgattgtagt	ttgtgttttc	agagatgggtg	ccttctggca	660
tagtagtggt	ttccataaaa	acgttttctt	cagaggcatt	tcttgcagtt	tggtttttta	720
cagtagtggt	ttctataaaa	cattctgaag	gagcaaatat	ttctggaaaa	gggttttctt	780
gaggactcag	gtctcctgag	gatgaaaaag	ccccttgtga	aggggaattt	atgaggctct	840
tcactgcaga	gaacggcggc	ctctttgcga	gcatcagttc	attgagataa	cttttctttc	900
tcaattttct	aatctttttg	gccttgggtg	ttctgtgggc	cacacgggag	tgagttttat	960
gaaagtggta	tttttttctg	gaatgtacga	ctcgttttagc	agccttcata	ttttttaact	1020
ctagcctttg	cattttctaa	aattaaaaatg	gtgtaggcta	agtctttcaa	tctgtctatg	1080
acctgaggta	gggcttttgc	agttgtggaa	ggcagaaggc	atgcccatgg	agaagggttt	1140
cagcaaaagag	gagactgttg	gcttctgctc	ttgggtgaat	gaaggcttgg	tgtagacggc	1200
gtttcccgcg	acgtttctcg	gcccctgcac	tatgtgaggg	tattccagct	cccttggggc	1260
tggactcccc	agcctttttt	ctttggcagc	attctcccca	aatgcctggg	caccctgttc	1320
cctcctgata	ctctgctttc	ccaccgcttt	gaagggcctt	ttctggatgc	tccttggggc	1380
catgaggagc	ctgttcactc	tctgcagggt	tttgcttaca	ctttgaacct	ttgccaggct	1440
gttttctctg	ggttggacag	tttctaattt	cttttcaaat	atttggcatt	taaatttggt	1500
acctagaagg	ctggactgca	taagcatggc	agttttttct	tcctttttta	cttcatcgat	1560
ttttttcttg	tattttctga	tctaacatct	tttctagcaa	atacaccttt	ctcaatttat	1620
tttcataagt	tgaattgttg	gatgcagggt	gaaacaaggg	gctctttgta	ttgtttttca	1680
aaacaggagc	ttatctccat	cttgcacatt	tgaaaaaagc	agtttaatga	atggtaacaa	1740
cattgattcc	gcatctagat	ttcctgttga	gaaataaggc	aagatgtaat	ttagcgaggt	1800
gataacatca	aagtgtctag	ctgtcactc	cgaagactg	acaagttggt		1860
gctaataaac	ctaattctaca	gaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1920
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa			1959

<210> 39
 <211> 2863
 <212> DNA
 <213> Homo sapiens

<400> 39						
ggcagcagca	gagatgtcag	gtagggtgga	agtagggtgac	aactggggcc	agcttctgag	60
ctataaaaact	gtacaaaacat	gaagaatagt	tttttcacag	tgagctgggc	tcttacttgc	120
tccttctctt	gggccacagt	gtaaatgaga	acacgtagtc	tctcttctct	ccacataatg	180
ccctcctggg	gaatgttatc	ccgccacacc	ttcagggttta	atccttgaac	aagcacctcc	240
taaacctcat	ctttgtctct	aaatgtgcta	ctgagccctg	gcagcctctt	gtcacaccca	300
tgggcttctt	atcctctgtg	tcctcggtcg	acctgggcac	ctttctgcca	tttttctctt	360
tcccattttt	ttctcccata	tcagtgcagc	cccattgggc	cttatcctga	atgcctctct	420
cgctctctcc	ctgcttctct	tgtgtctagc	aggcaccagt	gctttacatt	ctgccgcctg	480
gttatatctg	tgtgtcttct	ctctaccctc	acagcgttca	tcccagggtat	agactgaata	540
tccgaagtgc	tccaaaatct	caaatgtttt	gagcctaac	gtgacattta	aggggaatgt	600

ttatttgagc	cttgcaaatg	gatttggggt	gctcaaccag	taaatatgca	aatattccaa	660
agttcaaaaa	aatcccaaat	tcagaacact	tctgggtcca	ggcatctgag	ataagagata	720
ctcagcctgt	atcatctccc	ccttcctagc	ctcctggaag	tccacagcct	ctcctcctgt	780
agtttttccc	ttgaaacttc	ttttcgaagc	actttcactt	cgtctttttg	ttgtttcttc	840
accgtaagcc	agtgaagtga	gcagggttta	agtaagtgtc	ctcagtatat	tggtgaagga	900
acagacacag	ttaggggtca	agactctcat	gaggttactc	aaggaaaccag	agaaagaacg	960
ggactcagac	tcagatttct	cccctcttca	gcagactgag	ggtaagttgg	ggaggcatga	1020
agagggtcaag	gcttgggatc	agcctgccag	ctttgccaga	gcaggagggg	gctgaggcag	1080
agggtgatcag	gatagcaagt	gccaccagca	gctctcacat	agtgagcacc	tgccatgtgt	1140
cagggtgcca	gctagacact	tgatgagttc	tctctccttt	catcctcatc	atagtctgtg	1200
aggaaggaat	tcccataccc	actcacagat	gggaaaatga	ggcataagtg	aaggtggcga	1260
gggtgggttc	ttattcaagt	tcacacagcc	ggttaatata	gggatcaggt	ttgcaccag	1320
acctgtctag	ctcctagtct	ctttcctcct	gggcttggtg	cctcgagag	gcagctgagc	1380
agaatgcttg	aggatttggg	tctgcagcca	ggctgcctgg	gctttgtgac	tttgggcaat	1440
ctgcttaacc	ttctaggctt	cattttcttc	atctgtaaag	tgggggtaat	aatagtatct	1500
atctcacagg	gctgttggtg	ggatcaaggt	ctttcgccatt	tttcggcatt	tagaatagtt	1560
catgggtacat	aaagatctgg	aatgtccagg	agagccattc	atgagtaact	gccctccctc	1620
accacaggat	gccagcgaag	agacaagcac	ttccgtcatg	cagaaaaccc	ccatcatcct	1680
ctcaaaacct	ccagcagagc	gggtgagcag	agaaggaggg	aggaggggga	gccgttaggg	1740
aaagggttg	ccccattgat	gggatttttt	ttacctccgt	agtcaaaaaca	gccaccacct	1800
ccaaacagccc	ctgctgcccc	gcctgtctcca	gccccctctg	agaagcccat	cgttctcatg	1860
aagccacggg	aggaggggaa	ggggcctgtg	gccgtgacag	gtgcctctac	ccctgagggc	1920
accgccccac	cacccctgtc	agccctctcg	ccaccaagg	gggagaagga	ggggcagaga	1980
ccacacacagc	ctgtgtacca	gatccagaac	cggggcattg	gcactgccgc	accagcagcc	2040
atggaccgtg	agttggggct	gggcagtacc	aggttgggaa	ctggcgtctc	ctcacagatc	2100
ctactgcat	cctctgtctc	ctgctttctc	caatctccag	ctgtcgtggg	tcaggccaaa	2160
ctactgcccc	cgagcgcgat	gaagcacagc	atcaagttgg	tgatgacca	gatgaattgg	2220
tgtgacagtg	ccatcgaggt	accgaggggt	cctgcctgc	ctgagcttcc	gcacatctg	2280
catcctctga	tcttccacct	ctctgtaggc	aacaccagac	tgagggggtt	tgaggcaact	2340
tacagcagtg	agaggggggtg	gtatcagaac	attctcacct	aaccagagcg	gaatttcaac	2400
tagctcggtc	gtgcttgcta	gttggtaaaa	tacagaactc	ctttgggtacc	gattggtaaa	2460
gaagtactct	cactaccacc	ccaggacccc	tggtgctctc	cgtgccatcc	acagcagggg	2520
agtcttttgg	accctgtctc	agtacccttc	ttatttgggt	gaaacccttg	ctggtggctc	2580
atgcctgtaa	tcccagcact	ttgggaggcc	aaggtggggg	aatcgccctg	gcccgggagt	2640
tcaagaccag	cctgggcaac	atgggaatac	tccgtttcta	ccaaaaattt	aaaaatttag	2700
caggcatggt	ggcaggaggg	atccaggcca	ctcgggaggg	tgaggtagga	ggatcacttg	2760
actccgggag	gtcaaggctg	cggagagctg	tgatcatgac	attgcactcc	aacctcaaca	2820
acagagttag	accctgtctc	agtaaaaaaa	aaaaaaaaaa	aaa		2863

<210> 40
 <211> 2143
 <212> DNA
 <213> Homo sapiens

<400> 40						
ggcagcagat	ttcttatcac	aatggtgctg	ttagtagtaa	cactagtaaa	tctgagtatt	60
tataagctca	taaagcttgt	tacagcctta	agcaaaaagc	ttggggccaa	gggcgtttta	120
aaaaatgcac	actttatgag	gtgcaactgc	ggagaaatga	ggacgcgttc	ttaagctttg	180
gtattcacat	gggtggtggtg	ctggtagagg	ctgttacatt	tcttccagtg	aagctgttct	240
tgacagccgc	ttggaattca	cttcagggcc	agtttatgag	ccaccccaag	taatctgctt	300
ggagtctgag	catcatacct	tgtatttgac	caaaatatat	gtaacaaatt	taccatttta	360
accattgtta	agttttacaat	tcagtgggat	ttgcagtgtt	gtataaccgt	catcactgtc	420
tattttctaga	actttttcat	ctttgcaaac	tgaaaactctg	taccagtaaa	acaatatctc	480
cccatttccc	ttccctccag	cccttggtaa	cctcaattct	actttctgtc	tctgaattgg	540
cctattccag	gtacctcata	taaggggact	catacaatat	ttgtcctttt	gtgtctagct	600
tattttcatat	atattttatc	aaagctcata	atgttttcaa	ggttcattca	tggtgtagca	660
tgtatcagaa	tttatggctg	agtaatactc	ctgtgtatgt	cattgtatgt	atatactacg	720
ttttgcttat	ccattcatct	gtttatggac	tcttagttgt	ttccatcttt	tggtctattgt	780
gaataatgct	gctatgaaca	ttagtatctt	gagtccttgc	tttcaattca	attttttttt	840
tttttttaaac	aggatctctc	accccatcac	tcaggggggc	gcaatcacga	ctcattggct	900
cactgcagcc	taaacctccc	agctggagca	attctcctgc	ctcagccttc	tgagttagctg	960
ggactacagt	tggttctaaa	gagtggtgag	tcagaagaga	cgtcaggcag	caagcgactt	1020
gggccatggc	ctctgaccta	gacttctcac	ctccggaggt	gcccagagcc	actttcctgg	1080
agaacctgct	acgggtacgga	ctcttctctg	gagccatctt	ccagctcatc	tgtgtgctgg	1140
ccatcatcgt	accctattccc	aagtcccacg	aggcggaggg	tgaaccgtct	gagcccagaa	1200

23

gtgctgaggt	gacgaggaag	cccaaggctg	ctgttccttc	tgtgaacaag	aggcccaaga	1260
aagagactaa	gaagaagcgg	tagaagagga	ggcctgagga	gctgggagg	cagggagagg	1320
gtcttgagg	cagccctcct	gggaatctac	attgtgttcc	cccgcattcc	aggctcagg	1380
tctgaggagg	ctgtgacgcc	ctatgaccgc	agagatctag	acagtcgtaa	cagtccccag	1440
gctccagctg	ggcaatccac	cacttcctct	tccttctgct	tctgtgacgg	tttagagtca	1500
agggggctga	aacacactgt	gagcatagac	tgtattaggt	ttgttcagaa	gccgggtcag	1560
ctcacagaat	cacattttct	tgtcttagtca	tgtgtccctc	cttgagttgc	ccctccttg	1620
tgggtttaca	ctacatttgg	gagtcattgt	ctaagtctga	caagcacacc	ctctccatt	1680
atttgtgcac	tacagatctc	ctgctgatca	gtcacctttg	ttgctgctgt	gtagacagag	1740
ccaggcctca	cctgtttgtt	taggccaaga	tgccatggac	atgcagcgtt	agtgatccca	1800
ctagctgcga	cagccaggcc	cagaaaatgc	ctggcgtgag	agccagcaga	cagccaggcc	1860
ggggtaggca	gtgcctgctt	ctgctccatc	aggtgcagg	gatttggctg	aaggcgtgca	1920
tatttctcgg	gcacaaactt	cctgagcctc	tgaaatggga	ggctcgtcaa	tttcagacca	1980
acctcttttc	aacctcatcat	agcacgttca	aggtgtgcct	tttacttcta	cctgtacatc	2040
ccccatccct	tcaattcttt	cattccctga	ccagtgcag	ggttcctggg	ggaagtatgg	2100
tgaataaact	gacatgcatg	cttcaaaaaa	aaaaaaaaaa	aaa		2143

<210> 41
 <211> 600
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (594)
 <223> n equals a,t,g, or c

<400> 41						
gaattcsgca	cgagtgcacc	tgccaggctg	ctagtaagtg	gctaagctgg	cctgagaacc	60
caggagtcct	gtgctgacac	tggtgcctgc	tgtgctgccc	actgtgcggg	ggtatgtggg	120
catctgtcac	cttattctac	tgagtggtgt	gtaagacatc	tgcccgctct	gtaggcaaa	180
cttgccatca	aagtgtctgg	tgatgtgtgt	ctctcctgtg	tctgtgtgcc	cctttctccc	240
cagcctgcat	tttattaata	attggtgtaa	tgtctcatct	tgacctttgc	ctgtctttct	300
gttgggttgg	tttgtttttc	attgctcgct	ctttctctcc	tatgggggct	aattagggaa	360
ataaaactgag	tagcttttta	aaaatgtcat	tcccaggccc	ctgccccaga	gattctgtgt	420
ggatcagcag	gaggcctcak	gttctgtgtt	gtttaaaagc	ttcctgggga	gggtctgatg	480
tgtakccagt	ttgggtgagg	ggccctggag	aacctkggaa	atgggagtc	gttggtacac	540
ctctgagctt	tatgccacag	atagaaaatg	atgaatgtag	gctgggtgcg	gtgnctcacc	600

<210> 42
 <211> 512
 <212> DNA
 <213> Homo sapiens

<400> 42						
tttttttttg	cagaaaataa	cagctttatt	gctacagatg	tgagagcatt	tacaaaatgc	60
caaggaaaac	cattccgttt	tgagtctctg	gagcctgaac	tctcaccatg	taccagaaaa	120
gaatgccctc	ctttcgaaact	ttcaaacagt	tgggattatt	tttgtttctt	atcatcccaa	180
ttatttgctc	aagttttgct	ccattgggyc	ccgttcagag	tttcttgggc	tgtctgtact	240
agtcacagct	ccacttccat	ctcttctcag	gaagagggtg	gcacaagaca	catctgagcc	300
ccttagtatt	gtgatggtgg	ccaggaaaatg	atcaaagggt	agcatttagg	aaatcagcaa	360
actaaagcct	caaatacaag	gtggacaaat	gcattctcaa	ctcaaacagg	ttgggtaatg	420
ctttcataag	atacattatg	ttttkgtgta	cacagcacac	aaattttatt	atgtctacaa	480
acagattcag	gaaagatctc	caggctattt	cc			512

<210> 43
 <211> 2650
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2603)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2608)

<223> n equals a,t,g, or c

<400> 43

cggtctgtggc	gcaggetttcc	agccccacc	atgccgtggc	ccctgctgct	gctgctggcc	60
gtgagtgggg	cccagacaac	ccggccatgc	ttccccgggt	gccaatgcga	ggtggagacc	120
ttcggccttt	tcgacagctt	cagcctgact	cggtgtggatt	gtagcggcct	gggccccac	180
atcatgccgg	tgcccatccc	tctggacaca	gccacttgg	acctgtcctc	caaccggctg	240
gagatgggtga	atgagtcggt	gttggcgggg	ccgggctaca	cgacgttggc	tggcctggat	300
ctcagccaca	acctgtcac	cagcatctca	cccactgcct	tctccgcct	tcgctacctg	360
gagtcgcttg	acctcagcca	caatggcctg	acagccctgc	cagccgagag	cttcaccagc	420
tcacccctga	gcgacgtgaa	ccttagccac	aaccagctcc	gggaggtctc	agtgtctgcc	480
ttcacgacgc	acagtcaggg	ccgggcacta	cacgtggacc	tctccacaa	cctcattcac	540
cgctcgtgc	cccacccac	gagggccggc	ctgcctgcgc	ccaccattca	gagcctgaac	600
ctggcctgga	accggctcca	tgccgtgccc	aacctccgag	acttgccct	gcgctacctg	660
agcctggatg	ggaacctct	agctgtcatt	ggtccgggtg	ccttcgcggg	gctgggaggc	720
cttacacacc	tgtctctggc	cagcctgcag	aggctccctg	agctggcgcc	cagtggcttc	780
cgtgagctac	cgggcctgca	ggtcctggam	ctgtcgggca	accccaagct	taactgggca	840
ggagctgagg	tgttttcagg	cctgagctcc	ctgcaggagc	tggaccttcc	gggcaccaac	900
ctggtgcccc	tgccctgagg	gctgctcctc	cacctcccg	cactgcagag	cgtcagcgtg	960
ggccaggatg	tgccgtgccc	gcgcctgggtg	cgggagggca	cctacccccg	gaggcctggc	1020
tccagcccca	aggtggccct	gcactgcgta	gacacccggg	aatctgctgc	caggggcccc	1080
accatcttgt	gacaaatggt	gtggcccagg	gccacataac	agactgctgt	cctgggctgc	1140
ctcaggtccc	gagtaactta	tgttcaatgt	gccaacacca	gtggggagcc	cgcagcctat	1200
gtggcagcgt	caccacagga	gttgtgggccc	taggagaggc	tttggacctg	ggagccacac	1260
ctaggagcaa	agtctcacc	ctttgtctac	gttgcctccc	caaaccatga	gcagagggac	1320
ttcgatgcca	aaccagactc	gggtcccctc	ctgcttccct	tccccactta	tcccccaagt	1380
gccttcccct	atgcctgggc	cgccctgacc	cgcaatgggc	agagggtggg	tgggaccccc	1440
tgctgcaggg	cagagttcag	gtccactggg	ctgagtgtcc	ccttgggccc	atggcccagt	1500
cactcagggg	cgagtttctt	ttctaacata	gccctttctt	tgccatgagg	ccatgaggcc	1560
cgcttcatcc	ttttctattt	ccctagaacc	ttaatggtag	aaggaattgc	aaagaatcaa	1620
gtccaccctt	ctcatgtgac	agatggggaa	actgaggcct	tgagaaggaa	aaaggctaata	1680
ctaagttcct	gcgggcagtg	gcatgactgg	agcacagcct	cctgcctccc	agcccggacc	1740
caatgcactt	tcttgtctcc	tctaataagc	cccacccctc	ccgcctgggc	tcccccttgt	1800
gcccttgccct	gttccccatt	agcacaggag	tagcagcagc	aggacaggca	agagcctcac	1860
aagtgggact	ctgggcctct	gaccagctgt	gcggcatggg	ctaagtcact	ctgcccttcg	1920
gagcctcttg	aagcttaggg	cacattgggt	ccagcctagc	cagtttctca	ccctgggttg	1980
gggtccccc	gcattccagac	tggaaacct	cccattttcc	cctgagcatc	ctctagatgc	2040
tgccccaagg	agttgctgca	gttctggagc	ctcatctggc	tgggatctcc	aaggggcctc	2100
ctggattcag	tccccactgg	ccctgagcac	gacagccctt	cttaccctcc	caggaatgcc	2160
gtgaaaggag	acaaggtctg	cccgacccat	gtctatgtct	tacccccagg	gtagcatctc	2220
agcttccgaa	ccctgggctg	tttccttagt	cttcatttta	taaaagttgt	tgccctttta	2280
acggagtgtc	actttcaacc	ggcctcccct	accctgctg	gccggggatg	gagacatgtc	2340
atttgtaaaa	gcagaaaaag	gttgcatattg	ttcacttttg	taatattgtc	ctgggcctgt	2400
gttgggggtg	tgggggaagc	tgggcatcag	tggccacatg	ggcatcaggg	gctggcccca	2460
cagagacccc	acagggcagt	gagctctgtc	ttccccacc	tgcttagccc	atcatctatc	2520
taaccggctc	ttgatttaat	aaacactata	aaaagttaaa	aaaaaaaaaa	aaaaaaaaag	2580
ggcggccgct	ctagaggatc	cangcttnac	gtacgcgtgc	atgcgacgtg	catgactctt	2640
ctgatatgtc						2650

<210> 44

<211> 2159

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2035)

<223> n equals a,t,g, or c

<220>

<221> SITE
 <222> (2048)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2088)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2151)
 <223> n equals a,t,g, or c

<400> 44
 gaccctgatt acgccaagct cgaaattaac ccycactaaa gggaacaaar gctggagctc 60
 caccgcggtg gcggccgctc tagaactagt ggatcccccg ggctgcagga attccccggg 120
 gcgaggactg ttaactgttt ctggcaaaaca tgaagtcagg cctctggtat ttctttctct 180
 tctgtcttgc cattaaagt ttaacaggag aaatcaatgg ttctgccaat tatgagatgt 240
 ttatatttca caacggaggt gtacaaattt tatgcaata tctgacatt gtccagcaat 300
 ttaaaatgca gttgctgaaa ggggggcaaa tactctgcga tctactaag acaaaaggaa 360
 gtggaaacac agtgctccatt aagagtctga aattctgcca ttctcagtta tccaacaaca 420
 gtgtctcttt ttttctatac aacttggacc attctcatgc caactattac ttctgcaacc 480
 tatcaatttt tgatcttcct ccttttaaag taactcttac aggaggatat ttgcatattt 540
 atgaatcaca actttgttgc cagctgaagt tctggttacc cataggatgt gcagcctttg 600
 ttgtagtctg cattttggga tgcatactta tttgttggct tacaaaaaag aagtattcat 660
 ccagtgtgca cgaccctaac ggtgaatata tgttcatgag agcagtgaac acagccaaaa 720
 aatctagact cacagatgtg accctataat atggaactct ggacccagg catgaagcac 780
 gttggccagt tttctcaac ttgaagtga agattctctt atttccggga ccacggagag 840
 tctgacttaa ctacatacat cttctgttgc tggtttgttc aatctggaag aatgactgta 900
 tcagtcaatg gggattttta cagactgcct tggtaactgc ggtcctctc aaaacaaaca 960
 ccctcttgca accagctttg gagaaagccc agtctctgtg tgctactgg gagtggaatc 1020
 cctgtctcca catctgtctc tagcagtga tcagccagta aaacaaacac atttacaaga 1080
 aaaatgtttt aaagatgcca ggggtactga atctgcaaag caaatgagca gccaaggacc 1140
 agcatctgtc cgcatttcac tatcatacta cctcttctt ctgtagggaat gagaattcct 1200
 cttttaatca gtcaaggag atgcttcaaa gctggagcta ttttatttct gagatgttga 1260
 tgtgaactgt acattagtac atactcagta ctctccttca attgctgaac ccagttgac 1320
 cattttacca agactttaga tgctttcttg tgccctcaat tttcttttta aaaatacttc 1380
 tacatgactg cttgacagcc caacagccac tctcaataga gagctatgtc ttacattctt 1440
 tctctgtctg ctcaatagtt ttatatatct atgcatacat atatacacac atatgtatat 1500
 aaaattcata wtgaatatat ttgcctatat tctccctaca agaataattt tgctccagaa 1560
 agacatgttc ttttctcaaa ttcagttaaa atggtttact ttgttcaagt tagtggtagg 1620
 aaacattgcc cgggaattga agcaaattta ttttattatc ctattttcta ccattatcta 1680
 tgttttcatg gtgctattaa ttacaagttt agttcttttt gtagatcata ttaaaattgc 1740
 aaacaaaatc atctttaatg ggccagcatt ctcatgggt agagcagaat attcatttag 1800
 cctgaaagct gcagttacta taggttgcct tcagactata cccatggtgc ctctgggctt 1860
 gacaggttaa aayggtcccc atcagcctgg agcagccctc cagacctggg tggaattcca 1920
 ggggtgagag actccccctga gccagaggcc actagggtatt ctgtctcca gaggctgaag 1980
 tcaccctggg aatcacagt gtctacctgc attcataatt ccaggatctg tgaanagcac 2040
 atatgtmca gggcacaatt ccctctcata aaaaccacac agcctgnaa ttgccctggc 2100
 ccttcaagga tagccttctt tagaatatga tttggctaga aagattctta natattgga 2159

<210> 45
 <211> 553
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (524)
 <223> n equals a,t,g, or c

<400> 45
 tacgagtttt tttttttttt tttcagttgc tgaatatcaa atgtttattc tttgccttct 60
 tactactgtt aaaatctctt tgataagtgg ctctcttaa aactggattt gatttcacag 120

26

aaatTTTgtg	aattattatt	catcttgagg	tgtcccatgc	tggggatgag	gatgtgtcga	180
ggcacagctt	ggacaaccag	gccagggtggg	ccaccatgaa	ggttctcctc	cccatacccc	240
acccacacaca	cagaaacctg	caaacaactc	agggaaacacc	tgtgcaaagc	cagtcagggtt	300
gtccaagtca	gctgaaaaca	gaacaccata	ctagattcaa	attacaagtt	cagtactgta	360
ctgtacacat	ccagcattac	acatgcttaa	gataatataa	gtatgcataa	tgacatatcg	420
gggtctcact	tgtaaactat	aaggcacaca	gttacaaaat	gttaaactac	aacataatcc	480
cagttttacc	taaaagttac	caaatggtgg	ttgcatcgac	attnggctgg	cttcagaagc	540
cctggggcat	ggc					553

<210> 46
 <211> 364
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (280)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (289)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (322)
 <223> n equals a,t,g, or c

<400> 46	
ggcagagtcg	cacacgggct gccctggaga gacatttcca tggacatcct catgctgctt 60
ctgcttttgt	gtgtaatata tgggagattt tcccaagatg aatactccct caatcaagct 120
atccggaaag	aatttacaag aaatgccaga aactgcttgg gtggcctgag aaacatcgct 180
gactgggtgg	actggagtct gaccacactt ctggatggcc tgtaccgggg aggcaccccg 240
tcagcccgtg	tgccgggggc ttcagcctgg agctcttggg ggaaaatgnt tacctaatag 300
gcagtttccg	taattaggca gntaaaagtt ttttcctagg gcatttttgc aagccttcca 360
ggcc	364

<210> 47
 <211> 343
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (11)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (272)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (277)
 <223> n equals a,t,g, or c

<400> 47	
ccctgtgttg	ntggatgttt tttccagaag ggggagttgt aggctgtcgg acaaaccatt 60
aatcttcatc	agaagttcgt ctaacagatt tgcaaattca tccaagtagt aattgtgatt 120
ctcaaccatc	tcagcctctt ccaactttgg tgtttccagt ctcaaaaagg tgaggacctt 180
ttccacata	taagcagtga catctttaag tctcacaaaa gatttacttt gaaaagattt 240
tcttttttgg	ggtaaaagtca tgagaaaacc tntcagnatt ccaaaacaca gtgtggcaga 300

gactattaaa aggatcccaa agkaacaagc catggcccgc tgg

343

```
<210> 48
<211> 576
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (332)
<223> n equals a,t,g, or c
```

[illegible]

```
<210> 49
<211> 974
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (814)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (877)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (901)
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (959)
<223> n equals a,t,g, or c
```

<400> 49						
gccagccctg	gcgtgggccc	agccccggcc	aggcagcaat	gggttctctg	cagctgctgg	60
tcgtatcggt	gctggcatcc	gaacaccggg	tggctggctg	agccgaggtc	ttcgggaatt	120
ccagcagagg	tcttatcgaa	ttttctgtgg	ggaaatttag	atacttcgag	ctcaataggc	180
cctttccaga	ggaagctatt	ttgcatgata	tttcaagcaa	tgtgactttt	cttattttcc	240
aaatacactc	acagtatcag	aatacaactg	tttccttttc	tcgactctc	ctttccaatt	300
cctcgaaac	aggcactgcc	agtggactgg	ttttcactct	tagaccagag	cacagtcacat	360
gcacttggta	cttggggact	tcaggcatac	agcctgtcca	gaatatggct	atcctactct	420
cctactcaga	aagagatcct	gtccctggag	gctgtaattt	ggagttcgat	ttagatattg	480
atcccaacat	ttacttggag	tataatttct	ttgaaacgac	tatcaagttt	gccccagcaa	540
acctaggcta	tgcgagaggc	gtagatcccc	caccatgtga	cgctgggaca	gcacaggact	600
ccagggtggag	gttgacgtat	gatgtctatc	agtattttct	gcctgagaat	gacctcactg	660
aggagatgtt	gctgaagcat	ctgcagagga	tggtcagtgt	gccccagggt	aaggccagtg	720
ctctcaaggt	ggttacccta	acagctaatg	ataagacaag	tgtttctctc	tcctcctctc	780
cgggacaagg	tgctcatatac	aatgtcatgt	tttngggacc	ckttttctaaa	tcacatctgt	840

gcctacattc	ctgctcacac	atacggttgc	agctttngag	ggcagggaga	gggtagttkt	900
ngyttcccta	gggaagagtg	tyttccaaag	tggtctttca	tttttttggc	ccgcttggn	960
tcttcattgt	tttt					974

<210> 50
 <211> 2292
 <212> DNA
 <213> Homo sapiens

<400> 50

tcgagacagg	gtctctgtca	cccaagctgg	agtgcagtga	cacaatcaag	gctcactgta	60
gcctcaagct	tcagggctcc	agggatcctc	ccatctcagt	ctccttggga	gctgggagta	120
ggcatgtgcc	accatgcctg	gctaattttt	taattttttt	gtagagatgg	ggctctgtca	180
tggtgcccct	gtcgggtctca	aactcctggg	ctcaagcgat	actcccacct	tggtctccca	240
gtattgggat	tacagggtgtg	agccaccatg	tctggcttgc	ttctcttttt	gtattctaaa	300
attcaaaggc	ctaagtatca	aatccctaaa	tctccaaata	ctgtcacaga	taaagactca	360
ataataaact	ccctccgaaa	gttttagacag	gctcagggtga	gagacttggt	tcaagggggt	420
ataaaaagaa	acaccagtgc	tctgcagaag	aatcagtttt	taattttttt	aatgtatcta	480
tttaattggaa	taagttgatc	atagatttgt	aaaccaaag	gtaatttctc	aagtatttgg	540
aaataagaaa	aagcctccct	accaccaacc	ttttggctat	ctttctcatt	ctcttacaat	600
catcctaata	ccctagtaca	cccttaccat	atatcaataa	gggcaccata	atattatgca	660
aagaacagat	atatatgcct	gatctcttat	tagacttgca	ccagagactg	ttgaaccact	720
ccaggcatga	actccaaagc	tgaggcacac	tgaccaagcc	cctgggcatc	tacagaagca	780
aaggcggtct	ctctccagct	ggctgtctct	tctggaagag	ccctttaatc	tgggttaatc	840
ggccatagag	cctctctctc	aatggaggaa	tgtggtagct	aggggtccaga	atgtttgtca	900
ctcggcgctc	ctctctcttc	ttccataact	tgtatgggtg	gggagggaag	aacggtcgtc	960
ctctctctct	tcgaatctgt	aacgtaattc	cacttacagc	cagcatgccc	catactgcca	1020
ggataatgaa	gtcattagtt	tgaaaaggca	catttgtgaa	agctctgtgg	aaatccttgt	1080
tgagcgctct	cttgagtacg	ttcaaagtga	tgtaggaaag	gcttgtggac	cagtaactgt	1140
caatggctaa	aaccaccgaa	taggagccaa	tgactccaca	agtcagtatg	ttcagtattc	1200
ttaggcagcc	catgaaaact	actggaatga	ggatagctat	gcaagagaaa	gtgaccacga	1260
atacaccatc	atcatgaaaa	atcttttaggt	ttcccagtg	agtaaaagaa	gtcactgacg	1320
agatgaggaa	ccccagcact	agtccaacac	agagcatgca	gatcgagagg	attccaaatc	1380
gccaccacac	agctaccaag	aacattccac	cgacgcttcc	agtgacagct	gtcagaatca	1440
gattcacatc	atacttgata	gggtgtcagtc	ttgtaatcag	tatataaaaag	aagaatccca	1500
tgatgataaa	gcctatgaag	aataattctg	ttttccagaa	tctgtgtcca	aagaaacaaa	1560
tgaagaaacc	aagcagggca	aaaagagtga	agaacacttt	ggaagacact	cttcctaggg	1620
aagcacactc	accctctcct	gcctcaaagc	tgcaagcgta	tgtgtgagca	ggaatgtagg	1680
cagcagatgt	atttagaaac	gggtcccaaa	caatgacatt	gtatatgaca	ccttgtccc	1740
ggagggagga	gaaggaaaca	cttgtcttat	cattagctgt	tagggtaacc	accttgagag	1800
cactggcctt	cacctggggc	acactgacca	tcctctgcag	atgcttcagc	aacatctcct	1860
cagtggagtc	attctcaggg	agaaaatact	gatagacatc	atactgcaac	ctccacctgg	1920
agtctgtgtc	tgtcccagcg	tcacatggtg	ggggatctac	gcctcgagga	aaaggaaaca	1980
ggtgtattct	gatactgtga	gtgtatttgg	aaaataagaa	aagtcacatt	gcttgaaata	2040
tcattgcaaaa	tagcttcctc	tgaaaagggc	ctattgagct	cgaagtatct	aaatttcccc	2100
acagaaaatt	caataagacc	ytcgctggaa	ttcccgaaga	cctcggtctgc	accagccacc	2160
cggtgttcgg	atrcacgac	cgytacgacc	agcagctgca	ggaaccccat	tgctgcctgg	2220
gccgggctgg	gcccacgcca	gggctgggga	gaggtgcggg	cgtgcgcgcc	ggggccccgc	2280
agcctcgccc	at					2292

<210> 51
 <211> 364
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (361)
 <223> n equals a,t,g, or c

<400> 51

ggtcgaccca	cgcgtccgcc	tctacctgtg	taccacggcc	tgggatggac	cctgcagctg	60
tggccctcct	ggcactatcc	ctaccctgtg	ccctgggtgg	tgtrcagtgg	gaacaggcac	120
cctgggggtc	ttggaggctc	agcmtctcag	ccmtcacccc	cgagacccca	tcgtggcgcc	180

29

tgtgtccact	cagggattat	cccaagcctg	gccagaggtc	gggaggggac	agagggagcc	240
acattaggag	cctctaacca	gcccctttct	taccacaggg	tagggggcgc	ttccctcca	300
caggggtcttc	aggcttgtgg	gctcccccca	gctgcacagg	ccccagaggc	aattttggaa	360
nctt						364

<210> 52
 <211> 754
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (605)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (652)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (695)
 <223> n equals a,t,g, or c

<400> 52						
gggatacacg	tagtagaaga	gctatgacgt	cgcattgcacg	cgtacgtaag	cttggatcct	60
ctagagcggc	cgcccttttt	tttttttttt	cctattacca	gaaccctgtg	gggtttttat	120
tgatatttca	ctggattaca	aatgttgaaa	atgttgcaaa	atgaacatcc	tggttaactca	180
agtatttcat	ggaccctcac	aaacctctgc	ggacgcagag	tgtgtggggg	ggggagcctc	240
ggggaagggg	gctgtgggca	cctccaggat	ctgaggggaa	cccaggaata	gcccgtgaga	300
gaaacggggg	gcctacagcc	aagagtgcac	cctctagaag	acaaggaaga	aagaagaatg	360
caccctccca	acagccaggg	agtgtgagag	aggcccagcc	tccagtgcct	ggcagcttca	420
gcacccaact	cagccaggga	gccctgggca	ggcccagcca	tgccctccaa	accctcgtct	480
acggctgggc	gctgacatgc	agtgggtggg	aagtcaccaa	gttcaaggta	atttgttgca	540
cagcacgggt	acttaatgca	ggagggactc	gataaacatt	taggcaggaa	aagaagaaca	600
aaggntggac	ggaggagcca	ccaggaagga	aggaggggtg	ctgcagagac	cngccctggg	660
cagcagtacc	aggggcacag	ggagccttgg	ccggnccatt	gtcactggaa	ttcattgcca	720
tgacagacttc	tacatcaaag	ggaaacaaag	tcgg			754

<210> 53
 <211> 546
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (409)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (439)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (506)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (514)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (542)
 <223> n equals a,t,g, or c

<400> 53
 aattcccggg tcgaccacag cgctccgggmt gggggamtgs ccatgttact tgtcagrtcg 60
 tgctgcccag ccctgtttat ctgtgtaatt atttttgtaa acattgtatt ctctgtggtc 120
 gccacctcct cgccccagc ctggggttca gtctgtcttc caggcctgct tgcacctcac 180
 tgggctgctc cggggtctct gcccctcatt ccaggcctgg ctgtcaggcc cagccagcag 240
 gggcccgtga cccagcagcc tgcccaaagc atttgtttct gggggatggg gtgggggctg 300
 ctccacagga ggtttgagcc cagcaccctg gggaagggga ccctgcacga caccctctg 360
 cctccctcat gaggtaaagg ccagcttcca atggctgcct cggtatgtnc aaatggccca 420
 gccacatgcc ctccctctnt gagtggagcc cttcgaatgc taatcctgag gtattgccgc 480
 ttggatgaag ccgcaacact tacttnacat agnngcgcat ctgcattggc attgattagc 540
 anatta 546

<210> 54
 <211> 1210
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (595)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (603)
 <223> n equals a,t,g, or c

<400> 54
 tcgagttttt tttttttttt tttaaaacgc tttctcttga acctgggagg tagaaaggta 60
 cagtgcgctg agatcggtgc cactgcactc cagcgtgggc aacaagagcg aaactccatt 120
 tcaaacaac aaacaacaa acaacaac aaacaaacgc tttctcttga aactgggagg 180
 tagaaggtag agtgagctga gatcggtgcc actgcactcc agcgtgggca acaagagcga 240
 aaactccatt tcaaacaac aaacaacaa acaacaac aaacaaac gctttcttcc 300
 tgagttcctg ctctgtgagg ctgacctga ggggtttggc cctgtgtgtc ttgttagctc 360
 agcctgtacc tgaccccgcg acaatgacat cctccgactc ccacctcgca gacctgggt 420
 taagcctctt gtcctgcctg aaactcatca gctatcctct ggtctcccca agaagcctcc 480
 cctaattccc cactgtgtta ggtgcctccc cctgggtgct gcatttacta ctgtcccatt 540
 ggtgtgttgc ttgcccgcct cacagtgcag gaatggaggc tgmtgggttg gcttnttcat 600
 tgntgcacc tcagaacca gcaactgtga caaacaggc gttcacgaat gttcaagaag 660
 ttaatgaata aatgagacag aaataggcca tggggaagg gggagacagg gatctaccac 720
 ggggctcgaa gcagaaatgc tgggaatctca tgccctatct gcctgaaact caggctgcga 780
 ccctaaggcc agacttctct ggcctcctcc aagacaatgt gtcagccttg cccgacggcg 840
 ccaaaacctg tgaatttgat ggggactgtc ggggtgctgga gcccatcct gattcgatgt 900
 ggctccagct tagaaccaca cagacacagg gtggcctctc caggagctcc cagtctggag 960
 caggggcctc cacctgcttc aagggtgtca ggacccctg aaatagtatg caaacagaa 1020
 tggcacctat ctgtgctggc agacccagc cagcctgctc acagtgtatc cccaaggctc 1080
 aggaggacat gttatgggtg ctgactccag actccatcag gtccagatcc tacctctgct 1140
 gctctgaac aatgagagtc tggcagggtga ctttacctct tggagcctca ctcaacctcg 1200
 tgccgaattc 1210

<210> 55
 <211> 309
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (185)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (297)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (298)

<223> n equals a,t,g, or c

<400> 55

tagaaaatttc	attaaaatct	atggacttta	aaatcctagt	ggtgcacaat	gggcagggat	60
gggcccgcga	ccgttattgc	tacagaggat	tagagggtggc	ttggccgggg	ctgtcactgc	120
acagaggacg	gacaaatgaa	cacttcaggg	attcagacac	ttcagaaggg	gctccactc	180
caganaaggg	aggggcatgt	gggctggggc	catttggcac	atgaacgagg	gcagcacatt	240
tgggaagact	gggcctttag	cctcatggag	ggagggcaag	gggggtgtcgt	gcagggnncc	300
cttccccag						309

<210> 56

<211> 1892

<212> DNA

<213> Homo sapiens

<400> 56

cctgcctgc	cgggcggtccc	gctggctaga	wgaagtcttc	acttcccagg	agagccaaag	60
cgtgtctggc	cctaggtggg	aaaagaactg	gctgtgacct	ttgccctgac	ctggaagggc	120
ccagccttgg	gctgaatggc	agcaccacag	cccgcctgtc	cggtgctgac	ccacctgctg	180
gtggctctct	tcggcatggg	ctcctgggct	gcggtcaatg	ggatctgggt	ggagctacct	240
gtgggtggtca	aagagcttcc	agagggttgg	agcctccctc	cttacgtctc	tgtgcttgtg	300
gctctgggga	acctgggtct	gctgggtgtg	accctctgga	ggaggctggc	cccagaaaag	360
gacgagcagg	tccccatccg	ggtgggtgcag	gtgctgggca	tggtggggac	agccctgctg	420
gcctctctgt	ggcaccatgt	ggccccagtg	gcaggacagt	tgcattctgt	ggccttctta	480
gcaactggcct	ttgtgctggc	actggcatgc	tgtgcctcga	atgtcacttt	cctgcccttc	540
ttgagccacc	tgccacctcg	cttcttacgg	tcattcttcc	tgggtcaagg	cctgagtgcc	600
ctgctgccct	gcgtgctggc	cctagtgcag	gggtgtgggc	gcctcgagtg	cccgccagcc	660
cccataaacg	gcacccctgg	ccccccgctc	gacttccttg	agcgttttcc	cgccagcacc	720
ttcttctggg	cactgactgc	ccttctggtc	gcttcagctg	ctgccttcca	rggtcttctg	780
ctgctgttgc	cgccaccacc	atctgtacct	acaggggagt	taggatcagg	cctccaggtg	840
ggagccccag	gagcagagga	agaggtggaa	gagtcctcac	cactgcaaga	gccaccaagc	900
caggcagcag	gcaccacccc	tggtccagac	cctaaggcct	atcagcttct	atcagcccg	960
agtgcctgcc	tgttgggcct	gttggccgcc	accaacgcgc	tgaccaatgg	cgtgctgcct	1020
gccgtgcaga	gcttttctct	cttaccctac	gggcgtctgg	cctaccacct	ggctgtgggtg	1080
ctgggcagtg	ctgccaatcc	cctggcctgc	ttcctggcca	tgggtgtgct	gtgcagggtac	1140
acaaggaccc	ccagcccttg	tgccgggtgga	actcagggct	gggagccagg	tcctggcgca	1200
gtcagccctg	acattctgct	cgctcactgc	aggtccttgg	cagggtctggg	cggcctctct	1260
ctgctgggcg	tgttctgttg	gggctacctg	atggcgctgg	cagtccctgag	cccctgcccc	1320
cccctgggtg	gcacctcggc	gggggtggtc	ctcgtgggtg	tgtcgtgggt	gctgtgtctt	1380
ggcgtgttct	ctacagtga	gggtggcagcc	agctccctgc	tgcattggcg	gggcccggccg	1440
gcattgctgg	cagccggcgt	ggccatccag	gtgggtctct	tgctcggcgc	tggtgctatg	1500
ttccccccga	ccagcatcta	tcacgtgttc	cacagcagaa	aggactgtgc	agaccctgt	1560
gactcctgag	cctgggcagg	tggggacccc	gctccccaac	acctgtcttt	ccctcaatgc	1620
tgccaccatg	cctgagtgcc	tgccagcccag	gaggcccgca	caccgggtaca	ctcgtggaca	1680
cctacacact	ccataggaga	tcctggcttt	ccagggtggg	caagggcaag	gagcaggctt	1740
ggagccaggg	accagtgggg	gctgtagggt	aagccctga	gcctggggacc	tacatgtggt	1800
ttgcgtaata	aaacatttgt	atttaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1860
aaaaaaaaaa	aaaaaaaaaa	aaaagggcgg	cc			1892

<210> 57

<211> 331

<212> DNA

<213> Homo sapiens

<220>
 <221> SITE
 <222> (240)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (288)
 <223> n equals a,t,g, or c

<400> 57	
gaggaggagg gaggtggcgg cgccgtggcg gaggagcagg agcaggaggg ggatggagag	60
gagaaggctc ctgggtggca tggcgctcct gctcctccag gcgctgcca gcccttgtc	120
agccagggct gaacccccgc aggataagga agcctgtgtg ggtaccaaca atcaaagcta	180
catctgtgac acaggacact gctgtggaca gtctcagtgc tgcaaaactac tactatgaan	240
tctgggtggt ctggctgggtg tgggaccatc atcatcatcc tgagctgntg ctgtgtttgg	300
caccaccgcc gaaccgagca cggcttcaag g	331

<210> 58
 <211> 605
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (444)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (470)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (517)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (560)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (564)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (593)
 <223> n equals a,t,g, or c

<400> 58	
agggtagagg aggagagggg ggaggaggag ggaggtggcg gctcctgctc ctccaggcgc	60
tgcccagccc cttgtcagcc agggctgaac ccccgagga taaggaagcc tgtgtgggta	120
ccaacaatca aagctacatc tgtgacacag gacactgctg tggacagtct cagtgtgca	180
actactacta tgaactctgg tggttctggc tgggtggac catcatcatc atcctgagct	240
gctgctgtgt ttgccaccac cgccgagcca agcaccgcct tcaggcccag cagcggcaac	300
atgaaatcaa cctgatcgct taccgagaag cccacaatta ctcagcgctg ccattttatt	360
tcagggtttt gccaaactat ttactacctc ctttatgagg aagtgggtgaa acgacctcca	420
actccttccc ccaccataca gtgncttcca gctacagcag cagcagcttn ttccttccaa	480
cagtgttccc cttcaagttg gcagttcccc ccgggggnatc gattcccacc aagggggatt	540
cccagggggg gcaccagaan cagncccctt tgttttgagc cccagccaga aanccagcac	600
caaga	605

<210> 59
 <211> 832
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (16)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (29)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (90)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (193)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (783)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (802)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (804)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (827)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (830)
 <223> n equals a,t,g, or c

<400> 59
 ccctttgctt ccaaacttg ggggaaaanc ttgcttgctt ctkggaaatt tgggaaaaat 60
 tccttgcttc gttaattggt gttcaaccan caggccatkc cgggccggcc cgtgccmagg 120
 ttccgggtkc cccaaggctc tcragcttgc ttccctcarag actgmcagag ccttcctcyt 180
 catcaccagg ggnccgcaca tggcagctgt cgcagaagtc caggggcccc tccagagcat 240
 catcgatgag tgtgttgaaac tctttgaggt catcgatcat gtggccccgg ttgcacacac 300
 acaactcaat gcccgagtca cctgtgaagc ggcgatgtct cccaggcgct ttctctttgc 360
 tgtcgggtgc gccgtgttca gagctgtcat ctttcagcag ctccctcccta cattctgcat 420
 ctttgtccag gaaggccccc ggggtccagct cccccaggcc agccacagag ccactgggct 480
 ccattccctgg ggctttggtg gctgctcggt caactggtag gtcagaggga tcagggtcag 540
 cgatgcttgg gggctcttgg ctgcttctgc tgggctcaga caaggggctg ctctgtgccc 600
 cctgggatcc cctggtggga tcgatgcccg ggggactgcc acctgcaggg ccacactgtg 660
 gaggcagcag ctgctgctgc tgtagctgga aggcactgta tgggtggggga ggagttggag 720
 gtcggttcac cacttctca taaggaggta gtaaatagtt tggcaaaaac ctgaaataaa 780

atnccagcgc tgagtaattg tncncttctc ggtaagcgat caggttnatn aa

832

<210> 60
 <211> 2376
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (412)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2102)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2291)
 <223> n equals a,t,g, or c

<400> 60
 cccccctcg agtttttttt tttttttttt tttttgggat caatttttat ttgggcttct 60
 cacagtgggt agagccactc tgtcttcaga acaatcacag cacaggaaat gcgtcactga 120
 gactgcccag aaaagtctga ccagctgaat cttattgctt aaaatacaca tattcacaat 180
 aactgacaaa gggtaacgtg cctcacacag gaatgtgttc gcatttgcaa atcttctgac 240
 tggctgtagc accaaaccct ccaccgaccc cgtctcattc acgtggaaag ccagcctcag 300
 tcacatctcc ctggcccccct aacgattcct tcagctccct attaaatctc tctctgagca 360
 gggcagcatc ctgtagcggg ggccaaactg tgaccggga accaagccca gntccgcagg 420
 ttgcatttcc gtcttctcgt gccttttaga taggacgctg cagtgagtc caccagttaac 480
 acttggcccag tccccactc taactgggga aaggaaactg agaggctcag aactcatcca 540
 tttgatctgt taactgaaaa aggattcatt ttggtaaaa ttgttcgcct ttgagacact 600
 tcagttagtt atttgggatt cttaaaaaat aaaaaaagg ggaaggaaag gcattctgagg 660
 ggctgtgaca cactccggct acctctggcc acacgccagc ttgcttgtgc ctggtggact 720
 caccagaggc aggcaggccc tgcggctcct cttagagcctg caaagcctcc tcctggcaat 780
 tctgggaggc gccgatgtct gggccacagc tagtccaagc ctgtcattga agaccagtc 840
 aagcttctgt ctgaaattcc accttcttct gtcccaagtg gttgtggaca cccccggcg 900
 ctggtactga ggaccagcag cagccgaggg aggcagacag gctcagagca cgcttccatt 960
 tatagggaac agaacgcagg cctccgagtg tccacggagc aatgtgcaaa tcgcagtgat 1020
 gagtagagta aaacctctac ttcgagcaca gtatctctgg caaacacagg ggactgcagt 1080
 cgacaatgct cgggagtaca cccgagtaca cagtcagaca tttgttcgg aaacagtaaa 1140
 tgcgtaagat caatgacctt gagaggcctg tctgtgtctc agacgtgtgg ttcacgtgga 1200
 gagaatggct gccactcaaa gtatcttcac aggaaaacag ggcttgaggc acacacacaa 1260
 cagacagaca cacacggctc acccaaaaag tcaactgtga cggacttaac tttgttcaac 1320
 atggattttg gttttgtgga atctaaatgc agacactcgt ttacctaca cccttgatt 1380
 tgtctgtttt tggacatata tataatattt ttgtttgttt ctttcttct tccataacat 1440
 caatgcttcg tctgaatatc atcatcgttc aagagtgtgg ggaagaaaga cttcatatgc 1500
 acaggggccg gtggggaatg tttgttttgg ctgtttgtct cctccattca gattttccta 1560
 tcgcagctca gctggtgacc tgaaggcgag caacaggcac aagggtcccc agggccttcc 1620
 ggatggctgc tttcacctcc tgcctgggcc accgagtcct tacacagaaa aatgagtcac 1680
 ccgactcaaa aggggtgggg gtagaggcag ggacaaggca tgaaaaccac agataaccaa 1740
 ggtgtttctt ccaagtggtc agttttaaag aaacaactgc cmccaaaaaa aaaaaaaaac 1800
 cccacaaaaa atattttattc agaatacaag ataaaaact gtgtgagagc caggctacag 1860
 gggccctttc tctggggcca tcgcttcctc agtccgctgt ctgtttcctc atacggaaca 1920
 gtgagacttg aaggcccgca ggggtgtgtc ttgcgatgca ggctgacacg ggtcacctgt 1980
 gaacayagac caaaggcgag agaggcagag agaggcact ctatccactg ctgcgcttag 2040
 gcctcctgct cacagagggt ccaagacagc cgccacccca gccttcacac gagacatctt 2100
 cntggctcaa cagcaggcag gcttctttga aggccaaactt gggaaagagc cacaacgcgt 2160
 attttccaga agagaattct tgccctgcca ccggtgaagt tcttgttttc agctgtcttt 2220
 tgcgtgtttg ttttagagaa aaaaacaaac aaacaaagaa aaggcagtat aacctttcac 2280
 accagaagcc ntggggccag ccagagctgc ggggaagagg cccctcaagg acgcatgggg 2340
 tgcatagatc ttgtcacctg gaatttgaca gatcaa 2376

<210> 61
 <211> 928
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (884)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (885)
 <223> n equals a,t,g, or c

<400> 61						
cagcttggtga	ggaaaaacat	tttttaaatgt	aataaaaaata	tgccattatt	ctttgaaatg	60
ccaaatgata	taaatattttt	gcctaataaca	tattttattgt	agatgaaatg	cactcttctc	120
gatgaggcct	cgatttgaat	caatgggggtg	ggccacagga	aatgtcagag	gaaccagaac	180
tcagaactct	tcctcctgga	cctttcttcc	cttcccttgg	aggatccct	ttgaatcagg	240
cctctctctt	ctcatcagtc	tgtagcttcc	ccccctgtat	aacctgcttt	cctttttaca	300
tttattaaaa	gtggattttg	taaaagcatt	tcattgacac	gcgacctatc	acagacaatg	360
gaattcgtca	gtgggtggtaa	gactgaaatc	ctgatgcttt	tcacacttct	tgtctcttgc	420
tatgtatttc	tgccctctagc	cttgccatgt	tttgccctttt	tttttctttt	ttggccaatt	480
cctttttata	tgtgcccaca	acagaggtgg	ggagacacgg	agcaccctgg	gtccttccca	540
gcgctgctgg	gcaggccccg	tctccaggcc	ccagctggtg	aaactttgaa	gggcaacaaa	600
caaccatcca	cactgccgga	ccctaggctg	ttcagggagg	cagctcattt	ccaccccggc	660
cccaggacac	ccagcctgtg	ccccacaagg	atctctctaa	atgggaggga	ttgaggctac	720
ttttctgccca	agccctatta	agtagtaatg	tggggaaacc	cactgtgtca	gtgcagggaag	780
ccctagacaa	atgttttcaa	ataaatttca	ctgccagcc	tgacacagatt	tccatttgaa	840
gtacttccca	tccacccct	gaacacccca	aaaggggttt	tttnnggttt	tggtttttgt	900
tttttgaaaa	caggtccttg	ctttgggtt				928

<210> 62
 <211> 792
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (767)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (770)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (776)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (780)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (782)
 <223> n equals a,t,g, or c

<400> 62						
cttggaattg	cgagccacca	tgccctggctg	ggtttttttaa	aaatagaatc	tcactgatag	60

cctgcaagaa	acagatgcag	tgcctgcttc	cgtatcagtc	caaggagccc	tcgtgtttgc	120
cacctttacc	tttgaacctc	cccctgcttc	cctgcctgtg	tccgcttttg	cagctcaatg	180
cagccatgac	aaggaaagaa	aagacaaagg	aaggccagag	agccgcgcag	ttctctgcag	240
gtgcagatgc	aggcagtgga	ggtggcctga	gcaggcagaa	ggacaccaag	cgccctatgt	300
tgctttgtcat	tcatgacgtg	gtcttggagc	ttctgactag	ttcagactgc	cacgccaacc	360
ccagaaaata	ccccacatgc	cagaaaagtg	aagtcctagg	tgtttccatc	tatgtttcaa	420
tctgtccatc	taccaggcct	cgcgataaaa	acaaaacaaa	aaaacgctgc	caggttttag	480
aagcagttct	ggtctcaaaa	ccatcaggat	cctgccacca	gggttctttt	gaaatagtac	540
cacatgtaaa	aggggaatttg	gctttcactt	catctaata	ctgaattgtc	aggctttgat	600
tgataattgt	agaaataagt	agccttctgt	tgtgggaata	agttataatc	agtattcatc	660
tctttgtttt	ttgtcactct	tttctctcta	attgtgtcat	ttgtactggt	tgaaaaatat	720
ttcttctata	aaattaaact	aacctgcctt	aagaaaaaaa	cccccnacn	aggctnttan	780
cntcctcctc	tc					792

<210> 63

<211> 2086

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (2066)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2067)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2069)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2073)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (2079)

<223> n equals a,t,g, or c

<400> 63

tcctcacctc	tttcacaaca	ggacgtgtat	tgcgaaacac	tacttggagg	gccgggtacct	60
ccaaggaagt	ctccttttga	gttgatttat	gtgtactggt	cccagagcca	gctcgtaccc	120
atgaagagca	acataatttg	cgggtcatag	gagcaggaag	tgtcgacctt	gcagcaggat	180
ttggacactc	tgggagccaa	actggatgtg	gaagctccaa	aggtgcagaa	aaagggctcc	240
aaaatgttga	cttttacctc	tgtcctggaa	atcaccttga	cgctagctgt	agagatactt	300
accagttttt	ctgccctgat	tggacatgtg	taacttttagc	cacctactct	gggggatcaa	360
ctagatcttc	aactctttcc	ataagttgtg	ctcctcatcc	taaattatgt	actagaaaaa	420
attgtaatcc	tcttactata	actgtccatg	accctaattgc	agctcaatgg	tattatggca	480
tgatcatggg	attaagactt	tatatcccag	gatttgatgt	tgggactatg	ttcaccatcc	540
aaaagaaaaat	cttggyccta	tggagccccc	ccaagccaat	caggccttta	actgatctag	600
gtgaccctat	attccagaaa	caccttgaca	aagttgattt	aactgttctt	cagccattct	660
tagttcctag	accccagcta	caacaacaac	atcttcaacc	cagcctaattg	tctatactag	720
gtggagtaca	ccatctcctt	aacctcaccc	agcctaaact	agcccaagat	tgttggctat	780
gtttaaaagc	aaaaccccct	tattatgtag	gattaggagt	agaagccaca	cttaaactgt	840
gccctctatc	ttgtcataca	cgaccccggt	ctctcacaa	aggagatgtg	tctggaaatg	900
cttctctgtc	gattagtacc	gggtataact	tatctgcttc	tccttttcag	gctacttgta	960
atcagtcctt	gcttacttac	ataagcacct	cagtccttta	ccaagcacct	aacaatacct	1020
ggttggcctg	cacctcaggt	ctcactcgct	gcattaatgg	aactgaacca	ggacctctcc	1080
tgtgcgtgtt	agttcatgta	cttccccagg	tatatgtgta	cagtggacca	gaaggacgac	1140
aactcatcgc	tccccctgag	ttacatccca	ggttgcacca	agctgtccca	cttctgggtc	1200

cctattggc	tggtcttagc	atagctggat	cagcagccat	tggtacggct	gccctgggtc	1260
aaggagaaac	tggaactaata	tccctgtctc	aacaggtgga	tgctgatttt	agtaacctcc	1320
agtctgccat	agatatata	cattcccagg	tagagtctct	ggctgaagta	gttcttcaaa	1380
actgccgatg	cttagatctg	ctattcctct	ctcaaggagg	tttatgtgca	gctctaggag	1440
aaagttgttg	cttctatgcc	aatcaatctg	gagtcataaa	aggtacagta	aaaaaagttc	1500
gagaaaatct	agataggcac	caacaagaac	gagaaaataa	catcccctgg	tatcaaagca	1560
tggttaactg	gaacccatgg	ctaactactt	taatcactgg	gttagctgga	cctctcctca	1620
tcctactatt	aagtttaatt	tttgggcctt	gtatatataa	ttcgtttctt	aattttataa	1680
aacaacgcat	agcttctgtc	aaacttacgt	atcttaagac	tcaatatgac	acccttggtta	1740
ataactgagg	aatcaacaat	ttgattcccc	gaaaaacatg	gtggtgaatg	taatgcccaa	1800
cattgttttt	actaaccctg	tttttagact	ctcccttttg	ctctcttaat	cacctagcct	1860
tgtttcaca	tgactaaaac	tctcgcttag	ctgagaaagc	cggacaaaact	ccatctggcc	1920
cccttgattt	tcaagacatt	aaggactcct	taccacccc	cttcttcaag	gagttaactt	1980
gtgtaaacag	atttctcaaca	tatcaaaaaga	gtccaattaa	ctgataaggt	actgaaacar	2040
acratgtacg	aagtggcggg	tccagnngna	gtncgcccng	tgggaa		2086

<210> 64
 <211> 647
 <212> DNA
 <213> Homo sapiens

<400> 64						
ctcgagtttt	tttttttttt	ttttgggatg	aattaagagt	cctttatttta	gccggtggcc	60
aaagagaccg	ctaacgctca	aaattctctc	ggccatgagg	agggggcctg	attttctttt	120
atacttttgt	ttaggaagg	gaggggagct	caaacgcaac	aattctacag	aagtaaaaac	180
atgcaaaaat	taaaaggaca	aatgattaca	gagaaacaga	caatttaaaa	gacaaatggt	240
tacagaaaag	caacggtagc	aggtgcgggg	gctctaaatc	cttcataaga	tgtagatat	300
gggtgctatg	cgggacacag	actcaatgct	ttgtggtgtt	atcttttgag	caaaatcctg	360
ggaacttcgt	acattgtttg	tttcagtacc	ttatcagtta	attggactct	tttgatatgt	420
tgagaatctg	tttacacaag	ttaactcctt	gaagaagggg	gtgggtaagg	agtccttaat	480
gtcttacaaa	tcaagggggc	cagatggagt	ttgtccggct	ttctcagcta	agcgagaggt	540
ttagtcatgt	kgaacaarg	ctargtgatt	aagagagcaa	aagggagagt	ctwaaaacag	600
ggktagttaa	aaccaatggt	tggccttaca	ttcaccaccc	ctgtttt		647

<210> 65
 <211> 1159
 <212> DNA
 <213> Homo sapiens

<400> 65						
tgattacgcc	aagctcgaaa	ttaaccctca	ctaaaggga	caaaagctgg	agctccaccg	60
cgggtggcggc	cgctctagaa	ctagtggatc	ccccgkktg	ywgaattcg	gcacgagcgg	120
ggagggagcc	agcagcctag	ggcctaggcc	cgggccacca	tggtcgctgcc	tccaggccca	180
gccgccctcc	ggcacacact	gctgctcctg	ccagcccttc	tgagctcagg	ttggggggag	240
ttggagccac	aaatagatgg	tcagacctgg	gctgagcggg	cacttcggga	gaatgaacgc	300
cacgccttca	cctgccgggt	ggcagggggg	cctggcacc	ccagattggc	ctgggtatctg	360
gatggacagc	tgcaggaggc	cagcacctca	agactgctga	gcgtgggagg	ggaggccttc	420
tctggaggca	ccagcacctt	cactgtcact	gcccacggg	ccagcatga	gctcaactgc	480
tctctgcagg	accccgaaag	tggccgatca	gccaacgcct	ctgtcatcct	taatgtgcaa	540
ttcaagccag	akattgcca	agtcggcgcc	aagtaccagg	aagctcaggg	cccaggcctc	600
ctggttgtcc	tgtttgcctt	ggtgcgtgcc	aaccgcgcgg	ccaatgtcac	ctggatcgac	660
caggatgggc	cagtgaactgt	caacacctct	gacttcctgg	tgctggatgc	gcakaaactac	720
ccctggctca	ccaaccacac	ggtgcagctg	cagctccgca	gcctggcaca	caacctctcg	780
gtggtggcca	ccaatgacgt	gggtgtcacc	mgtgcgygc	ttccagcccc	aggccccctcc	840
cggcaccatc	ctctgatata	aagtgaactc	aacaacctaa	aactcaacaa	cgtgcgcctg	900
ccacggkaga	acatgtccct	cccatccaac	cttcagctca	atgacctcac	tccagattcc	960
agagcagtg	aaccagcaga	cgggcagatg	gctcagaaca	acagccggcc	agagcttctg	1020
gacccggagc	cgggcggcct	cctcaccagc	caaggtttca	tccgcctccc	agtgctgggc	1080
tatatctatc	gaktgtccag	cgtgagcagt	gatgaratct	ggctctgagc	cgcgggcgag	1140
acaggagtat	tctcttggg					1159

<210> 66
 <211> 1327

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (939)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1087)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1296)
<223> n equals a,t,g, or c

```

<400> 66
ctcgagtttt tttttttttt ttttttgaat tcagtcaagt ttatttaaact tgctgtgtgc      60
tcagcaccgc cctaggcagt aacatgaaaa acattacaaa agaagatctc aacaagggaa      120
aaatatattc tgtactatat taatttccaa tcattttacat gttgtctttt aaagtgttct      180
taggtcactt tggggtatgt ggtctccttc ttcttccatg ttccctctaa gcttccacac      240
tgttgaatta tgtgcctgtg gcgaccatcc tccaggaagg gcaccttcct gctgatgagg      300
caaccatggg ttggtcaggg ctgggggtccc gtggtggagg agacatgctg agagaaaaac      360
catcaacccc gagagctcag gacactcaca gtgaatccca gaaggccaaa cgtggggaag      420
ccacaaagag ggctctgggc ccctcactca cccctcctcc taggggatgt gcttaaagtg      480
ctaacgccgt aggaaaatga tgcatagcta caagccgtcc tgggtgctac tagactcatc      540
gcctgcctct tcctccctaa cttgtgctaa tactgggcga tggcacaggc caatagaaaa      600
gtctagtccc cagtgaagta gtagagaagg tccaacgtgt aacctagaat tccaagaggg      660
aggtggggac agaagagaag aagtgaaggg cagagacgtg tgcagcaaaa aggacgtttg      720
tgcttggccg gtaccgtgg gtcaggggtt ggtttctgtg caaagggcaa ttgggttctg      780
cacagctagc aggggtcctaa attttacctg agggaacaag gctacatagc ataggaagga      840
ggaaaatcca tgcagggccc tcctgtctcc ccacacaggc acgcccccat gcctactgta      900
caaggtgctg tggagtactg ggggtgggta tacagcagnc catgccacac ttggatgctg      960
gatgacatct gaacaccctt ggccaaagag ctccctcttg aagggcccag tcatcacatg     1020
cagggcccac cctgagtcag catgaggggc ttacgtccaa ctggtagcct tgccaaagat     1080
acctgtngcc tgcggtttac agcccagtga aatgcatcac gtgcatgaca tggagggcac     1140
cccagccagg agggcaagca aaagtggcag tggcataact tcttcacgtt ggtgacctag     1200
ctaggtagag gatgccttgg aggaatggga ggggtgccag aggccaagag aatactcctg     1260
tctcgccctc ggctcagagc cagatctcat camctntcac gctggacact cgatagatat     1320
agcccg                                           1327

```

<210> 67
<211> 979
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (977)
<223> n equals a,t,g, or c

```

<400> 67
aaanaatttt tccaaaaccc tttttacngg cccaccatt ttcagaggcc gcatggatcc      60

```

aatgtacgct	tcttctgtat	cccagaagga	caagtcaggg	tattcaccag	gttccaggat	120
gaaaggaaca	ccctgaaatc	cagggttctt	ataaatcagc	cacgtgcccc	aatgtacttt	180
catggaacaa	gtcttctgca	ttacaccaa	tccctgcatt	tcttcagtat	catcaaagta	240
ggaacttagg	attcctaacc	cttctgggtc	agtaaataag	tcaatgtgac	taactctgta	300
atcctgaacc	acatgtctga	tggaaccaat	caccactggc	ttatcagact	ctgcttcttc	360
gtgcctttcc	aaaatgtctt	ctatacccca	gagaccagag	agttccaatt	ctccttcttc	420
taaggggatg	gagtgccctt	caaaatktgg	ktgctcatac	aaaatccaac	atcctctaac	480
aacttttatg	agtatcactg	gagagaggct	ccaagaactg	caatcctgaa	tgctactgaa	540
aacttcaatg	cacttctcag	agacgtcggg	ttcactatat	atcactacct	ttccaggctg	600
gggattgagt	ttattttgga	cacttctctt	aagtgtcatt	gtgtctgata	atgacattcc	660
agaaaaagaa	atgcttgggt	cataccggct	tgatttgaaa	agacccatga	agtcgggtgc	720
actgtttgca	cagtttgcca	agtttgattt	aataaacactt	tcaatatgat	tagccttttc	780
catatcatca	ttcttcagtt	ttgacaattc	agaaaattta	gtttctggca	agtgtagggt	840
gcttcgtgaa	tccagatctt	ctttggtttt	ctctttttgc	gggtattttt	ccatgtggct	900
tggacttttc	aaactggagt	gtrattcgga	cgcgtgggtc	gacccgggaa	ttccggaccg	960
gtacctgcag	gcgtacntt					979

<210> 68

<211> 1361

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1297)

<223> n equals a,t,g, or c

<400> 68

acaaaagacc	ggagctccmc	cgcggtggcg	gccgctctag	aactagtgga	tcccccgk	60
tgcaggaatt	cggcacgagc	ccgcgcgct	gcctggcgct	gctgcatctc	ctgcagctgg	120
gttacctgta	cagggtcggt	caggagctgc	ggcaggggct	gctgggtgtg	cagcaggagg	180
agccctctga	gtttgacttg	gcctacgccg	acttcctcgc	cctggacatc	agcatgctgc	240
ggctcttcga	gaccttcttg	gagacggcac	cacagctcac	gctgggtgctg	gccatcatgc	300
tgcagagtgg	ccgggctgag	tactaccagt	gggttggcat	ctgcacatcc	ttcctgggca	360
tctcgtgggc	actgctcgac	taccacccgg	ccttgccgac	ctgcctcccc	tccaagccgc	420
tcctgggcct	gggctcctcc	gtgatctact	tcctgtggaa	cctgctgctg	ctgtggcccc	480
gagtcctggc	tgtggccctg	ttctcagccc	tcttccccag	ctatgtggcc	ctgcacttcc	540
tgggcctgtg	gctgtgtactg	ctgctctggg	tctggcttca	gggcacagac	ttcatgccgg	600
accccagctc	cgagtggctg	taccgggtga	cggtggccac	catcctctat	ttctcctggt	660
tcaacgtggc	tgagggccgc	acccgaggcc	gggccatcat	ccacttcgcc	ttcctcctga	720
gtgacagcat	tctcctgggtg	gccacctggg	tgactcatag	ctcctggctg	cccagcggga	780
ttccactgca	gctgtggctg	cctgtgggat	gcggctgcty	ctttctgggc	ctggctctgc	840
ggcttgtgta	ctaccactgg	ctgcacccta	gctgctgctg	gaagcccgc	cctgaccagg	900
taracggggc	ccggagtctg	ctttctccar	aggggtatca	gctgcctcag	aacaggcgca	960
tgacccattt	agcacagaag	ttttcccca	aggctaagga	tgaggctgct	tcgccagtga	1020
agggataggt	gaacggcgctc	ctttgaagca	ggactcagacc	cagccagcag	agatggagag	1080
tgactctgtt	ggcagaaggc	aggcgaggat	aagctaacga	tgctgctgtg	gcctctatgc	1140
actcagcaag	agcgggacgc	ctgtgctggg	ccgggcacca	gggatgggtc	tgatcsggca	1200
rargcctcct	ttcaaggagt	tcacagtga	caagatrara	agggctgggg	ccctgrgagg	1260
gtcaagaccc	attkttcaag	accttggaga	aaraaangac	tacttttccc	cccttgccaa	1320
ttgggtataa	gctgggtgcc	cccaaaaact	tccaacctcc	c		1361

<210> 69

<211> 783

<212> DNA

<213> Homo sapiens

<400> 69

ctcactatag	ggcgaattgg	gtaccggggc	ccccctcgag	tttttttttt	tttttttttt	60
ttgaggattt	catgaggctt	tawtcataac	ctaataatac	tgtraaaaac	aacacatctg	120
tcacttgyag	agaccacacg	gsacacacat	tctcttcctc	tcacatagac	tgaggtagga	180
ggtacactgg	ctaaggmawa	aaaaatactc	agtggctgtg	caaggctcag	accaggctca	240
caaggctcct	ggttgaaaag	cagccccctg	agagcargag	cagaggccag	gccagcttca	300
ctgagatccc	agaggttctg	actggggcyr	cccagagttg	ggcatccctg	rtctcyrgca	360

40

tttgrgatct	aacccgggac	tggttggtgc	aagtagsgga	tgaagctagg	ctggtagctg	420
gtcttggtcc	aggttgcaag	gacagaatga	tgttcctggc	acataaactg	ctcttggtcaa	480
agatttggtt	catgaattga	atgaatggtg	tgggggaggg	aaggaagaat	tctagaggac	540
agccctgtg	gcctcctagc	ccaggatagg	ggagctaagg	ggtggggcag	cacctatacc	600
agtcatttta	gaggtggcca	gggaggagg	tggaagtgtt	ggggcaccag	ctataaccaat	660
ggcaggggga	aaaaaaaaaa	cagggggggt	aagtcttctt	ttcctcccaa	agtgtcttgt	720
acataattrg	ggctcytgac	cctccagggc	ccaaggccct	tctcatcttg	ttcactgggg	780
gtg						783

<210> 70
 <211> 820
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (721)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (783)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (802)
 <223> n equals a,t,g, or c

<400> 70						
cgagattggc	acgaggtgsc	acgaggtggc	acgaggymga	ttctcaatca	agtccttttag	60
ccttattgat	taaaatagag	acatttacta	tcacaaaatg	atgcccccaa	acagcctcaa	120
acctgacaca	ttagtttccc	tttctgcct	ctgccccaaa	tgaatgtttt	tctttctctt	180
cccttgggtt	cttctctccc	tccctcctc	ttccctccct	ctctcccttc	tctattcttc	240
cctctccctc	tctatttgtc	cttctctgct	ccaagtcctg	ccacaacccc	aggattcatc	300
agcctccctg	gacacatccc	atccagctcc	tgaccgctca	cctccttcac	tcctcatcct	360
cagggccctt	tcttccatct	gcctcagccc	atgccagcgg	ccatgctgtg	cacctggagg	420
ggccacccac	ctgccaggaa	acagcacatt	cagccatgca	cctgactgca	gcctccactc	480
tagcagatta	gctcagtcac	ctgtgacaca	ctgttcctct	ggctcttttg	gactttcagc	540
ccatggacac	ctccatgccc	atccctcaat	ctctgtttct	ccacatctct	ccctttccat	600
ctcaaatcca	tgtccagca	ccaaacacta	actctttcca	ttctaaactc	cctctcccca	660
ttgktcttcc	cttacaggca	cctggcaaaa	tccagtcctc	aacaaatgca	gccaatggsg	720
nttgstaatg	scagcaaggc	tggcctgtca	actgtggtct	cctccctcag	stgggsctgs	780
arnagaatcc	ggaacctggt	gntcctartt	cagtctggtc			820

<210> 71
 <211> 357
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (335)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (338)
 <223> n equals a,t,g, or c

<400> 71						
gttttttttk	tttttctgt	gtctctgcc	ggttttagta	tcaggatgat	gctggcctca	60
taaaatgagt	tagggagggt	tccctccttt	tcaattgttt	ggaatagttt	cagaagtatt	120
gggggaaccc	gcccccaata	tttcaacgta	ggctccttct	attttcccca	agtgttggt	180

ggctctgagaa	ataaagagta	caaagagagg	aattctacag	ctgggctgct	gggggtgaca	240
tcacatagcg	gtaggaccgt	gatgcccaacc	tgagctgcaa	aaccagcaag	tttttatcag	300
ggatttcaaa	aggggagggg	gtgtacagaa	taagnccnga	aattgggggtg	ggttggg	357

<210> 72
 <211> 794
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (645)
 <223> n equals a,t,g, or c

<400> 72						
gaacaaggga	agacaacccat	aaggtctgac	tgccctgtagg	gtcrggcaaaa	aagagccata	60
tttttcttct	tgacagagagc	ctataaaakgg	gtgtgcaagt	aggagagata	ycgctaaatt	120
cttttcctag	caagaaatat	taatattaag	accttaggaa	aataattgca	tcccttgggg	180
gaggtctata	aatggccact	ctgggagtgt	ctgtcttaag	tggttgagat	aaggccctgg	240
tctcctgcag	taccatcagg	cttactagga	ttgggaaacc	ccaaccctgg	taaatttgag	300
ttcagactgg	ttctctgctc	ttgaaccctg	ttttctgtta	agatgtttat	caagactata	360
tgtgcaactgc	tgaacgtaga	cccttatcgg	gagttctgat	tttgtccttg	ctgtgtttcc	420
tcagaagcat	gtgatctttg	ctctgctttt	taccctttaa	agcatgtgac	ctactccctg	480
tttgtacacc	ccctcccttt	ttgaaatccc	tgataaaaac	ttgctgggtt	tgacagctcag	540
ggtggcatca	cggctcctacc	gctatgtgat	gtcaccctca	gcagcccagc	tgtagaattc	600
ctctctttgt	actctttatt	tctcagacca	gccaacactt	ggggnaaata	gaaggagcct	660
acgttgaaat	attggggggc	ggttccccc	atacttctga	aactattcca	aacaattgaa	720
aaggaggggac	acctccctaa	ctcattttat	gaggccagca	tcacctctgat	actaaaacct	780
ggcagagaca	cagc					794

<210> 73
 <211> 1277
 <212> DNA
 <213> Homo sapiens

<400> 73						
gggaatgtca	ctgcaaatgt	ctcgactgct	gtgaggtgtg	ggccccctgcg	gtggggccagg	60
ccttttggaat	ctgctctggg	ctgctttctg	gaattgctcc	gtggctcccc	agctcctctc	120
tccacatgca	ggcggcagga	gggctgacag	aacggctttg	tctcacatct	cggagttctt	180
gggtgggtgag	tggtatgtga	gtgacacagg	aataagaggg	gagtatcaga	cagagacaag	240
aggccttggg	gtccctggca	gctttgattt	ggggggcattg	atgacacttt	tggtggctcc	300
catccatgtt	ctgtgccctg	ggcttaggat	tttactcatt	ttttttttct	tttcgtcgca	360
ataagtcattg	aggcaatgtg	gctgttatta	tccccatttt	atagatgagg	aaactgtctt	420
gggaaggtaa	cgaatttgcc	caaggccaca	cagctagcaa	atgacacact	gtgcttatam	480
ccagctctgc	ctcctatgcc	tgggccaacc	tgcccaagcc	tgcccaccac	tgagcatggc	540
ctgacccccc	agaacgggag	ccagtgtcag	ggctgacttt	cacagggtgg	agcgtggaaa	600
tacaggtatc	ttgggcctaa	ctggctgaga	gggctttccc	cctscacgga	gccgagggaag	660
ctgtattttc	agacgtcttt	cctagatggg	ttaatggatc	tgccaacaag	tattttattgg	720
ctcaatggct	gagcagagga	ggctggcagc	tagccaaggg	ttctgggtatt	gatgaaggcc	780
agagagagtt	tgctctcacg	atgactacaa	ggacactgtc	tccttgccag	agctgcactc	840
aagaccttct	cgctagaccc	ccgtgcatct	cccggggtag	tgaggctctc	ccagcctcca	900
ggacatctgg	acttggcccc	tctgggctcg	gtcgcccttt	tgccccctac	ccttatmaat	960
ytgtcctgac	cccagctcac	ctccaggcct	cagccgagga	ctctggctct	gcatggggwg	1020
tttwkyactg	agttctctctg	catctgsagg	gttactcatt	tttccaccca	taggccttcy	1080
ttccccaaat	ggttatgaag	ttcctcaggg	cagggatgga	aaccagggag	gtatgcatgg	1140
tgaactggga	agawtaggga	catcatatgt	gcctattttac	ttgatatcgc	ttggatatatt	1200
gtttcctcma	aatctcgygt	tgaatatgaga	tccccmaast	tggaggtggg	gggtgggtggg	1260
aggtgattgg	gccgtgg					1277

<210> 74
 <211> 819
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (786)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (819)
 <223> n equals a,t,g, or c

<400> 74
 aattcggcac gagctcaaag agtaagaatc caagtgtgtg acattacata gctttgcatc 60
 tatggaaacc taaatcataa ttgtttccac tgcccaatta tgttcctttt cataacattt 120
 actattcttg ctatatttat catagaacct aggaacctta gagttgacct gaatctaatt 180
 aaatttcaga cctcctggcc aaagacccta gtggaagagc aaaactaaat caacatatta 240
 ccaatctcaa gtatttctct gaggaccag accactgact ttttgtgtc attttcaggt 300
 tgatcctata actgtatgtt ctacaatata tgtgctccac cagctcagtg aggaatcaac 360
 ggaatatcaa aagtaaatat tggtcacat atacctttt gtactagtct acgaaataat 420
 tggctgagga actgtttcat attaaaagaa agctaaaagc aatgtgtgat cttagattag 480
 acctatgatt ggaatgtatg tatattttat atacaaaata ttgaggaaat tgacaaaatt 540
 taaatacaga atatggatta gataatagga atgtatcaag gtcaatattt aaaaagataa 600
 tttcaacttt tattttattc agtgggtaca tgtgcagact ttgttttaca tagtaccxaa 660
 cagtttttca acgcttatcc cccaccctct agtaatctgc agwgwtatt attgycatct 720
 tcgtggctat tgtacatggg atccatactt gattttgctc tcaacatgaa cattattggt 780
 gtaganaaat gccactaagt tttkgtacgt tggcttttn 819

<210> 75
 <211> 501
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (490)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (500)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (501)
 <223> n equals a,t,g, or c

<400> 75
 ctcgagtttt tttttttttt ttttaacttta taatgttttt atttcaagt gatattcttg 60
 gttgtgaaac atatgtatgc cccgaaactc tatgcatcag aagaaataag tacagaaact 120
 gcaagagttt ttgaatattg agaaaccata attcaaatat tttgatttca caaaatcaat 180
 aatgtattct ctcatattat ttctttttat ggaggcacat gtcctcttca aatacacaca 240
 cacacacaca cacacacaca cacacacaca cacacacata tatatatata taaagtcaag 300
 agacaatctt ttataggtaa agttaatcta acagaagaaa acaatgaagt aaatcaggra 360
 agaaaattag tgttcccttc ttttcttttg gaaggtagag caatcaaaaa gaggtcaggt 420
 ttgaaacaat ttgaaaacat actaggaagg tggaatcctt cctatgttgg aattaatttg 480
 gaaaaatatn attggggggn n 501

<210> 76
 <211> 610
 <212> DNA
 <213> Homo sapiens

<220>

<221> SITE
 <222> (25)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (74)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (76)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (486)
 <223> n equals a,t,g, or c

<400> 76
 ccagggtaccg gcccggaat tcttnggtcg acccagcgcg ccggcatgac gaacttctcc 60
 cttgttccca gccnancct agaatatgtt gcctcttctc aaaaataacg taccacaaag 120
 cctctggtga cgggtggagca aaggaataga tggatgaatgt ctcataccca cttcgatcc 180
 agaacaggcc taggagagac tcagggtgga tctgctgctg aggaaaggag ttggggctga 240
 agttggagga agagggcagc tctaaaccac ctattcctgg ctctaggcct ctcaggccag 300
 acagcccccac cccgtttctg cagatgcccg catcatgggc ctgaggggat gggggctggc 360
 ctggagcytt tccccgtgg tgtgtggcta tagcggggac atgaaggggg tgtgttgggg 420
 acgtagtgc cactcccttc taccgtcaga ratcctgctt cccctgccc cctgccccty 480
 ctggntgtc cttcataacc cccacccac tccccacctg ccattctctg tgcttgtgcg 540
 gatccaggaa gcacctacct gggcacagag atcatcgctc ggtgcctcgc ccctacacaa 600
 gggcgattaa 610

<210> 77
 <211> 659
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (616)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (620)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (631)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (644)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (649)
 <223> n equals a,t,g, or c

<400> 77
 ctacgagttt tttttttttt tttttctgtc agcctcataa acatttttaa tgaccacat 60
 agcatgacat atacagtatc atgttttccc taagagaaat tactttacat tgactttaat 120

gacttgccct	cacagcttta	gatttcactt	gctaaagtat	tttgattgtg	catttaattt	180
aaaaagaaac	ctctaaacat	tttttttagt	gcaaaaaatt	ccaactttac	cagggagaag	240
aacatttttg	ggtgttcaac	tgtactggga	atgttttatt	tttaagctgg	ttagtgaata	300
catgggtgtt	cattttatta	cctcatatac	ttcatatgtt	ttaaataata	atacatttaa	360
aaatatgctt	tcttttattc	agatttctga	tgctagagga	atatgttcag	ttagtttact	420
tgtcctgaaa	tttaaacagt	aaccatttaa	attacgtgag	ctgtaaagag	attggcattt	480
ttctgtgagt	tgttccagac	actaggccca	gtgctgttaa	agatgagccc	cgcatttctt	540
ccaaatgaca	ccaggcccat	cattgtgttc	ctaggctcaa	gctcttctcc	gctggcatga	600
tgctcatcag	gtctanagcn	caaaaggaga	nttcggtggg	tagngggng	gatagattt	659

<210> 78
 <211> 189
 <212> DNA
 <213> Homo sapiens

<400> 78	
gaaagaatgg	ctcctctgtt
aggcacaaaag	cttgtggcct
tatagaatct	gggtagtggg
atgtttgaa	
tataacacac	ccaacaggaa
aaatgcctac	atgtgaagag
ttcactgtat	aattctttca
acaatctcct	
	60
	120
	180
	189

<210> 79
 <211> 637
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (358)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (523)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (552)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (589)
 <223> n equals a,t,g, or c

<400> 79	
ttttatatat	atatatatat
agaaaagaat	gtgcttggga
gtaagattgt	atatcttcca
aaaaacctgc	caaggcagaa
atcgggtccc	atctgacacc
aaactgagat	gctggcactt
attgcacagg	cttccttccc
cttacagcaa	taattacctg
ctgccagcca	cgtcttcttg
ccaccggaga	anacttgagc
gcggtctcat	ctttacagcc
aatgccagaa	agcagttttc
tatagcaaca	agacagagaa
tatatcccc	aaactcctca
tgggaaagga	gctttggcgg
ccacaggagc	catctaggaa
caatgagcta	aagcagtgtg
cagcgcacag	tcttcttgga
acttctgctg	canaactgat
atgatgggcc	tggtgtcant
tggtgtcant	tggagagaat
tggtgtcant	
	60
	120
	180
	240
	300
	360
	420
	480
	540
	600
	637

<210> 80
 <211> 878
 <212> DNA
 <213> Homo sapiens

<400> 80
gcgggacgcgt gggcaaaacaa aaaaacccca ccccagttga cactttaata tttcccaatg 60
aagactttat ttatggaatg gaatggaaaa aaaaacagct attttgaaaa tatatttata 120
tctacgaaaa gaagttggga aaacaaatat tttaatcaga gaattattcc ttaaagattt 180
aaaatgtatt tagttgtaca ttttatatgg gttcaacccc agcacatgaa gtataatggt 240
cagattttatt ttgtatttat ttactattat aaccactttt taggaaaaaa atagctaatt 300
tgtatttata tgtaatcaaa agaagtatcg ggtttgtaca taattttcca aaaattgtag 360
ttgttttcag ttgtgtgtat ttaagatgaa aagtcctacat ggaagggttac tctggcaaag 420
tgcttagcac gtttgctttt ttgcagtgc actgttgagt tcacaagttc aagtcagaa 480
aaaaaaagt gataatccac tctgctgact ttcaagatta ttatattatt caattctcag 540
gaatgttgca gagtgggtgt ccaatccatg agaatttaca tccttattag gtggaatatt 600
tggataagaa ccagacattg ctgatctatt atagaaactc tcctcctgcc ccttaattta 660
cagaaagaat aaagcaggat ccatagaaat aattaggaaa acgatgaacc tgcaggaaag 720
tgaatgatgg tttgtgttgc ttctttccta aattagtgat cccttcaaag gggctgatct 780
ggccaaagta ttcaataaaa cgtaagattt cttcattatt raaaaaaaaa aaaaaaagg 840
gcggccgctc tagaggatcc aagcttacgt acgcgtgc 878

<210> 81
<211> 472
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (425)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (447)
<223> n equals a,t,g, or c

<400> 81
aattcggcac gagcaaaaac cactcgggtca atgaagaaga gcaggaagaa caaggtgaag 60
gaagcgagga tgaatgggaa caagtgggcc cccggaacaa gacttccgtc acccgccagg 120
cggattttkt tcagactcca atcaccggca tttttggtgg acacatcagg tttgtgcttt 180
tctggaataa cttaatattt gccttttcta gggttttgcc atgttggtga agggggaagg 240
tgtgaggctt gttttgagac ttcttggacg taatggtttg catcttgctc ccctgcctgc 300
tcttctcttg cacttcctga tgcttcctt gtcagcccc gtggsttatt ctctccctgc 360
tgsgsatgt ctgcarggga caggagctc ctccttctac tctgtcaagt tcagtgggtc 420
actgntaggg ggtaagggaag agccagntaa ttggccatag ggggggtcag cc 472

<210> 82
<211> 733
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (652)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (675)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (685)
<223> n equals a,t,g, or c

<220>

<221> SITE
 <222> (704)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (719)
 <223> n equals a,t,g, or c

<400> 82
 ggcacagcaa aaggggcttc tattgtattg gtcataatattt attttggttt aaaaaatttt 60
 agagtaaattg tggcaaaatg ttaatgcttg ttaaattctga gtggagagta cattgggtgtt 120
 aagtgtgctg ctatgcaggg tgagtgaatt actcaataac taaataattg tgacataata 180
 tattttattta tgcttccctg ttatgatcta cacataaaat tactggagca ttattgctta 240
 acttcttgta aaaaagtctt gcaattgtag tgttattaag aaagtaatat tgatttgtat 300
 agtgacagag gattttttca gtgkcaactt gccagcagag atcttcatgg tgggcattgs 360
 ccctgcccac gtctcacttg gccctgggct tgcccacta ggtaccctgc ccacctggcc 420
 aggcaggctg tgcttggtt gagctctggc ccagatcctg cacttgctct gcggcttgag 480
 ccaggcatgc catgacctac ttccaccttg ggagccgcgt ctggatgagg ggaatgctgt 540
 gacacttgaa cagaagggtg catgtgacct caaagcccaa aagggggtgg tacagcatgc 600
 tacagtcttc agctacatca cagccacaat ggagtgtgt gccaaagtc tntccatgtt 660
 gcagcagaag gtgtntcagg tacanttggt gactgccgtg gggnttgagt ctttccatnc 720
 cagataagtg gct 733

<210> 83
 <211> 741
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (663)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (673)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (698)
 <223> n equals a,t,g, or c

<400> 83
 tcgagttttt tttttttttt ttttagctttt tttgcatact cacaaaccaa ttagcacata 60
 cactcccat ctgagcatat aaaagcccca ggctcagcca cactttgggc taccacattt 120
 taggtggtgg gaagactacc caacttcagg taagggtgct gtccaactca ggcttccttc 180
 tctgctgaga gctgttttgt tactgagtaa aactctttgc ctactcaac cgctagctgt 240
 cagcacaacc ttattcttgg acatgggaaa agaactcagg acccaccaaa cggcaagtgc 300
 aaacaaagct gtaaccctgt agcacacccc tcctgcttgc caaacaatgg gagaaggagac 360
 ctctgggcac cacacacctc catttgttgg gctgtggatg tgagactgaa agaactkttt 420
 gcactgtgta acacccctt tgggggcttt ggggtcacat gccacctct gttcaagtgt 480
 cacagcattc ccctcatcca gacgccggct cccaagggtg aagtaggtca tggcatgcct 540
 ggctcagccg cagagcaagt gcaggatct gggccaagag ctcaagccaa gcacagcctg 600
 cctggccagg tcggcagggt acctagtgg gcaagcccaa gggccaagtg agacattggg 660
 canggggcaa tgncccacca ttgaaaaatc ttctgctngg gcaaagtgc actgaaaaaa 720
 atccctcttg gtcaactata c 741

<210> 84
 <211> 951
 <212> DNA
 <213> Homo sapiens

```

<400> 84
ctctgggggtt tgcaactctc tccccagttc cggtcactgc ctttgggtgt accacttccc      60
ttttcttctc gcctgcacct ccctcatctt tcctctatga tgacatcgcc ctggggaaga      120
gaagctgaga ggaactcctc actcagctag cttcaggagc atgacrtcat ctctaccatg      180
gaaattccac tcaactctct gtgccccac atttgtccta ggctcagag tccctataaa      240
gagagattcc caastcagta tcagcacagg acacagctgg gttctgaagc tcttgagttc      300
tgcagcctca cctctgagaa aacctctttt ccaccaatac catgaagctc tgcgtgactg      360
tcctgtctct cctcatgcta gtagctgcct tctgtctctc agcgtctctc gcaccaatgg      420
gctcagacct tcccaccgcc tgctgctttt cttacaccgc gaggaagctt cctcgcaact      480
ttgtggtaga ttactatgag accagcagcc tctgtcccca gccagctgtg gtattccaaa      540
ccaaaagaag caagcaagtc tgtgctgac ccagtgartc ctgggtccag gagtacgtgt      600
atgacctgga actgaactga gctgctcaga gacaggaagt cttcagggaa ggtcacctga      660
gcccggatgc ttctccatga gacacatctc ctccatactc aggactcctc tccgcagttc      720
ctgtcccttc tcttaattta atctttttta tgtgccgtgt tattgtatta ggtgtcattt      780
ccattattta tattagttta gccaaaggat aagtgtcccc tatgggatg gtccactgtc      840
actgtttctc tgctgttgca aatacatgga taacacmktt gattctgtgt gttttcataa      900
taaaacttta aaataaaatg caaaaaaaaa aaaaaaaact cggggggggg g          951

```

```

<210> 85
<211> 535
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (517)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (528)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (532)
<223> n equals a,t,g, or c

```

```

<400> 85
ttaagctgga gctccaccgc ggtggcggcc gctctagaac tagtggatcc cccgggctgc      60
aggaattcgg cagcagagaa gattttccag gcaaaaaccca gatctgcttt agtgacttca      120
gaagaaaaaag atctgaggga ggatgagaag ccgatagcca atgggtatgtg tgtgaaaaca      180
cgtggcagac acacatgctc tccagcattc tatctcagct gatggtcagc aagccttggg      240
gcgctcttcat ctctctctcc ttcattctcac tgtctttcta ccatgccatc tctatcagtt      300
cagttcccgag tggaagacag gtggttttagc caaagaaaat ctaatgaggg gtctatttat      360
ctgtggtcag gggttgggat gcccatgtgc agtartgatg ccccagggat gaacaagatg      420
ggaagctgtg gccaccttga gactcaggcc aacagaargg actatgcttc tggagccctg      480
gggaagcggg aacttgga aaagccagaa gggtcanttt aaaaactntt gnccc          535

```

```

<210> 86
<211> 801
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> SITE
<222> (645)
<223> n equals a,t,g, or c

```

```

<220>
<221> SITE
<222> (648)
<223> n equals a,t,g, or c

```

<220>
<221> SITE
<222> (661)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (662)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (739)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (801)
<223> n equals a,t,g, or c

<400> 86
tcgagactaa gagaggtaac taactttata aaagcccaa gctaataaat ggtaatgctg 60
ggatttgaat ccattggctac atagtgcata agcctactct ctcaatcctt tggatagcga 120
ccctcatcct cataacctaa aaataaagaa tataagtgtt tacaactgac taaaaactga 180
ggccttgtct tttattcttg gaagactagg taaaggggca agctgccctg ctcataaaca 240
ctttcttcaa aaatcccca aattggaaa acattgaagc aacaaacccc tcttaggtta 300
ctcacaacat ctggtgcttc tcagattttc cagtgcacaa tgacaaaagg ggtaaacttt 360
gttgattgtt ctccatgtgt cccccaagt cccttctcca ccttctgtcc tgctttgacc 420
tcagaagggt ggccccata ggctgctaca ctgaggggct cttgccctcc agtttctggt 480
ttagccaatg caagccacca gcaagtcaaa ggggtcaagg gacagggtgt ggggtgtgat 540
tccccctgct cccgccatgc cttgccacag tctgggcagt ggttgcatct cctgtgact 600
atagcttctg aggtgacccc tcttgccctc ttccaaaagg gcctnttnc ccccccggc 660
nnccccagg gctccagaag catagtcctt ctgttgggcc tgaagggtct aaagggtggc 720
cacagcttcc ccaactctng ctcaatcccc ccctttttg gggggggggg gcataactaa 780
ctgcacatgg gggcattccc n 801

<210> 87
<211> 470
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (363)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (432)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (435)
<223> n equals a,t,g, or c

<400> 87
ctcgagtttt tttttttttt ttttcaagac ccaaatggga ttttattgtt aaaaaggaag 60
ggtgagaaaa aaccactgcc aagtaacaaa accagattcc ctccctcacc cacatcccca 120
attgtaatac gtgaagtgcc tgcggcgcc tccccacca tccaggatgc ccgtgccccca 180
cacgtgggcc aggaagcccc tctcactgtc agctactttc ccccgttacc aaggccgagg 240
ctggcctcag ggctgtgcag gttttggcaa cagcattctg tctcgtgccg aattcctgca 300
gccccgggga tccactagtt ctagagcggc cgccacgggc gtggagctcc agttttgttc 360
ccnttagtga agggtaattt cgagcttggg gtaatcatgg gtcatagtct tttcctgggg 420
gaaaatggta tncgntcaaa aattccacac aacattacga agccggaagc 470

<210> 88
 <211> 2027
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (39)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (40)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (45)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (46)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1949)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1959)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1964)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (2008)
 <223> n equals a,t,g, or c

<400> 88									
ccgcggtggc	ggccgctcta	gaactagtgg	atcccccggn	ctgtningaat	tcggcacgag				60
aaacccctg	tatgtgaacc	ttagattgta	aggcaagcca	gtgcactgtg	taatatgcaa				120
agggagtgg	gcaaaagaga	aggcaccgt	cccagctctc	catgcccttt	ccctggcagg				180
cgctgactga	gatggcgctg	agtgaatgtg	gaagggtgcta	agaccagtc	tcttcactgc				240
agggctgtt	acagccagtt	tcttttactc	tgaccttaag	gtttccactg	agctcatgaa				300
acttcaacat	atgggtgttta	aaagtttccc	actcaaatgc	acacttgaaa	attgggtccc				360
tcagcctcat	tactgaacta	aataagtga	gaagttgtat	ctttggggta	aaactttcca				420
gggccactta	attttttaac	cagttaagta	cgcatcttcc	tggtgggttca	gactttttta				480
gtcagtgtca	aagctgaaaa	gcgcccttcta	aatatgactg	tgagtttagt	ttgtatctta				540
catttagtaa	ctgttctgtt	gggccaggac	tatgcattta	attactatgt	acttattcat				600
cccacactct	gcactaaata	caccatagct	actatagcat	tgtggcaggc	actcattttt				660
gtggactcat	tccatacttc	tgctggcata	tttcgtttta	aatctagcta	aagattttca				720
tagtactgtg	ttaactagcc	agggtgaaa	agtgtgacag	gatatcaaat	tgactttcct				780
tggggaaaat	gttgctttgg	caatagtga	gtccaactcc	ttcattttaca	gaattagtga				840
ttactcatca	atttttgaaa	gtttagatt	aagtagtttt	atttactaaa	ttcttaacca				900
ctttgaagat	ttaagccagt	tgaaatgaaa	cattggctgg	atgcagttgg	ctagcacctg				960
taatcccaac	actttgggag	gccaaagggtg	gaggattgct	tgaggccagg	agctcaagac				1020
cagcctggga	aacatagatt	tgaaatcttt	tcaaaaatgt	ataaaaattt	aataaataaa				1080

taaatgaatc	cttactcaac	cataattatg	gcttttaaac	ccaaccaaca	gtaaacactt	1140
acttgaagcc	aaaacagtaa	atthtgaatg	aaatttgaat	tatgcttttg	gaagctgcca	1200
tgtcttaatt	cttgctggat	tttgattttc	aattttggaa	gtttttatca	aaactgtcca	1260
gtcatgagta	tatcaggtag	cagcctttaa	ggatctaagt	ttcattccta	taaagaacag	1320
gagggtgctgg	tatttcttgt	cttagcaagt	gatctgatgc	aggtctaaat	gggggttagc	1380
atctatacta	tggtcttaaaa	gtttcctcct	tggtcaccat	ttgggaggtg	atgggttcaa	1440
agctaagctt	tgctctcatg	tgacccttct	ttatcttaat	acccaataag	atataaacct	1500
ctcagagtca	acccagtgtg	gactcaaagg	gtcttagctt	catctatcag	ataagatcta	1560
tctgatttat	acaaagaatg	gtgctgtttt	tatatacata	ctaaaaaaat	ctaattctca	1620
aacaattttc	ttaatatatta	tgccagcaag	gtcaggaaag	actatthtgt	cctgtttaac	1680
tttagtagtg	aacaaactgc	tagagacatc	tgatcatcct	aacaggccac	tgtggtcctt	1740
atatactgac	cctcctttcc	aattaacgtc	ctttaatccc	atactagtcc	cataagagac	1800
ttgggcacat	aaaagcagta	ttttttttta	tgccatgtaa	actggccaga	aaaaaattat	1860
tgcccatggt	ggacctgttt	ctattccacc	tcttttctat	gggctatatt	agtctataca	1920
tgccagttt	ccgttacata	ctccatttnc	caaaggagnc	ccnnaaaccc	tggtgattag	1980
taggcactaa	ccagggattt	ttaggggntc	acaaaacatt	ttccttc		2027

<210> 89
 <211> 687
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (667)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (674)
 <223> n equals a,t,g, or c

<400> 89						
tacgcagttt	tttttttttt	ttttgtcat	tttattcttt	taataagaaa	cttttgctta	60
caaaaacaag	gtgtaaaaag	atttacaaaa	atcataaaaa	catgatttat	atttcacact	120
tgagagacaa	aaacaagccc	caaaacatgg	atthttaatgg	aggtggtttg	cttcatttta	180
aaagggaaaa	aaaaaaaaaa	ggaagctgta	accatacatt	gatgttaaca	tagcatgaag	240
tttattcttg	wrgaattttac	attgttgagc	aattattaggg	gaagaagcca	tttgggtgtg	300
catagcattt	tagtgcacca	gatgggtttt	ccagacacca	gggaggcac	attgctggaa	360
tagtgagggt	tggtggcaga	aagagggcag	tgatgtgtag	ggggaggcaa	agtgaagtaa	420
gcctgggcag	tggtcamtaa	agtgacactg	ctgaggcagc	tgcttccttc	agaaggaaat	480
gttttgtgam	cctaaaattc	aggtagtgtc	actrtccagg	ggtttggggg	ctcttkggaa	540
atggagtatg	tacggaamtg	ggcatgtata	gamttatata	ggccatagaa	agaggtggga	600
taggaaacag	gtccaccatg	ggcaatattt	ttttctgggc	cagtttaact	agggcattta	660
aaaaaantac	tggnthttatg	gtggcca				687

<210> 90
 <211> 3187
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (473)
 <223> n equals a,t,g, or c

<400> 90						
ccccgggctg	caggaattcg	gcacagccag	tgctgctgga	cgagccccc	gaggaggagg	60
acggcctgcg	tggtggggccg	ccaccggccg	ccgccgccca	ggccagggtc	agggagcaag	120
tttccgaggt	tggaagaag	tgacttcaact	gttttaacaaa	gatgatgagc	agcatctcct	180
ggaaagatgt	aaatctccca	agtccaaagg	aactaactta	cgattaaaag	aagagttgaa	240
ggcagagaag	aaatctggat	tttgggacaa	tttggtttta	aaacagaata	tacagtctaa	300
aaaaccagat	gaaattgaag	gttgggagcc	tccaaaactt	gctcttgaag	acatatcggc	360
tgacctgag	gacaccgtgg	gtggcaccca	tcctgggtcag	gctgggagga	tgacgccaag	420

ggctcgacca	agtacaccag	cctggccagc	tctgccaa	gctccagg	gancttgccg	480
gcggcaggga	aggctggtga	gcatccgacg	gcagagtaaa	ggccacctga	cagatagccg	540
gakgaggcgg	agtgaggggg	gctgygtggc	aagtgtgccc	cgacatgggtg	gccttttatg	600
agtataccat	gtagttgttg	agtcttttcc	gcgttagaaa	gaatagagag	tctacttttt	660
gcctatatatt	gatatttggg	cctctgtttc	tttattta	gaactctcac	acacactgtg	720
actccttggt	gaacacgtgc	agggattgta	catttgattg	ccttattgca	gaaatattca	780
cctatcagtc	catgttttgc	agaaactgga	gatgtgaatt	tatgatgtct	tcccataata	840
cagcagtaat	gatttgcagt	ttctcacaaa	atgattttca	tgctgtctctg	tgttgtagtt	900
ctgtttcaga	acttccgtac	ctttttcttg	tatgtagcac	gtataaatgc	agctgtcatg	960
cagttctttt	cttttgctag	aaaattagtc	aggaggtga	atgaatcttc	caaagttatg	1020
ttaaattttg	tttaacttga	caaattaaac	tttgttctta	ttaaacaaat	acgtaaacaa	1080
atactggaaa	ggcaaagggt	atatttggga	gtaaaaatgta	tcttaaatg	catgttcac	1140
ttttgctgag	ggaggaatag	cttctgttat	gtccactgga	tagtaacagt	ggttcttttt	1200
tggaaatttta	tttttacctc	ttttgaactt	ctaaatcggt	ccctttatatt	tcttaaaaca	1260
tttgctctct	ttttgttta	cagattaaa	aagtatggat	caattttagt	cagttgataa	1320
tttcatttag	gaaacattgt	cttgctcatt	atagagagtt	aagactgtgc	ataaaatact	1380
gaagtgcctc	ttttttatta	ggctcatatg	tttgttcttg	caaagcgaga	tgcttattgt	1440
gattggtggt	agatctgtaa	gaagctgtgt	tttttccaca	agaataatcg	acgaccrgtt	1500
tgagagcatc	tctcgcgttc	ttttctgttc	tgcttactgt	ccttgacaat	gtgatcctgc	1560
acagtatcag	gtgccagtta	tgctccctg	gaaggttggc	tcttatcagc	aagtcctgca	1620
gatatactct	agataaaagt	ggtttgaaa	aaaagggtata	tttttctttt	ttgtttaaaa	1680
gtaaaaataaa	acctccagtt	acactgtgca	ttccctcac	gtaaaaacaa	gacaaaaacc	1740
ctttcctgag	ttgctcgcca	tgactcctg	tgctgtttca	tgcatgtgga	tgttccttcc	1800
gtttgttccct	gtggaataac	tgagtgtgcc	tgatggcaga	acacactgca	gtgttatcag	1860
tgtctgcatg	ttttttaata	gaacaggttt	acttgatctg	tcactgttta	tgsaaaaaac	1920
agcaattact	tttgcattcca	tctagctaaa	tctataatct	gtgtcaatca	cttataccta	1980
tcaatcatcc	gtatctatcc	acctgtcctc	tatgtctgtc	ttctctcagt	ctacatccat	2040
ctagccttct	gtcaatcatc	tacttttttt	tttaatagaa	caagaagttt	acttatcaag	2100
tcttgaaagg	gggacatggt	tcaattggtg	ttcaaacaaa	aattccagct	tgtattagaa	2160
ccttgaaatg	gtgaagtgtg	ggaggttttc	tttgttccat	aatacagaga	caagttcata	2220
attttttagta	taacagctaa	gttgacaaat	tctaagtttc	ctcaggtaaa	tagtcgtaac	2280
tgctcctttc	cttagagaag	tgcttctgtg	gatagtaaaa	acatacacca	tttcatgact	2340
tctgcaaata	ctttccagcg	gaagtcagtg	taggtttgtt	tttggctaac	atggctcttg	2400
tgcgcaggaa	tgtaaacact	gtgtttgaaa	ctctggaaa	cacgtgtgtg	gggagatggg	2460
gacgcttccc	atgttgtggg	gagctctgtg	gctgtgatgg	ctgcagttgc	cgtgcctctg	2520
ttggaacgcc	aagtgcctgc	aactcacgtc	aatcatagaa	ttgtgacgca	cagttggcaa	2580
aatagttctt	tatgctattt	ctcaaaattt	gaggacaaac	ccagattggg	attggaatat	2640
gcactgtaaa	tcaaattttt	cttatctaca	aagactaatg	taaaaatgat	tttttcttct	2700
gtgccttgatt	aaatttaactg	tggttttttaa	tataaatatt	tattggtgtg	ctttgggaga	2760
aaaattatct	tttcttgaaa	gaagttatca	aagcaaat	attatcttca	caagttaatg	2820
ggagaatgtg	gttttgattc	tgggtgtttg	aattgtgtaa	acacacagct	tccttgtgtg	2880
aagagagttg	tctctgtctc	cttctactgt	acttttttta	ttttttaata	ggaaagtgat	2940
gtgcttcaga	gaaggttccc	tccttaatgt	tgaggttttt	taaaaataaa	aatactgttt	3000
ttaagctctt	tccttattgg	tttgcattgat	tattggcatc	tgcttacgat	ggctttaatc	3060
actcagagct	aatggcacct	ttcctatttta	gcctcatttt	agaatgcagt	caacacatgt	3120
agacttttca	caaataaatg	aacaacttca	accttggttt	tcaagatgtg	tcttctgcgt	3180
atttgaa						3187

<210> 91

<211> 775

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (747)

<223> n equals a,t,g, or c

<400> 91

aattcggcac	gagaactagt	cagtcctatg	cttgaaacga	gatgccctt	caatttttga	60
gacttactat	ccaagtattg	gtttcagatc	taacacttct	tgtaatcagt	gtgcaataaa	120
tgatgaaatg	acattcctgg	aaatcactaa	gcgatttact	tactcttttt	ctagctcagg	180
ctcagcagac	tttttctgta	aagggccagg	tagtaaatgt	ttgaggcttt	atggggccaca	240
gactatctct	gttgccctct	cttatttgtg	tctttttttc	gaccacttca	aaaatgtaaa	300
aatcattctt	agctcacaa	ccataaaaaa	cagactacag	gccagatttg	gcccatgggc	360

catagtttgc	caaccggtt	taaacactga	ggttcgagtc	tcccattaat	ggtggcattc	420
tctgggataa	cgctaaaaac	attggagttt	taattaagtt	gtattaagtc	accattatcg	480
aaaagatgta	ttakaaatta	tgaccgtac	agactgggtt	aaaatgtggc	ttgtgtgkct	540
tctgcagctt	gcacctgcct	gcccgcagg	tgattttgca	ggcacaatct	gagggctaga	600
acctggggct	ttctctgcct	ctgkctagtc	ctgctggatt	gtaagctcca	tgagggcagg	660
arcttgcttg	tkgttkgcta	ctatgttccc	agcacacaga	acactgctgg	gaaatatgtt	720
cggggctggt	tctcatttgt	cttgatngca	tccagatttt	tccaagttat	tggtct	775

<210> 92

<211> 1455

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (141)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (218)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (578)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1359)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1421)

<223> n equals a,t,g, or c

<400> 92

cgtagcttct	ttcgggggtt	agggccaaag	acccattaga	aattatgacc	cgtacagact	60
gggttaaaa	gtggtttgtg	tttcttctgc	agcttgcacc	tgctgcccg	cccagggtgat	120
tttgcaggca	caatctgagg	ngctagaacc	tggggctttc	tctgcctctg	tctagtcctg	180
ctggattgta	agctccatga	gggcaggagc	ttgcttgntg	tttgctacta	tgttcccagc	240
acacagraca	ctgctgggaa	atatgttcgg	ggctggttct	catttgtctt	gatagcatcc	300
agatttttcc	aagtagttgg	ctttccgtat	gtccatttta	ctctctgtcc	atatatatac	360
acaacattac	atagtactca	tgaccaggtt	accattccca	gggattatgt	aattcctcag	420
tacagccctg	tgtggtcttg	tgtctccatc	ttacagatga	gaggccatga	tcaggcagct	480
agtttgtaga	aagctgccag	ggtttgcacc	cagccattat	ggctacactg	ctgggactct	540
tagcaccctt	aaaggggaagc	acttgagtgg	ctcgttgntt	mtgtcaccat	caggcttcca	600
tctcccagca	gaystcagag	gatctctggt	tttcaactct	gtaacttttc	aaagctctat	660
cacccttttg	agaatataag	aacattctga	gacagacata	cagattttgtc	aaaactgccg	720
agtttgtcca	aactcactga	actgtaccct	taaaatgggt	gtgttctatt	atatataagt	780
tgtatctcag	taaagtgtgat	ttttaaaatt	gttctcatca	caaagtcaaa	tggatttgga	840
aagctttaat	tagagaagaa	aaaaagaaac	cttttttaat	cagaagagkc	cagcctcttc	900
caacaaaagt	tgtaatgtct	ttgttttoca	agctagctat	ttaaaaatca	ggagttcttg	960
ccaggcatgg	tggtctacgc	ctgtaatccc	agcacttttg	gaggcccag	gcaggcagat	1020
cacgaggtca	ggagattgag	accatcctgg	ctaacacgac	gaagccccgt	ctctactaaa	1080
aaatacaaaa	aattagctgg	gcatggtggc	gggcgcctgt	agtcccagct	actcaggagg	1140
ctgaggcagg	agaatggtgt	gaaccgggga	ggcggagctt	gcagtggacc	aagatctcgc	1200
cactgcactc	cagcctgggt	gacagagcaa	gactccatct	caaaaaaaaa	aaaaaaaaaa	1260
actcgagggg	gggcccggta	cccaattcgc	cctatagtga	gtcgtattac	aattcactgg	1320
ccgtcgtttt	acaacgtcgt	gacttgggaa	aacctgggnc	gttaccceac	ttaatcgctt	1380
tgcagcacat	ccccctttcg	ccagctggcg	taatagcgaa	naggcccccg	caccgatcgc	1440
ccttcccaac	agttg					1455

<210> 93
<211> 2586
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2569)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2570)
<223> n equals a,t,g, or c

<400> 93
ttcggcacga ggcattgccta agatttttcag gacagaagtc aagtgtaaat gatgatatat 60
tttgctcttc tattagcatc cctttttttt ctgcttaaag ttaaaagtca ctttggatgt 120
aaaaatgtaa ctaccacatc agccaggatt tttttaaagc catttgtgtac tccaaagtct 180
attttccctc tgagtagata tggaagaatg agctcctaag agactagcct aatcaaattt 240
aaaagcaaatt gtaaattttaa atcaaccatg cagccctgct gtgtggcaat taacatttca 300
aggtaaaatg aaatgtgatg atagtaaata ccagttctac gcagaatcgg aaacattctg 360
ttccatggta tatttgggca gagaatggaa agttgaaagg aaaaccatta ttaacacacc 420
aactttgaca tttcaagata taattcaaac ttgattagaa cttccactaa aaataaagtc 480
ttctattaaa aaaatcacag tttccccac ctcataggct acatcacagc ctctcaacct 540
tggcactctg gacattttgg actatctaatt tcttaggggc tttcttgtgc attgtgggac 600
gttttaactgc atccctggcc ctacatacta gatgccagta gtaactcacc tttctccatc 660
attgacagct atgaaaatca aaaatgtctc catataatac tgattgaaga atttagggaa 720
ctgggttact actcactagg cttaccagtc cctaactgtg tgttttgttt gtttgtttgt 780
tttgggtttt ttgtgttttc ttattctctc cgtatcatat ttcaacttaa atatatgagg 840
atztatagta gttttattaa gctctaaaat gatctgggtg aatcttctta ttactttttt 900
aaagggaaaa aacactattt cagagacaga aagtcctcga gggatgggtc ttgggggata 960
agcagaagga agtatgatat gaaaaaaggg tttaaaattg tttgcagcaa aagcaaaact 1020
accagagcca tgcataattt ttataagtggt catccaagag tcggaatttt tacagtgtgt 1080
gttgggttacc atggatatta gtttgaagga cttggaaaag tggaagagga ggggtgtggg 1140
tagtgggatg atggccataa tacatttctc aggagtgttc aagaagtaaa atttacgttc 1200
tatgtaattt gtataatttt tctgaaaaga aaaacttttc aggtaaaaca ggtattatta 1260
tttatacctt actgtatagg agctgtatag ttctgagtta agtgactcac ctaaaattat 1320
gatctagcaa ttacgttggc tcaagcttct tttcttctac tyagaaagtg gaggaaagca 1380
tttgccctct gaaggcggaa ggctcattgc taatyttcag tgytcacaaa awctgctgct 1440
gtggatttct tggggcttct gacaaggaca ggaagccaca cattggkgaa gcatccatgc 1500
attggcagca ctattgstgg ataattggaga ttctaattta atcagcctga gttagggaaa 1560
gcacaatata aatgaacact ttgtaaagat gcttgatttg tcatgatcag aacagaatat 1620
ccaggtagac ctggtgcttc ttccctttatt gkgtttgktc atcctgggtc ttttctaaga 1680
catcagttgc tcattggccc tttcccaga tcatctgatg kgatkgtgac akgtacmctt 1740
gggtgkgattg tgattamcaa tasctggcca gtggscactg ctgctgtttg cggcmaactc 1800
atcctttctt cctgatgaga atcactttta ttggacgtta tccttaatac ccagtcfaat 1860
gagcctctct tgaaatctgg cttctctgta acctgctgct accacattta ctctattggc 1920
atcaaacagg gtcgtatata aatgcaagtt aatttcttga aatctgttaa agaggatgat 1980
cttttgctct gtagcatgca gattatgttg gtaaaacttag taatacatar taatmcattg 2040
gagtttagcac aggaataggg caattctgtt ctttttcttg ttgcaaagct aggggacagg 2100
taatttatta tacacgtatt caccctgaat aggtcagaac catgaaattt aagaatcctt 2160
cattggaggc tatcaagtca ttggggagat taaatctaca ttgtacttta atctgccgga 2220
tgccattgca catcagtaaa atgtcggatc tgtcggcatt gttaattgtaa ggggcaccgt 2280
ctgggtaatc atcaactgaa tgcagtgaac agtaatttta ttgaagtacc aagtaagaac 2340
ttaaccctct tgattttttt cccttgaacc cattttctta cttttgatgg aatgaggaca 2400
tttttagaaa atacagttag ttctatgtca gttttaaaca aaatgtttct cacccttaca 2460
cctaaattta gttcatctga gaggatagc caagaagraa agaagaatta rcarattacc 2520
aaaaaaaaaa agtaatttta caaaatttaa agcacgggct ttttcccn n gagctaagga 2580
agaatt 2586

<210> 94
<211> 1153
<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (975)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1038)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1077)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1129)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1132)

<223> n equals a,t,g, or c

<400> 94

ctcgagtttt	tttttttttt	ttttttttct	gatatcagta	tagtaagtag	ttacaaaatt	60
acttacaatt	cacttcacag	ttatatattc	ctaagcatga	atagagtgcc	tatacacgta	120
tgtatcaaatt	tgtgatttta	tattttataa	acagaaaaat	ttgtgatcaa	gcttatactg	180
gtatacaaca	actgcagaat	acagattcca	tttttaatat	ctgacttcta	agcttttgta	240
aaatcctatc	atcttgaatt	atttaagaag	ctcaaagttt	aatctgtatt	tcttctttta	300
cctactaaat	tctcagtcta	aaaggggaaag	agaacatatt	ctattatgaa	aagttagttc	360
cagcaaatatc	aaggattaat	acgactccag	tacatacgtg	gtgggagaag	aatttgtctc	420
tctgttcaga	agcaaaatgt	aaatactcca	aaggattact	ataaaaaatag	tgacttagca	480
aagatagaaa	aagagagtgc	tttaaatttt	gtaaaattac	tttttttttt	tggtaatctg	540
tttaattcttc	ttttcttctt	ggcatatcct	ctcagatgaa	ctaaatttag	gtgtaagggt	600
gagaaacatt	ttgttttaaaa	ctgacatagr	actcactgta	ttttctaaaa	atgtcctcat	660
tccatcaaaa	gtaagraaat	gggktaagg	graaaaaatc	magagggtta	agttcttact	720
tggtacttca	ataaaaattac	ttgtcactgc	attcagttga	tgattaccca	gacgggtgcc	780
cttacattaa	caatgccgac	agatccgaca	ttttactgat	ggcaatggcc	atccggcaga	840
ttaaagtaca	atgtagattt	aatctcccca	atgacttgat	agcctccaat	gaaggattct	900
taaaatttcat	ggwtctgacc	tattcagggg	gaataaccgt	tataataaat	tacctgtccc	960
ctagctttgc	aacangaaaa	agaacagaat	tggcctattc	ctgtgctaac	tccaatggat	1020
tactatggat	tactaagntt	accaaactta	atcctgcatg	ctacagagcc	aaaagancca	1080
tcctctttta	acaagatttt	ccaagaaaaat	ttaaccttgc	aatttgatnt	tnccgaaccc	1140
cttgttttgg	att					1153

<210> 95

<211> 626

<212> DNA

<213> Homo sapiens

<400> 95

gccccacgct	ccgcctaaac	acagtcacca	tgaagctggg	ctgtgtcctc	atggcctggg	60
ccctctacct	ttcccttggt	gtgctctggg	tggcccagat	gctactggct	gccagttttg	120
agacgctgca	gtgtgagggg	cctgtctgca	ctgaggagag	cagctgccac	acggaggatg	180
acttgactga	tgcaagggaa	gctggcttcc	aggccaaggc	ctacactttc	agtgaacctt	240
tccacctgat	tgtgtcctat	gactggctga	tcctccaagg	tccagccaag	ccagtttttg	300
aaaggggacct	gctgggttctg	cgctgccagg	cctggcaaga	ctggccactg	actcaggtga	360
ccttctaccg	agatggctca	gctctgggtc	cccccgggcc	taacagggaa	ttctccatca	420
ccgtgggtaca	aaagggcagac	agcgggcact	accamtgcag	tggcatcttc	cagagccctg	480
gtcctgggat	cccagaaaca	gcactctgtt	tggctatcac	agtccaagaa	ctgtttccag	540
cgccaattct	ccttctacaa	ggatgggaag	atagtgcaaa	gcaggggggc	tctcctcaga	600

attccagatc cccacagctt cagaaa

626

<210> 96
 <211> 152
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (41)
 <223> n equals a,t,g, or c

<400> 96							
cagcccagct	tcatgggtgac	tgtgttttagg	tctccctcgt	nccgaattcc	tgcagcccg		60
gggatccact	agttctagag	cggccgccac	cgcggttag	ctccagcttt	tgttcccttt		120
agtgagggtt	aatttcgagc	ttggcgtaat	ca				152

<210> 97
 <211> 1760
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1693)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1748)
 <223> n equals a,t,g, or c

<400> 97							
gggaattctc	catcacctg	gtacaaaagg	cagacagcgg	gcactaccac	tgcagtgcac		60
cttccasagc	cctggctcctg	ggatcccaga	aacagcatct	gttgtggcta	tcacagtcca		120
agaactgttt	ccagcgccaa	ttctcagagc	tgtaccctca	gctgaacccc	aagcaggarg		180
ccccatgacc	ctgagttgtc	agacaaaagt	gccccctgcag	aggtcagctg	cccgcctcct		240
cttctccttc	tacaaggatg	gaaggatagt	gcaaagcagg	gggctctcct	cagaattcca		300
gatccccaca	gcttcagaag	atcactccgg	gtcatactgg	tgtgaggcag	ccactgagga		360
caaccaagtt	tggaaacaga	gccccagct	agagatcaga	gtgcagggtg	cttcagctc		420
tgctgcacct	cccacattga	atccagctcc	tcagaaatca	gctgctccag	gaactgctcc		480
tgaggaggcc	cctggctctg	cctccgccgc	caaccccatc	ttctgaggat	ccaggctttt		540
cttctcctct	ggggatgcc	gatcctcatc	tgtatcacca	gatgggcctt	cttctcaaac		600
acatgcagga	tgtgagagtc	ctcctcggtc	acctgctcat	ggagttgagg	gaattatctg		660
gccaccrgaa	gcttgggacc	acaaaggcta	ctgctgaata	gaagtaaaca	gttcatccat		720
gatctcactt	aaccacccca	ataaatctga	ttctttatct	tctcttctctg	tcctgcacat		780
atgcataagt	actttttacaa	gttgtcccag	tgttttgtta	gaataatgta	gttaggtgag		840
tgtaaaataaa	tttatataaaa	gtgagaatta	gagtttagct	ataattgtgt	attctctctt		900
aacacaacag	aattctgctg	tctagatcag	gaatttctat	ctgttatatc	gaccagaatg		960
ttgtgattta	aagagaacta	atggaagtgg	attgaataca	gcagtctcaa	ctgggggcaa		1020
ttttgcccc	aagaggacat	tgggcaatgt	ttggagacat	tttggtcatt	atacttgggg		1080
ggttggggga	tgggtgggatg	tgtgtgctac	tggcatccag	taaatagaag	ccaggggtgc		1140
cgctaaacat	cctataatgc	acagggcagt	acccacacac	gaaaaataat	ctggcccaaa		1200
atgtcagttg	tactgagttt	gagaaacccc	agcctaata	aaccctaggt	gttgggctct		1260
ggaaatggga	ctttgtccyt	tctaattatt	atctctttcc	agcctcattc	agctattctt		1320
actgacatac	cagtcctttag	ctgggtctat	ggctgttctt	ttagttctag	ttgtatccc		1380
ctcaaaagcc	attatgttga	aatcctaata	cccaagggtga	tggcattaag	aagtgggcct		1440
ttgggaagtg	attagatcag	gagtgacag	ccctcatgat	taggattagt	gcccttattt		1500
aaaaaggccc	cagagagcta	actcaccctt	ccaccataatg	aggacgtggc	aagaagatga		1560
catgtatgag	aaccaaataaa	cagtgctgcc	aaacaccgac	tctgtcgttg	ccttgatctt		1620
gaacttccag	cctccagaac	tatgagaaat	aaaattctgt	tgtttgtaag	ctaattccagt		1680
tgtgtaattt	ggnatagtag	cccaaatgga	ctaggcagtt	ggcctctggc	cacatgatga		1740
gttatggnat	gtaaaaatac						1760

<210> 98
 <211> 2771
 <212> DNA
 <213> Homo sapiens

<400> 98
 ggcacgagag cgctyakggc gctgacccac tgetcttctt ctttaagaaag tgctccattc 60
 cttccggcgc ccggagctgc tggcccaaag ggatccggag cgagctaggg cagacacccat 120
 gaccaccctt gatgataagt tgctggggga gaaactgcag tactactata gcagcagtga 180
 ggatgaggac agtgaccacg aggacaagga ccgaggcaga tgtgccccag ccagcagttc 240
 tgtgcctgca gaggctgagc tggcaggcga aggcattctca gttaacacag gccccaaagg 300
 tgtgatcaat gactggcgcc gcttcaagca gttggagaca gagcagaggg agggagcagt 360
 ccgggagatg gaaaggctga tcaagaagct gtcaatgact tgcaaggctcc atctggatga 420
 agaggaggag .caacagaaac agaagagcct ccaggagaag atcagtggga agatgactct 480
 gaaggagttt gccataatga atgaggacca agatgatgaa gattttctgc agcagtaccg 540
 gaagcagcga atggaagaga tgcggcagca gcttcacaag gggccccaat tcaagcaggt 600
 ttttgagatc tccagtggag aagggttttt agacatgatt gataaagaac agaaaagcat 660
 tgtcatcatg gttcatattt atgaggatgg cattccaggg accgaagcca tgaatgggtg 720
 catgatctgc cttgccgcag agtaccagc tgtcaagttc tgcaagggtga agagctcagt 780
 tattggcgcc agcagtcagt tcaccaggaa tgccttctct gccctgctga tctataaggg 840
 ggggtgaattg atcggcaatt ttgttcgtgt tactgaccag ctgggggatg atttctttgc 900
 tgtggacctt gaagcttttc tccaggaatt tggattactc ccagaaaagg aagtcttggt 960
 gctgacatct gtgcgtaact ctgccacgtg tcacagtgag gatagcgacc tggaaataga 1020
 ttgaactgat agtctagtgt catagatttc tcattgtttg ggttggataa caggtcattg 1080
 tttatttttg ttctttgttc ttctggcttt tcagctgttc tttgtagtcc cttttattat 1140
 gcataaaata aagaaattct tagattaaat cagaatgctg aataaccttg tagctagcaa 1200
 taaggtgact tacartttga taaacaggaa gccaggcttt tgaactgttt acttaagatt 1260
 ctgtggtgtg acatctctgt tattgtttcc agtcaatatt tacaagcat cctaaagaca 1320
 ggggtcttga aattgtcttc agatgatctt agaggtctct gccaaagtct agagtataat 1380
 tctgtaggta ttgtgttatt tgcaacgtaa atagtgcatt ttcttaatca aatgattgta 1440
 aattatattt acttgtaatc agttccatag ctttagacgg tggtagattt tttttttcc 1500
 ccaccagggt cttgttttaa ggggtgagcc accgcaccca gtctgaggg gtggcctctg 1560
 ctgctggatt tcatgtcttc ctccagcatg actaagtctg gaacagcagg aagggttgat 1620
 gcttactgac ctggtgatgt tagaagacaa gtatgttatg gatttaacaa ttagagctgg 1680
 agtggggctg gaaatctttg taaaggaagt tctttcagta agatgccctt gcttgtcttt 1740
 gtctcttttt tgtttaacaa ggtaactttt tgtttaacaa ggtaactttt tgtttaacct 1800
 agattttttt taaaactttt ttttttttct atattggaaa agtaattcat attcagtaga 1860
 ggaaaactga ccaaaacaga agcaaaaata agaaaattaa aataatctct aatcctacta 1920
 cctagaataa aacactatta atattttggt ctgtttctct ccaagggtgt ttctgtgtat 1980
 acatggatat tttgtttgtt ttttaacaaa acgatgggat cattctgaac atactgttct 2040
 atagtattgg cagctaataa tatatcagac ctttttttat attattaaat attctacaac 2100
 tttttaaaaa tgtctattaa tattccatcg tatagatgtg atataatttg cttgatggtt 2160
 gtctcttaaa aagaaagata gcaaaacttt tttttaaatt acaaaagtga tagatgttca 2220
 ttgtagaaaa tgtaataaac actgttaaga cttaaaagcc atataattcc accaaccaaa 2280
 attaatccct tttgtcatat ttctagtcat tttttttcta tttttttcta tgtatttata 2340
 ataattatca tttgcgtttt ttctcttttt ttaactttta aaatgtatat tctagggtca 2400
 ggggaaatgt aatctggaat taaatattag ccttaaaaatt cacaattttg attttctctg 2460
 cttttcagga attgactaac tgtaaaagag tcttgaaagt atttagtcaa caaacagagt 2520
 gcattttttt tttttttgac taagaaagct cgttgtagta gaaagggtgg aatgtattga 2580
 aaattattag aagcaggga gtaattgttag tctagcttat ttcttttcag tcttttttca 2640
 atatttttat aaacattgag tacttactga atttagttct gtgctcttcc ttatttagtg 2700
 ttgtatcata aatactttga tgtttcaaac attctaaata aataattttc agtggcttca 2760
 aaaaaaaaaa a 2771

<210> 99
 <211> 543
 <212> DNA
 <213> Homo sapiens

<400> 99
 gaattcggca cgaggacaga tgtaaatggg cagacacctc tcatgtttatc agctcacaaa 60
 gtaattgggc cagaaccaac tggatttctt ttaaagttta atccttctct caatgtggtt 120
 gataaaatc accaaaacac tccacttcac tgggcagttg cagcaggaaa tggttaatgca 180
 gttgataagc ttttggaaagc tggttctagc ctggatatcc agaattgttaa gggagaaaca 240

57

cctcttgata	tggtctctaca	aaacaaaaat	cagctcatta	ttcatatgct	aaaaacagaa	300
gccaaaatga	gagccaacca	aaagttcaga	ctttggaggt	ggctgcagaa	atgcgagctc	360
ttcctgctgc	tgatgctttc	tgtgattacc	atgtgggcta	ttggatacat	attggacttc	420
aattcagatt	cttggctttt	aaaaggatkt	cttctakta	cactgtttt	tctgacatct	480
ttgtttccaa	ggttcttggt	tgggtataar	aaccttgat	acttaccac	agctttctgc	540
ttaa						543

<210> 100
 <211> 1829
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (649)
 <223> n equals a,t,g, or c

<400> 100						
ggcagagga	cagatgtaaa	tgggcagaca	cctctcatgt	tatcagctca	caaagtaatt	60
gggccagaac	caactggatt	tcttttaaa	tttaatcctt	ctctcaatgt	ggttgataaa	120
atacaccaaa	acactccact	tcactgggca	gttgagcag	gaaatgttaa	tgagttgat	180
aagcttttgg	aagctgggtc	tagcctggat	atccagaatg	ttaagggaga	aacacctctt	240
gatattggctc	tacaaaacaa	aaatcagctc	attattcata	tgctaaaaac	agaagccaaa	300
atgagagcca	acaaaagtt	cagactttgg	aggtggctgc	agaaatgcga	gctcttcctg	360
ctgctgatgc	tttctgtgat	taccatgtgg	gctattggat	acatattgga	cttcaattca	420
gattcttggc	ttttaaaagg	atgtcttcta	ttaacactgt	ttttctgac	atctttgttt	480
ccaaggttct	tggttgggta	taaaaacctt	gtatacttac	caacagcctt	tctgctaagt	540
tctgtttttt	ggatatctat	gacttgggtc	atcttatttt	ttcctgattt	agcaggagcc	600
cctttctatt	tcagtttcat	tttcagcata	gtagcctttc	tatactttnt	ctataatact	660
tgggcaactg	atccaggctt	cactaaggct	tctgaagaag	aaaagaaaag	gaatatcatc	720
acccttgcag	aaactggctc	tctggacttc	agaacatttt	gtacatcatg	tcttataatg	780
aagccattaa	ggtcactcca	ctgccatgta	tgcaactgct	gtgtgggctc	gatatgatca	840
acactgcctg	tggactggac	ggtgcatagg	ttttggcaac	catcactatt	acatattctt	900
cttgtttttt	ctttccatgg	tatgtggctg	gattatatat	ggatctttca	tctatttggc	960
cagtcattgt	gccacaacat	tcaaagaaga	tggattatgg	acttacctca	atcagattgt	1020
ggcctgttcc	ccttgggttt	tatatatctt	gatgctagca	actttccatt	tctcatggtc	1080
aacattttta	ttattaaatc	aactctttca	gattgccttt	ctgggcctga	cctcccatga	1140
gagaatcagc	ctgcagaagc	agagcaagca	tatgaaacag	acgttgtccc	tcaggaagac	1200
accatacaat	ccttggattca	tgcagaacct	ggcagatttc	tttcagtggtg	gctgctttgg	1260
cttgggtgaag	ccctgtgtgg	tagattggac	atcacagtac	accatggctt	ttcaccagc	1320
caggggagaag	gttcttcgct	cagtatgaag	aaaagcaacc	caaaactctc	aatctgattt	1380
gtttttgttt	atgtcgatgc	cctgtagttt	gaaagtgaag	ttaaagattta	gaattcacct	1440
aagtccaaag	gaaaacacgt	ggttttttaa	gccattaggt	aaaaaaaagt	ctcaataaag	1500
gcattacaat	tttttaggtt	tagaaagatg	gacttttctg	aaaaatcttg	gcagacatct	1560
aaaaaaaaaa	ccataatttt	cacaagaaaa	tgcaagttac	tttttttggg	aataatactc	1620
actgattatg	gataaaatgg	aataattttc	gatactatat	tggtgttttc	aaaatagtac	1680
tattctttta	acttgtaatt	tttgctaagt	tatttgtctt	tggtgtatct	ataaatatgt	1740
aaaaaatatt	taaatagatg	tacctgtttt	gctttcacac	ttaataaaaa	attttttttt	1800
gtagttgaaa	aaaaaaaaaa	aaaaaaaaaa				1829

<210> 101
 <211> 1127
 <212> DNA
 <213> Homo sapiens

<400> 101						
agaaactggc	tctctggact	tcagaacatt	ttgtacatca	tgtcttataa	ggaagccatt	60
aaggtcactc	cactgccatg	tatgcaactg	ctgtgtggct	cgatatgatc	aacactgcct	120
gtggactgga	cggtgcatag	gttttggcaa	ccatcactat	tacatattct	tcttgttttt	180
cctttccatg	gtatgtggct	ggattatata	tggatctttc	atctatttgt	ccagtcattg	240
tgccacaaca	ttcaaagaag	atggattatg	gacttacctc	aatcagattg	tggcctgttc	300
cccttgggtt	ttatatatct	tgatgctagc	aactttccat	ttctcatggt	caacattttt	360
attattaaat	caactctttc	agattgcctt	tctgggctg	acctcccatg	agagaatcag	420
cctgcagaag	cagagcaagc	ataagaacaa	gacgttgttc	ctcaggaaga	caccatacaa	480

58

tcttggattc	atgcagaacc	tggcagattt	ctttcagtg	ggctgctttg	gcttggtgaa	540
gcctctgtgtg	gtagattgga	catcacagta	caccatgggtc	tttcacccag	ccagggagaa	600
ggttcttcgc	tcagtatgaa	gaaaagcaac	ccaaaactct	caatctgatt	tgtttttgtt	660
tatgtcgatg	cctgtagtt	tgaaagtga	gtaaagattt	agaattcacc	taagtccaaa	720
ggaaaacacg	tggtttttaa	agccattagg	taaaaaaagt	tctcaataaa	ggcattacaa	780
tttttttaggt	ttagaaagat	ggacttttct	gataaatctt	ggcagacatc	taaaaaaaaa	840
accatatttt	tcacaagaaa	atgcaagtta	cttttttttg	aaataatact	caactgattat	900
ggataaaaatg	gaatattttc	agatactata	ttggctgttt	caaaaatagta	ctattcttta	960
aaacttgtaat	ttttgctaag	ttatttgtct	ttgttgtatc	tataaatatg	taaaaaatat	1020
ttaaatagat	gtacctgttt	tgctttcaca	cttaataaaa	aatttttttt	tgtagttgaa	1080
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aactcga		1127

<210> 102

<211> 538

<212> DNA

<213> Homo sapiens

<400> 102

ggtttcactc	tctaaatgaa	caaagtggga	gatcactgtc	atggccaaag	ttacatggcc	60
aagacaaact	atggcctggg	agtcccaggt	tctcctgtgt	gggcactttc	ctggcatatg	120
ctaaatgatg	ggaaagtctg	ggtctcatgt	ttctgtgtgg	tcctcacctc	actcgacttc	180
tgctctttct	gttcactctg	ggcttctgtg	ctttcattaa	tatagtctct	agttttccac	240
tggtctgtat	cccattctgc	cttggacgcc	tttacttcct	gctgctcact	gagaagcctc	300
atcaggaggc	ctgtcctgga	gatgagcttg	gcacaggcca	cttgacata	ggtctcggag	360
cagtccgtct	tcaaggtcca	gataacatga	gaaatgaagy	ttctcasaty	ggtgttgggg	420
atgamggact	gtagtgtgatg	ggttagcgga	atttcaaact	gatcamctgg	ggatgagagc	480
aatgggtaac	tkaagctttt	kgggytcggg	ggacaggcca	gtgccacgt	tgttgtat	538

<210> 103

<211> 1181

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (1030)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1137)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1170)

<223> n equals a,t,g, or c

<400> 103

agcagagatg	tcaggtaggg	tggaagtagg	tgacaactgg	ggccagcttc	tgagctataa	60
aactgtacaa	acatgaagaa	tagttttttc	acagtgaagt	gggctcttac	ttgctccttc	120
tcttgggcca	cagtgtaaat	gagaacacgt	agtctctctt	ccttccacat	aatgccctcc	180
tggggaatgt	tatcccgcga	caccttcagg	tttaatecct	gaacaagcac	ctcctaaacc	240
tcatctttgt	ctctaaatgt	gctactgagc	cctggcagcc	tcttgtcaca	cccattgggt	300
tcttatactc	tgtgtcccgt	gctgacctcg	gcacttttct	gccatttttc	ctcttcccat	360
ttttttctcc	catatcagtg	acagcccatt	gggccttata	ctgaatgcct	ctctcgcctc	420
tcccctgctt	cctctgtgct	agtcaggcac	cagtgcctta	cattctgccg	cctgggtata	480
tctgtgtgtc	ttctctctac	cctcacagcg	ttcatcccag	gtatagactg	aatatccgaa	540
gtgtctcaaa	attccaaatg	ttttgagcac	caacgtgaca	tttaagggaa	atgtttattg	600
gagccttgca	aatggatttg	gggtgctcaa	ccagtaaata	tgcaaatatt	ccmaagtcca	660
aaaaaatccc	aaattcagaa	cacttctggg	cccaggcatc	tgagataaga	gatactcagc	720
ctgtatcatc	tcccccttcc	tagcctcctg	gaagtccaca	gcctctscct	ctgtagtttt	780
tcccctgaaa	cttcttttcc	aagcactttc	acttctctct	tttgtttgtt	cttcaccgta	840
agccagtgaa	gtgagcaggg	tttaagtaag	tgtcctcagt	atattggtga	aggaacagac	900

acagttaggg	gtcaagactc	tcatgaggtt	actcaaggaa	ccagagaaa	aacgggactc	960
agactcagat	ttctcccctc	ttcagcagac	tgagggttaag	ttggggaggc	atgaagaggt	1020
caaggcttgn	gatcagcctg	ccagctttgc	cagagcagga	gggggctgag	gcagaggtga	1080
tcaggatagc	aagtgccacc	agcagctctc	acatagttag	cacctgccat	gtgtcangtg	1140
ccatgctaga	cacttgatga	gttctctctn	ctttatcctc	a		1181

<210> 104
 <211> 1089
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (936)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1047)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1052)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1071)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (1083)
 <223> n equals a,t,g, or c

<400> 104	
ctcgagtttt	tttttttttt
gagtgcattg	tcatgatcac
cctacctcag	cctcccaggt
aatttttggg	agaaacggag
caggcgattc	tcccaccttg
aagggtttca	accaaataag
gatggcacgg	gagatcccag
gtaccaaagg	agttctgtat
gctctgggta	ggtagaatg
aaccctccag	tctgggtgtg
gaagctcagg	cagggcagga
ggatcatccac	caacttgatg
ccacgacagc	tggagattgg
agacgccagt	tcccacactg
cggcagtgcc	catgcccccg
ccttctcccc	cttgggtggc
tagaggcacc	tgtcacgcca
tgggcttctc	cagaggggct
tgntttgac	

<210> 105
 <211> 540
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE

<222> (480)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (494)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (524)
 <223> n equals a,t,g, or c

<220>
 <221> SITE
 <222> (527)
 <223> n equals a,t,g, or c

<400> 105
 gaacatccccg tctccagagg tcaagagatt attagcccaa agtgtagcta cttgcagata 60
 gagcagggggc ttttgtcctc tgcttcccaa ctcttgccct atctttctat tgtaccactc 120
 caaatatttc ttatcacaat gttgctgtta gtagtaacac tagtaaatct gagtatttat 180
 aagctcataa agcttggttac agccttaagc aaaaagcttg gggccaaggg cgttttaaaa 240
 aatgcacact ttatgaggtg caactgcgga gaaatgagga cgcgttctta agctttggta 300
 ttcacatggt ggtggtgctg gtagaggctg ttacatttct tccagtgaag ctgttcttgc 360
 agccgccttg gaattcactt cagggccagt ttatgagcca cccaagtaa tctgcttggg 420
 agtctgagca tcataccttg gtatttgacc aaaatatatg taacaaattt acccttttn 480
 accattgtta agnnttaciaa ttcagtggta ttttgcagtg ttgnatnacc gtcactcactg 540

<210> 106
 <211> 1326
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1305)
 <223> n equals a,t,g, or c

<400> 106
 gcgcgggagg atctctcacc ccgtcactca ggggtggcgca atcacgactc attggctcac 60
 tgcagcctag acctcccagc tggagcaatt ctcttgccctc agccttctga gtagctggga 120
 ctacagttgg ttctaaagag tgggtagtcga gaagagacgt caggcagcaa gcgacttggg 180
 ccatggcctc tgacctagac ttctcacctc cggaggtgcc cgagcccact ttcttgagga 240
 acctgctacg gtacggactc ttctggggag ccattctcca gctcatctgt gtgctggcca 300
 tcatcgtagc cattcccaag tcccacgagg cggaggtgga accgtctgag cccagaagtg 360
 ctgaggtgac gaggaagccc aaggctgctg ttcttctctgt gaacaagagg cccaagaaa 420
 agactaagaa gaagcggtag aagaggaggc ctgaggagct gggcgggcag ggagagggtc 480
 ttggggacag ccctcctggg aatctacatt gtgttcccc gcattccagg ctgagggtct 540
 gaggaggctg tgacgcccta tgaccgcaga gatctagaca gtcgtaacag tccccaggct 600
 ccagctgggc aatccaccac ttctcttctc ttctgcttct gtgacggttt agagtcaagg 660
 gggctgaaac aactgtgag catagactgt attaggtttg ttcagaagcc gggtcagctc 720
 acagartcac attttcttgc ttagtcatgt gtcctcctt gatttgcccc ctcttgttg 780
 gtttacacta cattttggag tcattgtcta atgctgacaa gcacaccctc tccattatt 840
 tgtgcactac agatctccts ctgatcagtc acctttgttg ctgctgtgta gacagagcca 900
 ggcctcacct gtttgtttag gccaaagatgc catggacatg cagcgttagt gatccacta 960
 gctgygacag ccaggcccag aaaatgcctg gcgtgagagc cagcagacag ccaggccrgg 1020
 gtaggcagtg cctgcttctg ctccatcagg tgcaggggat ttggctgaag gcgtgcatat 1080
 ttcttgggca caaacttctt gagcctctga aatgggaggc tcgtcaattt cagaccaacc 1140
 tcttttcaac ccatcatagc acgttcaagg tgtgcctttt acttctacct gtacatccc 1200
 catcccttca attctttcat tccctgacca gtgagagggt tcttggggga agtatgggtga 1260
 ataaactgac atgcatgctt cagaaaaaaa aaaaaaaaaa aattnctgctg gtccgcaagg 1320
 gaattc 1326


```
<210> 107
<211> 841
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (748)  
<223> n equals a,t,g, or c
```

```
<220>
<221> SITE
<222> (769)
<223> n equals a,t,g, or c
```

```
<220>  
<221> SITE  
<222> (802)  
<223> n equals a,t,g, or c
```

<400>	107						
tacgagttttt	ttttttttttt	ttttgtggt	ttgcaataaa	tttatttaat	cagaacttca		60
gagggttcta	gaaacctgca	tttttaacaa	ggactgcaga	tgattctagg	ttttgattaa		120
aagtgtggtt	tggggaagca	actttaccct	ttattgtgtg	ttaaattaca	tatacaataa		180
aacaaaaagt	cacgtaatgg	aacaaaaaat	tgctttatac	aaaatattag	tagataccca		240
aatataatat	ggtcttaaaa	ataaaatcat	atgtatatag	ttgtattcct	aggtacagta		300
gtgccccct	catccaaagt	ttccctttct	gtggttttgg	ttacctgtag	tcaaccacat		360
tctaaaatag	gtgagtactg	tacaagaaga	tattttgaaa	gcaagagaga	ccaaccacat		420
tcacataact	tttattatag	tatgtttatca	ttgttctatt	acattattat	taatctcttg		480
ctatgcttaa	tttatacatat	atactttatc	atagttatat	atatattgga	aaaacagtgt		540
ataaagttt	ggtatctgtt	gaggtttcag	gagttcactg	ggggccttgg	aatgtatctc		600
cgaagagtaa	gggggaacta	ctgtaagcaa	aatygaagac	tatacaacaa	tcaggaaatg		660
gggaagagag	ccaaatccca	aggтатаagg	tgaaggccat	tcctcttgga	attccccag		720
ccattccatc	cgagccatcc	aaaacggncc	ccaatccttt	taggtcccnt	tttccctggg		780
accattatct	ctggtatccc	cncattcct	cctggcatct	ggattggggg	gccccccagg		840
g							841

```
<210> 108
<211> 580
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (14)
<223> n equals a,t,g, or c
```

[illegible]

```
<210> 109
<211> 522
<212> DNA
<213> Homo sapiens
```

<400> 109
 tcgagttttt tttttttttt tttttttttt ttgtactttt agtagagacg gggtttcacc 60
 gtgttarcca ggatggtctc catctcctga cctcatgac cgcctgcctc gtcctcccaa 120
 agtgctggga ttacaggcgt gagcaccgcg cctggccggc tgtaaatcaa gtgagacagg 180
 gtcctcaaaaa gatgtgcaca agtcctggca tggagtaagg accaaggaat gaaactgggg 240
 agattattaa atgccccatt ttcttgccaa accctgacga ggcatgtccc tgaatatgca 300
 cagggaaatg aggacagagg ggaccaggc tctagataca cgcattgtggc ccagctgtta 360
 gcagaggccc aaaccacgca tgagcaggga tctgggctgc tccccctgct gtgtgtccct 420
 gacaacctcc ttgggcctca ggctaccctc tgcagaacag acagcagcag actctgtctt 480
 aggaggagct ccarggggca cacartgggt ctctggggac aa 522

<210> 110
 <211> 353
 <212> PRT
 <213> Homo sapiens

<400> 110
 Met Pro Trp Pro Leu Leu Leu Leu Ala Val Ser Gly Ala Gln Thr
 1 5 10 15
 Thr Arg Pro Cys Phe Pro Gly Cys Gln Cys Glu Val Glu Thr Phe Gly
 20 25 30
 Leu Phe Asp Ser Phe Ser Leu Thr Arg Val Asp Cys Ser Gly Leu Gly
 35 40 45
 Pro His Ile Met Pro Val Pro Ile Pro Leu Asp Thr Ala His Leu Asp
 50 55 60
 Leu Ser Ser Asn Arg Leu Glu Met Val Asn Glu Ser Val Leu Ala Gly
 65 70 75 80
 Pro Gly Tyr Thr Thr Leu Ala Gly Leu Asp Leu Ser His Asn Leu Leu
 85 90 95
 Thr Ser Ile Ser Pro Thr Ala Phe Ser Arg Leu Arg Tyr Leu Glu Ser
 100 105 110
 Leu Asp Leu Ser His Asn Gly Leu Thr Ala Leu Pro Ala Glu Ser Phe
 115 120 125
 Thr Ser Ser Pro Leu Ser Asp Val Asn Leu Ser His Asn Gln Leu Arg
 130 135 140
 Glu Val Ser Val Ser Ala Phe Thr Thr His Ser Gln Gly Arg Ala Leu
 145 150 155 160
 His Val Asp Leu Ser His Asn Leu Ile His Arg Leu Val Pro His Pro
 165 170 175
 Thr Arg Ala Gly Leu Pro Ala Pro Thr Ile Gln Ser Leu Asn Leu Ala
 180 185 190
 Trp Asn Arg Leu His Ala Val Pro Asn Leu Arg Asp Leu Pro Leu Arg
 195 200 205
 Tyr Leu Ser Leu Asp Gly Asn Pro Leu Ala Val Ile Gly Pro Gly Ala
 210 215 220
 Phe Ala Gly Leu Gly Gly Leu Thr His Leu Ser Leu Ala Ser Leu Gln
 225 230 235 240
 Arg Leu Pro Glu Leu Ala Pro Ser Gly Phe Arg Glu Leu Pro Gly Leu
 245 250 255

Gln Val Leu Asp Leu Ser Gly Asn Pro Lys Leu Asn Trp Ala Gly Ala
 260 265 270
 Glu Val Phe Ser Gly Leu Ser Ser Leu Gln Glu Leu Asp Leu Ser Gly
 275 280 285
 Thr Asn Leu Val Pro Leu Pro Glu Ala Leu Leu Leu His Leu Pro Ala
 290 295 300
 Leu Gln Ser Val Ser Val Gly Gln Asp Val Arg Cys Arg Arg Leu Val
 305 310 315 320
 Arg Glu Gly Thr Tyr Pro Arg Arg Pro Gly Ser Ser Pro Lys Val Ala
 325 330 335
 Leu His Cys Val Asp Thr Arg Glu Ser Ala Ala Arg Gly Pro Thr Ile
 340 345 350
 Leu

<210> 111
 <211> 199
 <212> PRT
 <213> Homo sapiens

<400> 111
 Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
 1 5 10 15
 Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
 20 25 30
 Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
 35 40 45
 Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
 50 55 60
 Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
 65 70 75 80
 Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
 85 90 95
 Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser
 100 105 110
 Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu
 115 120 125
 His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro
 130 135 140
 Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu
 145 150 155 160
 Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro
 165 170 175
 Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser
 180 185 190
 Arg Leu Thr Asp Val Thr Leu
 195

<210> 112
 <211> 561
 <212> PRT ,
 <213> Homo sapiens

<400> 112
 Met Asp Ile Leu Met Leu Leu Leu Leu Leu Cys Val Ile Tyr Gly Arg
 1 5 10 15
 Phe Ser Gln Asp Glu Tyr Ser Leu Asn Gln Ala Ile Arg Lys Glu Phe
 20 25 30
 Thr Arg Asn Ala Arg Asn Cys Leu Gly Gly Leu Arg Asn Ile Ala Asp
 35 40 45
 Trp Trp Asp Trp Ser Leu Thr Thr Leu Leu Asp Gly Leu Tyr Pro Gly
 50 55 60
 Gly Thr Pro Ser Ala Arg Val Pro Gly Ala Gln Pro Gly Ala Leu Gly
 65 70 75 80
 Gly Lys Cys Tyr Leu Ile Gly Ser Ser Val Ile Arg Gln Leu Lys Val
 85 90 95
 Phe Pro Arg His Leu Cys Lys Pro Pro Arg Pro Phe Ser Ala Leu Ile
 100 105 110
 Glu Asp Ser Ile Pro Thr Cys Ser Pro Glu Val Gly Gly Pro Glu Asn
 115 120 125
 Pro Tyr Leu Ile Asp Pro Glu Asn Gln Asn Val Thr Leu Asn Gly Pro
 130 135 140
 Gly Gly Cys Gly Thr Arg Glu Asp Cys Val Leu Ser Leu Gly Arg Thr
 145 150 155 160
 Arg Thr Glu Ala His Thr Ala Leu Ser Arg Leu Arg Ala Ser Met Trp
 165 170 175
 Ile Asp Arg Ser Thr Arg Ala Val Ser Val His Phe Thr Leu Tyr Asn
 180 185 190
 Pro Pro Thr Gln Leu Phe Thr Ser Val Ser Leu Arg Val Glu Ile Leu
 195 200 205
 Pro Thr Gly Ser Leu Val Pro Ser Ser Leu Val Glu Ser Phe Ser Ile
 210 215 220
 Phe Arg Ser Asp Ser Ala Leu Gln Tyr His Leu Met Leu Pro Gln Leu
 225 230 235 240
 Val Phe Leu Ala Leu Ser Leu Ile His Leu Cys Val Gln Leu Tyr Arg
 245 250 255
 Met Met Asp Lys Gly Val Leu Ser Tyr Trp Arg Lys Pro Arg Asn Trp
 260 265 270
 Leu Glu Leu Ser Val Val Gly Val Ser Leu Thr Tyr Tyr Ala Val Ser
 275 280 285
 Gly His Leu Val Thr Leu Ala Gly Asp Val Thr Asn Gln Phe His Arg
 290 295 300
 Gly Leu Cys Arg Ala Phe Met Asp Leu Thr Leu Met Ala Ser Trp Asn

65

305 310 315 320
 Gln Arg Ala Arg Trp Leu Arg Gly Ile Leu Leu Phe Leu Phe Thr Leu
 325 330 335
 Lys Cys Val Tyr Leu Pro Gly Ile Gln Asn Thr Met Ala Ser Cys Ser
 340 345 350
 Ser Met Met Arg His Ser Leu Pro Ser Ile Phe Val Ala Gly Leu Val
 355 360 365
 Gly Ala Leu Met Leu Ala Ala Leu Ser His Leu His Arg Phe Leu Leu
 370 375 380
 Ser Met Trp Val Leu Pro Pro Gly Thr Phe Thr Asp Ala Phe Pro Gly
 385 390 395 400
 Leu Leu Phe His Phe Pro Arg Arg Ser Gln Lys Asp Cys Leu Leu Gly
 405 410 415
 Leu Ser Lys Ser Asp Gln Arg Ala Met Ala Cys Tyr Phe Gly Ile Leu
 420 425 430
 Leu Ile Val Ser Ala Thr Leu Cys Phe Gly Met Leu Arg Gly Phe Leu
 435 440 445
 Met Thr Leu Pro Gln Lys Arg Lys Ser Phe Gln Ser Lys Ser Phe Val
 450 455 460
 Arg Leu Lys Asp Val Thr Ala Tyr Met Trp Glu Lys Val Leu Thr Phe
 465 470 475 480
 Leu Arg Leu Glu Thr Pro Lys Leu Glu Glu Ala Glu Met Val Glu Asn
 485 490 495
 His Asn Tyr Tyr Leu Asp Glu Phe Ala Asn Leu Leu Asp Glu Leu Leu
 500 505 510
 Met Lys Ile Asn Gly Leu Ser Asp Ser Leu Gln Leu Pro Leu Leu Glu
 515 520 525
 Lys Thr Ser Asn Asn Thr Gly Glu Ala Arg Thr Glu Glu Ser Pro Leu
 530 535 540
 Val Asp Ile Ser Ser Tyr Gln Ala Ala Glu Pro Ala Asp Ile Lys Asp
 545 550 555 560
 Phe

<210> 113
 <211> 363
 <212> PRT
 <213> Homo sapiens

<400> 113
 Met Gly Phe Leu Gln Leu Leu Val Val Ala Val Leu Ala Ser Glu His
 1 5 10 15
 Arg Val Ala Gly Ala Ala Glu Val Phe Gly Asn Ser Ser Glu Gly Leu
 20 25 30
 Ile Glu Phe Ser Val Gly Lys Phe Arg Tyr Phe Glu Leu Asn Arg Pro
 35 40 45

66

Phe Pro Glu Glu Ala Ile Leu His Asp Ile Ser Ser Asn Val Thr Phe
 50 55 60
 Leu Ile Phe Gln Ile His Ser Gln Tyr Gln Asn Thr Thr Val Ser Phe
 65 70 75 80
 Ser Pro Thr Leu Leu Ser Asn Ser Ser Glu Thr Gly Thr Ala Ser Gly
 85 90 95
 Leu Val Phe Ile Leu Arg Pro Glu Gln Ser Thr Cys Thr Trp Tyr Leu
 100 105 110
 Gly Thr Ser Gly Ile Gln Pro Val Gln Asn Met Ala Ile Leu Leu Ser
 115 120 125
 Tyr Ser Glu Arg Asp Pro Val Pro Gly Gly Cys Asn Leu Glu Phe Asp
 130 135 140
 Leu Asp Ile Asp Pro Asn Ile Tyr Leu Glu Tyr Asn Phe Phe Glu Thr
 145 150 155 160
 Thr Ile Lys Phe Ala Pro Ala Asn Leu Gly Tyr Ala Arg Gly Val Asp
 165 170 175
 Pro Pro Pro Cys Asp Ala Gly Thr Asp Gln Asp Ser Arg Trp Arg Leu
 180 185 190
 Gln Tyr Asp Val Tyr Gln Tyr Phe Leu Pro Glu Asn Asp Leu Thr Glu
 195 200 205
 Glu Met Leu Leu Lys His Leu Gln Arg Met Val Ser Val Pro Gln Val
 210 215 220
 Lys Ala Ser Ala Leu Lys Val Val Thr Leu Thr Ala Asn Asp Lys Thr
 225 230 235 240
 Ser Val Ser Phe Ser Ser Leu Pro Gly Gln Gly Val Ile Tyr Asn Val
 245 250 255
 Ile Val Trp Asp Leu Phe Leu Asn Thr Ser Ala Ala Tyr Ile Pro Ala
 260 265 270
 His Thr Tyr Ala Cys Ser Phe Glu Ala Gly Glu Gly Ser Cys Ala Ser
 275 280 285
 Leu Gly Arg Val Ser Ser Lys Val Phe Phe Thr Leu Phe Ala Leu Leu
 290 295 300
 Gly Phe Phe Ile Cys Phe Phe Gly Gln Arg Phe Trp Lys Thr Glu Leu
 305 310 315 320
 Phe Phe Ile Gly Phe Ile Ile Met Gly Phe Phe Phe Tyr Ile Leu Ile
 325 330 335
 Thr Arg Leu Thr Pro Ile Lys Tyr Asp Ala Glu His Thr Asp Leu Trp
 340 345 350
 Ser His Trp Leu Leu Phe Gly Gly Phe Ser His
 355 360

<210> 114
 <211> 103
 <212> PRT
 <213> Homo sapiens

67

<400> 114
 Met Asp Pro Ala Ala Val Ala Leu Leu Ala Leu Ser Leu Pro Cys Ala
 1 5 10 15
 Leu Val Gly Val Gln Trp Glu Gln Ala Pro Trp Gly Pro Trp Arg Leu
 20 25 30
 Ser Leu Leu Ser Pro His Pro Arg Asp Pro Ile Val Ala Pro Val Ser
 35 40 45
 Thr Gln Gly Leu Ser Gln Ala Trp Pro Glu Val Gly Arg Gly Gln Arg
 50 55 60
 Glu Pro His Arg Ser Leu Tyr Gln Pro Leu Ser Tyr His Arg Val Gly
 65 70 75 80
 Ala Leu Pro Ser His Arg Val Ser Gly Leu Trp Ala Pro Pro Ser Cys
 85 90 95
 Thr Gly Pro Arg Gly His Phe
 100

<210> 115
 <211> 90
 <212> PRT
 <213> Homo sapiens
 <220>
 <221> SITE
 <222> (5)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 115
 Val Thr Cys Gln Xaa Val Leu Pro Ser Pro Val Tyr Leu Cys Asn Tyr
 1 5 10 15
 Phe Cys Lys His Cys Ile Leu Cys Gly Arg His Leu Leu Ala Pro Ser
 20 25 30
 Leu Gly Phe Ser Leu Ser Ser Arg Pro Ala Cys Thr Ser Leu Gly Cys
 35 40 45
 Ser Gly Val Ser Ala Pro His Ser Arg Pro Gly Cys Gln Ala Gln Pro
 50 55 60
 Ala Gly Ala Arg Asp Pro Ala Ala Cys Pro Lys His Leu Phe Leu Gly
 65 70 75 80
 Asp Gly Val Gly Ala Ala Pro Gln Glu Val
 85 90

<210> 116
 <211> 445
 <212> PRT
 <213> Homo sapiens

<400> 116
 Met Ala Ala Pro Thr Pro Ala Arg Pro Val Leu Thr His Leu Leu Val
 1 5 10 15
 Ala Leu Phe Gly Met Gly Ser Trp Ala Ala Val Asn Gly Ile Trp Val
 20 25 30
 Glu Leu Pro Val Val Val Lys Glu Leu Pro Glu Gly Trp Ser Leu Pro

35					40					45				
Ser	Tyr	Val	Ser	Val	Leu	Val	Ala	Leu	Gly	Asn	Leu	Gly	Leu	Val
50					55					60				
Val	Thr	Leu	Trp	Arg	Arg	Leu	Ala	Pro	Gly	Lys	Asp	Glu	Gln	Val
65					70					75				80
Ile	Arg	Val	Val	Gln	Val	Leu	Gly	Met	Val	Gly	Thr	Ala	Leu	Ala
				85					90				95	
Ser	Leu	Trp	His	His	Val	Ala	Pro	Val	Ala	Gly	Gln	Leu	His	Ser
			100					105					110	Val
Ala	Phe	Leu	Ala	Leu	Ala	Phe	Val	Leu	Ala	Leu	Ala	Cys	Cys	Ala
			115				120					125		Pro
Asn	Val	Thr	Phe	Leu	Pro	Phe	Leu	Ser	His	Leu	Pro	Pro	Arg	Phe
						135					140			Leu
Arg	Ser	Phe	Phe	Leu	Gly	Gln	Gly	Leu	Ser	Ala	Leu	Leu	Pro	Cys
145						150					155			160
Leu	Ala	Leu	Val	Gln	Gly	Val	Gly	Arg	Leu	Glu	Cys	Pro	Pro	Ala
				165					170					175
Ile	Asn	Gly	Thr	Pro	Gly	Pro	Pro	Leu	Asp	Phe	Leu	Glu	Arg	Phe
			180					185					190	Pro
Ala	Ser	Thr	Phe	Phe	Trp	Ala	Leu	Thr	Ala	Leu	Leu	Val	Ala	Ser
			195				200					205		Ala
Ala	Ala	Phe	Gln	Gly	Leu	Leu	Leu	Leu	Pro	Pro	Pro	Pro	Ser	Val
						215			220					
Pro	Thr	Gly	Glu	Leu	Gly	Ser	Gly	Leu	Gln	Val	Gly	Ala	Pro	Gly
225						230					235			240
Glu	Glu	Glu	Val	Glu	Glu	Ser	Ser	Pro	Leu	Gln	Glu	Pro	Pro	Ser
				245					250					255
Ala	Ala	Gly	Thr	Thr	Pro	Gly	Pro	Asp	Pro	Lys	Ala	Tyr	Gln	Leu
			260					265					270	Leu
Ser	Ala	Arg	Ser	Ala	Cys	Leu	Leu	Gly	Leu	Leu	Ala	Ala	Thr	Asn
			275				280					285		Ala
Leu	Thr	Asn	Gly	Val	Leu	Pro	Ala	Val	Gln	Ser	Phe	Ser	Cys	Leu
						295					300			Pro
Tyr	Gly	Arg	Leu	Ala	Tyr	His	Leu	Ala	Val	Val	Leu	Gly	Ser	Ala
305						310					315			320
Asn	Pro	Leu	Ala	Cys	Phe	Leu	Ala	Met	Gly	Val	Leu	Cys	Arg	Ser
				325					330					335
Ala	Gly	Leu	Gly	Gly	Leu	Ser	Leu	Leu	Gly	Val	Phe	Cys	Gly	Gly
			340					345					350	Tyr
Leu	Met	Ala	Leu	Ala	Val	Leu	Ser	Pro	Cys	Pro	Pro	Leu	Val	Gly
			355				360					365		Thr
Ser	Ala	Gly	Val	Val	Leu	Val	Val	Leu	Ser	Trp	Val	Leu	Cys	Leu
						375					380			Gly
Val	Phe	Ser	Tyr	Val	Lys	Val	Ala	Ala	Ser	Ser	Leu	Leu	His	Gly
														Gly


```
<210> 117
<211> 363
<212> PRT
<213> Homo sapiens
```

<400>	117															
Met	Glu	Arg	Arg	Arg	Leu	Leu	Gly	Gly	Met	Ala	Leu	Leu	Leu	Leu	Gln	
1				5					10						15	
Ala	Leu	Pro	Ser	Pro	Leu	Ser	Ala	Arg	Ala	Glu	Pro	Pro	Gln	Asp	Lys	
			20					25					30			
Glu	Ala	Cys	Val	Gly	Thr	Asn	Asn	Gln	Ser	Tyr	Ile	Cys	Asp	Thr	Gly	
		35					40					45				
His	Cys	Cys	Gly	Gln	Ser	Gln	Cys	Cys	Asn	Tyr	Tyr	Tyr	Glu	Leu	Trp	
	50					55					60					
Trp	Phe	Trp	Leu	Val	Trp	Thr	Ile	Ile	Ile	Ile	Leu	Ser	Cys	Cys	Cys	
65					70				75						80	
Val	Cys	His	His	Arg	Arg	Ala	Lys	His	Arg	Leu	Gln	Ala	Gln	Gln	Arg	
				85					90					95		
Gln	His	Glu	Ile	Asn	Leu	Ile	Ala	Tyr	Arg	Glu	Ala	His	Asn	Tyr	Ser	
			100					105					110			
Ala	Leu	Pro	Phe	Tyr	Phe	Arg	Phe	Leu	Pro	Asn	Tyr	Leu	Leu	Pro	Pro	
		115					120					125				
Tyr	Glu	Glu	Val	Val	Asn	Arg	Pro	Pro	Thr	Pro	Pro	Pro	Pro	Tyr	Ser	
	130					135					140					
Ala	Phe	Gln	Leu	Gln	Gln	Gln	Gln	Leu	Leu	Pro	Pro	Gln	Cys	Gly	Pro	
145					150					155					160	
Ala	Gly	Gly	Ser	Pro	Pro	Gly	Ile	Asp	Pro	Thr	Arg	Gly	Ser	Gln	Gly	
				165					170					175		
Ala	Gln	Ser	Ser	Pro	Leu	Ser	Glu	Pro	Ser	Arg	Ser	Ser	Thr	Arg	Pro	
			180					185					190			
Pro	Ser	Ile	Ala	Asp	Pro	Asp	Pro	Ser	Asp	Leu	Pro	Val	Asp	Arg	Ala	
		195					200					205				
Ala	Thr	Lys	Ala	Pro	Gly	Met	Glu	Pro	Ser	Gly	Ser	Val	Ala	Gly	Leu	
	210					215					220					
Gly	Glu	Leu	Asp	Pro	Gly	Ala	Phe	Leu	Asp	Lys	Asp	Ala	Glu	Cys	Arg	
225					230					235					240	
Glu	Glu	Leu	Leu	Lys	Asp	Asp	Ser	Ser	Glu	His	Gly	Ala	Pro	Asp	Ser	
				245					250					255		

70

Lys Glu Lys Thr Pro Gly Arg His Arg Arg Phe Thr Gly Asp Ser Gly
 260 265 270
 Ile Glu Val Cys Val Cys Asn Arg Gly His His Asp Asp Asp Leu Lys
 275 280 285
 Glu Val Asn Thr Leu Ile Asp Asp Ala Leu Asp Gly Pro Leu Asp Phe
 290 295 300
 Cys Asp Ser Cys His Val Arg Pro Pro Gly Asp Glu Glu Glu Gly Leu
 305 310 315 320
 Cys Gln Pro Ser Glu Glu Gln Ala Arg Glu Pro Gly His Pro His Leu
 325 330 335
 Pro Arg Pro Pro Ala Cys Leu Leu Leu Asn Thr Ile Asn Glu Gln Asp
 340 345 350
 Ser Pro Asn Ser Gln Ser Asn Ser Ser Pro Ser
 355 360

<210> 118
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 118
 Met Glu Phe Val Ser Gly Gly Lys Thr Glu Ile Leu Met Leu Phe Thr
 1 5 10 15
 Leu Leu Val Ser Cys Tyr Val Phe Leu Pro Leu Ala Leu Pro Cys Phe
 20 25 30
 Ala Phe Phe Phe Ser Phe Trp Pro Ile Pro Phe Tyr Met Cys Pro Gln
 35 40 45
 Gln Arg Trp Gly Asp Thr Glu His Pro Gly Ser Phe Pro Ala Leu Leu
 50 55 60
 Gly Arg Pro Arg Leu Gln Ala Pro Ala Val Glu Thr Leu Lys Gly Asn
 65 70 75 80
 Lys Gln Pro Ser Thr Leu Pro Asp Pro Arg Leu Phe Arg Glu Ala Ala
 85 90 95
 His Phe His Pro Gly Pro Arg Thr Pro Ser Leu Cys Pro Thr Arg Ile
 100 105 110
 Ser Leu Asn Gly Arg Asp
 115

<210> 119
 <211> 438
 <212> PRT
 <213> Homo sapiens

<400> 119
 Leu Thr Ile Thr Val His Asp Pro Asn Ala Ala Gln Trp Tyr Tyr Gly
 1 5 10 15
 Met Ser Trp Gly Leu Arg Leu Tyr Ile Pro Gly Phe Asp Val Gly Thr
 20 25 30
 Met Phe Thr Ile Gln Lys Lys Ile Leu Val Ser Trp Ser Pro Pro Lys

35					40					45					
Pro	Ile	Arg	Pro	Leu	Thr	Asp	Leu	Gly	Asp	Pro	Ile	Phe	Gln	Lys	His
	50					55					60				
Pro	Asp	Lys	Val	Asp	Leu	Thr	Val	Pro	Gln	Pro	Phe	Leu	Val	Pro	Arg
	65					70					75				80
Pro	Gln	Leu	Gln	Gln	Gln	His	Leu	Gln	Pro	Ser	Leu	Met	Ser	Ile	Leu
				85					90					95	
Gly	Gly	Val	His	His	Leu	Leu	Asn	Leu	Thr	Gln	Pro	Lys	Leu	Ala	Gln
			100					105					110		
Asp	Cys	Trp	Leu	Cys	Leu	Lys	Ala	Lys	Pro	Pro	Tyr	Tyr	Val	Gly	Leu
		115					120					125			
Gly	Val	Glu	Ala	Thr	Leu	Lys	Arg	Gly	Pro	Leu	Ser	Cys	His	Thr	Arg
	130					135					140				
Pro	Arg	Ala	Leu	Thr	Ile	Gly	Asp	Val	Ser	Gly	Asn	Ala	Ser	Cys	Leu
	145					150					155				160
Ile	Ser	Thr	Gly	Tyr	Asn	Leu	Ser	Ala	Ser	Pro	Phe	Gln	Ala	Thr	Cys
				165					170					175	
Asn	Gln	Ser	Leu	Leu	Thr	Tyr	Ile	Ser	Thr	Ser	Val	Ser	Tyr	Gln	Ala
			180					185					190		
Pro	Asn	Asn	Thr	Trp	Leu	Ala	Cys	Thr	Ser	Gly	Leu	Thr	Arg	Cys	Ile
		195					200					205			
Asn	Gly	Thr	Glu	Pro	Gly	Pro	Leu	Leu	Cys	Val	Leu	Val	His	Val	Leu
	210					215					220				
Pro	Gln	Val	Tyr	Val	Tyr	Ser	Gly	Pro	Glu	Gly	Arg	Gln	Leu	Ile	Ala
	225					230					235				240
Pro	Pro	Glu	Leu	His	Pro	Arg	Leu	His	Gln	Ala	Val	Pro	Leu	Leu	Val
				245					250					255	
Pro	Leu	Leu	Ala	Gly	Leu	Ser	Ile	Ala	Gly	Ser	Ala	Ala	Ile	Gly	Thr
			260					265					270		
Ala	Ala	Leu	Val	Gln	Gly	Glu	Thr	Gly	Leu	Ile	Ser	Leu	Ser	Gln	Gln
		275					280					285			
Val	Asp	Ala	Asp	Phe	Ser	Asn	Leu	Gln	Ser	Ala	Ile	Asp	Ile	Leu	His
	290					295					300				
Ser	Gln	Val	Glu	Ser	Leu	Ala	Glu	Val	Val	Leu	Gln	Asn	Cys	Arg	Cys
	305					310					315				320
Leu	Asp	Leu	Leu	Phe	Leu	Ser	Gln	Gly	Gly	Leu	Cys	Ala	Ala	Leu	Gly
				325					330					335	
Glu	Ser	Cys	Cys	Phe	Tyr	Ala	Asn	Gln	Ser	Gly	Val	Ile	Lys	Gly	Thr
			340					345					350		
Val	Lys	Lys	Val	Arg	Glu	Asn	Leu	Asp	Arg	His	Gln	Gln	Glu	Arg	Glu
		355					360					365			
Asn	Asn	Ile	Pro	Trp	Tyr	Gln	Ser	Met	Phe	Asn	Trp	Asn	Pro	Trp	Leu
		370				375					380				
Thr	Thr	Leu	Ile	Thr	Gly	Leu	Ala	Gly	Pro	Leu	Leu	Ile	Leu	Leu	Leu

```
<210> 120
<211> 322
<212> PRT
<213> Homo sapiens
```

<400>	120															
Met	Ala	Leu	Pro	Pro	Gly	Pro	Ala	Ala	Leu	Arg	His	Thr	Leu	Leu	Leu	
1				5					10					15		
Leu	Pro	Ala	Leu	Leu	Ser	Ser	Gly	Trp	Gly	Glu	Leu	Glu	Pro	Gln	Ile	
			20					25					30			
Asp	Gly	Gln	Thr	Trp	Ala	Glu	Arg	Ala	Leu	Arg	Glu	Asn	Glu	Arg	His	
		35					40					45				
Ala	Phe	Thr	Cys	Arg	Val	Ala	Gly	Gly	Pro	Gly	Thr	Pro	Arg	Leu	Ala	
	50					55					60					
Trp	Tyr	Leu	Asp	Gly	Gln	Leu	Gln	Glu	Ala	Ser	Thr	Ser	Arg	Leu	Leu	
65				70						75					80	
Ser	Val	Gly	Gly	Glu	Ala	Phe	Ser	Gly	Gly	Thr	Ser	Thr	Phe	Thr	Val	
				85					90					95		
Thr	Ala	His	Arg	Ala	Gln	His	Glu	Leu	Asn	Cys	Ser	Leu	Gln	Asp	Pro	
			100					105					110			
Arg	Ser	Gly	Arg	Ser	Ala	Asn	Ala	Ser	Val	Ile	Leu	Asn	Val	Gln	Phe	
		115					120					125				
Lys	Pro	Glu	Ile	Ala	Gln	Val	Gly	Ala	Lys	Tyr	Gln	Glu	Ala	Gln	Gly	
	130					135					140					
Pro	Gly	Leu	Leu	Val	Val	Leu	Phe	Ala	Leu	Val	Arg	Ala	Asn	Pro	Pro	
145				150						155					160	
Ala	Asn	Val	Thr	Trp	Ile	Asp	Gln	Asp	Gly	Pro	Val	Thr	Val	Asn	Thr	
			165						170					175		
Ser	Asp	Phe	Leu	Val	Leu	Asp	Ala	Gln	Asn	Tyr	Pro	Trp	Leu	Thr	Asn	
		180						185					190			
His	Thr	Val	Gln	Leu	Gln	Leu	Arg	Ser	Leu	Ala	His	Asn	Leu	Ser	Val	
		195					200					205				
Val	Ala	Thr	Asn	Asp	Val	Gly	Val	Thr	Ser	Ala	Ser	Leu	Pro	Ala	Pro	
	210					215					220					
Gly	Pro	Ser	Arg	His	Pro	Ser	Leu	Ile	Ser	Ser	Asp	Ser	Asn	Asn	Leu	
225					230					235					240	
Lys	Leu	Asn	Asn	Val	Arg	Leu	Pro	Arg	Glu	Asn	Met	Ser	Leu	Pro	Ser	
			245						250					255		

73

Asn Leu Gln Leu Asn Asp Leu Thr Pro Asp Ser Arg Ala Val Lys Pro
 260 265 270
 Ala Asp Arg Gln Met Ala Gln Asn Asn Ser Arg Pro Glu Leu Leu Asp
 275 280 285
 Pro Glu Pro Gly Gly Leu Leu Thr Ser Gln Gly Phe Ile Arg Leu Pro
 290 295 300
 Val Leu Gly Tyr Ile Tyr Arg Val Ser Ser Val Ser Ser Asp Glu Ile
 305 310 315 320
 Trp Leu

<210> 121
 <211> 264
 <212> PRT
 <213> Homo sapiens

<400> 121
 Met Leu Arg Leu Phe Glu Thr Phe Leu Glu Thr Ala Pro Gln Leu Thr
 1 5 10 15
 Leu Val Leu Ala Ile Met Leu Gln Ser Gly Arg Ala Glu Tyr Tyr Gln
 20 25 30
 Trp Val Gly Ile Cys Thr Ser Phe Leu Gly Ile Ser Trp Ala Leu Leu
 35 40 45
 Asp Tyr His Arg Ala Leu Arg Thr Cys Leu Pro Ser Lys Pro Leu Leu
 50 55 60
 Gly Leu Gly Ser Ser Val Ile Tyr Phe Leu Trp Asn Leu Leu Leu Leu
 65 70 75 80
 Trp Pro Arg Val Leu Ala Val Ala Leu Phe Ser Ala Leu Phe Pro Ser
 85 90 95
 Tyr Val Ala Leu His Phe Leu Gly Leu Trp Leu Val Leu Leu Leu Trp
 100 105 110
 Val Trp Leu Gln Gly Thr Asp Phe Met Pro Asp Pro Ser Ser Glu Trp
 115 120 125
 Leu Tyr Arg Val Thr Val Ala Thr Ile Leu Tyr Phe Ser Trp Phe Asn
 130 135 140
 Val Ala Glu Gly Arg Thr Arg Gly Arg Ala Ile Ile His Phe Ala Phe
 145 150 155 160
 Leu Leu Ser Asp Ser Ile Leu Leu Val Ala Thr Trp Val Thr His Ser
 165 170 175
 Ser Trp Leu Pro Ser Gly Ile Pro Leu Gln Leu Trp Leu Pro Val Gly
 180 185 190
 Cys Gly Cys Phe Phe Leu Gly Leu Ala Leu Arg Leu Val Tyr Tyr His
 195 200 205
 Trp Leu His Pro Ser Cys Cys Trp Lys Pro Asp Pro Asp Gln Val Asp
 210 215 220
 Gly Ala Arg Ser Leu Leu Ser Pro Glu Gly Tyr Gln Leu Pro Gln Asn
 225 230 235 240

Arg Arg Met Thr His Leu Ala Gln Lys Phe Phe Pro Lys Ala Lys Asp
245 250 255

Glu Ala Ala Ser Pro Val Lys Gly
260

```
<210> 122
<211> 155
<212> PRT
<213> Homo sapiens
```

```

<400> 122
Met Phe Phe Phe Leu Phe Pro Trp Val Leu Leu Ser Leu Pro Ser Ser
  1          5          10          15
Ser Leu Pro Leu Ser Leu Leu Tyr Ser Ser Leu Ser Leu Ser Ile Cys
          20          25          30
Pro Ser Leu Leu Gln Val Leu Pro Gln Pro Gln Asp Ser Ser Ala Ser
          35          40          45
Leu Asp Thr Ser His Pro Ala Pro Asp Arg Ser Pro Pro Ser Leu Leu
  50          55          60
Ile Leu Arg Ala Leu Ser Ile Cys Leu Ser Pro Cys Gln Arg Pro
  65          70          75          80
Cys Cys Ala Pro Gly Gly Ala Thr His Leu Pro Gly Asn Ser Thr Phe
          85          90          95
Ser His Ala Pro Asp Cys Ser Leu His Ser Ser Arg Leu Ala Gln Ser
          100          105          110
Pro Val Thr His Cys Ser Ser Gly Ser Leu Gly Leu Ser Ala His Gly
          115          120          125
His Leu His Ala His Pro Ser Ile Ser Val Ser Pro His Leu Ser Leu
          130          135          140
Ser Ile Ser Asn Pro Cys Ser Ser Thr Lys His
          145          150          155

```

```
<210> 123
<211> 5
<212> PRT
<213> Homo sapiens
```

```
<400> 123
Met Ser Arg Leu Leu
  1                               5
```

```
<210> 124
<211> 42
<212> PRT
<213> Homo sapiens
```

```

<400> 124
Met Phe Leu Phe Ile Thr Phe Thr Ile Leu Ala Ile Phe Ile Ile Glu
. 1 5 10 15
Pro Arg Asn Leu Arg Val Asp Leu Asn Leu Ile Lys Phe Gln Thr Ser
20 25 30

```

75

Trp Pro Lys Thr Leu Val Glu Glu Gln Asn
 35 40

<210> 125
 <211> 91
 <212> PRT
 <213> Homo sapiens

<400> 125
 Met Val Leu Arg Gly Trp Gly Leu Ala Trp Ser Leu Ser Pro Val Val
 1 5 10 15
 Cys Gly Tyr Ser Gly Asp Met Lys Gly Val Cys Trp Gly Arg Ser Asp
 20 25 30
 His Ser Leu Leu Pro Ser Glu Ile Leu Leu Pro Pro Ala Pro Cys Pro
 35 40 45
 Ser Ser Ala Val Leu His Asn Pro Pro Pro Thr Pro His Leu Pro Ser
 50 55 60
 Pro Val Leu Val Arg Ile Gln Glu Ala Pro Thr Trp Ala Gln Arg Ser
 65 70 75 80
 Ser Leu Gly Ala Ser Pro Leu His Lys Gly Asp
 85 90

<210> 126
 <211> 13
 <212> PRT
 <213> Homo sapiens

<400> 126
 Met Lys Ser Leu His Gly Arg Leu Leu Trp Gln Ser Ala
 1 5 10

<210> 127
 <211> 71
 <212> PRT
 <213> Homo sapiens

<400> 127
 Met Leu Val Lys Gly Glu Gly Val Arg Leu Val Leu Arg Leu Leu Gly
 1 5 10 15
 Arg Asn Gly Leu His Leu Ala Pro Leu Pro Ala Leu Leu Leu His Phe
 20 25 30
 Leu Met Leu Pro Leu Ser Ala Pro Val Ala Tyr Ser Leu Pro Ala Gly
 35 40 45
 Ala Cys Leu Gln Gly Thr Gly Ser Ser Ser Leu Leu Leu Cys Gln Val
 50 55 60
 Gln Leu Leu Thr Ala Arg Glu
 65 70

<210> 128
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 128

Asp Leu His Ile Lys Leu Leu Glu His Tyr Cys Leu Thr Ser Cys Lys
 1 5 10 15

Lys Val Leu Gln Leu
 20

<210> 129

<211> 35

<212> PRT

<213> Homo sapiens

<400> 129

Met Val Ser Lys Pro Trp Gly Val Phe Ile Ser Phe Ser Phe Ile Ser
 1 5 10 15

Leu Ser Phe Tyr His Ala Ile Ser Ile Ser Ser Val Pro Ser Gly Arg
 20 25 30

Gln Val Val
 35

<210> 130

<211> 58

<212> PRT

<213> Homo sapiens

<400> 130

Met Trp Lys Val Leu Arg Pro Ser Leu Phe Thr Ala Gly Leu Phe Thr
 1 5 10 15

Ala Ser Phe Phe Tyr Ser Asp Leu Lys Val Ser Thr Glu Leu Met Lys
 20 25 30

Leu Gln His Met Val Phe Lys Ser Phe Pro Leu Lys Cys Thr Leu Glu
 35 40 45

Asn Trp Val Pro Gln Pro Gln Leu Leu Asn
 50 55

<210> 131

<211> 62

<212> PRT

<213> Homo sapiens

<400> 131

Met Phe Cys Arg Asn Trp Arg Cys Glu Phe Met Met Leu Ser His Asn
 1 5 10 15

Thr Ala Val Met Ile Cys Ser Phe Ser Gln Asn Asp Phe His Ala Ala
 20 25 30

Leu Cys Cys Ser Ser Val Ser Glu Leu Pro Tyr Leu Phe Leu Val Cys
 35 40 45

Ser Thr Tyr Lys Cys Ser Cys His Ala Val Leu Phe Phe Cys
 50 55 60

<210> 132

<211> 31

<212> PRT

<213> Homo sapiens

<400> 132

Met Phe Glu Ala Leu Trp Ala Thr Asp Tyr Leu Cys Cys Leu Phe Leu
 1 5 10 15

Phe Val Ser Phe Phe Arg Pro Leu Gln Lys Cys Lys Asn His Ser
 20 25 30

<210> 133

<211> 56

<212> PRT

<213> Homo sapiens

<400> 133

Met Met Ile Tyr Phe Ala Leu Leu Leu Ala Ser Leu Phe Phe Leu Leu
 1 5 10 15

Lys Val Lys Ser His Phe Gly Cys Lys Asn Val Thr Thr Thr Ser Ala
 20 25 30

Arg Ile Phe Leu Lys Pro Leu Cys Thr Pro Lys Ser Ile Phe Pro Leu
 35 40 45

Ser Arg Tyr Gly Arg Met Ser Ser
 50 55

<210> 134

<211> 359

<212> PRT

<213> Homo sapiens

<400> 134

Met Lys Leu Gly Cys Val Leu Met Ala Trp Ala Leu Tyr Leu Ser Leu
 1 5 10 15

Gly Val Leu Trp Val Ala Gln Met Leu Leu Ala Ala Ser Phe Glu Thr
 20 25 30

Leu Gln Cys Glu Gly Pro Val Cys Thr Glu Glu Ser Ser Cys His Thr
 35 40 45

Glu Asp Asp Leu Thr Asp Ala Arg Glu Ala Gly Phe Gln Val Lys Ala
 50 55 60

Tyr Thr Phe Ser Glu Pro Phe His Leu Ile Val Ser Tyr Asp Trp Leu
 65 70 75 80

Ile Leu Gln Gly Pro Ala Lys Pro Val Phe Glu Gly Asp Leu Leu Val
 85 90 95

Leu Arg Cys Gln Ala Trp Gln Asp Trp Pro Leu Thr Gln Val Thr Phe
 100 105 110

Tyr Arg Asp Gly Ser Ala Leu Gly Pro Pro Gly Pro Asn Arg Glu Phe
 115 120 125

Ser Ile Thr Val Val Gln Lys Ala Asp Ser Gly His Tyr His Cys Ser
 130 135 140

Gly Ile Phe Gln Ser Pro Gly Pro Gly Ile Pro Glu Thr Ala Ser Val
 145 150 155 160

Val Ala Ile Thr Val Gln Glu Leu Phe Pro Ala Pro Ile Leu Arg Ala

78

165 170 175
 Val Pro Ser Ala Glu Pro Gln Ala Gly Gly Pro Met Thr Leu Ser Cys
 180 185 190
 Gln Thr Lys Leu Pro Leu Gln Arg Ser Ala Ala Arg Leu Leu Phe Ser
 195 200 205
 Phe Tyr Lys Asp Gly Arg Ile Val Gln Ser Arg Gly Leu Ser Ser Glu
 210 215 220
 Phe Gln Ile Pro Thr Ala Ser Glu Asp His Ser Gly Ser Tyr Trp Cys
 225 230 235 240
 Glu Ala Ala Thr Glu Asp Asn Gln Val Trp Lys Gln Ser Pro Gln Leu
 245 250 255
 Glu Ile Arg Val Gln Gly Ala Ser Ser Ser Ala Ala Pro Pro Thr Leu
 260 265 270
 Asn Pro Ala Pro Gln Lys Ser Ala Ala Pro Gly Thr Ala Pro Glu Glu
 275 280 285
 Ala Pro Gly Pro Leu Pro Pro Pro Pro Thr Pro Ser Ser Glu Asp Pro
 290 295 300
 Gly Phe Ser Ser Pro Leu Gly Met Pro Asp Pro His Leu Tyr His Gln
 305 310 315 320
 Met Gly Leu Leu Leu Lys His Met Gln Asp Val Arg Val Leu Leu Gly
 325 330 335
 His Leu Leu Met Glu Leu Arg Glu Leu Ser Gly His Arg Lys Pro Gly
 340 345 350
 Thr Thr Lys Ala Thr Ala Glu
 355

<210> 135
 <211> 25
 <212> PRT
 <213> Homo sapiens

<400> 135
 Met Ile Ser Leu Leu Trp Thr Leu Lys Leu Phe Ser Arg Asn Leu Asp
 1 5 10 15
 Tyr Ser Gln Lys Arg Lys Ser Trp Cys
 20 25

<210> 136
 <211> 143
 <212> PRT
 <213> Homo sapiens

<400> 136
 Met Val Cys Gly Trp Ile Ile Tyr Gly Ser Phe Ile Tyr Leu Ser Ser
 1 5 10 15
 His Cys Ala Thr Thr Phe Lys Glu Asp Gly Leu Trp Thr Tyr Leu Asn
 20 25 30
 Gln Ile Val Ala Cys Ser Pro Trp Val Leu Tyr Ile Leu Met Leu Ala
 35 40 45

Thr Phe His Phe Ser Trp Ser Thr Phe Leu Leu Leu Asn Gln Leu Phe
 50 55 60
 Gln Ile Ala Phe Leu Gly Leu Thr Ser His Glu Arg Ile Ser Leu Gln
 65 70 75 80
 Lys Gln Ser Lys His Met Lys Gln Thr Leu Ser Leu Arg Lys Thr Pro
 85 90 95
 Tyr Asn Leu Gly Phe Met Gln Asn Leu Ala Asp Phe Phe Gln Cys Gly
 100 105 110
 Cys Phe Gly Leu Val Lys Pro Cys Val Val Asp Trp Thr Ser Gln Tyr
 115 120 125
 Thr Met Val Phe His Pro Ala Arg Glu Lys Val Leu Arg Ser Val
 130 135 140

<210> 137
 <211> 35
 <212> PRT
 <213> Homo sapiens

<400> 137
 Met Leu Asn Asp Gly Lys Val Trp Val Ser Cys Phe Cys Val Val Leu
 1 5 10 15
 Thr Ser Leu Asp Phe Cys Ser Phe Cys Ser Leu Trp Ala Ser Val Leu
 20 25 30
 Ser Leu Ile
 35

<210> 138
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 138
 Met Lys Asn Ser Phe Phe Thr Val Ser Trp Ala Leu Thr Cys Ser Phe
 1 5 10 15
 Ser Trp Ala Thr Val
 20

<210> 139
 <211> 50
 <212> PRT
 <213> Homo sapiens

<400> 139
 Met Leu Leu Leu Val Val Thr Leu Val Asn Leu Ser Ile Tyr Lys Leu
 1 5 10 15
 Ile Lys Leu Val Thr Ala Leu Ser Lys Lys Leu Gly Ala Lys Gly Val
 20 25 30
 Leu Lys Asn Ala His Phe Met Arg Cys Asn Cys Gly Glu Met Arg Thr
 35 40 45
 Arg Ser
 50

80

<210> 140
 <211> 26
 <212> PRT
 <213> Homo sapiens

<400> 140
 Met Cys Val Ser Pro Val Ser Val Cys Pro Phe Leu Pro Ser Leu His
 1 5 10 15
 Phe Ile Asn Asn Trp Cys Asn Val Ser Ser
 20 25

<210> 141
 <211> 39
 <212> PRT
 <213> Homo sapiens

<400> 141
 Met Pro Leu Phe Arg Thr Phe Lys Gln Leu Gly Leu Phe Leu Phe Leu
 1 5 10 15
 Ile Ile Pro Ile Ile Cys Ser Ser Leu Pro Pro Leu Gly Pro Val Gln
 20 25 30
 Ser Phe Leu Gly Cys Leu Tyr
 35

<210> 142
 <211> 353
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (260)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 142
 Met Pro Trp Pro Leu Leu Leu Leu Leu Ala Val Ser Gly Ala Gln Thr
 1 5 10 15
 Thr Arg Pro Cys Phe Pro Gly Cys Gln Cys Glu Val Glu Thr Phe Gly
 20 25 30
 Leu Phe Asp Ser Phe Ser Leu Thr Arg Val Asp Cys Ser Gly Leu Gly
 35 40 45
 Pro His Ile Met Pro Val Pro Ile Pro Leu Asp Thr Ala His Leu Asp
 50 55 60
 Leu Ser Ser Asn Arg Leu Glu Met Val Asn Glu Ser Val Leu Ala Gly
 65 70 75 80
 Pro Gly Tyr Thr Thr Leu Ala Gly Leu Asp Leu Ser His Asn Leu Leu
 85 90 95
 Thr Ser Ile Ser Pro Thr Ala Phe Ser Arg Leu Arg Tyr Leu Glu Ser
 100 105 110
 Leu Asp Leu Ser His Asn Gly Leu Thr Ala Leu Pro Ala Glu Ser Phe
 115 120 125

81

Thr Ser Ser Pro Leu Ser Asp Val Asn Leu Ser His Asn Gln Leu Arg
 130 135 140
 Glu Val Ser Val Ser Ala Phe Thr Thr His Ser Gln Gly Arg Ala Leu
 145 150 155 160
 His Val Asp Leu Ser His Asn Leu Ile His Arg Leu Val Pro His Pro
 165 170 175
 Thr Arg Ala Gly Leu Pro Ala Pro Thr Ile Gln Ser Leu Asn Leu Ala
 180 185 190
 Trp Asn Arg Leu His Ala Val Pro Asn Leu Arg Asp Leu Pro Leu Arg
 195 200 205
 Tyr Leu Ser Leu Asp Gly Asn Pro Leu Ala Val Ile Gly Pro Gly Ala
 210 215 220
 Phe Ala Gly Leu Gly Gly Leu Thr His Leu Ser Leu Ala Ser Leu Gln
 225 230 235 240
 Arg Leu Pro Glu Leu Ala Pro Ser Gly Phe Arg Glu Leu Pro Gly Leu
 245 250 255
 Gln Val Leu Xaa Leu Ser Gly Asn Pro Lys Leu Asn Trp Ala Gly Ala
 260 265 270
 Glu Val Phe Ser Gly Leu Ser Ser Leu Gln Glu Leu Asp Leu Ser Gly
 275 280 285
 Thr Asn Leu Val Pro Leu Pro Glu Ala Leu Leu Leu His Leu Pro Ala
 290 295 300
 Leu Gln Ser Val Ser Val Gly Gln Asp Val Arg Cys Arg Arg Leu Val
 305 310 315 320
 Arg Glu Gly Thr Tyr Pro Arg Arg Pro Gly Ser Ser Pro Lys Val Ala
 325 330 335
 Leu His Cys Val Asp Thr Arg Glu Ser Ala Ala Arg Gly Pro Thr Ile
 340 345 350
 Leu

<210> 143
 <211> 199
 <212> PRT
 <213> Homo sapiens

<400> 143
 Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
 1 5 10 15
 Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
 20 25 30
 Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
 35 40 45
 Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
 50 55 60
 Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
 65 70 75 80

Lys	Phe	Cys	His	Ser 85	Gln	Leu	Ser	Asn	Asn 90	Ser	Val	Ser	Phe	Phe 95	Leu
Tyr	Asn	Leu	Asp 100	His	Ser	His	Ala	Asn 105	Tyr	Tyr	Phe	Cys	Asn 110	Leu	Ser
Ile	Phe	Asp 115	Pro	Pro	Pro	Phe	Lys 120	Val	Thr	Leu	Thr	Gly 125	Gly	Tyr	Leu
His	Ile 130	Tyr	Glu	Ser	Gln	Leu 135	Cys	Cys	Gln	Leu	Lys 140	Phe	Trp	Leu	Pro
Ile 145	Gly	Cys	Ala	Ala	Phe 150	Val	Val	Val	Cys	Ile 155	Leu	Gly	Cys	Ile	Leu 160
Ile	Cys	Trp	Leu	Thr 165	Lys	Lys	Lys	Tyr	Ser 170	Ser	Ser	Val	His	Asp 175	Pro
Asn	Gly	Glu	Tyr 180	Met	Phe	Met	Arg	Ala 185	Val	Asn	Thr	Ala	Lys 190	Lys	Ser
Arg	Leu	Thr 195	Asp	Val	Thr	Leu									

```
<210> 144
<211> 74
<212> PRT
<213> Homo sapiens
```

```

<400> 144
Leu Ala Leu His Arg Cys Ser Leu Ser Cys Leu Gln Val Ser Val Cys
  1                               10                      15
Gly Val Gly Tyr Gly Glu Glu Asn Leu His Gly Gly Pro Pro Gly Leu
                20                      25                      30
Val Val Gln Ala Val Pro Arg His Ile Leu Ile Pro Ser Met Gly His
          35                          40                      45
Leu Lys Met Asn Asn Asn Ser Gln Asn Phe Cys Glu Ile Lys Ser Ser
  50                      55                      60
Phe Lys Arg Ser His Leu Ser Lys Arg Phe
  65                      70

```

```
<210> 145
<211> 85
<212> PRT
<213> Homo sapiens
```

```
<220>  
<221> SITE  
<222> (81)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 145
Met Asp Ile Leu Met Leu Leu Leu Leu Cys Val Ile Tyr Gly Arg
1 5 10 15

[illegible]

```
<210> 146
<211> 114
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (7)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>  
<221> SITE  
<222> (111)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

```

<400> 146
Gln Arg Ala Met Ala Cys Xaa Phe Gly Ile Leu Leu Ile Val Ser Ala
  1          5          10          15
Thr Leu Cys Phe Gly Xaa Leu Xaa Gly Phe Leu Met Thr Leu Pro Gln
          20          25          30
Lys Arg Lys Ser Phe Gln Ser Lys Ser Phe Val Arg Leu Lys Asp Val
          35          40          45
Thr Ala Tyr Met Trp Glu Lys Val Leu Thr Phe Leu Arg Leu Glu Thr
          50          55          60
Pro Lys Leu Glu Glu Ala Glu Met Val Glu Asn His Asn Tyr Tyr Leu
          65          70          75          80
Asp Glu Phe Ala Asn Leu Leu Asp Glu Leu Leu Met Lys Ile Asn Gly
          85          90          95
Leu Ser Asp Ser Leu Gln Leu Pro Leu Leu Glu Lys Thr Ser Xaa Asn
          100          105          110
Thr Gly

```

<210> 147
 <211> 59
 <212> PRT
 <213> Homo sapiens

<400> 147
 Met Gly Asn Gln Asp Glu Asn Gln Gly Leu Ser Val Ile Arg Leu Leu
 1 5 10 15
 Leu Ile Ile Thr Ile Arg Arg Val Gln Met Trp Asp Lys Ile Leu Thr
 20 25 30
 Pro Ala Phe Ser Gln Met Val Asn Leu Pro Val Ala Leu Glu Leu His
 35 40 45
 Ile Val Leu Phe Val Cys Phe Thr Glu Ser Val
 50 55

<210> 148
 <211> 285
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (259)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (262)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (280)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 148
 Met Gly Phe Leu Gln Leu Leu Val Val Ala Val Leu Ala Ser Glu His
 1 5 10 15
 Arg Val Ala Gly Ala Ala Glu Val Phe Gly Asn Ser Ser Glu Gly Leu
 20 25 30
 Ile Glu Phe Ser Val Gly Lys Phe Arg Tyr Phe Glu Leu Asn Arg Pro
 35 40 45
 Phe Pro Glu Glu Ala Ile Leu His Asp Ile Ser Ser Asn Val Thr Phe
 50 55 60
 Leu Ile Phe Gln Ile His Ser Gln Tyr Gln Asn Thr Thr Val Ser Phe
 65 70 75 80
 Ser Pro Thr Leu Leu Ser Asn Ser Ser Glu Thr Gly Thr Ala Ser Gly
 85 90 95
 Leu Val Phe Ile Leu Arg Pro Glu Gln Ser Thr Cys Thr Trp Tyr Leu
 100 105 110
 Gly Thr Ser Gly Ile Gln Pro Val Gln Asn Met Ala Ile Leu Leu Ser
 115 120 125

85

Tyr Ser Glu Arg Asp Pro Val Pro Gly Gly Cys Asn Leu Glu Phe Asp
 130 135 140
 Leu Asp Ile Asp Pro Asn Ile Tyr Leu Glu Tyr Asn Phe Phe Glu Thr
 145 150 155 160
 Thr Ile Lys Phe Ala Pro Ala Asn Leu Gly Tyr Ala Arg Gly Val Asp
 165 170 175
 Pro Pro Pro Cys Asp Ala Gly Thr Asp Gln Asp Ser Arg Trp Arg Leu
 180 185 190
 Gln Tyr Asp Val Tyr Gln Tyr Phe Leu Pro Glu Asn Asp Leu Thr Glu
 195 200 205
 Glu Met Leu Leu Lys His Leu Gln Arg Met Val Ser Val Pro Gln Val
 210 215 220
 Lys Ala Ser Ala Leu Lys Val Val Thr Leu Thr Ala Asn Asp Lys Thr
 225 230 235 240
 Ser Val Ser Phe Ser Ser Leu Pro Gly Gln Gly Val Ile Tyr Asn Val
 245 250 255
 Ile Val Xaa Gly Pro Xaa Ser Lys Tyr Ile Cys Cys Leu His Ser Cys
 260 265 270
 Ser His Ile Arg Leu Gln Leu Xaa Arg Ala Gly Arg Gly
 275 280 285

<210> 149
 <211> 417
 <212> PRT
 <213> Homo sapiens

<400> 149
 Leu Phe Leu Phe Ser Lys Tyr Thr His Ser Ile Arg Ile Gln Leu Phe
 1 5 10 15
 Pro Phe Leu Arg Gly Val Asp Pro Pro Cys Asp Ala Gly Thr Asp
 20 25 30
 Gln Asp Ser Arg Trp Arg Leu Gln Tyr Asp Val Tyr Gln Tyr Phe Leu
 35 40 45
 Pro Glu Asn Asp Leu Thr Glu Glu Met Leu Leu Lys His Leu Gln Arg
 50 55 60
 Met Val Ser Val Pro Gln Val Lys Ala Ser Ala Leu Lys Val Val Thr
 65 70 75 80
 Leu Thr Ala Asn Asp Lys Thr Ser Val Ser Phe Ser Ser Leu Pro Gly
 85 90 95
 Gln Gly Val Ile Tyr Asn Val Ile Val Trp Asp Pro Phe Leu Asn Thr
 100 105 110
 Ser Ala Ala Tyr Ile Pro Ala His Thr Tyr Ala Cys Ser Phe Glu Ala
 115 120 125
 Gly Glu Gly Ser Cys Ala Ser Leu Gly Arg Val Ser Ser Lys Val Phe
 130 135 140
 Phe Thr Leu Phe Ala Leu Leu Gly Phe Phe Ile Cys Phe Phe Gly His
 145 150 155 160

Arg	Phe	Trp	Lys	Thr	Glu	Leu	Phe	Phe	Ile	Gly	Phe	Ile	Ile	Met	Gly	
				165					170					175		
Phe	Phe	Phe	Tyr	Ile	Leu	Ile	Thr	Arg	Leu	Thr	Pro	Ile	Lys	Tyr	Asp	
				180					185					190		
Val	Asn	Leu	Ile	Leu	Thr	Ala	Val	Thr	Gly	Ser	Val	Gly	Gly	Met	Phe	
				195					200					205		
Leu	Val	Ala	Val	Trp	Trp	Arg	Phe	Gly	Ile	Leu	Ser	Ile	Cys	Met	Leu	
				210					215					220		
Cys	Val	Gly	Leu	Val	Leu	Gly	Phe	Leu	Ile	Ser	Ser	Val	Thr	Phe	Phe	
				225					230					235		
Thr	Pro	Leu	Gly	Asn	Leu	Lys	Ile	Phe	His	Asp	Asp	Gly	Val	Phe	Trp	
				245					250					255		
Val	Thr	Phe	Ser	Cys	Ile	Ala	Ile	Leu	Ile	Pro	Val	Val	Phe	Met	Gly	
				260					265					270		
Cys	Leu	Arg	Ile	Leu	Asn	Ile	Leu	Thr	Cys	Gly	Val	Ile	Gly	Ser	Tyr	
				275					280					285		
Ser	Val	Val	Leu	Ala	Ile	Asp	Ser	Tyr	Trp	Ser	Thr	Ser	Leu	Ser	Tyr	
				290					295					300		
Ile	Thr	Leu	Asn	Val	Leu	Lys	Arg	Ala	Leu	Asn	Lys	Asp	Phe	His	Arg	
				305					310					315		
Ala	Phe	Thr	Asn	Val	Pro	Phe	Gln	Thr	Asn	Asp	Phe	Ile	Ile	Leu	Ala	
				325					330					335		
Val	Trp	Gly	Met	Leu	Ala	Val	Ser	Gly	Ile	Thr	Leu	Gln	Ile	Arg	Arg	
				340					345					350		
Glu	Arg	Gly	Arg	Pro	Phe	Phe	Pro	Pro	His	Pro	Tyr	Lys	Leu	Trp	Lys	
				355					360					365		
Gln	Glu	Arg	Glu	Arg	Arg	Val	Thr	Asn	Ile	Leu	Asp	Pro	Ser	Tyr	His	
				370					375					380		
Ile	Pro	Pro	Leu	Arg	Glu	Arg	Leu	Tyr	Gly	Arg	Leu	Thr	Gln	Ile	Lys	
				385					390					395		
Gly	Leu	Phe	Gln	Lys	Glu	Gln	Pro	Ala	Gly	Glu	Arg	Thr	Pro	Leu	Leu	
				405					410					415		

<210> 150

<211> 70

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (29)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (37)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 150

Met Asp Pro Ala Ala Val Ala Leu Leu Ala Leu Ser Leu Pro Cys Ala
1 5 10 15

Leu Val Gly Val Gln Trp Glu Gln Ala Pro Trp Gly Xaa Trp Arg Leu
20 25 30

Ser Xaa Ser Ala Xaa Thr Pro Glu Thr Pro Ser Trp Arg Leu Cys Pro
35 40 45

Leu Arg Asp Tyr Pro Lys Pro Gly Gln Arg Ser Gly Gly Asp Arg Gly
50 55 60

Ser His Ile Arg Ser Leu
65 70

<210> 151

<211> 194

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (3)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (33)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 151

Gln Trp Xaa Gly Gln Gly Ser Leu Cys Pro Trp Tyr Cys Cys Pro Gly
1 5 10 15

Xaa Val Ser Ala Val Thr Leu Leu Pro Ser Trp Trp Leu Leu Arg Pro
20 25 30

Xaa Phe Val Leu Leu Phe Leu Pro Lys Cys Leu Ser Ser Pro Ser Cys
35 40 45

Ile Lys Tyr Pro Cys Cys Ala Thr Asn Tyr Leu Glu Leu Gly Asp Phe
50 55 60

Thr Thr Thr Ala Cys Gln Arg Pro Ala Val Asp Glu Gly Leu Gly Gly
65 70 75 80

Met Ala Gly Pro Ala Gln Gly Ser Leu Ala Glu Val Gly Ala Glu Ala
85 90 95

Ala Arg His Trp Arg Leu Gly Leu Ser His Thr Pro Trp Leu Leu Gly
100 105 110

88

Gly Cys Ile Leu Leu Ser Ser Leu Ser Ser Arg Gly Cys Thr Leu Gly
 115 120 125
 Cys Arg Pro Pro Val Ser Leu Thr Gly Tyr Ser Trp Gly Ser Leu Arg
 130 135 140
 Ser Trp Arg Cys Pro Gln Pro Pro Ser Pro Arg Leu Pro Pro Pro His
 145 150 155 160
 Thr Leu Arg Pro Gln Arg Phe Val Arg Val His Glu Ile Leu Glu Leu
 165 170 175
 Pro Gly Cys Ser Phe Cys Asn Ile Phe Asn Ile Cys Asn Pro Val Lys
 180 185 190
 Tyr Gln

<210> 152
 <211> 101
 <212> PRT
 <213> Homo sapiens

<400> 152
 Pro Ala Leu Phe Ile Cys Val Ile Ile Phe Val Asn Ile Val Phe Ser
 1 5 10 15
 Val Val Ala Thr Ser Ser Pro Pro Ala Ser Gly Ser Val Cys Leu Pro
 20 25 30
 Gly Leu Leu Ala Pro His Trp Ala Ala Pro Gly Ser Leu Pro Leu Ile
 35 40 45
 Pro Gly Leu Ala Val Arg Pro Ser Gln Gln Gly Pro Val Thr Gln Gln
 50 55 60
 Pro Ala Gln Ser Ile Cys Phe Trp Gly Met Gly Trp Gly Leu Leu His
 65 70 75 80
 Arg Arg Phe Glu Pro Ser Thr Leu Gly Lys Gly Thr Leu His Asp Thr
 85 90 95
 Pro Leu Pro Pro Ser
 100

<210> 153
 <211> 119
 <212> PRT
 <213> Homo sapiens

<400> 153
 Asp Leu Asp Leu Met Glu Ser Gly Val Ser Thr His Asn Met Ser Ser
 1 5 10 15
 Trp Thr Leu Gly Ile His Cys Glu Gln Ala Gly Trp Gly Leu Pro Ala
 20 25 30
 Gln Ile Gly Ala Ile Leu Phe Cys Ile Leu Phe Gln Gly Val Leu Asn
 35 40 45
 Thr Leu Lys Gln Val Glu Ala Pro Ala Pro Asp Trp Glu Leu Leu Glu
 50 55 60
 Arg Pro Pro Cys Val Cys Val Val Leu Ser Trp Ser His Ile Glu Ser

89

```
<210> 154
<211> 58
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (24)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```

<400> 154
Arg Pro Ser Leu Pro Lys Cys Ala Ala Leu Val His Val Pro Asn Gly
 1                    5                      10                15

Pro Ser Pro His Ala Pro Pro Xaa Ser Gly Val Gly Ala Pro Ser Glu
                20                      25                30

Val Ser Glu Ser Leu Lys Cys Ser Phe Val Arg Pro Leu Cys Ser Asp
      35                      40                45

Ser Pro Gly Gln Ala Thr Ser Asn Pro Leu
 50                      55

```

```

<210> 155
<211> 477
<212> PRT
<213> Homo sapiens

<400> 155
Met Ala Ala Pro Thr Pro Ala Arg Pro Val Leu Thr His Leu Leu Val
  1          5          10
Ala Leu Phe Gly Met Gly Ser Trp Ala Ala Val Asn Gly Ile Trp Val
  20          25
Glu Leu Pro Val Val Val Lys Glu Leu Pro Glu Gly Trp Ser Leu Pro
  35          40          45
Ser Tyr Val Ser Val Leu Val Ala Leu Gly Asn Leu Gly Leu Leu Val
  50          55          60
Val Thr Leu Trp Arg Arg Leu Ala Pro Gly Lys Asp Glu Gln Val Pro
  65          70          75          80
Ile Arg Val Val Gln Val Leu Gly Met Val Gly Thr Ala Leu Leu Ala
  85          90          95
Ser Leu Trp His His Val Ala Pro Val Ala Gly Gln Leu His Ser Val
  100         105
Ala Phe Leu Ala Leu Ala Phe Val Leu Ala Leu Ala Cys Cys Ala Ser
  115         120         125

```

Asn Val Thr Phe Leu Pro Phe Leu Ser His Leu Pro Pro Arg Phe Leu
 130 135 140
 Arg Ser Phe Phe Leu Gly Gln Gly Leu Ser Ala Leu Leu Pro Cys Val
 145 150 155 160
 Leu Ala Leu Val Gln Gly Val Gly Arg Leu Glu Cys Pro Pro Ala Pro
 165 170 175
 Ile Asn Gly Thr Pro Gly Pro Pro Leu Asp Phe Leu Glu Arg Phe Pro
 180 185 190
 Ala Ser Thr Phe Phe Trp Ala Leu Thr Ala Leu Leu Val Ala Ser Ala
 195 200 205
 Ala Ala Phe Gln Gly Leu Leu Leu Leu Leu Pro Pro Pro Pro Ser Val
 210 215 220
 Pro Thr Gly Glu Leu Gly Ser Gly Leu Gln Val Gly Ala Pro Gly Ala
 225 230 235 240
 Glu Glu Glu Val Glu Glu Ser Ser Pro Leu Gln Glu Pro Pro Ser Gln
 245 250 255
 Ala Ala Gly Thr Thr Pro Gly Pro Asp Pro Lys Ala Tyr Gln Leu Leu
 260 265 270
 Ser Ala Arg Ser Ala Cys Leu Leu Gly Leu Leu Ala Ala Thr Asn Ala
 275 280 285
 Leu Thr Asn Gly Val Leu Pro Ala Val Gln Ser Phe Ser Cys Leu Pro
 290 295 300
 Tyr Gly Arg Leu Ala Tyr His Leu Ala Val Val Leu Gly Ser Ala Ala
 305 310 315 320
 Asn Pro Leu Ala Cys Phe Leu Ala Met Gly Val Leu Cys Arg Tyr Thr
 325 330 335
 Arg Thr Pro Ser Pro Cys Ala Gly Gly Thr Gln Gly Trp Glu Pro Gly
 340 345 350
 Pro Gly Ala Val Ser Pro Asp Ile Leu Leu Ala His Cys Arg Ser Leu
 355 360 365
 Ala Gly Leu Gly Gly Leu Ser Leu Leu Gly Val Phe Cys Gly Gly Tyr
 370 375 380
 Leu Met Ala Leu Ala Val Leu Ser Pro Cys Pro Pro Leu Val Gly Thr
 385 390 395 400
 Ser Ala Gly Val Val Leu Val Val Leu Ser Trp Val Leu Cys Leu Gly
 405 410 415
 Val Phe Ser Tyr Val Lys Val Ala Ala Ser Ser Leu Leu His Gly Gly
 420 425 430
 Gly Arg Pro Ala Leu Leu Ala Ala Gly Val Ala Ile Gln Val Gly Ser
 435 440 445
 Leu Leu Gly Ala Val Ala Met Phe Pro Pro Thr Ser Ile Tyr His Val
 450 455 460
 Phe His Ser Arg Lys Asp Cys Ala Asp Pro Cys Asp Ser
 465 470 475

<210> 156
 <211> 52
 <212> PRT
 <213> Homo sapiens

<400> 156
 Met Ala Leu Leu Leu Gln Ala Leu Pro Ser Pro Leu Ser Ala Arg
 1 5 10 15
 Ala Glu Pro Pro Gln Asp Lys Glu Ala Cys Val Gly Thr Asn Asn Gln
 20 25 30
 Ser Tyr Ile Cys Asp Thr Gly His Cys Cys Gly Gln Ser Gln Cys Cys
 35 40 45
 Lys Leu Leu Leu
 50

<210> 157
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 157
 Leu Leu Leu Leu Gln Ala Leu Pro Ser Pro Leu Ser Ala Arg Ala Glu
 1 5 10 15
 Pro Pro Gln Asp Lys Glu Ala Cys Val Gly Thr Asn Asn Gln Ser Tyr
 20 25 30
 Ile Cys Asp Thr Gly His Cys Cys Gly Gln Ser Gln Cys Cys Asn Tyr
 35 40 45
 Tyr Tyr Glu Leu Trp Trp Phe Trp Leu Val Trp Thr Ile Ile Ile Ile
 50 55 60
 Leu Ser Cys Cys Cys Val Cys His His Arg Arg Ala Lys His Arg Leu
 65 70 75 80
 Gln Ala Gln Gln Arg Gln His Glu Ile Asn Leu Ile Ala Tyr Arg Glu
 85 90 95
 Ala His Asn Tyr Ser Ala Leu Pro Phe Tyr Phe Arg Phe Leu Pro Asn
 100 105 110
 Tyr Leu Leu Pro Pro Leu
 115

<210> 158
 <211> 201
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (10)
 <223> Xaa equals any of the naturally occurring L-amino acids
 <220>
 <221> SITE
 <222> (19)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 158
 Leu Ser Ser Leu Leu Pro Gln Arg Leu Xaa Glu Pro Ser Ser Ser Ser
 1 5 10 15
 Pro Gly Xaa Arg Thr Trp Gln Leu Ser Gln Lys Ser Arg Gly Pro Ser
 20 25 30
 Arg Ala Ser Ser Met Ser Val Leu Asn Ser Leu Arg Ser Ser Ser Trp
 35 40 45
 Trp Pro Arg Leu His Thr His Thr Ser Met Pro Glu Ser Pro Val Lys
 50 55 60
 Arg Arg Cys Leu Pro Gly Val Phe Ser Leu Leu Ser Gly Ala Pro Cys
 65 70 75 80
 Ser Glu Leu Ser Ser Phe Ser Ser Ser Ser Leu His Ser Ala Ser Leu
 85 90 95
 Ser Arg Lys Ala Pro Gly Ser Ser Ser Pro Arg Pro Ala Thr Glu Pro
 100 105 110
 Leu Gly Ser Ile Pro Gly Ala Leu Val Ala Ala Arg Ser Thr Gly Arg
 115 120 125
 Ser Glu Gly Ser Gly Ser Ala Met Leu Gly Gly Leu Val Leu Leu Leu
 130 135 140
 Leu Gly Ser Asp Lys Gly Leu Leu Cys Ala Pro Trp Asp Pro Leu Val
 145 150 155 160
 Gly Ser Met Pro Gly Gly Leu Pro Pro Ala Gly Pro His Cys Gly Gly
 165 170 175
 Ser Ser Cys Cys Cys Cys Ser Trp Lys Ala Leu Tyr Gly Gly Gly Gly
 180 185 190
 Val Gly Gly Arg Phe Thr Thr Ser Ser
 195 200

<210> 159
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (36)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 159
 Gly Ser Asp Gly Pro Arg Glu Arg Ala Pro Val Ala Trp Leu Ser His
 1 5 10 15
 Ser Ile Leu Ser Leu Ile Leu Asn Lys Tyr Phe Leu Trp Gly Phe Phe
 20 25 30
 Phe Phe Leu Xaa Ala Val Val Cys Phe Lys Leu Thr Thr Trp Lys Lys
 35 40 45
 His Leu Gly Tyr Leu Trp Phe Ser Cys Leu Val Pro Ala Ser Thr Pro
 50 55 60
 Thr Pro Phe Glu Ser Gly Asp Ser Phe Phe Cys Val Glu Thr Arg Trp
 65 70 75 80

Pro Arg Gln Glu Val Lys Ala Ala Ile Arg Lys Ala Leu Gly Thr Leu
 85 90 95

Val Pro Val Ala Arg Leu Gln Val Thr Ser
 100 105

<210> 160
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 160
 Met Glu Phe Val Ser Gly Gly Lys Thr Glu Ile Leu Met Leu Phe Thr
 1 5 10 15
 Leu Leu Val Ser Cys Tyr Val Phe Leu Pro Leu Ala Leu Pro Cys Phe
 20 25 30
 Ala Phe Phe Phe Ser Phe Trp Pro Ile Pro Phe Tyr Met Cys Pro Gln
 35 40 45
 Gln Arg Trp Gly Asp Thr Glu His Pro Gly Ser Phe Pro Ala Leu Leu
 50 55 60
 Gly Arg Pro Arg Leu Gln Ala Pro Ala Val Glu Thr Leu Lys Gly Asn
 65 70 75 80
 Lys Gln Pro Ser Thr Leu Pro Asp Pro Arg Leu Phe Arg Glu Ala Ala
 85 90 95
 His Phe His Pro Gly Pro Arg Thr Pro Ser Leu Cys Pro Thr Arg Ile
 100 105 110
 Ser Leu Asn Gly Arg Asp
 115

<210> 161
 <211> 157
 <212> PRT
 <213> Homo sapiens

<400> 161
 Ser Cys Leu Pro Pro Leu Pro Leu Asn Leu Pro Leu Pro Pro Cys Leu
 1 5 10 15
 Cys Pro Leu Leu Gln Leu Asn Ala Ala Met Thr Arg Lys Glu Lys Thr
 20 25 30
 Lys Glu Gly Gln Arg Ala Ala Gln Phe Ser Ala Gly Ala Asp Ala Gly
 35 40 45
 Ser Gly Gly Gly Leu Ser Arg Gln Lys Asp Thr Lys Arg Pro Met Leu
 50 55 60
 Leu Val Ile His Asp Val Val Leu Glu Leu Leu Thr Ser Ser Asp Cys
 65 70 75 80
 His Ala Asn Pro Arg Lys Tyr Pro Thr Cys Gln Lys Ser Glu Val Leu
 85 90 95
 Gly Val Ser Ile Tyr Val Ser Ile Cys Pro Ser Thr Arg Pro Arg Asp
 100 105 110

Lys Asn Lys Thr Lys Lys Arg Cys Gln Val Leu Glu Ala Val Leu Val
 115 120 125
 Ser Lys Pro Ser Gly Ser Cys His Gln Gly Ser Phe Glu Ile Val Pro
 130 135 140
 His Val Lys Gly Asn Leu Ala Phe Thr Ser Ser Asn His
 145 150 155

<210> 162
 <211> 438
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (42)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 162
 Leu Thr Ile Thr Val His Asp Pro Asn Ala Ala Gln Trp Tyr Tyr Gly
 1 5 10 15
 Met Ser Trp Gly Leu Arg Leu Tyr Ile Pro Gly Phe Asp Val Gly Thr
 20 25 30
 Met Phe Thr Ile Gln Lys Lys Ile Leu Xaa Ser Trp Ser Pro Pro Lys
 35 40 45
 Pro Ile Arg Pro Leu Thr Asp Leu Gly Asp Pro Ile Phe Gln Lys His
 50 55 60
 Pro Asp Lys Val Asp Leu Thr Val Pro Gln Pro Phe Leu Val Pro Arg
 65 70 75 80
 Pro Gln Leu Gln Gln Gln His Leu Gln Pro Ser Leu Met Ser Ile Leu
 85 90 95
 Gly Gly Val His His Leu Leu Asn Leu Thr Gln Pro Lys Leu Ala Gln
 100 105 110
 Asp Cys Trp Leu Cys Leu Lys Ala Lys Pro Pro Tyr Tyr Val Gly Leu
 115 120 125
 Gly Val Glu Ala Thr Leu Lys Arg Gly Pro Leu Ser Cys His Thr Arg
 130 135 140
 Pro Arg Ala Leu Thr Ile Gly Asp Val Ser Gly Asn Ala Ser Cys Leu
 145 150 155 160
 Ile Ser Thr Gly Tyr Asn Leu Ser Ala Ser Pro Phe Gln Ala Thr Cys
 165 170 175
 Asn Gln Ser Leu Leu Thr Tyr Ile Ser Thr Ser Val Ser Tyr Gln Ala
 180 185 190
 Pro Asn Asn Thr Trp Leu Ala Cys Thr Ser Gly Leu Thr Arg Cys Ile
 195 200 205
 Asn Gly Thr Glu Pro Gly Pro Leu Leu Cys Val Leu Val His Val Leu
 210 215 220
 Pro Gln Val Tyr Val Tyr Ser Gly Pro Glu Gly Arg Gln Leu Ile Ala
 225 230 235 240

[illegible]

```
<210> 163
<211> 63
<212> PRT
<213> Homo sapiens
```

```

<400> 163
Phe Leu His Val Phe Thr Ser Val Glu Leu Leu Arg Leu Ser Ser Pro
  1             5             10             15
Pro Leu Pro Lys Pro Lys Tyr Lys Arg Lys Ser Ser Pro Leu Leu Met
          20          25          30
Ala Glu Arg Ile Leu Ser Val Ser Gly Leu Phe Gly His Arg Leu Asn
      35          40          45
Lys Gly Leu Leu Ile His Pro Lys Lys Lys Lys Lys Leu Glu
    50          55          60

```

```
<210> 164
<211> 322
<212> PRT
<213> Homo sapiens
```

<220>
<221> SITE

<222> (131)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (185)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (218)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (220)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (250)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (312)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 164
 Met Ala Leu Pro Pro Gly Pro Ala Ala Leu Arg His Thr Leu Leu Leu
 1 5 10 15
 Leu Pro Ala Leu Leu Ser Ser Gly Trp Gly Glu Leu Glu Pro Gln Ile
 20 25 30
 Asp Gly Gln Thr Trp Ala Glu Arg Ala Leu Arg Glu Asn Glu Arg His
 35 40 45
 Ala Phe Thr Cys Arg Val Ala Gly Gly Pro Gly Thr Pro Arg Leu Ala
 50 55 60
 Trp Tyr Leu Asp Gly Gln Leu Gln Glu Ala Ser Thr Ser Arg Leu Leu
 65 70 75 80
 Ser Val Gly Gly Glu Ala Phe Ser Gly Gly Thr Ser Thr Phe Thr Val
 85 90 95
 Thr Ala His Arg Ala Gln His Glu Leu Asn Cys Ser Leu Gln Asp Pro
 100 105 110
 Arg Ser Gly Arg Ser Ala Asn Ala Ser Val Ile Leu Asn Val Gln Phe
 115 120 125
 Lys Pro Xaa Ile Ala Gln Val Gly Ala Lys Tyr Gln Glu Ala Gln Gly
 130 135 140
 Pro Gly Leu Leu Val Val Leu Phe Ala Leu Val Arg Ala Asn Pro Pro
 145 150 155 160
 Ala Asn Val Thr Trp Ile Asp Gln Asp Gly Pro Val Thr Val Asn Thr
 165 170 175
 Ser Asp Phe Leu Val Leu Asp Ala Xaa Asn Tyr Pro Trp Leu Thr Asn
 180 185 190
 His Thr Val Gln Leu Gln Leu Arg Ser Leu Ala His Asn Leu Ser Val

195	200	205
Val Ala Thr Asn Asp	Val Gly Val Thr Xaa Ala	Xaa Leu Pro Ala Pro
210	215	220
Gly Pro Ser Arg His	Pro Ser Leu Ile Ser	Ser Asp Ser Asn Asn Leu
225	230	235 240
Lys Leu Asn Asn Val	Arg Leu Pro Arg Xaa	Asn Met Ser Leu Pro Ser
245	250	255
Asn Leu Gln Leu Asn Asp	Leu Thr Pro Asp Ser Arg	Ala Val Lys Pro
260	265	270
Ala Asp Arg Gln Met	Ala Gln Asn Asn Ser	Arg Pro Glu Leu Leu Asp
275	280	285
Pro Glu Pro Gly Gly	Leu Leu Thr Ser Gln Gly	Phe Ile Arg Leu Pro
290	295	300
Val Leu Gly Tyr Ile	Tyr Arg Xaa Ser Ser	Val Ser Ser Asp Glu Ile
305	310	315 320

Trp Leu

<210> 165
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 165
 Leu Leu Met Arg Gln Pro Trp Val Gly Gln Gly Trp Gly Pro Val Val
 1 5 10 15

Glu Glu Thr Cys
 20

<210> 166
 <211> 23
 <212> PRT
 <213> Homo sapiens

<400> 166
 Ala Trp Ile Gln Cys Thr Leu Leu Leu Tyr Pro Arg Arg Thr Ser Gln
 1 5 10 15

Gly Ile His Gln Val Pro Gly
 20

<210> 167
 <211> 264
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (196)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (224)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (233)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 167

Met	Leu	Arg	Leu	Phe	Glu	Thr	Phe	Leu	Glu	Thr	Ala	Pro	Gln	Leu	Thr	1	5	10	15
Leu	Val	Leu	Ala	Ile	Met	Leu	Gln	Ser	Gly	Arg	Ala	Glu	Tyr	Tyr	Gln	20	25	30	
Trp	Val	Gly	Ile	Cys	Thr	Ser	Phe	Leu	Gly	Ile	Ser	Trp	Ala	Leu	Leu	35	40	45	
Asp	Tyr	His	Arg	Ala	Leu	Arg	Thr	Cys	Leu	Pro	Ser	Lys	Pro	Leu	Leu	50	55	60	
Gly	Leu	Gly	Ser	Ser	Val	Ile	Tyr	Phe	Leu	Trp	Asn	Leu	Leu	Leu	Leu	65	70	75	80
Trp	Pro	Arg	Val	Leu	Ala	Val	Ala	Leu	Phe	Ser	Ala	Leu	Phe	Pro	Ser	85	90	95	
Tyr	Val	Ala	Leu	His	Phe	Leu	Gly	Leu	Trp	Leu	Val	Leu	Leu	Leu	Trp	100	105	110	
Val	Trp	Leu	Gln	Gly	Thr	Asp	Phe	Met	Pro	Asp	Pro	Ser	Ser	Glu	Trp	115	120	125	
Leu	Tyr	Arg	Val	Thr	Val	Ala	Thr	Ile	Leu	Tyr	Phe	Ser	Trp	Phe	Asn	130	135	140	
Val	Ala	Glu	Gly	Arg	Thr	Arg	Gly	Arg	Ala	Ile	Ile	His	Phe	Ala	Phe	145	150	155	160
Leu	Leu	Ser	Asp	Ser	Ile	Leu	Leu	Val	Ala	Thr	Trp	Val	Thr	His	Ser	165	170	175	
Ser	Trp	Leu	Pro	Ser	Gly	Ile	Pro	Leu	Gln	Leu	Trp	Leu	Pro	Val	Gly	180	185	190	
Cys	Gly	Cys	Xaa	Phe	Leu	Gly	Leu	Ala	Leu	Arg	Leu	Val	Tyr	Tyr	His	195	200	205	
Trp	Leu	His	Pro	Ser	Cys	Cys	Trp	Lys	Pro	Asp	Pro	Asp	Gln	Val	Xaa	210	215	220	
Gly	Ala	Arg	Ser	Leu	Leu	Ser	Pro	Xaa	Gly	Tyr	Gln	Leu	Pro	Gln	Asn	225	230	235	240
Arg	Arg	Met	Thr	His	Leu	Ala	Gln	Lys	Phe	Phe	Pro	Lys	Ala	Lys	Asp	245	250	255	
Glu	Ala	Ala	Ser	Pro	Val	Lys	Gly	260											

<210> 168

<211> 115

<212> PRT

<213> Homo sapiens

<220>

<221> SITE
 <222> (60)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (73)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (75)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <220>
 <221> SITE
 <222> (82)
 <223> Xaa equals any of the naturally occurring L-amino acids

 <400> 168
 Leu Pro Tyr Pro Gly Leu Gly Gly His Arg Gly Cys Pro Leu Glu Phe
 1 5 10 15
 Phe Leu Pro Ser Pro Thr Pro Phe Ile Gln Phe Met Lys Gln Ile Phe
 20 25 30
 Ala Lys Ser Ser Leu Cys Ala Arg Asn Ile Ile Leu Ser Leu Gln Pro
 35 40 45
 Gly Thr Arg Pro Ala Thr Ser Leu Ala Ser Ser Xaa Thr Cys Thr Asn
 50 55 60
 Gln Ser Arg Val Arg Ser Gln Met Xaa Glu Xaa Arg Asp Ala Gln Leu
 65 70 75 80
 Trp Xaa Ala Pro Val Arg Thr Ser Gly Ile Ser Val Lys Leu Ala Trp
 85 90 95
 Pro Leu Leu Leu Leu Ser Arg Gly Cys Phe Ser Thr Lys Ser Leu Val
 100 105 110
 Ser Leu Val
 115

 <210> 169
 <211> 57
 <212> PRT
 <213> Homo sapiens

 <400> 169
 Met Asn Val Phe Leu Ser Leu Pro Leu Gly Ser Ser Leu Pro Pro Leu
 1 5 10 15
 Leu Phe Pro Pro Ser Leu Pro Ser Leu Phe Phe Pro Leu Pro Leu Tyr
 20 25 30
 Leu Ser Phe Ser Ala Pro Ser Pro Ala Thr Thr Pro Gly Phe Ile Ser
 35 40 45
 Leu Pro Gly His Ile Pro Ser Ser Ser
 50 55

 <210> 170
 <211> 52

100

<212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (50)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 170
 Lys Glu Pro Thr Leu Lys Tyr Trp Gly Arg Val Pro Pro Ile Leu Leu
 1 5 10 15
 Lys Leu Phe Gln Thr Ile Glu Lys Glu Gly His Leu Pro Asn Ser Phe
 20 25 30
 Tyr Glu Ala Ser Ile Ile Leu Ile Leu Lys Pro Gly Arg Asp Thr Ala
 35 40 45
 Lys Xaa Lys Lys
 50

<210> 171
 <211> 49
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (26)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 171
 Cys His Pro Gln Gln Pro Ser Cys Arg Ile Pro Leu Phe Val Leu Phe
 1 5 10 15
 Ile Ser Gln Thr Ser Gln His Leu Gly Xaa Ile Glu Gly Ala Tyr Val
 20 25 30
 Glu Ile Leu Gly Ala Gly Ser Pro Asn Thr Ser Glu Thr Ile Pro Asn
 35 40 45
 Asn

<210> 172
 <211> 5
 <212> PRT
 <213> Homo sapiens

<400> 172
 Met Ser Arg Leu Leu
 1 5

<210> 173
 <211> 42
 <212> PRT
 <213> Homo sapiens

<400> 173
 Met Phe Leu Phe Ile Thr Phe Thr Ile Leu Ala Ile Phe Ile Ile Glu
 1 5 10 15
 Pro Arg Asn Leu Arg Val Asp Leu Asn Leu Ile Lys Phe Gln Thr Ser

20 25 30

Trp Pro Lys Thr Leu Val Glu Glu Gln Asn
35 40

<210> 174
<211> 76
<212> PRT
<213> Homo sapiens

<400> 174
Ile Asn Phe Thr Tyr Lys Arg Leu Ser Leu Asp Phe Ile Tyr Ile Tyr
1 5 10 15
Met Cys Val Cys Val Cys Val Cys Val Cys Val Cys Val Cys Val Tyr
20 25 30
Leu Lys Arg Thr Cys Ala Ser Ile Lys Gly Asn Lys Met Arg Glu Tyr
35 40 45
Ile Ile Asp Phe Val Lys Ser Lys Tyr Leu Asn Tyr Gly Phe Ser Ile
50 55 60
Phe Lys Asn Ser Cys Ser Phe Cys Thr Tyr Phe Phe
65 70 75

<210> 175
<211> 91
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (12)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (51)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 175
Met Val Leu Arg Gly Trp Gly Leu Ala Trp Ser Xaa Ser Pro Val Val
1 5 10 15
Cys Gly Tyr Ser Gly Asp Met Lys Gly Val Cys Trp Gly Arg Ser Asp
20 25 30
His Ser Leu Leu Pro Ser Glu Ile Leu Leu Pro Pro Ala Pro Cys Pro
35 40 45
Xaa Ser Xaa Val Leu His Asn Pro Pro Pro Thr Pro His Leu Pro Ser
50 55 60
Pro Val Leu Val Arg Ile Gln Glu Ala Pro Thr Trp Ala Gln Arg Ser
65 70 75 80
Ser Leu Gly Ala Ser Pro Leu His Lys Gly Asp
85 90

<210> 176
<211> 4
<212> PRT
<213> Homo sapiens

<400> 176
Leu Arg Glu Leu
1

<210> 177
<211> 14
<212> PRT
<213> Homo sapiens

<400> 177
Gly Cys Ser Leu Tyr Asn Ser Phe Asn Asn Leu Leu Cys Leu
1 5 10

<210> 178
<211> 6
<212> PRT
<213> Homo sapiens

<400> 178
Trp Ala Leu Pro Met Ser
1 5

<210> 179
<211> 13
<212> PRT
<213> Homo sapiens

<400> 179
Met Lys Ser Leu His Gly Arg Leu Leu Trp Gln Ser Ala
1 5 10

<210> 180
<211> 79
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (49)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (69)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids

103

<400> 180

Met Leu Val Lys Gly Glu Gly Val Arg Leu Val Leu Arg Leu Leu Gly
 1 5 10 15
 Arg Asn Gly Leu His Leu Ala Pro Leu Pro Ala Leu Leu Leu His Phe
 20 25 30
 Leu Met Leu Pro Leu Ser Ala Pro Val Xaa Tyr Ser Leu Pro Ala Gly
 35 40 45
 Xaa Cys Leu Gln Gly Thr Gly Ser Ser Ser Phe Tyr Ser Val Lys Phe
 50 55 60
 Ser Gly Ser Leu Xaa Gly Gly Lys Gly Lys Pro Xaa Asn Trp Pro
 65 70 75

<210> 181

<211> 21

<212> PRT

<213> Homo sapiens

<400> 181

Asp Leu His Ile Lys Leu Leu Glu His Tyr Cys Leu Thr Ser Cys Lys
 1 5 10 15
 Lys Val Leu Gln Leu
 20

<210> 182

<211> 67

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (13)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 182

Pro Gln Ser Pro Gln Arg Gly Cys Tyr Ser Met Leu Xaa Val Leu Ser
 1 5 10 15
 Val Ser His Pro Gln Pro Asn Lys Trp Arg Cys Val Val Pro Arg Gly
 20 25 30
 Pro Phe Ser His Cys Leu Ala Ser Arg Arg Gly Val Leu Gln Gly Tyr
 35 40 45
 Ser Phe Val Cys Thr Cys Arg Leu Val Gly Pro Glu Phe Phe Ser His
 50 55 60
 Val Gln Glu
 65

<210> 183

<211> 91

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (41)

104

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 183

Val Trp Arg Arg Cys Val Ser Trp Arg Ser Ile Arg Ala Gln Val Thr
1 5 10 15Phe Pro Glu Asp Phe Leu Ser Leu Ser Ser Val Gln Phe Gln Val
20 25 30Ile His Val Leu Leu Asp Pro Gly Xaa Thr Gly Ile Ser Thr Asp Leu
35 40 45Leu Ala Ser Phe Gly Leu Glu Tyr His Ser Trp Leu Gly Ala Glu Ala
50 55 60Ala Gly Leu Ile Val Ile Tyr His Lys Val Ala Arg Lys Leu Pro Arg
65 70 75 80Gly Val Arg Lys Ala Ala Gly Gly Gly Arg Val
85 90

<210> 184

<211> 44

<212> PRT

<213> Homo sapiens

<400> 184

Met Leu Ser Ser Ile Leu Ser Gln Leu Met Val Ser Lys Pro Trp Gly
1 5 10 15Val Phe Ile Ser Phe Ser Phe Ile Ser Leu Ser Phe Tyr His Ala Ile
20 25 30Ser Ile Ser Ser Val Pro Ser Gly Arg Gln Val Val
35 40

<210> 185

<211> 150

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (12)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (38)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (43)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (145)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 185

Cys Pro Pro Pro Lys Arg Gly Gly Ile Glu Xaa Glu Leu Gly Lys
1 5 10 15

105

Leu Trp Pro Thr Phe Glu Thr Phe Arg Ala Asn Arg Arg Thr Met Leu
 20 25 30
 Leu Glu Pro Leu Gly Xaa Pro Gly Gly Gly Xaa Arg Pro Phe Trp Lys
 35 40 45
 Arg Ala Arg Gly Val Thr Ser Glu Ala Ile Val Thr Gly Arg Cys Asn
 50 55 60
 His Cys Pro Asp Cys Gly Lys Ala Trp Arg Glu Gln Gly Glu Ser Thr
 65 70 75 80
 Pro Ser Thr Cys Pro Phe Asp Pro Leu Thr Cys Trp Trp Leu Ala Leu
 85 90 95
 Ala Lys Pro Glu Thr Gly Gly Gln Glu Pro Leu Ser Val Ala Ala Tyr
 100 105 110
 Gly Gly Gln Pro Ser Glu Val Lys Ala Gly Gln Lys Val Glu Lys Gly
 115 120 125
 Leu Gly Gly Thr His Gly Glu Gln Ser Thr Lys Phe Thr Pro Phe Val
 130 135 140
 Xaa Trp His Trp Lys Ile
 145 150

<210> 186
 <211> 67
 <212> PRT
 <213> Homo sapiens

<400> 186
 Asp Gly Ala Pro Gly Pro Arg Val Gly His Gly His Pro Gly Trp Leu
 1 5 10 15
 Gly Arg Arg Arg Gln Ala Leu His Val Leu Gln Leu Gly Met Trp Val
 20 25 30
 Arg Glu Gly Ile Trp Phe Cys Tyr Leu Ala Val Val Phe Ser His Pro
 35 40 45
 Ser Phe Leu Thr Ile Lys Ser His Leu Gly Leu Glu Lys Lys Lys Lys
 50 55 60
 Lys Thr Arg
 65

<210> 187
 <211> 56
 <212> PRT
 <213> Homo sapiens

<400> 187
 Met Trp Lys Val Leu Arg Pro Ser Leu Phe Thr Ala Gly Leu Phe Thr
 1 5 10 15
 Ala Ser Phe Phe Tyr Ser Asp Leu Lys Val Ser Thr Glu Leu Met Lys
 20 25 30
 Leu Gln His Met Val Phe Lys Ser Phe Pro Leu Lys Cys Thr Leu Glu
 35 40 45

106

Asn Trp Val Pro Gln Pro His Tyr
 50 55

<210> 188
 <211> 88
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (19)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (81)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 188
 Xaa His Lys Thr Phe Pro Ser Glu Gly Ser Ser Cys Leu Ser Ser Val
 1 5 10 15
 Thr Leu Xaa Thr Thr Ala Gln Ala Tyr Phe Thr Leu Pro Pro Pro Thr
 20 25 30
 His His Cys Pro Leu Ser Ala Thr Lys Pro His Tyr Ser Ser Asn Asp
 35 40 45
 Ala Ser Leu Val Ser Gly Lys Pro Ile Trp Cys Thr Lys Met Leu Cys
 50 55 60
 Asn Thr Lys Trp Leu Leu Pro Leu Ile Leu Leu Asn Asn Val Asn Ser
 65 70 75 80
 Xaa Arg Ile Asn Phe Met Leu Cys
 85

<210> 189
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 189
 Met Phe Cys Arg Asn Trp Arg Cys Glu Phe Met Met Leu Ser His Asn
 1 5 10 15
 Thr Ala Val Met Ile Cys Ser Phe Ser Gln Asn Asp Phe His Ala Ala
 20 25 30
 Leu Cys Cys Ser Ser Val Ser Glu Leu Pro Tyr Leu Phe Leu Val Cys
 35 40 45
 Ser Thr Tyr Lys Cys Ser Cys His Ala Val Leu Phe Phe Cys
 50 55 60

<210> 190
 <211> 31
 <212> PRT

107

<213> Homo sapiens

<400> 190

Met Phe Glu Ala Leu Trp Ala Thr Asp Tyr Leu Cys Cys Leu Phe Leu
 1 5 10 15

Phe Val Ser Phe Phe Arg Pro Leu Gln Lys Cys Lys Asn His Ser
 20 25 30

<210> 191

<211> 26

<212> PRT

<213> Homo sapiens

<400> 191

Glu Ile Met Thr Arg Thr Asp Trp Val Lys Met Trp Phe Val Phe Leu
 1 5 10 15

Leu Gln Leu Ala Pro Ala Cys Pro Pro Arg
 20 25

<210> 192

<211> 56

<212> PRT

<213> Homo sapiens

<400> 192

Met Met Ile Tyr Phe Ala Leu Leu Leu Ala Ser Leu Phe Phe Leu Leu
 1 5 10 15

Lys Val Lys Ser His Phe Gly Cys Lys Asn Val Thr Thr Thr Ser Ala
 20 25 30

Arg Ile Phe Leu Lys Pro Leu Cys Thr Pro Lys Ser Ile Phe Pro Leu
 35 40 45

Ser Arg Tyr Gly Arg Met Ser Ser
 50 55

<210> 193

<211> 75

<212> PRT

<213> Homo sapiens

<400> 193

Glu Asp Met Pro Arg Arg Lys Glu Glu Leu Thr Asp Tyr Gln Lys Lys
 1 5 10 15

Lys Val Ile Leu Gln Asn Leu Lys His Ser Leu Phe Leu Ser Leu Leu
 20 25 30

Ser His Tyr Phe Tyr Ser Asn Pro Leu Glu Tyr Leu His Phe Ala Ser
 35 40 45

Glu Gln Arg Asp Lys Phe Phe Ser His His Val Cys Thr Gly Val Val
 50 55 60

Leu Ile Leu Asp Ile Ala Gly Thr Asn Phe Ser
 65 70 75

<210> 194

<211> 199

108

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (142)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 194

```

Met Lys Leu Gly Cys Val Leu Met Ala Trp Ala Leu Tyr Leu Ser Leu
 1           5           10           15
Gly Val Leu Trp Val Ala Gln Met Leu Leu Ala Ala Ser Phe Glu Thr
      20           25           30
Leu Gln Cys Glu Gly Pro Val Cys Thr Glu Glu Ser Ser Cys His Thr
      35           40           45
Glu Asp Asp Leu Thr Asp Ala Arg Glu Ala Gly Phe Gln Val Lys Ala
      50           55           60
Tyr Thr Phe Ser Glu Pro Phe His Leu Ile Val Ser Tyr Asp Trp Leu
      65           70           75           80
Ile Leu Gln Gly Pro Ala Lys Pro Val Phe Glu Gly Asp Leu Leu Val
      85           90           95
Leu Arg Cys Gln Ala Trp Gln Asp Trp Pro Leu Thr Gln Val Thr Phe
      100          105          110
Tyr Arg Asp Gly Ser Ala Leu Gly Pro Pro Gly Pro Asn Arg Glu Phe
      115          120          125
Ser Ile Thr Val Val Gln Lys Ala Asp Ser Gly His Tyr Xaa Cys Ser
      130          135          140
Gly Ile Phe Gln Ser Pro Gly Pro Gly Ile Pro Glu Thr Ala Ser Val
      145          150          155          160
Val Ala Ile Thr Val Gln Glu Leu Phe Pro Ala Pro Ile Leu Leu Leu
      165          170          175
Gln Gly Trp Lys Asp Ser Ala Lys Gln Gly Gly Ser Pro Gln Asn Ser
      180          185          190
Arg Ser Pro Gln Leu Gln Lys
      195

```

<210> 195

<211> 2

<212> PRT

<213> Homo sapiens

<400> 195

Ser Trp

1

<210> 196

<211> 32

<212> PRT

<213> Homo sapiens

<400> 196

Cys Leu Glu Thr Phe Trp Ser Leu Tyr Leu Gly Gly Trp Gly Met Val

109

1 5 10 15
Gly Cys Val Cys Tyr Trp His Pro Val Asn Arg Ser Gln Gly Cys Arg
 20 25 30

<210> 197
<211> 25
<212> PRT
<213> Homo sapiens

<400> 197
Met Ile Ser Leu Leu Trp Thr Leu Lys Leu Phe Ser Arg Asn Leu Asp
1 5 10 15
Tyr Ser Gln Lys Arg Lys Ser Trp Cys
 20 25

<210> 198
<211> 18
<212> PRT
<213> Homo sapiens

<400> 198
Thr Lys Ser Ser Asp Phe Gly Gly Gly Cys Arg Asn Ala Ser Ser Ser
1 5 10 15

Cys Cys

<210> 199
<211> 18
<212> PRT
<213> Homo sapiens

<400> 199
Thr Lys Ser Ser Asp Phe Gly Gly Gly Cys Arg Asn Ala Ser Ser Ser
1 5 10 15

Cys Cys

<210> 200
<211> 26
<212> PRT
<213> Homo sapiens

<400> 200
Gly Cys Phe Lys Ile Val Leu Phe Phe Lys Leu Val Ile Phe Ala Lys
1 5 10 15

Leu Phe Val Phe Val Val Ser Ile Asn Met
 20 25

<210> 201
<211> 101
<212> PRT
<213> Homo sapiens

110

<220>
 <221> SITE
 <222> (91)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (93)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (99)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 201
 Trp Glu Ser Leu Gly Leu Met Phe Leu Cys Gly Pro His Leu Thr Arg
 1 5 10 15
 Leu Leu Leu Phe Leu Phe Thr Leu Gly Phe Cys Ala Phe Ile Asn Ile
 20 25 30
 Val Leu Ser Phe Pro Leu Val Cys Ile Pro Phe Cys Leu Gly Arg Leu
 35 40 45
 Tyr Phe Leu Leu Leu Thr Glu Lys Pro His Gln Glu Ala Cys Pro Gly
 50 55 60
 Asp Glu Leu Gly Thr Gly His Leu His Ile Gly Leu Gly Ala Val Arg
 65 70 75 80
 Leu Gln Gly Pro Asp Asn Met Arg Asn Glu Xaa Ser Xaa Ile Val Val
 85 90 95
 Gly Asp Xaa Gly Leu
 100

<210> 202
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 202
 Met Lys Asn Ser Phe Phe Thr Val Ser Trp Ala Leu Thr Cys Ser Phe
 1 5 10 15
 Ser Trp Ala Thr Val
 20

<210> 203
 <211> 199
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (2)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (6)
 <223> Xaa equals any of the naturally occurring L-amino acids

111

<220>
 <221> SITE
 <222> (14)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (34)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 203
 Gln Xaa Lys Pro Pro Xaa Pro Ala Ala Pro Ala Ala Pro Xaa Ala Pro
 1 5 10 15
 Ala Pro Leu Glu Lys Pro Ile Arg Ser His Glu Ala Thr Gly Gly Gly
 20 25 30
 Glu Xaa Ala Cys Gly Val Thr Gly Ala Ser Thr Pro Glu Gly Thr Ala
 35 40 45
 Pro Pro Xaa Pro Ala Ala Pro Ala Pro Pro Lys Gly Glu Lys Glu Gly
 50 55 60
 Gln Arg Pro Thr Gln Pro Val Tyr Gln Ile Gln Asn Arg Gly Met Gly
 65 70 75 80
 Thr Ala Ala Pro Ala Ala Met Asp Arg Glu Leu Gly Leu Gly Ser Thr
 85 90 95
 Arg Leu Gly Thr Gly Val Ser Ser Gln Ile Leu Thr Ala Ser Ser Val
 100 105 110
 Ser Cys Phe Leu Gln Ser Pro Ala Val Val Gly Gln Ala Lys Leu Leu
 115 120 125
 Pro Pro Glu Arg Met Lys His Ser Ile Lys Leu Val Asp Asp Gln Met
 130 135 140
 Asn Trp Cys Asp Ser Ala Ile Glu Val Pro Arg Gly Pro Ala Leu Pro
 145 150 155 160
 Glu Leu Pro His Ile Leu His Pro Leu Ile Phe His Leu Ser Val Gly
 165 170 175
 Asn Thr Arg Leu Glu Gly Phe Glu Ala Thr Tyr Ser Ser Glu Arg Gly
 180 185 190
 Trp Tyr Gln Asn Ile Leu Thr
 195

<210> 204
 <211> 50
 <212> PRT
 <213> Homo sapiens

<400> 204
 Met Leu Leu Leu Val Val Thr Leu Val Asn Leu Ser Ile Tyr Lys Leu
 1 5 10 15
 Ile Lys Leu Val Thr Ala Leu Ser Lys Lys Leu Gly Ala Lys Gly Val

112

20 25 30
Leu Lys Asn Ala His Phe Met Arg Cys Asn Cys Gly Glu Met Arg Thr
35 40 45

Arg Ser
50

```
<210> 205
<211> 135
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (129)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 205
Ala Lys Met Pro Trp Thr Cys Ser Val Ser Asp Pro Thr Ser Cys Asp
1 5 10 15

Ser Gln Ala Gln Lys Met Pro Gly Val Arg Ala Ser Arg Gln Pro Gly
20 25 30

Xaa Gly Arg Gln Cys Leu Leu Leu His Gln Val Gln Gly Ile Trp
35 40 45

Leu Lys Ala Cys Ile Phe Pro Gly His Lys Leu Pro Glu Pro Leu Lys
50 55 60

Trp Glu Ala Arg Gln Phe Gln Thr Asn Leu Phe Ser Thr His His Ser
65 70 75 80

Thr Phe Lys Val Cys Leu Leu Leu Leu Pro Val His Pro Pro Ser Leu
85 90 95

Gln Phe Phe His Ser Leu Thr Ser Glu Arg Val Pro Gly Gly Ser Met
100 105 110

Val Asn Lys Leu Thr Cys Met Leu Gln Lys Lys Lys Lys Lys Lys Ile
115 120 125

Xaa Ala Val Arg Lys Gly Ile
130 135

```
<210> 206
<211> 69
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (6)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>
<221> SITE
<222> (13)

113

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (51)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 206

Trp	Tyr	Gln	Gly	Lys	Xaa	Asp	Leu	Lys	Gly	Leu	Gly	Xaa	Val	Leu	Asp
1				5					10					15	

Gly	Ser	Asp	Gly	Met	Ala	Gly	Gly	Ile	Pro	Glu	Gly	Met	Ala	Phe	Thr
			20					25					30		

Leu	Tyr	Leu	Gly	Ile	Trp	Leu	Ser	Ser	Pro	Phe	Pro	Asp	Cys	Cys	Ile
		35					40					45			

Ala	Phe	Xaa	Phe	Ala	Tyr	Ser	Ser	Ser	Pro	Leu	Ser	Ser	Gly	Asp	Thr
	50					55					60				

Phe	Gln	Gly	Pro	Gln
65				

<210> 207

<211> 2

<212> PRT

<213> Homo sapiens

<400> 207

Leu	Leu
1	

<210> 208

<211> 114

<212> PRT

<213> Homo sapiens

<400> 208

Gly	Pro	Arg	Arg	Leu	Ser	Gly	Thr	His	Ser	Arg	Gly	Ser	Ser	Pro	Asp
1				5					10					15	

Pro	Cys	Ser	Cys	Val	Val	Trp	Ala	Ser	Ala	Asn	Ser	Trp	Ala	Thr	Cys
			20					25					30		

Val	Tyr	Leu	Glu	Pro	Gly	Ser	Pro	Leu	Ser	Ser	Phe	Pro	Cys	Ala	Tyr
		35					40					45			

Ser	Gly	Thr	Cys	Leu	Val	Arg	Val	Trp	Gln	Glu	Asn	Gly	Ala	Phe	Asn
	50					55					60				

Asn	Leu	Pro	Ser	Phe	Ile	Pro	Trp	Ser	Leu	Leu	His	Ala	Arg	Thr	Cys
65					70					75					80

Ala	His	Leu	Phe	Gly	Ala	Leu	Ser	His	Leu	Ile	Asp	Ser	Arg	Pro	Gly
				85					90					95	

Ala	Val	Leu	Thr	Pro	Val	Ile	Pro	Ala	Leu	Trp	Glu	Asp	Glu	Ala	Gly
			100					105					110		

Gly	Ser
-----	-----

<210> 209

114

<211> 294

<212> PRT

<213> Homo sapiens

<400> 209

```

Arg Arg Leu Pro Ala Pro Thr Met Pro Trp Pro Leu Leu Leu Leu Leu
 1           5           10           15
Ala Val Ser Gly Ala Gln Thr Thr Arg Pro Cys Phe Pro Gly Cys Gln
          20           25           30
Cys Glu Val Glu Thr Phe Gly Leu Phe Asp Ser Phe Ser Leu Thr Arg
      35           40           45
Val Asp Cys Ser Gly Leu Gly Pro His Ile Met Pro Val Pro Ile Pro
      50           55           60
Leu Asp Thr Ala His Leu Asp Leu Ser Ser Asn Arg Leu Glu Met Val
      65           70           75           80
Asn Glu Ser Val Leu Ala Gly Pro Gly Tyr Thr Thr Leu Ala Gly Leu
          85           90           95
Asp Leu Ser His Asn Leu Leu Thr Ser Ile Ser Pro Thr Ala Phe Ser
          100          105          110
Arg Leu Arg Tyr Leu Glu Ser Leu Asp Leu Ser His Asn Gly Leu Thr
      115          120          125
Ala Leu Pro Ala Glu Ser Phe Thr Ser Ser Pro Leu Ser Asp Val Asn
      130          135          140
Leu Ser His Asn Gln Leu Arg Glu Val Ser Val Ser Ala Phe Thr Thr
      145          150          155          160
His Ser Gln Gly Arg Ala Leu His Val Asp Leu Ser His Asn Leu Ile
          165          170          175
His Arg Leu Val Pro His Pro Thr Arg Ala Gly Leu Pro Ala Pro Thr
          180          185          190
Ile Gln Ser Leu Asn Leu Ala Trp Asn Arg Leu His Ala Val Pro Asn
      195          200          205
Leu Arg Asp Leu Pro Leu Arg Tyr Leu Ser Leu Asp Gly Asn Pro Leu
      210          215          220
Ala Val Ile Gly Pro Gly Ala Phe Ala Gly Leu Gly Gly Leu Thr His
      225          230          235          240
Leu Ser Leu Ala Ser Leu Gln Arg Leu Pro Glu Leu Ala Pro Ser Gly
          245          250          255
Phe Arg Glu Leu Pro Gly Leu Gln Val Leu Asp Leu Ser Gly Asn Pro
          260          265          270
Lys Leu Asn Trp Ala Gly Ala Glu Val Phe Ser Gly Leu Ser Ser Leu
      275          280          285
Gln Glu Leu Asp Leu Ser
      290

```

<210> 210

<211> 292

<212> PRT

115

<213> Homo sapiens

<400> 210

```

Arg Leu Leu Val Ala Pro Leu Leu Leu Ala Trp Val Ala Gly Ala Thr
 1           5           10           15
Ala Ala Val Pro Val Val Pro Trp His Val Pro Cys Pro Pro Gln Cys
          20           25           30
Ala Cys Gln Ile Arg Pro Trp Tyr Thr Pro Arg Ser Ser Tyr Arg Glu
          35           40           45
Ala Thr Thr Val Asp Cys Asn Asp Leu Phe Leu Thr Ala Val Pro Pro
          50           55           60
Ala Leu Pro Ala Gly Thr Gln Thr Leu Leu Leu Gln Ser Asn Ser Ile
          65           70           75           80
Val Arg Val Asp Gln Ser Glu Leu Gly Tyr Leu Ala Asn Leu Thr Glu
          85           90           95
Leu Asp Leu Ser Gln Asn Ser Phe Ser Asp Ala Arg Asp Cys Asp Phe
          100          105          110
His Ala Leu Pro Gln Leu Leu Ser Leu His Leu Glu Glu Asn Gln Leu
          115          120          125
Thr Arg Leu Glu Asp His Ser Phe Ala Gly Leu Ala Ser Leu Gln Glu
          130          135          140
Leu Tyr Leu Asn His Asn Gln Leu Tyr Arg Ile Ala Pro Arg Ala Phe
          145          150          155          160
Ser Gly Leu Ser Asn Leu Leu Arg Leu His Leu Asn Ser Asn Leu Leu
          165          170          175
Arg Ala Ile Asp Ser Arg Trp Phe Glu Met Leu Pro Asn Leu Glu Ile
          180          185          190
Leu Met Ile Gly Gly Asn Lys Val Asp Ala Ile Leu Asp Met Asn Phe
          195          200          205
Arg Pro Leu Ala Asn Leu Arg Ser Leu Val Leu Ala Gly Met Asn Leu
          210          215          220
Arg Glu Ile Ser Asp Tyr Ala Leu Glu Gly Leu Gln Ser Leu Glu Ser
          225          230          235          240
Leu Ser Phe Tyr Asp Asn Gln Leu Ala Arg Val Pro Arg Arg Ala Leu
          245          250          255
Glu Gln Val Pro Gly Leu Lys Phe Leu Asp Leu Asn Lys Asn Pro Leu
          260          265          270
Gln Arg Val Gly Pro Gly Asp Phe Ala Asn Met Leu His Leu Lys Glu
          275          280          285
Leu Gly Leu Asn
          290

```

<210> 211

<211> 199

<212> PRT

<213> Homo sapiens

116

<400> 211

Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
 1 5 10 15
 Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
 20 25 30
 Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
 35 40 45
 Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
 50 55 60
 Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
 65 70 75 80
 Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
 85 90 95
 Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser
 100 105 110
 Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu
 115 120 125
 His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro
 130 135 140
 Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu
 145 150 155 160
 Ile Cys Trp Leu Thr Lys Lys Lys Tyr Ser Ser Ser Val His Asp Pro
 165 170 175
 Asn Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser
 180 185 190
 Arg Leu Thr Asp Val Thr Leu
 195

<210> 212

<211> 31

<212> PRT

<213> Homo sapiens

<400> 212

Met Thr Met Ile Thr Pro Ser Ser Asn Thr Thr His Tyr Arg Glu Ser
 1 5 10 15
 Trp Tyr Ala Cys Arg Tyr Arg Ser Gly Ile Pro Gly Ser Thr His
 20 25 30

<210> 213

<211> 31

<212> PRT

<213> Homo sapiens

<400> 213

Ala Ser Gly Leu Gly Asp Cys Pro Val Leu Leu Val Arg Leu Cys Cys
 1 5 10 15
 Pro Ala Leu Phe Ile Cys Val Ile Ile Phe Val Asn Ile Val Phe
 20 25 30

117

<210> 214
<211> 31
<212> PRT
<213> Homo sapiens

<400> 214
Ser Val Val Ala Thr Ser Ser Pro Pro Ala Ser Gly Ser Val Cys Leu
1 5 10 15
Pro Gly Leu Leu Ala Pro His Trp Ala Ala Pro Gly Ser Leu Pro
20 25 30

<210> 215
<211> 31
<212> PRT
<213> Homo sapiens

<400> 215
Leu Ile Pro Gly Leu Ala Val Arg Pro Ser Gln Gln Gly Pro Val Thr
1 5 10 15
Gln Gln Pro Ala Gln Ser Ile Cys Phe Trp Gly Met Gly Trp Gly
20 25 30

<210> 216
<211> 31
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 216
Leu Leu His Arg Arg Phe Glu Pro Xaa Thr Leu Gly Lys Gly Thr Leu
1 5 10 15
His Asp Thr Pro Leu Pro Ser Leu His Glu Ala Lys Gly Pro Val
20 25 30

<210> 217
<211> 33
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (22)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 217
Phe Pro Asn Val Leu Pro Ser Phe Met Cys Gln Met Ala Pro Ala His
1 5 10 15
Met Pro Leu Pro Ser Xaa Glu Trp Glu Pro Leu Leu Lys Cys Leu Asn
20 25 30

Pro

118

<210> 218
 <211> 79
 <212> PRT
 <213> Homo sapiens

<400> 218
 Gln Asp Lys Glu Ala Cys Val Gly Thr Asn Asn Gln Ser Tyr Ile Cys
 1 5 10 15
 Asp Thr Gly His Cys Cys Gly Gln Ser Gln Cys Cys Asn Tyr Tyr Tyr
 20 25 30
 Glu Leu Trp Trp Phe Trp Leu Val Trp Thr Ile Ile Ile Ile Leu Ser
 35 40 45
 Cys Cys Cys Val Cys His His Arg Arg Ala Lys His Arg Leu Gln Ala
 50 55 60
 Gln Gln Arg Gln His Glu Ile Asn Leu Ile Ala Tyr Arg Glu Ala
 65 70 75

<210> 219
 <211> 79
 <212> PRT
 <213> Homo sapiens

<400> 219
 Gln Leu Arg Glu Leu Cys Pro Gly Val Asn Asn Gln Pro Tyr Leu Cys
 1 5 10 15
 Glu Ser Gly His Cys Cys Gly Glu Thr Gly Cys Cys Thr Tyr Tyr Tyr
 20 25 30
 Glu Leu Trp Trp Phe Trp Leu Leu Trp Thr Val Leu Ile Leu Phe Ser
 35 40 45
 Cys Cys Cys Ala Phe Arg His Arg Arg Ala Lys Leu Arg Leu Gln Gln
 50 55 60
 Gln Gln Arg Gln Arg Glu Ile Asn Leu Leu Ala Tyr His Gly Ala
 65 70 75

<210> 220
 <211> 350
 <212> PRT
 <213> Homo sapiens

<400> 220
 Leu Phe Asn Leu Val Gln Gly Ala Phe Leu Thr Leu Asn Ala Thr Asn
 1 5 10 15
 Pro Gly Ala Thr Lys Ser Cys Trp Leu Cys Leu Ala Met Gly Pro Pro
 20 25 30
 Tyr Tyr Glu Ala Ile Ala Ser Leu Gly Glu Val Ala Tyr Ser Thr Ser
 35 40 45
 Gln Asp Arg Cys His Trp Gly Thr Gln Gly Lys Leu Thr Leu Thr Glu
 50 55 60
 Val Ser Gly His Gly Leu Cys Ile Gly Lys Val Pro Phe Thr His Gln
 65 70 75 80
 His Leu Cys Asn Gln Thr Leu Ser Ile Asn Ser Ser Glu Gly His Gln

119

85										90				95			
Tyr	Leu	Leu	Pro 100	Ser	Asn	His	Ser	Trp 105	Trp	Ala	Cys	Ser	Thr 110	Gly	Leu		
Thr	Pro	Cys 115	Leu	Ser	Thr	Ser	Val 120	Phe	Asn	Gln	Ser	Arg 125	Asp	Phe	Cys		
Ile	Gln 130	Val	Gln	Leu	Ile	Pro 135	Arg	Ile	Tyr	Tyr	Tyr 140	Pro	Glu	Glu	Val		
Leu 145	Leu	Gln	Ala	Tyr	Asp 150	Asp	Ser	His	Pro	Arg 155	Pro	Lys	Arg	Glu	Ala 160		
Val	Ser	Leu	Thr	Leu 165	Ala	Val	Leu	Leu	Gly 170	Leu	Gly	Ile	Thr	Ala 175	Gly		
Ile	Gly	Thr	Gly 180	Ser	Thr	Ala	Leu	Ile 185	Lys	Gly	Pro	Ile	Asp 190	Leu	Gln		
Gln	Gly	Leu 195	Thr	Ser	Leu	Gln	Ile 200	Ala	Ile	Asp	Ala	Asp 205	Leu	Arg	Ala		
Leu	Gln 210	Asp	Ser	Val	Ser	Lys 215	Leu	Glu	Asp	Ser	Leu	Thr 220	Ser	Leu	Ser		
Glu 225	Val	Val	Leu	Gln	Asn 230	Arg	Arg	Gly	Leu	Asp 235	Leu	Leu	Phe	Leu	Lys 240		
Glu	Gly	Gly	Leu	Cys 245	Ala	Ala	Leu	Lys	Glu 250	Glu	Cys	Cys	Phe	Tyr 255	Ile		
Asp	His	Ser	Gly 260	Ala	Val	Arg	Asp	Ser 265	Met	Lys	Lys	Leu	Lys 270	Glu	Lys		
Leu	Asp	Lys 275	Arg	Gln	Leu	Glu	Arg 280	Gln	Lys	Asn	Gln	Asn 285	Trp	Tyr	Glu		
Gly	Trp 290	Phe	Asn	Asn	Ser	Pro 295	Trp	Phe	Thr	Thr	Leu 300	Leu	Ser	Thr	Ile		
Ala 305	Gly	Pro	Leu	Leu	Leu 310	Leu	Leu	Leu	Leu	Leu 315	Ile	Leu	Gly	Pro	Cys 320		
Ile	Ile	Asn	Lys	Leu 325	Val	Gln	Phe	Ile	Asn 330	Asp	Arg	Ile	Ser	Ala 335	Val		
Lys	Ile	Leu	Val 340	Leu	Arg	Gln	Lys	Tyr 345	Gln	Ala	Leu	Asp	Asn 350				

```
<210> 221
<211> 346
<212> PRT
<213> Homo sapiens
```

```

<400> 221
Leu Met Ser Ile Leu Gly Gly Val His His Leu Leu Asn Leu Thr Gln
  1             5             10             15

Pro Lys Leu Ala Gln Asp Cys Trp Leu Cys Leu Lys Ala Lys Pro Pro
      20             25             30

Tyr Tyr Val Gly Leu Gly Val Glu Ala Thr Leu Lys Arg Gly Pro Leu
      35             40             45

```

120

Ser Cys His Thr Arg Pro Arg Ala Leu Thr Ile Gly Asp Val Ser Gly
 50 55 60
 Asn Ala Ser Cys Leu Ile Ser Thr Gly Tyr Asn Leu Ser Ala Ser Pro
 65 70 75 80
 Phe Gln Ala Thr Cys Asn Gln Ser Leu Leu Thr Tyr Ile Ser Thr Ser
 85 90 95
 Val Ser Tyr Gln Ala Pro Asn Asn Thr Trp Leu Ala Cys Thr Ser Gly
 100 105 110
 Leu Thr Arg Cys Ile Asn Gly Thr Glu Pro Gly Pro Leu Leu Cys Val
 115 120 125
 Leu Val His Val Leu Pro Gln Val Tyr Val Tyr Ser Gly Pro Glu Gly
 130 135 140
 Arg Gln Leu Ile Ala Pro Pro Glu Leu His Pro Arg Leu His Gln Ala
 145 150 155 160
 Val Pro Leu Leu Val Pro Leu Leu Ala Gly Leu Ser Ile Ala Gly Ser
 165 170 175
 Ala Ala Ile Gly Thr Ala Ala Leu Val Gln Gly Glu Thr Gly Leu Ile
 180 185 190
 Ser Leu Ser Gln Gln Val Asp Ala Asp Phe Ser Asn Leu Gln Ser Ala
 195 200 205
 Ile Asp Ile Leu His Ser Gln Val Glu Ser Leu Ala Glu Val Val Leu
 210 215 220
 Gln Asn Cys Arg Cys Leu Asp Leu Leu Phe Leu Ser Gln Gly Gly Leu
 225 230 235 240
 Cys Ala Ala Leu Gly Glu Ser Cys Cys Phe Tyr Ala Asn Gln Ser Gly
 245 250 255
 Val Ile Lys Gly Thr Val Lys Lys Val Arg Glu Asn Leu Asp Arg His
 260 265 270
 Gln Gln Glu Arg Glu Asn Asn Ile Pro Trp Tyr Gln Ser Met Phe Asn
 275 280 285
 Trp Asn Pro Trp Leu Thr Thr Leu Ile Thr Gly Leu Ala Gly Pro Leu
 290 295 300
 Leu Ile Leu Leu Leu Ser Leu Ile Phe Gly Pro Cys Ile Leu Asn Ser
 305 310 315 320
 Phe Leu Asn Phe Ile Lys Gln Arg Ile Ala Ser Val Lys Leu Thr Tyr
 325 330 335
 Leu Lys Thr Gln Tyr Asp Thr Leu Val Asn
 340 345

<210> 222
 <211> 139
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (100)

121

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 222

```

Ile Asp Gly Gln Thr Trp Ala Glu Arg Ala Leu Arg Glu Asn Glu Arg
 1           5           10           15

His Ala Phe Thr Cys Arg Val Ala Gly Gly Pro Gly Thr Pro Arg Leu
          20           25           30

Ala Trp Tyr Leu Asp Gly Gln Leu Gln Glu Ala Ser Thr Ser Arg Leu
          35           40           45

Leu Ser Val Gly Gly Glu Ala Phe Ser Gly Gly Thr Ser Thr Phe Thr
 50           55           60

Val Thr Ala His Arg Ala Gln His Glu Leu Asn Cys Ser Leu Gln Asp
 65           70           75           80

Pro Arg Ser Gly Arg Ser Ala Asn Ala Ser Val Ile Leu Asn Val Gln
          85           90           95

Phe Lys Pro Xaa Ile Ala Gln Val Gly Ala Lys Tyr Gln Glu Ala Gln
          100           105           110

Gly Pro Gly Leu Leu Val Val Leu Phe Ala Leu Val Arg Ala Asn Pro
 115           120           125

Pro Ala Asn Val Thr Trp Ile Asp Gln Asp Gly
 130           135

```

<210> 223

<211> 139

<212> PRT

<213> Homo sapiens

<400> 223

```

Ile Glu Gly Pro Pro Glu Gly Gln Lys Leu Arg Ala Gly Thr Arg Val
 1           5           10           15

Arg Leu Val Cys Leu Ala Ile Gly Gly Asn Pro Glu Pro Ser Leu Met
          20           25           30

Trp Tyr Lys Asp Ser Arg Thr Val Thr Glu Ser Arg Leu Pro Gln Glu
          35           40           45

Ser Arg Arg Val His Leu Gly Ser Val Glu Lys Ser Gly Ser Thr Phe
          50           55           60

Ser Arg Glu Leu Val Leu Val Thr Gly Pro Ser Asp Asn Gln Ala Lys
          65           70           75           80

Phe Thr Cys Lys Ala Gly Gln Leu Ser Ala Ser Thr Gln Leu Ala Val
          85           90           95

Gln Phe Pro Pro Thr Asn Val Thr Ile Leu Ala Asn Ala Ser Ala Leu
          100           105           110

Arg Pro Gly Asp Ala Leu Asn Leu Thr Cys Val Ser Val Ser Ser Asn
          115           120           125

Pro Pro Val Asn Leu Ser Trp Asp Lys Glu Gly
          130           135

```

<210> 224

122

<211> 56
 <212> PRT
 <213> Homo sapiens

<400> 224
 Lys Asn His Ser Val Asn Glu Glu Glu Gln Glu Glu Gln Gly Glu Gly
 1 5 10 15
 Ser Glu Asp Glu Trp Glu Gln Val Gly Pro Arg Asn Lys Thr Ser Val
 20 25 30
 Thr Arg Gln Ala Asp Phe Val Gln Thr Pro Ile Thr Gly Ile Phe Gly
 35 40 45
 Gly His Ile Arg Ser Val Val Tyr
 50 55

<210> 225
 <211> 56
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (39)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 225
 Lys Asn His Ser Val Asn Glu Glu Glu Gln Glu Glu Gln Gly Glu Gly
 1 5 10 15
 Ser Glu Asp Glu Trp Glu Gln Val Gly Pro Arg Asn Lys Thr Ser Val
 20 25 30
 Thr Arg Gln Ala Asp Phe Xaa Gln Thr Pro Ile Thr Gly Ile Phe Gly
 35 40 45
 Gly His Ile Arg Phe Val Leu Phe
 50 55

<210> 226
 <211> 100
 <212> PRT
 <213> Homo sapiens

<400> 226
 Ser Glu Ala Val His Leu Glu Val Phe Ser Asp Trp Leu Leu Leu Gln
 1 5 10 15
 Ala Ser Ala Glu Glu Val Ile Glu Gly Lys Ala Leu Val Leu Arg Cys
 20 25 30
 Arg Gly Trp Lys Asp Trp Asp Val Phe Lys Val Ile Tyr Tyr Lys Asp
 35 40 45
 Gly Lys Pro Leu Glu Tyr Trp Tyr Glu Asn Lys Asn Ile Ser Ile Glu
 50 55 60
 Ser Ala Thr Thr Glu Asn Ser Gly Thr Tyr Tyr Cys Glu Gly Ala Phe
 65 70 75 80
 Asn Phe Lys Arg Thr Ser Glu Arg Tyr Thr Ser Asp Tyr Leu Asn Ile
 85 90 95

123

Thr Val Lys Lys
100

<210> 227
<211> 21
<212> PRT
<213> Homo sapiens

<400> 227
Ala Arg Ser Pro Ser Arg Ser Gly Pro Gly Lys Arg Glu Thr Ala Gln
1 5 10 15

Ala Gln Tyr Arg Gly
20

<210> 228
<211> 301
<212> PRT
<213> Homo sapiens

<400> 228
Met Thr Thr Leu Asp Asp Lys Leu Leu Gly Glu Lys Leu Gln Tyr Tyr
1 5 10 15

Tyr Ser Ser Ser Glu Asp Glu Asp Ser Asp His Glu Asp Lys Asp Arg
20 25 30

Gly Arg Cys Ala Pro Ala Ser Ser Ser Val Pro Ala Glu Ala Glu Leu
35 40 45

Ala Gly Glu Gly Ile Ser Val Asn Thr Gly Pro Lys Gly Val Ile Asn
50 55 60

Asp Trp Arg Arg Phe Lys Gln Leu Glu Thr Glu Gln Arg Glu Glu Gln
65 70 75 80

Cys Arg Glu Met Glu Arg Leu Ile Lys Lys Leu Ser Met Thr Cys Arg
85 90 95

Ser His Leu Asp Glu Glu Glu Glu Gln Gln Lys Gln Lys Asp Leu Gln
100 105 110

Glu Lys Ile Ser Gly Lys Met Thr Leu Lys Glu Phe Ala Ile Met Asn
115 120 125

Glu Asp Gln Asp Asp Glu Glu Phe Leu Gln Gln Tyr Arg Lys Gln Arg
130 135 140

Met Glu Glu Met Arg Gln Gln Leu His Lys Gly Pro Gln Phe Lys Gln
145 150 155 160

Val Phe Glu Ile Ser Ser Gly Glu Gly Phe Leu Asp Met Ile Asp Lys
165 170 175

Glu Gln Lys Ser Ile Val Ile Met Val His Ile Tyr Glu Asp Gly Ile
180 185 190

Pro Gly Thr Glu Ala Met Asn Gly Cys Met Ile Cys Leu Ala Ala Glu
195 200 205

Tyr Pro Ala Val Lys Phe Cys Lys Val Lys Ser Ser Val Ile Gly Ala
210 215 220


Ser Ser Gln Phe Thr Arg Asn Ala Leu Pro Ala Leu Leu Ile Tyr Lys

124

225					230					235					240
Gly	Gly	Glu	Leu	Ile	Gly	Asn	Phe	Val	Arg	Val	Thr	Asp	Gln	Leu	Gly
				245					250					255	
Asp	Asp	Phe	Phe	Ala	Val	Asp	Leu	Glu	Ala	Phe	Leu	Gln	Glu	Phe	Gly
			260					265					270		
Leu	Leu	Pro	Glu	Lys	Glu	Val	Leu	Val	Leu	Thr	Ser	Val	Arg	Asn	Ser
		275					280					285			
Ala	Thr	Cys	His	Ser	Glu	Asp	Ser	Asp	Leu	Glu	Ile	Asp			
	290					295					300				

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US00/29363

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.1, 23.5, 24.31; 530/300, 350; 435/6, 69.1, 252.3, 320.1, 325 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X,P	Database GenBank Accession NO: AC024602; SMITH et al.; human chromosome 10 clone; 10 JUNE 2000; having 100% sequence identity and 97.6% query match with SEQ ID NO: 11, see entire document.	1-7, 21												
X,P	Database GenBank Accession NO: AL110276; KOEHRER et al.; human cDNA clone, similarity to platelet membrane glycoprotein V; 18 February 2000; having 100% sequence identity and 85% query match with SEQ ID NO: 11; vector: pSport1; host cell: DH10B, see entire document.	1-10, 21												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z* document member of the same patent family</td> </tr> <tr> <td>*U* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family	*U* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family													
U document referring to an oral disclosure, use, exhibition or other means														
P document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 26 DECEMBER 2000		Date of mailing of the international search report 23 FEB 2001												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer RITA MITRA  Telephone No. (703) 308-0196												

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/29363

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
XP	Database GenBank (N_Geneseq_36); Accession NO: A37137; BAKER et al.; "New mammalian DNA sequences encoding transmembrane, receptor or secreted PRO polypeptides, useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ ligand interactions"; 09 MARCH 2000; having 99.8% sequenc identity and 99.2% query match with SEQ ID NO: 11, see entire document.	1-7, 21
X,P	Database GenBank (A_Geneseq_36); Accession NO: Y99455; BAKER et al.; "New mammalian DNA sequences encoding transm embrane, receptor or secreted PRO polypeptides, useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interactions"; 09 MARCH 2000; having 99.7% sequence identity and 99.7% query match with SEQ ID NO: 110, see the entire document.	1-7, 21
X,P	Database GenBank (SPTREMBL_14); Accession NO: Q9UJX9; CHARPENTIER et al.; "Changes in global gene expression following estradiol treatment of human breast cancer cells."; 01 MAY 2000; having 99.7% sequence identity and 99.7% query match with SEQ ID NO: 110. see entire document.	1-7, 21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/29363

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10, 14, 15 and 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/L S00/29363

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

C07H 21/04; C07H 21/02; C07K 5/00; C07K 14/00; C12Q 1/68; C12N 1/21; C12N 15/63; C12N 15/85; 15/86

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

536/23.1, 23.5, 24.31; 536/300, 350; 435/6, 69.1, 252.3, 320.1, 325

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST, STN (Database: biosis, embase, medline, scisearch, lifesci, caplus)

Search terms: secreted protein or peptide, signal peptide, linkage analysis, chromosome 11, tumor marker, breast tissue, ovarian, lung and liver tumor tissue.

GenBank (Databases: GenEmbl, N_Geneseq-36, Issued_Patents, EST, A_Geneseq_36, PIR_65, SwissProt_39, Sptrembl_14)

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group 1 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 11 and Y is 110

Group 2 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 12 and Y is 111

Group 3 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 13 and Y is 112

Group 4 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 14 and Y is 113

Group 5 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 15 and Y is 114

Group 6 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 16 and Y is 115

Group 7 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 17 and Y is 116

Group 8 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 18 and Y is 117

Group 9 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 19 and Y is 118

Group 10 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/29363

SEQ ID NO: Y wherein: X is 20 and Y is 119

Group 11 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 21 and Y is 120

Group 12 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 22 and Y is 121

Group 13 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 23 and Y is 122

Group 14 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 24 and Y is 123

Group 15 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 25 and Y is 124

Group 16 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 26 and Y is 125

Group 17 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 27 and Y is 126

Group 18 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 28 and Y is 127

Group 19 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 29 and Y is 128

Group 20 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 30 and Y is 129

Group 21 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 31 and Y is 130

Group 22 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 32 and Y is 131

Group 23 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 33 and Y is 132

Group 24 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 34 and Y is 133

Group 25 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 35 and Y is 134

Group 26 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 36 and Y is 135

Group 27 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 37 and Y is 136

Group 28 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 38 and Y is 137

Group 29 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 39 and Y is 138

Group 30 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 40 and Y is 139

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 28 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 38 and Y is 137

Group 29 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 39 and Y is 138

Group 30 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 40 and Y is 139

Group 31 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 41 and Y is 140

Group 32 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 42 and Y is 141

Group 33 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 43 and Y is 142

Group 34 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 44 and Y is 143

Group 35 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 45 and Y is 144

Group 36 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 46 and Y is 145

Group 37 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 47 and Y is 146

Group 38 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 48 and Y is 147

Group 39 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 49 and Y is 148

Group 40 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 50 and Y is 149

Group 41 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 51 and Y is 150

Group 42 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 52 and Y is 151

Group 43 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 53 and Y is 152

Group 44 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 54 and Y is 153

Group 45 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 55 and Y is 154

Group 46 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 56 and Y is 155

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 47 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 57 and Y is 156

Group 48 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 58 and Y is 157

Group 49 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 59 and Y is 158

Group 50 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 60 and Y is 159

Group 51 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 61 and Y is 160

Group 52 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 62 and Y is 161

Group 53 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 63 and Y is 162

Group 54 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 64 and Y is 163

Group 55 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 65 and Y is 164

Group 56 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 66 and Y is 165

Group 57 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 67 and Y is 166

Group 58 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 68 and Y is 167

Group 59 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 69 and Y is 168

Group 60 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 70 and Y is 169

Group 61 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 71 and Y is 170

Group 62 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 72 and Y is 171

Group 63 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 73 and Y is 172

Group 64 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 74 and Y is 173

Group 65 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 75 and Y is 174

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 66 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 76 and Y is 175

Group 67 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 77 and Y is 176

Group 68 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 78 and Y is 177

Group 69 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 79 and Y is 178

Group 70 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 80 and Y is 179

Group 71 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 81 and Y is 180

Group 72 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 82 and Y is 181

Group 73 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 83 and Y is 182

Group 74 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 84 and Y is 183

Group 75 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 85 and Y is 184

Group 76 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 86 and Y is 185

Group 77 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 87 and Y is 186

Group 78 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 88 and Y is 187

Group 79 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 89 and Y is 188

Group 80 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 90 and Y is 189

Group 81 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 91 and Y is 190

Group 82 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 92 and Y is 191

Group 83 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 93 and Y is 192

Group 84 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 94 and Y is 193

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 85 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 95 and Y is 194

Group 86 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 96 and Y is 195

Group 87 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 97 and Y is 196

Group 88 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 98 and Y is 197

Group 89 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 99 and Y is 198

Group 90 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 100 and Y is 199

Group 91 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 101 and Y is 200

Group 92 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 102 and Y is 201

Group 93 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 103 and Y is 202

Group 94 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 104 and Y is 203

Group 95 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 105 and Y is 204

Group 96 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 106 and Y is 205

Group 97 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 107 and Y is 206

Group 98 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 108 and Y is 207

Group 99 Claims 1-10, 14, 15 and 21 directed to an isolated nucleic acid of SEQ ID NO: X or encoding a peptide of SEQ ID NO: Y wherein: X is 109 and Y is 208

Group 100 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 110

Group 101 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 111

Group 102 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 112

Group 103 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 113

Group 104 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 114

Group 105 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 115

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 106 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 116

Group 107 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 117

Group 108 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 118

Group 109 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 119

Group 110 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 120

Group 111 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 121

Group 112 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 122

Group 113 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 123

Group 114 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 124

Group 115 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 125

Group 116 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 126

Group 117 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 127

Group 118 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 128

Group 119 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 129

Group 120 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 130

Group 121 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 131

Group 122 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 132

Group 123 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 133

Group 124 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 134

Group 125 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 135

Group 126 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 136

Group 127 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 137

Group 128 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 138

Group 129 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 139

Group 130 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 140

Group 131 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 141

Group 132 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 142

Group 133 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 143

Group 134 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 144

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 135 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 145

Group 136 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 146

Group 137 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 147

Group 138 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 148

Group 139 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 149

Group 140 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 150

Group 141 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 151

Group 142 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 152

Group 143 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 153

Group 144 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 154

Group 145 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 155

Group 146 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 156

Group 147 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 157

Group 148 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 158

Group 149 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 159

Group 150 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 160

Group 151 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 161

Group 152 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 162

Group 153 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 163

Group 154 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 164

Group 155 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 165

Group 156 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 166

Group 157 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 167

Group 158 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 168

Group 159 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 169

Group 160 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 170

Group 161 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 171

Group 162 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 172

Group 163 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 173

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 164 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 174

Group 165 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 175

Group 166 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 176

Group 167 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 177

Group 168 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 178

Group 169 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 179

Group 170: Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 180

Group 171 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 181

Group 172 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 182

Group 173 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 183

Group 174 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 184

Group 175 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 185

Group 176 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 186

Group 177 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 187

Group 178 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 188

Group 179 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 189

Group 180 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 190

Group 181 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 191

Group 182 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 192

Group 183 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 193

Group 184 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 194

Group 185 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 195

Group 186 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 196

Group 187 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 197

Group 188 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 198

Group 189 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 199

Group 190 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 200

Group 191 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 201

Group 192 Claims 11, 12, 16, and 23 directed to a peptide of SFQ ID NO: Y wherein: Y is 202

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

- Group 193 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 203
- Group 194 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 204
- Group 195 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 205
- Group 196 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 206
- Group 197 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 207
- Group 198 Claims 11, 12, 16, and 23 directed to a peptide of SEQ ID NO: Y wherein: Y is 208
- Group 199 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 110
- Group 200 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 111
- Group 201 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 112
- Group 202 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 113
- Group 203 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 114
- Group 204 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 115
- Group 205 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 116
- Group 206 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 117
- Group 207 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 118
- Group 208 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 119
- Group 209 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 120
- Group 210 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 121
- Group 211 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 122
- Group 212 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 123
- Group 213 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 124

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

- Group 214 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 125
- Group 215 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 126
- Group 216 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 127
- Group 217 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 128
- Group 218 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 129
- Group 219 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 130
- Group 220 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 131
- Group 221 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 132
- Group 222 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 133
- Group 223 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 134
- Group 224 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 135
- Group 225 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 136
- Group 226 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 137
- Group 227 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 138
- Group 228 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 139
- Group 229 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 140
- Group 230 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 141
- Group 231 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 142
- Group 232 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 143
- Group 233 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

is 144

Group 234 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 145

Group 235 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 146

Group 236 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 147

Group 237 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 148

Group 238 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 149

Group 239 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 150

Group 240 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 151

Group 241 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 152

Group 242 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 153

Group 243 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 154

Group 244 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 155

Group 245 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 156

Group 246 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 157

Group 247 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 158

Group 248 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 159

Group 249 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 160

Group 250 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 161

Group 251 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 162

Group 252 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

is 163

Group 253 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 164

Group 254 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 165

Group 255 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 166

Group 256 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 167

Group 257 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 168

Group 258 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 169

Group 259 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 170

Group 260 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 171

Group 261 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 172

Group 262 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 173

Group 263 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 174

Group 264 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 175

Group 265 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 176

Group 266 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 177

Group 267 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 178

Group 268 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 179

Group 269 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 180

Group 270 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 181

Group 271 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

is 182

Group 272 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 183

Group 273 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 184

Group 274 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 185

Group 275 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 186

Group 276 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 187

Group 277 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 188

Group 278 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 189

Group 279 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 190

Group 280 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 191

Group 281 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 192

Group 282 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 193

Group 283 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 194

Group 284 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 195

Group 285 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 196

Group 286 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 197

Group 287 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 198

Group 288 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 199

Group 289 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 200

Group 290 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

is 201

Group 291 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 202

Group 292 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 203

Group 293 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 204

Group 294 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 205

Group 295 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 206

Group 296 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 207

Group 297 Claim 13, directed to an isolated antibody where the antibody binds a protein with SEQ ID NO: Y wherein: Y is 208

Group 298 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 110

Group 299 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 111

Group 300 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 112

Group 301 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 113

Group 302 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 114

Group 303 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 115

Group 304 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 116

Group 305 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 117

Group 306 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 118

Group 307 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 119

Group 308 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 120

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 309 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 121

Group 310 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 122

Group 311 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 123

Group 312 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 124

Group 313 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 125

Group 314 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 126

Group 315 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 127

Group 316 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 128

Group 317 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 129

Group 318 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 130

Group 319 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 131

Group 320 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 132

Group 321 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 133

Group 322 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 134

Group 323 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 135

Group 324 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 136

Group 325 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 137

Group 326 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 138

Group 327 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 139

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 328 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 140

Group 329 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 141

Group 330 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 142

Group 331 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 143

Group 332 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 144

Group 333 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 145

Group 334 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 146

Group 335 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 147

Group 336 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 148

Group 337 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 149

Group 338 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 150

Group 339 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 151

Group 340 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 152

Group 341 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 153

Group 342 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 154

Group 343 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 155

Group 344 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 156

Group 345 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 157

Group 346 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 158

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Group 347 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 159

Group 348 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 160

Group 349 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 161

Group 350 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 162

Group 351 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 163

Group 352 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 164

Group 353 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 165

Group 354 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 166

Group 355 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 167

Group 356 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 168

Group 357 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 169

Group 358 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 170

Group 359 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 171

Group 360 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 172

Group 361 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 173

Group 362 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 174

Group 363 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 175

Group 364 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 176

Group 365 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 177

Group 366 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

administration of a polypeptide of SEQ ID NO: Y wherein: Y is 178

Group 367 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 179

Group 368 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 180

Group 369 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 181

Group 370 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 182

Group 371 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 183

Group 372 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 184

Group 373 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 185

Group 374 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 186

Group 375 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 187

Group 376 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 188

Group 377 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 189

Group 378 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 190

Group 379 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 191

Group 380 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 192

Group 381 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 193

Group 382 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 194

Group 383 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 195

Group 384 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 196

Group 385 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

administration of a polypeptide of SEQ ID NO: Y wherein: Y is 197

Group 386 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 198

Group 387 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 199

Group 388 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 200

Group 389 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 201

Group 390 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 202

Group 391 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 203

Group 392 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 204

Group 393 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 205

Group 394 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 206

Group 395 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 207

Group 396 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polypeptide of SEQ ID NO: Y wherein: Y is 208

Group 397 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 110

Group 398 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 111

Group 399 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 112

Group 400 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 113

Group 401 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 114

Group 402 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 115

Group 403 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 116

International application No.
PCT/US00/2936?

Group 422 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein : Y is 135

International application No.
PCT/US00/29363

Group 441 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 154

International application No.
PCT/US00/29363

Group 460 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 173

International application No.
PCT/US00/29363

Group 479 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 192

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (Julv 1998)

International application No.
PCT/US00/29363

Group 480 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 193

Group 481 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 194

Group 482 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 195

Group 483 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 196

Group 484 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 197

Group 485 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 198

Group 486 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 199

Group 487 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 200

Group 488 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 201

Group 489 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 202

Group 490 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 203

Group 491 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 204

Group 492 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 205

Group 493 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 206

Group 494 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 207

Group 495 Claim 17, directed to a method for preventing, treating, or ameliorating an undefined medical condition by administration of a polynucleotide encoding a protein of SEQ ID NO: Y wherein: Y is 208

Group 496 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 11

Group 497 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 12

Group 498 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 13

International application No.
PCT/US00/29363

Group 518 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the

International application No.
PCT/US00/29363

Group 537 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the

International application No.
PCT/US00/29363

Group 556 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the

International application No.
PCT/US00/29363

Group 575 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 90

Group 576 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 91

Group 577 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 92

Group 578 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 93

Group 579 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 94

Group 580 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 95

Group 581 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 96

Group 582 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 97

Group 583 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 98

Group 584 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 99

Group 585 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 100

Group 586 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 101

Group 587 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 102

Group 588 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 103

Group 589 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 104

Group 590 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 105

Group 591 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 106

Group 592 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 107

Group 593 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 108

Group 594 Claim 18 and 19, directed to a method of diagnosis of an undefined pathological condition by determining the

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

presence or absence of a mutation in a polynucleotide of SEQ ID NO: X wherein: X is 109

Group 595 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 110

Group 596 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 111

Group 597 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 112

Group 598 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 113

Group 599 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 114

Group 600 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 115

Group 601 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 116

Group 602 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 117

Group 603 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 118

Group 604 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 119

Group 605 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 120

Group 606 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 121

Group 607 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 122

Group 608 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 123

Group 609 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 124

Group 610 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 125

Group 611 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 126

Group 612 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y wherein: Y is 127

Group 613 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Y wherein: Y is 128

Group 614 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 129

Group 615 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 130

Group 616 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 131

Group 617 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 132

Group 618 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 133

Group 619 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 134

Group 620 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 135

Group 621 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 136

Group 622 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 137

Group 623 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 138

Group 624 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 139

Group 625 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 140

Group 626 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 141

Group 627 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 142

Group 628 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 143

Group 629 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 144

Group 630 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 145

Group 631 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 146

Group 632 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Y wherein: Y is 147

Group 633 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 148

Group 634 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 149

Group 635 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 150

Group 636 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 151

Group 637 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 152

Group 638 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 153

Group 639 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 154

Group 640 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 155

Group 641 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 156

Group 642 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 157

Group 643 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 158

Group 644 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 159

Group 645 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 160

Group 646 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 161

Group 647 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 162

Group 648 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 163

Group 649 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 164

Group 650 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 165

Group 651 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Y wherein: Y is 166

Group 652 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 167

Group 653 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 168

Group 654 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 169

Group 655 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 170

Group 656 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 171

Group 657 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 172

Group 658 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 173

Group 659 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 174

Group 660 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 175

Group 661 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 176

Group 662 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 177

Group 663 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 178

Group 664 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 179

Group 665 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 180

Group 666 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 181

Group 667 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 182

Group 668 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 183

Group 669 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 184

Group 670 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Y wherein: Y is 185

Group 671 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 186

Group 672 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 187

Group 673 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 188

Group 674 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 189

Group 675 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 190

Group 676 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 191

Group 677 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 192

Group 678 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 193

Group 679 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 194

Group 680 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 195

Group 681 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 196

Group 682 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 197

Group 683 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 198

Group 684 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 199

Group 685 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 200

Group 686 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO: Y
wherein: Y is 201

Group 687 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 202

Group 688 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 203

Group 689 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (July 1998)

International application No.
PCT/US00/29363

Y wherein: Y is 204

Group 690 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 205

Group 691 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 206

Group 692 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 207

Group 693 Claim 20, directed to a method of identification of a binding partner to a polypeptide defined by SEQ ID NO:
Y wherein: Y is 208

Group 694 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 11

Group 695 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 12

Group 696 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 13

Group 697 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 14

Group 698 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 15

Group 699 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 16

Group 700 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 17

Group 701 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 18

Group 702 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 19

Group 703 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 20

Group 704 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 21

Group 705 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 22

Group 706 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 23

Group 707 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 24

Group 708 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in

International application No.
PCT/US00/29363

Group 727 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in

International application No.
PCT/US00/29363

Group 746 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in

International application No.
PCT/US00/29363

Group 765 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in

International application No.
PCT/US00/29363

Group 784 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in

INTERNATIONAL SEARCH REPORT
Form PCT/ISA/210 (extra sheet) (Julv 1998)

International application No.
PCT/US00/29363

the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 101

Group 785 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 102

Group 786 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 103

Group 787 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 104

Group 788 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 105

Group 789 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 106

Group 790 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 107

Group 791 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 108

Group 792 Claim 22, directed to a method of identifying an activity in a biological assay by identification of the protein in the supernatant wherein the cell expresses a polynucleotide encoded by SEQ ID NO: X wherein: X is 109

The inventions listed as Groups 1-792 do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The polynucleotides and polypeptides of each invention are unrelated, each to the other. The polynucleotide sequences encode structurally distinct polypeptides. Additionally, the claimed methods produce different products and/or different results which are not coextensive.